Peplife 2.0 - Basic Search Results

Browsing by half-Life: Between 60 to 3600 Seconds

Browse Results:

Filter by Year
From
Upto

ID	PMID	YEAR	Sequence	Name	Length	N-ter MOD	C-ter MOD	Linear/Cyclic	Chirality	Chem-MOD	Origin	Nature	Incubation Time	Concentration	Half Life	Protease	Assay	Test Sample	Vivo/Vitro	Reference	Patent No.	Activity
1001	20844765	2010	RRWQWR	Lfc1	6	Free	Free	Linear	L	None	Bovine lactoferricin	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=60Î¼M for E.coli
1002	20844765	2010	RRWQWR	Lfc1	6	Free	Free	Linear	L	None	Bovine lactoferricin	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=30Î¼M for S. aureus
1003	20844765	2010	RRWQWR	Lfc1	6	Free	Free	Linear	L	None	Bovine lactoferricin	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=7.5 Î¼M for B. subtilis
1004	20844765	2010	RRWWRF	Com1	6	Free	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=60Î¼M for E.coli
1005	20844765	2010	RRWWRF	Com1	6	Free	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=7.5Î¼M for S. aureus
1006	20844765	2010	RRWWRF	Com1	6	Free	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=1.9 Î¼M for B. subtilis
1007	20844765	2010	RRWQWR	Lfc2	6	Free	Amidation	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=15Î¼M for E.coli
1008	20844765	2010	RRWQWR	Lfc2	6	Free	Amidation	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=15Î¼M for S. aureus
1009	20844765	2010	RRWQWR	Lfc2	6	Free	Amidation	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=1.9Î¼M for B. subtilis
1010	20844765	2010	RRWWRF	Com2	6	Free	Amidation	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=30Î¼M for E.coli
1011	20844765	2010	RRWWRF	Com2	6	Free	Amidation	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=30Î¼M for S. aureus
1012	20844765	2010	RRWWRF	Com2	6	Free	Amidation	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	<30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=0.9 Î¼M for B. subtilis
1013	20844765	2010	RRWQWR	Lfc3	6	Acetylation	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	~60	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=120Î¼M for E.coli
1014	20844765	2010	RRWQWR	Lfc3	6	Acetylation	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	~60	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99>120Î¼M for S. aureus
1015	20844765	2010	RRWQWR	Lfc3	6	Acetylation	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	~60	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=60 Î¼M for B. subtilis
1016	20844765	2010	RRWWRF	Com3	6	Acetylation	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	~60	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=120Î¼M for E.coli
1017	20844765	2010	RRWWRF	Com3	6	Acetylation	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	~60	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=30Î¼M for S. aureus
1018	20844765	2010	RRWWRF	Com3	6	Acetylation	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	~60	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=7.5Î¼M for B. subtilis
1037	20844765	2010	RRWQWRMKKLG	Lfc7	11	Free	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	>30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=15Î¼M for E.coli
1038	20844765	2010	RRWQWRMKKLG	Lfc7	11	Free	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	>30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=7.5Î¼M for S. aureus
1039	20844765	2010	RRWQWRMKKLG	Lfc7	11	Free	Free	Linear	L	None	Synthetic	Antimicrobial	9 hours	5 µM	>30	Human serum proteases	RP-HPLC	Human serum	in vitro	None	None	LD99.99=0.9Î¼M for B. subtilis
1056	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1a	18	Acetylation	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	5mg/kg	7.6	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=1.1nM for fVIIa binding assay
1057	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1b	18	Acetylation [(C6H6)2-CO-]	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	5mg/kg	15	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=4nM for fVIIa binding assay
1058	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1c	18	Acetylation [(CH3)2-CH-CH2-(C6H6)-CH(CH3)-CO]	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	4.9mg/kg	24	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=14.6nM for fVIIa binding assay
1059	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1c	18	Acetylation [(CH3)2-CH-CH2-(C6H6)-CH(CH3)-CO]	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	17	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=14.6nM for fVIIa binding assay
1060	12270169	2002	ALCDNPRIDRWYCQFVEG	Peptide 1m	18	Acetylation (Napthalene acyl sulfonamide)	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	30	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=1.0nM for fVIIa binding assay
1061	12699744	2003	ALCDNPRIDRWYCQFVEG	Peptide 1a	18	Acetylation	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	1.11mg/kg	4.18	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=9.7nM for fVIIa binding assay in presence 0f 0.1% rabbit serum albumin
1062	12699744	2003	ALCDNPRIDRWYCQFVEG	Peptide 1b	18	Acetylation(Naphthalene acylsulfonamide)	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	30	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=24nM for fVIIa binding assay in presence 0f 0.1% rabbit serum albumin
1064	12699744	2003	ALCDNPRIDRWYCQFVEG	Peptide 5b	18	Acetylation (Naphthalene)	Amidation	Linear	L	None	Synthetic	Anticoagulant	Not reported	2mg/kg	34.8	Rabbit blood proteases	ELISA	Intravenouly administered into rabbit blood	in vivo	None	None	IC50=9.2nM for fVIIa binding assay in presence 0f 0.1% rabbit serum albumin
1066	15322125	2004	DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV	AÎ²(1 €“ 40)	40	Free	Free	Linear	L	None	Derivative of human A precursor protein APP770	Neurodegenerative	120 minutes	2x107 cpm of 125I-AÎ²42 peptide	2.4	Mouse plasma proteases	Radioactivity measured by scintillation counter	Intravenouly injected into male B6SJLF1/J mice and blood samples collected from tail vein to prepare plasma samples	in vivo	None	None	Neurodegeneration caused by oligomerization
1067	15322125	2004	DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA	AÎ²(1 €“ 42)	42	Free	Free	Linear	L	None	Derivative of human Aprecursor protein APP771	Neurodegenerative	121 minutes	2x107 cpm of 125I-AÎ²40 peptide	2.8	Mouse plasma proteases	Radioactivity measured by scintillation counter	Intravenouly injected into male B6SJLF1/J mice and blood samples collected from tail vein to prepare plasma samples	in vivo	None	None	Neurodegeneration caused by oligomerization
1074	15012592	2004	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Free	Linear	L	None	Glucagon	Antihyperglycaemic, insulinotropic	Not reported	25 nM/kg body weight	< 2	Adult obese diabetic (ob /ob ) mice blood protease	LC/MS equipped with a microbore C-18 HPLC	Intraperitoneally administered to adult obese diabetic (ob /ob ) mice	in vivo	None	None	IC50 = 0 ·37 nM of binding to a receptor
1078	2147696	1990	PINPRLDG	Control peptide	8	Free	Free	Linear	L	None	Synthetic peptide (scrambled amino acids of human protein S)	Anticoagulant	Not reported	Not mentioned	15	Rabbit blood proteases	Spectrofluorometry	Intravenously injected in male New Zealand white rabbits and blood samples withdrawn and plasma sample prepared	in vivo	None	None	No activity found
1079	2147696	1990	DGEQLADLIV	Control peptide	10	Free	Free	Linear	L	None	Synthetic peptide (amino acids 400-407 of human protein S)	Anticoagulant	Not reported	Not mentioned	15	Rabbit blood proteases	Spectrofluorometry	Intravenously injected in Male New Zealand white rabbits and blood samples withdrawn and plasma sample prepared	in vivo	None	None	No activity found
1080	11553691	2001	KKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQNIATVIVITLVML	APP-C59	59	Free	Free	Linear	L	None	Amyloid precursor protein derivative	Regulator of synapse formation	2 hours	Not mentioned	~5	Fetal calf serum proteases	Pulse chase experiment	BHK cell line	in vitro	None	None	Not reported
1081	11553691	2001	KKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQNIATVIVITLVML	APP-C59	59	Free	Free	Linear	L	None	Amyloid precursor protein derivative	Regulator of synapse formation	2 hours	Not mentioned	~5	Fetal calf serum proteases	Pulse chase experiment	Primary cultures of neurons from PS1 knockout mice's 14 day embryos	in vitro	None	None	Not reported
1086	12039708	2002	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Glucagon-like peptide-1 (GLP-1)	30	Free	Amidation	Linear	L	None	Derived from proteolytic cleavage of proglucagon	Insulinotropic	Not reported	Not mentioned	1.5 €“5	Plasma proteases	Radioimmunoassay	Rat plasma	in vivo	24199154	None	GLP-1 normalizes blood glucose levels
1087	12859428	2003	SPKMMHKSGCFGRRLDRIGSLSGLGCNVLRKY	BNP-32	32	Free	Free	Linear	L	None	Canine B-type natriuretic peptide	Diuretic, natriuretic, hypotensive and smooth muscle relaxant activities	Not reported	Not mentioned	1.57 ± 0.14	Dog plasma proteases	Radioimmunoassay	Injected intravenously into dogs	in vivo	None	None	44.7 ±0.3% RBC during BNP-32 infusion
1094	12578830	2003	LPFFD	iAÎ²5p-C1	5	Free	Amidation	Linear	L	None	Synthetic	Î²-sheet breaker peptides	Not reported	20 nmol	5	Human plasma proteases	RP-HPLC	Human plasma	in vitro	None	None	>80% inhibition of amyloid fibrillogenesis
1097	12578830	2003	LPFFD	iAÎ²5p	5	Free	Free	Linear	L	None	Synthetic	Î²-sheet breaker peptides	Not reported	20 nmol	15	Human plasma proteases	RP-HPLC	Human plasma	in vitro	None	None	100% inhibition of amyloid fibrillogenesis
1103	12578830	2003	LPFFD	iAÎ²5p-C1	5	Free	Amidation	Linear	L	None	Synthetic	Î²-sheet breaker peptides	Not reported	20 nmol	<1	Proteases in rat brain homogenate	RP-HPLC	Rat brain homogenate	in vitro	None	None	>80% inhibition of amyloid fibrillogenesis
1104	12578830	2003	Sar-LPFFD	iAÎ²5p-C2	5	Sar	Amidation	Linear	L	None	Synthetic	Î²-sheet breaker peptides	Not reported	20 nmol	41	Proteases in rat brain homogenate	RP-HPLC	Rat brain homogenate	in vitro	None	None	>80% inhibition of amyloid fibrillogenesis
1105	12578830	2003	(Nme)-Sar-LPFFD	iAÎ²5p-C3	5	(NMe)Sar	Amidation	Linear	L	None	Synthetic	Î²-sheet breaker peptides	Not reported	20 nmol	25	Proteases in rat brain homogenate	RP-HPLC	Rat brain homogenate	in vitro	None	None	>80% inhibition of amyloid fibrillogenesis
1113	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=3 µg/ml for M. Luteus ATCC 9341
1114	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=4 µg/ml for M. Luteus ATCC 9341
1115	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=7 µg/ml for M. Luteus ATCC 9341
1118	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=3 µg/ml for M. Luteus ATCC 9343
1120	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=6 µg/ml for M. Luteus ATCC 9345
1121	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=6.25 µg/ml for S. Aureus ATCC 6538
1122	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=9 µg/ml for S. Aureus ATCC 6538
1123	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=19 µg/ml for S. Aureus ATCC 6539
1126	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=10 µg/ml for S. Aureus ATCC 6542
1128	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=11 µg/ml for S. Aureus ATCC 6544
1129	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=1.56 µg/ml for S. Epidemidis ATCC 12228
1130	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=1.56 µg/ml for S. Epidemidis ATCC 12229
1131	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=3.12 µg/ml for S. Epidemidis ATCC 12228
1134	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=1.56 µg/ml for S. Epidemidis ATCC 12229
1136	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	Not reported
1137	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=25 µg/ml for MRSA SR 1550
1138	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=50 µg/ml for MRSA SR 1551
1139	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=100 µg/ml for MRSA SR 1552
1142	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=42 µg/ml for MRSA SR 1555
1144	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=16 µg/ml for MRSA SR 1557
1145	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for M. smegmatis ATCC 607
1146	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=25 µg/ml for M. smegmatis ATCC 607
1147	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=>100 µg/ml for M. smegmatis ATCC 607
1150	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for M. smegmatis ATCC 612
1152	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	Not reported
1153	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=10 µg/ml for E. coli ATCC 2592
1154	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for E. coli ATCC 2592
1155	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=23 µg/ml for E. coli ATCC 2592
1158	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=21 µg/ml for E. coli ATCC 2592
1160	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=11 µg/ml for E. coli ATCC 2592
1161	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=4 µg/ml for P. aeruginosa ATCC 9027
1162	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for P. aeruginosa ATCC 9027
1163	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=20 µg/ml for P. aeruginosa ATCC 9027
1166	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=10 µg/ml for P. aeruginosa ATCC 9027
1168	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=5 µg/ml for P. aeruginosa ATCC 9027
1169	10461747	1998	KKVVFKVKFK	KSL	10	Free	Free	Linear	L	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	6	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for C. albicans ATCC 36232
1170	10461747	1998	KÎ¨[CH2NH]KVVFKVKFK	KSL1	10	Free	Free	Linear	L	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	14	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=9 µg/ml for C. albicans ATCC 36232
1171	10461747	1998	KÎ¨[CH2NH]KVVFKVKFk	KSL2	10	Free	Free	Linear	Mix	Reduced amide bonds Î¨(CH2NH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=17 µg/ml for C. albicans ATCC 36232
1174	10461747	1998	KÎ¨[CH2OCONH]KVVFKVKFk	KSL5	10	Free	Free	Linear	Mix	Reduced carbamate Î¨(CH2OCONH)	Synthetic	Antimicrobial	Not reported	100 µg/mL	23	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=10 µg/ml for C. albicans ATCC 36232
1176	10461747	1998	kKVVFKVKFk	KSL7	10	Free	Free	Linear	Mix	None	Synthetic	Antimicrobial	Not reported	100 µg/mL	22	Mouse serum proteases	RP-HPLC	Mouse serum	in vitro	None	None	MIC=12.5 µg/ml for C. albicans ATCC 36232
1181	10773009	2000	TaLIDNNATEEILY	TX14(A)	14	Free	Free	Linear	Mix	None	Synthetic derivative of prosaposin	Neurotrophic factor	9 minutes	Not mentioned	4.2 ±0.3	Rat serum proteases	Radioactivity measured with a gamma counter	Injected in jugular vein of male Sprague-Dawley rats	in vivo	None	None	ED50=1.00 ±0.11ng/ml
1182	10773009	2000	TaIIDNNKTEKEISY	TX15-2	15	Free	Free	Linear	Mix	None	Synthetic derivative of prosaposin	Neurotrophic factor	9 minutes	Not mentioned	2.5 ±0.3	Rat serum proteases	Radioactivity measured by a gamma counter	Injected in jugular vein of male Sprague-Dawley rats	in vivo	None	None	ED50=1.00 ±0.09ng/ml
1185	11054637	2000	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	Human brain natriuretic peptide (hBNP)	32	Free	Free	Linear	L	None	Cardiac origin	Regulation of extracellular fluid and blood pressure homeostasis	Not mentioned	Not mentioned	12.7	Sheep blood proteases	HPLC	Infused in pulmonary artery of sheep	in vivo	2136732	None	Kd=8pM for receptor binding
1186	11054637	2000	MMRDSGCFGRRLDRIGSLSGLGCNVLRRY	Ovine Brain natriuretic peptide (oBNP)	29	Free	Free	Linear	L	None	Cardiac origin	Regulation of extracellular fluid and blood pressure homeostasis	Not mentioned	Not mentioned	2.6	Sheep blood proteases	HPLC	Infused in pulmonary artery of sheep	in vivo	None	None	Kd=16pM for receptor binding
1187	11054637	2000	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Atrial natriuretic peptide (ANP)	28	Free	Free	Linear	L	None	Cardiac origin	Regulation of extracellular fluid and blood pressure homeostasis	Not mentioned	Not mentioned	3	Sheep blood proteases	HPLC	Infused in pulmonary artery of sheep	in vivo	1826098	None	Kd=10pM for receptor binding
1188	11054637	2000	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	Human brain natriuretic peptide (hBNP)	32	Free	Free	Linear	L	None	Cardiac origin	Regulation of extracellular fluid and blood pressure homeostasis	Not mentioned	Not mentioned	3.1	Human blood proteases	HPLC	Injected in humans	in vivo	2136732	None	Kd=8pM for receptor binding
1189	11054637	2000	MMRDSGCFGRRLDRIGSLSGLGCNVLRRY	Ovine Brain natriuretic peptide (oBNP)	29	Free	Free	Linear	L	None	Cardiac origin	Regulation of extracellular fluid and blood pressure homeostasis	Not mentioned	Not mentioned	3.1	Human blood proteases	HPLC	Injected in humans	in vivo	None	None	Kd=16pM for receptor binding
1190	11054637	2000	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Atrial natriuretic peptide (ANP)	28	Free	Free	Linear	L	None	Cardiac origin	Regulation of extracellular fluid and blood pressure homeostasis	Not mentioned	Not mentioned	22	Human blood proteases	HPLC	Injected in humans	in vivo	1826098	None	Kd=10pM for receptor binding
1191	10670753	1999	SPTLAYAVP	Human thyrotropin-releasing hormone (TRH)-associated peptide 3 (hTAP-3)	9	Free	Free	Linear	L	None	Product of proteolysis of preproTRH	Serum hTAP-3 concentration was increased in patients with hyperthyroidism	15 min	Not mentioned	3.5	Human serum proteases	Radioimmunoassay	Human serum	in vivo	None	None	Not reported
1192	14980787	2004	LW	Leucyl-tryptophane	2	Free	Free	Linear	L	None	Synthetic	Angiotensin Coverting Enzyme inhibitor	Not mentioned	Not mentioned	7.4	Rat plasma proteases	Spectrophotometry	Rat plasma	in vitro	None	None	IC50=15 µM
1193	14980787	2004	SY	Seryl-tyrosine	2	Free	Free	Linear	L	None	Synthetic	Angiotensin Coverting Enzyme inhibitor	Not mentioned	Not mentioned	5.2	Rat plasma proteases	Spectrophotometry	Rat plasma	in vitro	None	None	IC50=41 µM
1194	14980787	2004	VY	Valyl-tyrosine	2	Free	Free	Linear	L	None	Synthetic	Angiotensin Coverting Enzyme inhibitor	Not mentioned	Not mentioned	15	Rat plasma proteases	Spectrophotometry	Rat plasma	in vitro	None	None	IC50=11 µM
1195	14980787	2004	LY	Leucyl-tyrosine	2	Free	Free	Linear	L	None	Synthetic	Angiotensin Coverting Enzyme inhibitor	Not mentioned	Not mentioned	4.3	Rat plasma proteases	Spectrophotometry	Rat plasma	in vitro	None	None	IC50=44 µM
1196	14980787	2004	AY	Alanyl-tyrosine	2	Free	Free	Linear	L	None	Synthetic	Angiotensin Coverting Enzyme inhibitor	Not mentioned	Not mentioned	9.4	Rat plasma proteases	Spectrophotometry	Rat plasma	in vitro	None	None	IC50=40 µM
1197	14980787	2004	YY	Tyrosyl-tyrosine	2	Free	Free	Linear	L	None	Synthetic	Angiotensin Coverting Enzyme inhibitor	Not mentioned	Not mentioned	16	Rat plasma proteases	Spectrophotometry	Rat plasma	in vitro	None	None	IC50=9 µM
1200	20382695	2010	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	hGLP-1(7-36)NH2	30	Free	Amidation	Linear	L	None	Glucagon like peptide-1	Regulate blood glucose	Not mentioned	Not mentioned	50	Rat plasma protease	RP-HPLC	Rat plasma	in vitro	14759771	None	EC50=0.08nM for stimulating cAMP production
1203	20418955	2010	HSQGTFTSDYSKYLDSRRAQDFVQWLMNT	Glucagon	29	Free	Free	Linear	L	None	Glucagon	Regulate blood glucose	Not mentioned	Not mentioned	<10	Not reported	Not mentioned	Not reported	in vivo	None	None	Elevated blood glucose levels for <2 hours
1210	21114599	2010	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	hGLP-1(7-36)NH2	30	Free	Amidation	Linear	L	None	Glucagon like peptide-1	Regulate blood glucose	Not mentioned	Not mentioned	0.9 ±0.1	Rat plasma proteases	HPLC	Rat plasma	in vitro	14759771	None	EC50=0.08 ±0.03nM for cAMP stimulation
1218	20587645	2010	VRRADRAAVPGGGGRG	HM-3	16	Free	Free	Linear	L	None	Derivative of endostatin	Anti-angiogenetic	Not mentioned	Not mentioned	10 to 27	SD rat plasma proteases	RP-HPLC	SD rat plasma	in vitro	http://pubs.rsc.org/En/content/articlepdf/2014/tb/	None	39.68% inhibitory effect on mouse tumors
1221	20593470	2010	GGFAEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS	Peptide 1	41	Free	Amidation	Linear	L	None	Synthetic dipeptide extended GLP-analogs	Regulate blood glucose	168 hours	Not mentioned	0.9	None	HPLC	PBS	in vitro	None	None	Not reported
1223	20593470	2010	GFFAEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS	Peptide 3	41	Free	Amidation	Linear	L	None	Synthetic dipeptide extended GLP-analogs	Regulate blood glucose	168 hours	Not mentioned	0.7	None	HPLC	PBS	in vitro	None	None	Not reported
1224	20593470	2010	GfFAEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS	Peptide 4	41	Free	Amidation	Linear	Mix	None	Synthetic dipeptide extended GLP-analogs	Regulate blood glucose	168 hours	Not mentioned	0.9	None	HPLC	PBS	in vitro	None	None	Not reported
1228	20593470	2010	G-PhG-FAEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS	Peptide 8	41	Free	Amidation	Linear	L	PhG=phenylglycine	Synthetic dipeptide extended GLP-analogs	Regulate blood glucose	168 hours	Not mentioned	0.5	None	HPLC	PBS	in vitro	None	None	Not reported
1229	20593470	2010	G-Aib-FAEGTFTSDVSSYLEGQAAKEFIAWLVKGRPSSGAPPPS	Peptide 9	41	Free	Amidation	Linear	L	Aib=Î±-aminoisobutyric acid	Synthetic dipeptide extended GLP-analogs	Regulate blood glucose	168 hours	Not mentioned	0.8	None	HPLC	PBS	in vitro	None	None	Not reported
1246	17292977	2007	HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS	AC3174	39	Free	Amidation	Linear	L	None	Analog of exendin-4	Regulates blood glucose	Not mentioned	Not mentioned	42 ±3.4	Rat plasma proteases	ELISA	Subcutaneously administion of 10 µg/kg dose to Sprague Dawley rats	in vivo	None	None	ED50=1.2 µg/kg for glucose lowering in db/db mice
1247	17292977	2007	HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS	AC3174	39	Free	Amidation	Linear	L	None	Analog of exendin-4	Regulates blood glucose	Not mentioned	Not mentioned	43 ±4.0	Rat plasma proteases	ELISA	Subcutaneously administion of 100 µg/kg dose to Sprague Dawley rats	in vivo	None	None	ED50=1.3 µg/kg for glucose lowering in C57BL/6 mice
1248	22286034	2012	FVPIFTYGELQRMQEKERNKGQ	Motilin	22	Free	Free	Linear	L	None	Motilin is a gastro-intestinal peptide hormone	Endocrine regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	3.3 ±1.0	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=8.9x10-11nM for GPR38 agonist activity
1249	22286034	2012	FVPIFTYGELQRSPEHQRVQQRKESKKPPAKLQPR	Motilin(1 €“12)ghrelin(6 €“28)	35	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	11.7 ±3.4	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=1.5x10-9nM for GPR38 agonist activity
1250	22286034	2012	FVPIFTYGELQREHQRVQQRKESKKPPAKLQPR	Motilin(1 €“12)ghrelin(8 €“28)	33	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	11.1 ±0.7	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=1.4x10-10nM for GPR38 agonist activity
1251	22286034	2012	FVPIFTYGELQRQRVQQRKESKKPPAKLQPR	Motilin(1 €“12)ghrelin(10 €“28)	31	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	8.9 ±0.5	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=1.6x10-10nM for GPR38 agonist activity
1252	22286034	2012	FVPIFTYGELQRVQQRKESKKPPAKLQPR	Motilin(1 €“12)ghrelin(12 €“28)	29	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	8.9 ±0.5	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=8.6x10-11nM for GPR38 agonist activity
1253	22286034	2012	FVPIFTYGELQRQRKESKKPPAKLQPR	Motilin(1 €“12)ghrelin(14 €“28)	27	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	8.0 ±0.7	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=6.1x10-10nM for GPR38 agonist activity
1254	22286034	2012	FVPIFTYGELQRKESKKPPAKLQPR	Motilin(1 €“12)ghrelin(16 €“28)	25	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	9.4 ±0.6	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=1.2x10-9nM for GPR38 agonist activity
1255	22286034	2012	FVPIFTYGELQRSKKPPAKLQPR	Motilin(1 €“12)ghrelin(18 €“28)	23	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	5.3 ±1.3	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=1.0x10-10nM for GPR38 agonist activity
1256	22286034	2012	FVPIFTYGELQRKKPPAKLQPR	Motilin(1 €“12)ghrelin(19 €“28)	22	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	6.0 ±0.3	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=1.1x10-10nM for GPR38 agonist activity
1257	22286034	2012	FVPIFTYGELQRVQQRKESKKPPAKLQ	Motilin(1 €“12)ghrelin(12 €“26)	27	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	10.4 ±0.1	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=8.5x10-9nM for GPR38 agonist activity
1258	22286034	2012	FVPIFTYGELQRVQQRKESKKPPAK	Motilin(1 €“12)ghrelin(12 €“24)	25	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	5.8 ±0.7	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=4.8x10-11nM for GPR38 agonist activity
1259	22286034	2012	FVPIFTYGELQRVQQRKESKKPP	Motilin(1 €“12)ghrelin(12 €“22)	23	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	6.3 ±0.5	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=2.4x10-11nM for GPR38 agonist activity
1260	22286034	2012	FVPIFTYGELQRVQQRKESKK	Motilin(1 €“12)ghrelin(12 €“20)	21	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	7.0 ±2.6	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=7.3x10-11nM for GPR38 agonist activity
1261	22286034	2012	FVPIFTYGELQRVQQRKES	Motilin(1 €“12)ghrelin(12 €“18)	19	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	3.1 ±0.7	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=8.8x10-10nM for GPR38 agonist activity
1262	22286034	2012	FVPIFTYGELQRVQQRK	Motilin(1 €“12)ghrelin(12 €“16)	17	Free	Free	Linear	L	None	Chimeric peptide of motilin and ghrelin	Regulator of gastro-intestinal motility	Not mentioned	10 nmol/kg	2.4 ±0.7	Rat plasma proteases	Radioimmunoassay	Intravenouly injected in Sprague-Dawley rats	in vivo	None	None	EC50=1.2x10-10nM for GPR38 agonist activity
1263	17107718	2006	HADGSFSDEMNTILDNLAARDFINWLIQTKITD	Glucagon-like peptide-2 (GLP-2)	33	Free	Free	Linear	L	None	Posttranslational processing of proglucagon	Stimulate intestinal growth	Not mentioned	Not mentioned	6.8 ±0.8	Pig plasma proteases	ELISA	Infused into blood of pigs	in vivo	None	None	Not reported
1264	17107718	2006	HADGSFSDEMNTILDNLAARDFINWLIQTKITD	Glucagon-like peptide-2 (GLP-2)	33	Free	Free	Linear	L	None	Posttranslational processing of proglucagon	Stimulate intestinal growth	Not mentioned	Not mentioned	9.9 ±0.8	Pig plasma proteases with valine-pyrrolidide (DPP-IV inhibitor)	ELISA	Infused into blood of pigs	in vivo	None	None	Not reported
1265	14499707	2003	YADAIFTNSYRKVLGQLSARKLLQDIMSR	GRF1-29	29	Free	Amidation	Linear	L	None	Growth hormone-releasing hormone (GRF) analogue	Stimulates release of growth hormone	Not mentioned	Not mentioned	10 to 20	Human plasma proteases	Not mentioned	Human plasma	in vivo	None	None	EC50=0.18nM
1644	22592200	2012	GSSFLSPEHQKAQQRKESKKPPAKLQPR	Ghrelin	28	Free	Free	Linear	L	Fatty acid ie n-octanoic acid present at serine at position 3, (125)I labelling	Ghrelin	GH-releasing and appetite stimulating peptide	Not reported	Not mentioned	15-18	Rat blood proteases	Radioactivity measured by scintillation counter	Administered into blood of rats	in vivo	15788704	None	Not reported
1647	17904340	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Lys34-biotin-GLP-1	30	Free	Amidation	Linear	L	Biotinylation at Lys at 34th position	Biotinylated derivative of GLP-1	Regulates blood glucose levels	Not reported	200 µg/ml	1.17 ±0.08	Proteases in rat intestinal fluid	RP-HPLC	Rat intestinal fluid	in vitro	None	None	Intraperitoneal hypoglycemic efficacy in db/db mice was 30 ±7.2%
1648	17904340	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Lys34-biotin-GLP-1	30	Free	Amidation	Linear	L	Biotinylation at Lys at 34th position	Biotinylated derivative of GLP-1	Regulates blood glucose levels	Not reported	200 µg/ml	1.34 ±0.07	Proteases in rat intestinal homogenate	RP-HPLC	Rat intestinal homogenate	in vitro	None	None	Intraperitoneal hypoglycemic efficacy in db/db mice was 30 ±7.2%
1649	17904340	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Lys26,34-biotin-GLP-1	30	Free	Amidation	Linear	L	Biotinylation at Lys at 34th and 26th position	Biotinylated derivative of GLP-1	Regulates blood glucose levels	Not reported	200 µg/ml	4.34 ±0.21	Proteases in rat intestinal fluid	RP-HPLC	Rat intestinal fluid	in vitro	None	None	Oral hypoglycemic efficacy in db/db mice was 25.3 ±6.6%
1650	17904340	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Lys26,34-biotin-GLP-1	30	Free	Amidation	Linear	L	Biotinylation at Lys at 34th and 26th position	Biotinylated derivative of GLP-1	Regulates blood glucose levels	Not reported	200 µg/ml	2.77 ±0.05	Proteases in rat intestinal homogenate	RP-HPLC	Rat intestinal homogenate	in vitro	None	None	Oral hypoglycemic efficacy in db/db mice was 25.3 ±6.6%
1653	17904340	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Lys34-biotin-GLP-1	30	Free	Amidation	Linear	L	Biotinylation at Lys at 34th position	Biotinylated derivative of GLP-1	Regulates blood glucose levels	Not reported	200 µg/ml	1.17 ±0.08	Proteases in rat intestinal fluid	RP-HPLC	Rat intestinal fluid	in vitro	None	None	EC50=3.82 ±0.32nM insulinotropic activity
1654	17904340	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Lys34-biotin-GLP-1	30	Free	Amidation	Linear	L	Biotinylation at Lys at 34th position	Biotinylated derivative of GLP-1	Regulates blood glucose levels	Not reported	200 µg/ml	1.34 ±0.07	Proteases in rat intestinal homogenate	RP-HPLC	Rat intestinal homogenate	in vitro	None	None	EC50=3.82 ±0.32nM insulinotropic activity
1655	17904340	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Lys26,34-biotin-GLP-1	30	Free	Amidation	Linear	L	Biotinylation at Lys at 34th and 26th position	Biotinylated derivative of GLP-1	Regulates blood glucose levels	Not reported	200 µg/ml	4.34 ±0.21	Proteases in rat intestinal fluid	RP-HPLC	Rat intestinal fluid	in vitro	None	None	EC50=3.85 ±0.21nM insulinotropic activity
1656	17904340	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Lys26,34-biotin-GLP-1	30	Free	Amidation	Linear	L	Biotinylation at Lys at 34th and 26th position	Biotinylated derivative of GLP-1	Regulates blood glucose levels	Not reported	200 µg/ml	2.77 ±0.05	Proteases in rat intestinal homogenate	RP-HPLC	Rat intestinal homogenate	in vitro	None	None	EC50=3.85 ±0.21nM insulinotropic activity
1657	20585128	2010	RRWRIVVIRVRR	Sub3	12	Free	Amidation	Linear	L	None	Derived from bovine peptide bactenecin	Antimicrobial	Not reported	150 µg/ml	~60	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=1 µg/ml for S. Aureus
1659	20585128	2010	aRRWRIVVIRVRRh	Sub3-D	14	Free	Amidation	Linear	Mix	None	Derivative of Sub4	Antimicrobial	Not reported	150 µg/ml	~60	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=1 µg/ml for S. Aureus
1661	20585128	2010	RRWRIVVIRVRR	Sub3	12	Free	Amidation	Linear	L	None	Derived from bovine peptide bactenecin	Antimicrobial	Not reported	150 µg/ml	~60	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=2 µg/ml for P. Aeruginosa
1663	20585128	2010	aRRWRIVVIRVRRh	Sub3-D	14	Free	Amidation	Linear	Mix	None	Derivative of Sub4	Antimicrobial	Not reported	150 µg/ml	~60	Proteases in mouse serum	RP-HPLC	25% aqueous mouse serum	in vitro	None	None	MIC=2 µg/ml for P. Aeruginosa
1676	9740616	1998	DRVYIHP	Ang-(1-7)	7	Free	Free	Linear	L	None	Angiotensinogen	Antihypertensive	30 min	10 µg	~60 ±1	Angiotensin-converting enzyme and lisinopril(inhibitor)	Radioimmunoassay and HPLC	Blood sample of normotensive Sprague-Dawley rat	in vivo	None	None	Not mentioned
1682	9806949	1998	NDWF-Dpr-L	MEN 11420	6	Glycosylation	Free	Cyclic	L	Dpr-2,3-Diaminopropionic acid	MEN 10627	Tachykinin NK2 receptor antagonist	Not reported	Not mentioned	44 ±3	Not mentioned	HPLC	Rat blood plasma	in vivo	None	None	Not mentioned
1683	9822665	1998	MLPGLALLLLAAWTARALEVPYPYDVPDYASNKGAIIGLMVGGVVIATVIVITLVVMLKKKQYEQKLISEEDL	H26-57C	74	Free	Free	Linear	L	None	Amyloid precursor protein	Not mentioned	40 minutes	Not mentioned	8	Î³-secretase	Pulse chase experiment	Human embryonic kidney cells	in vitro	None	None	Not mentioned
1684	9822665	1998	MLPGLALLLLAAWTARALEVPYPYDVPDYASNKGAIIGLMVGGVVIATVIVITLVVMLKKKQYEQKLISEEDL	H26-57C	74	Free	Free	Linear	L	None	Amyloid precursor protein	Not mentioned	40 minutes	Not mentioned	1	Î³-secretase (protease) Lactacystin(protease inhibitor)	Pulse chase experiment	Human embryonic kidney cells	in vitro	None	None	Not mentioned
1686	659633	1978	EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ	C-peptide	31	Free	Free	Linear	L	None	Proinsulin	Not mentioned	Not reported	0.75pmol/ml	33.5(mean)	Not mentioned	Single-dose injection technique	6 Normal human male blood plasma sample	in vivo	None	None	Not mentioned
1687	659633	1978	EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ	C-peptide	31	Free	Free	Linear	L	None	Proinsulin	Not mentioned	Not reported	0.9pmol/ml	42.5(mean)	Not mentioned	Single-dose injection technique	7 Diabetic human male blood plasma sample	in vivo	None	None	Not mentioned
1693	3343338	1987	GRGDS	Anti-cell adhesive pentapeptide	5	Free	Free	Linear	L	None	Central cell- binding domain of fibronectin	Anti metastatic	Not reported	6 µmol	8	Not mentioned	Radioactivity measured by scintillation counter	Blood sample of C57BL/6 mice	in vivo	None	None	Percentage inhibition of melanotic colony formation=90
1694	6086405	1984	Glp-PPGGSKVILF	Hydra head activator	11	Free	Free	Linear	L	Glp-Pyroglutamic acid	Hydra but also found in rat intestine,human and bovine hypothalamus	In hydra-stimulatory effects on growth and differentition,in human-in digestion control process	2 hour	20-100 fmol/ml	7	Not mentioned	Radioimmunoassay	Human plasma	in vitro	None	None	Not mentioned
1695	6117506	1981	AGCKNFFWKTFTSC	Somatostatin	14	Free	Free	Cyclic (C3-C14)	L	None	Ovine	Local transmitters either paracrine or neurocrine	5 days	100ng	1.0 ±0.2	Not mentioned	Radioimmunoassay	Blood plasma sample from five mongrel dogs	in vivo	4682131	None	Not mentioned
1696	7439398	1980	ECG	Glutathione	3	Free	Free	Linear	L	Gamma peptide linkage between the carboxyl group of the glutamate side-chain and the amine group of cysteine	Synthetic	Not mentioned	Not reported	25 ng/kg/min of Bradykinin and the rate doubled every 5 min until a final rate of 200 ng/kg/min was	1.6	Not mentioned	Kinetic assay	Human blood plasma sample	in vivo	None	None	Not mentioned
1699	8257427	1993	SDKP	AcSDKP	4	Acetylation	Free	Linear	L	None	Human bone marrow	Negative regulator of proliferation of haematopoietic stem cells	Not reported	10nM conc.	50	None	Radioactivity measured with liquid-scintillation counter	Human venous blood sample	in vitro	None	None	Not mentioned
1700	8257427	1993	SDKP	AcSDKP	4	Acetylation	Free	Linear	L	None	Human bone marrow	Negative regulator of proliferation of haematopoietic stem cells	Not reported	10-4M conc	10	Rabbit lung angiotensin I converting enzyme	Radioactivity measured with liquid-scintillation counter	Human venous blood sample	in vitro	None	None	Not mentioned
1701	8257427	1993	SDKP	AcSDKP	4	Acetylation	Free	Linear	L	None	Human bone marrow	Negative regulator of proliferation of haematopoietic stem cells	Not reported	10-7M conc.	25	Rabbit lung angiotensin I converting enzyme	Radioactivity measured with liquid-scintillation counter	Human venous blood sample	in vitro	None	None	Not mentioned
1705	10611139	1999	H(2me)wAWfK	Hexarelin	6	Free	Amidation	Linear	Mix	2me-2-methyl(tryptophan)	Analog of GHRP-6	Peptidyl growth hormone causing GH releasing effect.	Not reported	50 µg/kg	57.0 ±9.1	Blood proteases	LC-MS/MS	Intravenous injection,Blood sample from male Sprague-Dawley rats	in vivo	None	None	Not mentioned
1706	10647619	2000	GPRPP-Aba-GGaG	TP 850	10	Free	Free	Linear	Mix	4-aminobutyric acid (Aba)	Modified fibrin Î± chain N-terminal peptide	Blood Coagulation	Not reported	11 to 25 iu of oxytocin	4	Blood proteases	Radiolabelling and HPLC	Intravenous injection,Blood sample of rabbit	in vivo	None	None	Platelet aggregation inhibition, IC50=236Î¼m for dog and IC50=167Î¼m for rabbit.
1710	12119302	2002	ALCDNPRIDRWYCQFVEG	1a	18	Acetylation	Amidation	Linear	L	None	Synthetic	Coagulation factor VIIa peptide exosite inhibitor	Not reported	106 cpm/200Î¼l/mouse	7.6	Blood proteases	ESI-LC ˆ’MS/MS	Rabbit blood sample	in vivo	None	None	Not mentioned
1712	3799211	1986	YFQNCPrG	(I-deamino-8-D-arginine vasopressin)DDAVP	9	1-Î²-mercaptopropionic acid	Free	Linear	Mix	None	Modified form of Vasopressin	Antidiuretic agent	Not reported	45mg	55	Plasma proteases	Radioimmunoassay	Human blood sample	N.A.	None	US 5500413 A patent	Not mentioned
1713	10454085	1999	CYIQNCPLG	Oxytocin	9	Free	Amidation	Cyclic (C1-C6)	L	None	Hypothalamus	Involved in aiding mechanical clearance mechanism and improving fertility	60 minutes	90mg	6.78	Blood protease	Radioimmunoassay	Intravenous injection of oxytocin in normal mares	in vivo	None	None	Prostaglandin F metabolite(PGFM) release on administeration of 10 iu of oxytocin= 18.48 ±3.62 pg/ml
1714	10454085	1999	CYIQNCPLG	Oxytocin	9	Free	Amidation	Cyclic (C1-C6)	L	None	Hypothalamus	Involved in aiding mechanical clearance mechanism and improving fertility	60 minutes	180mg	6.78	Blood protease	Radioimmunoassay	Intravenous injection of oxytocin in normal mares	in vivo	None	None	Prostaglandin F metabolite(PGFM) release on administeration of 25 iu of oxytocin= 20.09 ±3.29 pg/ml
1715	10544005	1999	YIGSR	YIGSR	5	Free	Free	Linear	L	None	Core sequence located at the Î²-1 chain of laminin	Antimetastatic effect.	Not reported	Not mentioned	<1	Blood protease	Radioactivity measured with a gamma counter	Intravenous injection of labelled peptide in C57BL/6 mice	in vivo	None	None	At 1.5Î¼mol reduced number of colonies of B16-BL6 melanoma cells in lung by 50%
1716	10544005	1999	YIGSR	PEG5000 -YIGSR	5	Pegylated by addition of PEG5000	Free	Linear	L	None	Core sequence located at the Î²-1 chain of laminin	Antimetastatic effect.	Not reported	Not mentioned	2.2	Blood protease	Radioactivity measured with a gamma counter	Intravenous injection of labelled peptide in C57BL/6 mice	in vivo	None	None	At 0.15Î¼mol reduced number of colonies of B16-BL6 melanoma cells in lung by 70% approx.
1717	10544005	2000	YIGSR	PEG12,000 -YIGSR	5	Pegylated by addition of PEG12,000	Free	Linear	L	None	Core sequence located at the Î²-1 chain of laminin	Antimetastatic effect.	Not reported	Not mentioned	2.5	Blood protease	Radioactivity measured with a gamma counter	Intravenous injection of labelled peptide in C57BL/6 mice	in vivo	None	None	At 0.15Î¼mol reduced number of colonies of B16-BL6 melanoma cells in lung by 50%
1718	10544005	2001	YIGSR	PVP6,000 -YIGSR	5	Addition of Polyvinyl pyrrolidone(PVP6,000)	Free	Linear	L	None	Core sequence located at the Î²-1 chain of laminin	Antimetastatic effect.	Not reported	Not mentioned	14.5	Blood protease	Radioactivity measured with a gamma counter	Intravenous injection of labelled peptide in C57BL/6 mice	in vivo	None	None	At 0.015Î¼mol reduced number of colonies of B16-BL6 melanoma cells in lung by 70% approx.
1724	1697165	1990	SLRRSSGGRIDRIGAQSGLGCNSFRY	ANP'	26	Free	Free	Cyclic	L	None	Atrial natriuretic peptide	Natriuretic, diuretic and vasorelaxant	Not reported	0.17-0.25 MBq	1.04	Rat blood proteases	Radioimmunoassay and RP-HPLC	Rat blood plasma (infused into fumoral vein and right carotid artery)	in vivo	None	None	Not given
1725	1697165	1990	SLRRSSCFGGRIDRIGAQSGLGCNSFRY	Atrial natriuretic peptide (ANP)	28	Free	Free	Cyclic (C7-C23)	L	None	Atrial natriuretic peptide	Natriuretic, diuretic and vasorelaxant	Not reported	0.17-0.25 MBq	7.81 ± 0.38	Kallikrein and Endopeptidase 24.11 in presence of inhibitor Phosphoramidon	Radioimmunoassay and RP-HPLC	Rat blood plasma (infused into fumoral vein and right carotid artery)	in vivo	None	None	Not given
1726	1697165	1990	SLRRSSCFGGRIDRIGAQSGLGCNSFRY	Atrial natriuretic peptide (ANP)	28	Free	Free	Cyclic (C7-C23)	L	None	Atrial natriuretic peptide	Natriuretic, diuretic and vasorelaxant	Not reported	0.17-0.25 MBq	2.51 ±0.25	Kallikrein and Endopeptidase 24.11 in presence of inhibitor Aprotinin	Radioimmunoassay and RP-HPLC	Rat blood plasma (infused into fumoral vein and right carotid artery)	in vivo	None	None	Not given
1727	1697165	1990	SLRRSSCFGGRIDRIGAQSGLGCNSFRY	Atrial natriuretic peptide (ANP)	28	Free	Free	Cyclic (C7-C23)	L	None	Atrial natriuretic peptide	Natriuretic, diuretic and vasorelaxant	Not reported	0.17-0.25 MBq	15.2 ± 1.01	Kallikrein and Endopeptidase 24.11 in presence of inhibitors phosphoramidon and aprotinin both	Radioimmunoassay and RP-HPLC	Rat blood plasma (infused into fumoral vein and right carotid artery)	in vivo	None	None	Not given
1728	1939259	1991	APRLRFYSL	Î±-bag cell peptide Î±-BCP(1-9)	9	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	26	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1729	1939259	1991	APRLRFYSL	Î±-bag cell peptide Î±-BCP(1-9)	9	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-6 M conc. of peptide	35	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1731	1939259	1991	APRLRFYS	Î±-BCP(1-8)	8	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	27	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1732	1939259	1991	APRLRF	Î±-BCP(1-6)	6	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	11	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1733	1939259	1991	APRLR	Î±-BCP(1-5)	5	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	16	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1734	1939259	1991	RLRFYSL	Î±-BCP(3-9)	7	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	2.1	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1735	1939259	1991	RLRFYSL	Î±-BCP(3-9)	7	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-6 M conc. of peptide	2.7	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1736	1939259	1991	LRFYSL	Î±-BCP(4-9)	6	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	2.7	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1737	1939259	1991	RFYSL	Î±-BCP(5-9)	5	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	1.5	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1739	1939259	1991	YSL	Î±-BCP(7-9)	3	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	9.7	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1740	1939259	1991	RLRFYS	Î±-BCP(3-8)	6	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	1.5	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1741	1939259	1991	LRFYS	Î±-BCP(4-8)	5	Free	Free	Linear	L	None	Bag cells in the abdominal ganglion of the marine snail Aplysia	Neurotransmitter	Not reported	10-5 M conc. of peptide	1.5	Aplysia haemolymph proteases	HPLC	Heamolymph of Aplysia	in vitro	None	None	Not given
1743	15769092	2005	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Amidation	Linear	L	None	Proglucagon molecule	Glucose-dependent insulinotropic effect	Not reported	10 µg/kg	9.09	Rat blood proteases	ELISA	Rat blood plasma (Subcutaneous Injection)	in vivo	None	None	100nmol/L GLP-1 enhanced insulin release by 3.4 ±0.7-fold per islet in presence of 16.8mmol/L glucose
1744	15769092	2005	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	PEG2k-Lys-GLP-1	30	Free	Amidation	Linear	L	Pegylation at Lysine	Proglucagon molecule	Glucose-dependent insulinotropic effect	Not reported	10 µg/kg	21.67	Rat blood proteases	ELISA	Rat blood plasma (Subcutaneous Injection)	in vivo	None	None	100nmol/L GLP-1 stimulated insulin release of 306.6 ±72.8 pmol/L per islet in presence of 16.8mmol/L glucose
1745	15769092	2005	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Amidation	Linear	L	None	Proglucagon molecule	Glucose-dependent insulinotropic effect	Not reported	1 µg/kg	2.61	Rat blood proteases	ELISA	Rat blood plasma (Intravenous injection)	in vivo	None	None	100nmol/L GLP-1 enhanced insulin release by 3.4 ±0.7-fold per islet in presence of 16.8mmol/L glucose
1746	15769092	2005	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	PEG2k-Lys-GLP-1	30	Free	Amidation	Linear	L	Pegylation at Lysine	Proglucagon molecule	Glucose-dependent insulinotropic effect	Not reported	1 µg/kg	33.36	Rat blood proteases	ELISA	Rat blood plasma (Intravenous injection)	in vivo	None	None	100nmol/L GLP-1 stimulated insulin release of 306.6 ±72.8 pmol/L per islet in presence of 16.8mmol/L glucose
1747	15882144	2005	DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV	Ucn1 (urocortin 1)	40	Free	Free	Linear	L	None	Urocortin 1	Coronary and peripheral vasodilatation, stimulation of cardiac natriuretic peptide secretion,stress and inflammatory responses, suppression of appetite	Not reported	50 Î¼g	54 ±3	Human blood proteases	Not mentioned	Human blood plasma(Male patients with stable congestive heart failure) (Intravenous injection)	in vivo	None	None	Not given
1748	15882144	2005	DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV	Ucn1 (urocortin 1)	40	Free	Free	Linear	L	None	Urocortin 1	Coronary and peripheral vasodilatation, stimulation of cardiac natriuretic peptide secretion,stress and inflammatory responses, suppression of appetite	Not reported	50 Î¼g	52 ±3	Human blood proteases	Not mentioned	Human blood plasma (Normal humans) (Intravenous)	in vivo	None	None	Not given
1749	16099941	2005	ELRMSSSYPTGLADVKAGPAQTLIRPQDMKGASRSPEDSSPDAARIRV	proADM 45 €“92 (Adrenomedullin)	48	Free	Free	Linear	L	None	Synthetically synthesised proADM 45 €“92	Vasodilatory peptide	Not reported	0.29nmol/L	22	Human blood proteases	Sandwich immunoluminometric Assay	Human blood plasma	in vitro	None	None	Not given
1750	16476851	2014	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	BNP	32	Free	Free	Linear	L	None	B-type cardiac natriuretic peptides	Vasodilator	Not reported	Not mentioned	5.6 ±0.45	Human blood proteases	Not mentioned	Human plasma of patients with mild, stable heart failure	in vivo	None	None	Not given
1751	16476851	2014	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	BNP	32	Free	Free	Linear	L	None	B-type cardiac natriuretic peptides	Vasodilator	Not reported	Not mentioned	11 ±1.3	Human blood proteases	Not mentioned	Human plasma of patients with mild, stable heart failure given infusion of metoprolol	in vivo	None	None	Not given
1752	16476851	2014	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	BNP	32	Free	Free	Linear	L	None	B-type cardiac natriuretic peptides	Vasodilator	Not reported	Not mentioned	5.7 ±0.8	Human blood proteases	Not mentioned	Human plasma (Normal humans)	in vivo	None	None	Not given
1753	16476851	2014	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	BNP	32	Free	Free	Linear	L	None	B-type cardiac natriuretic peptides	Vasodilator	Not reported	Not mentioned	6.6 ±1.3	Human blood proteases	Not mentioned	Human plasma (Normal humans given infusion of metoprolol)	in vivo	None	None	Not given
1757	16472750	2006	TVPVDLASRQEEEEQSPDSTEQEPVTLPR	E2-PESTE304Q	29	Free	Free	Linear	L	None	E2 protein from papillomavirus	Gene transcription	Not reported	Not mentioned	24	Not mentioned	Pulse chase experiment	pMEP-E2 CV-1 cell lines	in vitro	15014086	None	Not mentioned
1759	16586064	2006	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP1	30	Free	Amidation	Linear	L	None	Synthetically synthesized Glucagon-like peptide-1	Insulinotropic	Not reported	Not mentioned	6 ±0.5	Rat liver proteases	RP-HPLC	Rat liver homogenate	in vitro	16505481	None	380 ([pmol/l] islet-1 h-1) insulin release at -7 (log [mol/l])
1760	16586064	2006	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP1	30	Free	Amidation	Linear	L	None	Synthetically synthesized Glucagon-like peptide-1	Insulinotropic	Not reported	Not mentioned	1 ±0.2	Rat kidney proteases	RP-HPLC	Rat kidney homogenate	in vitro	16505481	None	380 ([pmol/l] islet-1 h-1) insulin release at -7 (log [mol/l])
1763	16586064	2006	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	N-PEG/GLP-1	30	Free	Amidation	Linear	L	Pegylation at N terminus His7	Synthetically synthesized Glucagon-like peptide-1 analogues	Insulinotropic	Not reported	Not mentioned	23 ±7	Rat kidney proteases	RP-HPLC	Rat kidney homogenate	in vitro	16505481	None	290 ([pmol/l] islet-1 h-1) insulin release at -7 (log [mol/l])
1766	16586064	2006	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Lys-PEG/GLP-1	30	Free	Amidation	Linear	L	Pegylation on Lys34	Synthetically synthesized Glucagon-like peptide-1 analogues	Insulinotropic	Not reported	Not mentioned	28 ±1	Rat kidney proteases	RP-HPLC	Rat kidney homogenate	in vitro	16505481	None	150 ([pmol/l] islet-1 h-1) insulin release at -7 (log [mol/l])
1774	16990557	2006	CNGRCGGK	cNGR	8	Acetylation	Amidation	Cyclic	L	None	Synthetic peptide	Targets CD13/APN which is present on angiogenic vessels so used for molecular imaging	Not reported	0.75Î¼g/g	15.4 ±3.4	Mouse plasma proteases	Fluorometery	Mouse plasma of Murine myocardial infarction (MI) model	in vivo	None	None	Not given
1776	17374660	2007	IPP	IPP	3	Free	Free	Linear	L	None	Lactotripeptide	ACE(Angeotensin converting enzyme)-inhibiting peptide	Not reported	Not mentioned	~ 30	Pancreatic proteases	RP-HPLC	Human blood plasma (oral)	in vivo	None	None	Not given
1777	17479256	2007	SLRRSSCFGGRIDRIGAQSGCNSFRY	ANP	26	Free	Free	Linear	L	None	Synthetic peptide	Atrial natriuratic peptide	Not reported	0.05 Î¼g/kg per minute	2.4 ±0.7	Human blood proteases	Radioimmunoassay	Human blood plasma	in vitro	None	None	Not given
1778	17479256	2007	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	BNP	32	Free	Free	Linear	L	None	Synthetic peptide	Vasodilator	Not reported	0.01 Î¼g/kg per minute	12.1 ±3.0	Human blood proteases	Radioimmunoassay	Human blood plasma	in vitro	None	None	Not given
1791	17640899	2007	MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	T-651	36	Free	Free	Linear	L	None	Synthetic peptide	Antiviral peptide	Not reported	~1 €“2mg/kg	0.3	Monkey blood proteases	RP-HPLC and ESI-MS	Male cynomolgus monkey blood plasma (Intravenous)	in vivo	None	None	IC50=0.008 µg/ml against IIIB virus
1792	17640899	2007	MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	T-651	36	Free	Free	Linear	L	None	Synthetic peptide	Antiviral peptide	Not reported	~1 €“2mg/kg	0.3	Monkey blood proteases	RP-HPLC and ESI-MS	Male cynomolgus monkey blood plasma (Intravenous)	in vivo	None	None	IC50=0.033 µg/ml against 098 virus
1793	17640899	2007	MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	T-651	36	Free	Free	Linear	L	None	Synthetic peptide	Antiviral peptide	Not reported	~1 €“2mg/kg	0.3	Monkey blood proteases	RP-HPLC and ESI-MS	Male cynomolgus monkey blood plasma (Intravenous)	in vivo	None	None	IC50=0.060 µg/ml against 098-T20 virus
1794	17640899	2007	MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	T-651	36	Free	Free	Linear	L	None	Synthetic peptide	Antiviral peptide	Not reported	~1 €“2mg/kg	0.3	Monkey blood proteases	RP-HPLC and ESI-MS	Male cynomolgus monkey blood plasma (Intravenous)	in vivo	None	None	IC50=0.151 µg/ml against 098-T1249 virus virus
1795	17640899	2007	MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	T-651	36	Free	Free	Linear	L	None	Synthetic peptide	Antiviral peptide	Not reported	~1 €“2mg/kg	0.3	Monkey blood proteases	RP-HPLC and ESI-MS	Male cynomolgus monkey blood plasma (Intravenous)	in vivo	None	None	IC50=7.599 µg/ml against 098-T651 virus
1869	18085721	2007	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Free	Linear	L	None	Glucagon	Counter-regulatory hormone	Not reported	Not mentioned	~2	DPP-IV	ELISA	Mouse plasma	in vivo	None	None	Not given
1870	18307313	2007	R-X-R	CAP 1	2	Free	NHBn	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	1	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 83 µM for S.aureus
1871	18307313	2007	R-X-R	CAP 1	2	Free	NHBn	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	1	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 50 µM for Methicillin- resistant S.aureus
1872	18307313	2007	R-X-R	CAP 1	2	Free	NHBn	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	1	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 25 µM for Methicillin- resistant S.epidermis
1882	18307313	2007	R-X-R	CAP 5	2	Free	NHBn	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	1	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 11 µM for S.aureus
1883	18307313	2007	R-X-R	CAP 5	2	Free	NHBn	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	1	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 9 µM for Methicillin- resistant S.aureus
1884	18307313	2007	R-X-R	CAP 5	2	Free	NHBn	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	1	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 6 µM for Methicillin- resistant S.epidermis
1885	18307313	2007	R-X-R	CAP 6	2	Free	NHBn	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	1	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 14 µM for S.aureus
1886	18307313	2007	R-X-R	CAP 6	2	Free	NHBn	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	1	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 9 µM for Methicillin- resistant S.aureus
1887	18307313	2007	R-X-R	CAP 6	2	Free	NHBn	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	1	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 6 µM for Methicillin- resistant S.epidermis
1933	18307313	2007	R-X-R	CAP 19	2	Free	CH2CH2Ph	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 29 µM for S.aureus
1934	18307313	2007	R-X-R	CAP 19	2	Free	CH2CH2Ph	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 29 µM for Methicillin- resistant S.aureus
1935	18307313	2007	R-X-R	CAP 19	2	Free	CH2CH2Ph	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 20 µM for Methicillin- resistant S.epidermis
1936	18307313	2007	R-Bip-R	CAP 19	2	Acetylation	Y= structure given in paper	Linear	L	Bip	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 29 µM for S.aureus
1937	18307313	2007	R-Bip-R	CAP 19	2	Acetylation	Y= structure given in paper	Linear	L	Bip	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 29 µM for Methicillin- resistant S.aureus
1938	18307313	2007	R-Bip-R	CAP 19	2	Acetylation	Y= structure given in paper	Linear	L	Bip	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 20 µM for Methicillin- resistant S.epidermis
1939	18307313	2007	R-X-R	CAP 20	2	Free	CH2CH2Ph	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 50 µM for S.aureus
1940	18307313	2007	R-X-R	CAP 20	2	Free	CH2CH2Ph	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 50 µM for Methicillin- resistant S.aureus
1941	18307313	2007	R-X-R	CAP 20	2	Free	CH2CH2Ph	Linear	L	X= structure given in paper	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 10 µM for Methicillin- resistant S.epidermis
1942	18307313	2007	R-Bip-R	CAP 20	2	Acetylation	Y= structure given in paper	Linear	L	Bip	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 50 µM for S.aureus
1943	18307313	2007	R-Bip-R	CAP 20	2	Acetylation	Y= structure given in paper	Linear	L	Bip	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 50 µM for Methicillin- resistant S.aureus
1944	18307313	2007	R-Bip-R	CAP 20	2	Acetylation	Y= structure given in paper	Linear	L	Bip	Synthetic peptide	Antimicrobial	Not reported	1 mg/mL	0.6	Trypsin	RP-HPLC	Trypsin	in vitro	None	None	MIC= 10 µM for Methicillin- resistant S.epidermis
1962	18481852	2008	((POG)5 (PQGPGGPPG) (POG)5)3	3A	117	Acetylation	Amidation	Linear	L	None	Synthetic Collagen peptide	Structural component of connective tissues	Not reported	Not mentioned	580	Not mentioned	HPLC and MALDI-TOF	Not reported	in vitro	None	None	Not available
1963	18481852	2008	((POG)5 (PQGPGSPPG) (POG)5)3	3A'	117	Acetylation	Amidation	Linear	L	None	Synthetic Collagen peptide	Structural component of connective tissues	Not reported	Not mentioned	910	Not mentioned	HPLC and MALDI-TOF	Not reported	in vitro	None	None	Not available
1964	18481852	2008	((POG)5 (PVGAAGATG) (POG)5)3	3B	117	Acetylation	Amidation	Linear	L	None	Synthetic Collagen peptide	Structural component of connective tissues	Not reported	Not mentioned	345	Not mentioned	HPLC and MALDI-TOF	Not reported	in vitro	None	None	Not available
1965	18481852	2008	((POG)5 (PVGAASATG) (POG)5)3	3B'	117	Acetylation	Amidation	Linear	L	None	Synthetic Collagen peptide	Structural component of connective tissues	Not reported	Not mentioned	655	Not mentioned	HPLC and MALDI-TOF	Not reported	in vitro	None	None	Not available
1966	18481852	2008	(POG)5 (PQGPGGPPG) (POG)5 (PKG)5 (PQGPGGPPG) (PKG)5 (DOG)5 (PVGAAGATG) (DOG)5	A.A.B	117	Acetylation	Amidation	Linear	L	None	Synthetic Collagen peptide	Structural component of connective tissues	Not reported	Not mentioned	190	Not mentioned	HPLC and MALDI-TOF	Not reported	in vitro	None	None	Not available
1967	18481852	2008	(POG)5 (PQGPGGPPG) (POG)5 (PKG)5 (PQGPGGPPG) (PKG)5 (DOG)5 (PVGAAGATG) (DOG)6	A.A.B'	117	Acetylation	Amidation	Linear	L	None	Synthetic Collagen peptide	Structural component of connective tissues	Not reported	Not mentioned	300	Not mentioned	HPLC and MALDI-TOF	Not reported	in vitro	None	None	Not available
1968	18481852	2008	(POG)5 (PQGPGSPPG) (POG)5 (PKG)5 (PQGPGSPPG) (PKG)5 (PKG)5 (PQGPGSPPG) (PKG)5	A'.A'.B	117	Acetylation	Amidation	Linear	L	None	Synthetic Collagen peptide	Structural component of connective tissues	Not reported	Not mentioned	325	Not mentioned	HPLC and MALDI-TOF	Not reported	in vitro	None	None	Not available
1969	18481852	2008	(POG)5 (PQGPGSPPG) (POG)5 (PKG)5 (PQGPGSPPG) (PKG)5 (POG)5 (PVGAASATG) (POG)5	A'.A'.B'	117	Acetylation	Amidation	Linear	L	None	Synthetic Collagen peptide	Structural component of connective tissues	Not reported	Not mentioned	470	Not mentioned	HPLC and MALDI-TOF	Not reported	in vitro	None	None	Not available
1970	18553094	2008	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	BNP	32	Free	Free	Linear	L	None	Pro-Brain natriuretic peptide	Vasodilator	Not reported	Not mentioned	~22	Human blood proteases	ELISA	Human plasma	in vitro	None	None	Not available
1974	19223422	2009	SPRGDLAVLGHKY	HBP-1	13	Free	Free	Linear	L	None	Synthetic peptide	Not mentioned	Not reported	Not mentioned	55	Not mentioned	HPLC	Human serum	in vitro	None	None	IC50=38.9nM
1975	19403044	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1/Fc	30	Free	Amidation	Linear	L	None	Proglucagon molecule	Antidiabetic	Not reported	16nM	~20	Rabbit serum proteases	Luciferase reporter assay	Rabbit serum	ex vivo	None	None	Not available
1976	19403044	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Amidation	Linear	L	None	Proglucagon molecule	Antidiabetic	Not reported	0.4nM	<5	Rabbit serum proteases	Luciferase reporter assay	Rabbit serum	ex vivo	None	None	Not available
1977	19413309	2009	IRRADRAAVPGGGGRGD	HM3	17	Free	Free	Linear	L	None	RGD- modified endostatin derived peptide	Antitumor	Not reported	1mg/ml	27.66 ± 7.37	Rat blood proteases	RP-HPLC	Rat blood serum (Intravenous injection)	in vivo	None	None	Less active in the inhibition of angiogenesis in the chorioallantoic membrane of chick embryos
1979	19458086	2009	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP	28	Free	Free	Cyclic (C7-C23)	L	None	C terminus of atrial natriuretic peptide	Natriuretic, diuretic and vasorelaxant	Not reported	1 µM	2.6	Human kidney membrane proteases	Radioimmunoassay	Human kidney membranes	in vitro	None	None	IC50=2.4nM
1980	19458086	2009	SLRRSSCFGGRMDRIGAQSGLGCNSFRYRITAREDKQGWA	fsANP	40	Free	Free	Cyclic (C7-C23)	L	None	C terminus of atrial natriuretic peptide	Natriuretic, diuretic and vasorelaxant	Not reported	1 µM	4.5	Human kidney membrane proteases	Radioimmunoassay	Human kidney membranes	in vitro	None	None	IC50=3.2nM
1981	19531053	2009	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Amidation	Linear	L	None	Proglucagon molecule	Antidiabetic	Not reported	Not mentioned	20	DPP IV	ELISA	Mice (Subcutaneous injection)	in vivo	None	None	Not available
1983	19552923	2011	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Amidation	Linear	L	None	Proglucagon molecule	Insulinomimetic and insulinotropic	Not reported	27.9 ± 5.8 Î¼g/ml	1 to 2	Rabbit blood proteases	ELISA	Rabbit blood	in vivo	None	None	Not available
1984	19572636	2009	NISHTKEKKKGKAKKKRLTK	N-WASP181-200	20	Free	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	1 mg/mL	6.7	Not mentioned	HPLC	Rat renal brush border membrane suspension	in vitro	None	None	IC50=0.041 mM with gentamicin
1985	19572636	2009	NISHTKEKKKGKAKKKRLTK	PEG1k-N-W	20	Pegylation	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100 µg/mL	12.9	Not mentioned	HPLC	Rat renal brush border membrane suspension	in vitro	None	None	IC50=0.128 mM with gentamicin
1986	19572636	2009	NISHTKEKKKGKAKKKRLTK	N-WASP181-200	20	Free	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100 µg/mL	6.7	Not mentioned	HPLC	Rat renal brush border membrane suspension	in vitro	None	None	IC50=46.1 mg/kg with Arbekacin
1987	19572636	2009	NISHTKEKKKGKAKKKRLTK	N-WASP181-200	20	Free	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100mg/kg	2.7	Not mentioned	HPLC	Rat blood plasma (Intravenous)	in vivo	None	None	IC50=46.1 mg/kg with Arbekacin
1988	19572636	2009	NISHTKEKKKGKAKKKRLTK	PEG1k-N-W	20	Pegylation	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100mg/kg	4.6	Not mentioned	HPLC	Rat blood plasma (Intravenous)	in vivo	None	None	IC50=17.8 mg/kg with Arbekacin
1989	19572636	2009	NISHTKEKKKGKAKKKRLTK	PEG1k-N-W	20	Pegylation	Free	Linear	L	None	Synthetic peptide	Inhibits renal accumulation of aminoglycoside antibiotics	Not reported	100 µg/mL	12.9	Not mentioned	HPLC	Rat renal brush border membrane suspension	in vitro	None	None	IC50=17.8 mg/kg with Arbekacin
2001	11962721	2001	DIRCKDDEFTHLYTLIVRPDNTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDAAKPEDWDERAKIDDPTDSKPEDWDKPEHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNP	CTR-S domain	124	Free	Free	Linear	L	None	CTR (Calreticulin)	It binds to C1q, prevents the formation of C1 and so inhibits activation of the classical pathway	Not reported	Not mentioned	1.21 ± 0.34 in distribution phase	Serine Proteases	Radioactivity measured with a gamma counter	Rat plasma	in vivo	None	None	Biological activity =2 m Ci/nmol
2002	11962721	2001	DIRCKDDEFTHLYTLIVRPDNTYEVKIDNSQVESGSLEDDWDFLPPKKIKDPDAAKPEDWDERAKIDDPTDSKPEDWDKPEHIPDPDAKKPEDWDEEMDGEWEPPVIQNPEYKGEWKPRQIDNP	CTR-S domain	124	Free	Free	Linear	L	None	CTR (Calreticulin)	It binds to C1q, prevents the formation of C1 and so inhibits activation of the classical pathway	Not reported	Not mentioned	40.5 ± 2.7 in elimination phase	Serine Proteases	Radioactivity measured with a gamma counter	Rat plasma	in vivo	None	None	Biological activity =2 m Ci/nmol
2003	11976797	2002	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Amidation	Linear	L	Radiolabelling of GLP-1by [123I]	Proglucagon molecule	Antidiabetic	Not reported	10 MBq of the radiolabelled peptides	7.0 ±2.1 for É‘ phase	Rat blood proteases	Scintigraphy	NEDH Rats (rat tumour model)	in vivo	None	None	Not mentioned
2005	11976797	2002	HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exendin 3	39	Free	Free	Linear	L	Radiolabelling of exendin 3 at position 1 (histidine)	Heloderma horridum venom	GLP-1 agonist	Not reported	10 MBq of the radiolabelled peptides	13 ±3.2	Rat blood proteases	Scintigraphy	NEDH Rats (rat tumour model)	in vivo	None	None	Not mentioned
2007	15587934	2004	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	Human BNP	32	Free	Free	Linear	L	None	B-type cardiac natriuretic peptides	Vasodilator	Not reported	Not mentioned	3.1	Not mentioned	EIA	Mice plasma (Intravenous injection)	in vivo	None	None	EC50 =0.46 ± 1.1 nM
2011	17292492	2007	NPMYNAVSNADLMDFKNLLDHLEEKMPLEDEVVPPQVLSEPNEEAGAALSPLPEVPPWTGEVSPAQRDGGALGRGPWDSSDRSALLKSKLRALLTAPR	NT-ANP	98	Free	Free	Linear	L	None	ANP (A- type natriuretic peptide)	Natriuretic, diuretic and vasorelaxant	Not reported	650fmol/ml	1	Human blood proteases	Radioimmunoassay	Human blood	in vitro	None	None	Not mentioned
2012	18353507	2008	HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK	PACAP38	38	Free	Amidation	Linear	L	None	Synthetically synthesised pituitary adenylate cyclase-activating polypeptide	Therapeutic Neuropeptide for neurodegenerative diseases.	Not reported	10-5 M	23 ±6	DPP IV	RP-HPLC and MS-MALDI-TOF	DPP IV	in vitro	None	None	IC50 = 7.7 ±1.4 nM
2013	18353507	2008	HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK	PACAP38	38	Free	Amidation	Linear	L	None	Synthetically synthesised pituitary adenylate cyclase-activating polypeptide	Therapeutic Neuropeptide for neurodegenerative diseases.	Not reported	10-4 M	4.3 ±0.3	Human plasma proteases	RP-HPLC and MS-MALDI-TOF	Human plasma	in vitro	None	None	IC50 = 7.7 ±1.4 nM
2018	18353507	2008	HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK	[ÏˆCH2-NH21-22]PACAP38	38	Free	Amidation	Linear	L	[ÏˆCH2-NH21-22]	Synthetic analog of PACAP38	Therapeutic Neuropeptide for neurodegenerative diseases.	Not reported	10-4 M	18 ±2	Human plasma proteases	RP-HPLC and MS-MALDI-TOF	Human plasma	in vitro	None	None	IC50 = 59 ±17 nM
2019	18353507	2008	HSDGIFTDSYSRYRKQMAVAKYLAAVLGKRYKQRVKNK	[Ala20]PACAP38	38	Free	Amidation	Linear	L	None	Synthetic analog of PACAP38	Therapeutic Neuropeptide for neurodegenerative diseases.	Not reported	10-4 M	8.3 ±1.2	Human plasma proteases	RP-HPLC and MS-MALDI-TOF	Human plasma	in vitro	None	None	IC50 = 1.2 ±0.4 nM
2020	18353507	2008	HSDGIFTDSYSRYRKQMAVKAYLAAVLGKRYKQRVKNK	[Ala21]PACAP38	38	Free	Amidation	Linear	L	None	Synthetic analog of PACAP38	Therapeutic Neuropeptide for neurodegenerative diseases.	Not reported	10-4 M	6.6 ±0.5	Human plasma proteases	RP-HPLC and MS-MALDI-TOF	Human plasma	in vitro	None	None	IC50 = 2.0 ±0.5 nM
2024	18353507	2008	HSDGIFTDSYSRYAKQMAVAKYLAAVLGKRYKQRVKNK	Acetyl-[Ala14, Ala20]PACAP38-propylamide	38	Acetylation	Propylamidation	Linear	L	None	Synthetic analog of PACAP38	Therapeutic Neuropeptide for neurodegenerative diseases.	Not reported	10-4 M	15 ±2	Human plasma proteases	RP-HPLC and MS-MALDI-TOF	Human plasma	in vitro	None	None	IC50 = 5.3 ±1.7 nM
2026	18353507	2008	HSDGIFTDSYSRYRAQMAVAKYLAAVLGKRYKQRVKNK	Acetyl-[Ala15, Ala20]PACAP38-propylamide	38	Acetylation	Propylamidation	Linear	L	None	Synthetic analog of PACAP38	Therapeutic Neuropeptide for neurodegenerative diseases.	Not reported	10-4 M	25 ±2	Human plasma proteases	RP-HPLC and MS-MALDI-TOF	Human plasma	in vitro	None	None	IC50 = 1.8 ±0.7 nM
2027	18353507	2008	HSDGIFTDSYSRYRKQMAVKKYLAAVL	PACAP27	27	Free	Amidation	Linear	L	None	Synthetically synthesised pituitary adenylate cyclase-activating polypeptide	Therapeutic Neuropeptide for neurodegenerative diseases.	Not reported	10-5 M	39 ±4	DPP IV	RP-HPLC and MS-MALDI-TOF	DPP IV	in vitro	None	None	IC50 = 9.6 ±2.4 nM
2037	19041716	2009	AGCKNFFWKTFTSC	SST (Somatostatin)	14	Free	Free	Cyclic (C3-C14)	L	None	Somatostatin	Neurotransmitter	Not reported	1.8 mg/ml	7.6	Rat blood proteases	ELISA	Rat plasma (Intravenous injection)	in vivo	None	None	Not available
2038	19041716	2009	AGCKNFFWKTFTSC	LCNP/SST (Somatostatin adsorbed on Liquid crystalline nanoparticles for 10 min)	14	Free	Free	Cyclic (C3-C14)	L	None	Somatostatin adsorbed on Liquid crystalline nanoparticles	Neurotransmitter	Not reported	1.8 mg/ml	0.73 ±0.03	Rat blood proteases	ELISA	Rat plasma (Intravenous injection)	in vivo	None	None	Not available
2039	19041716	2009	AGCKNFFWKTFTSC	LCNP/SST (Somatostatin adsorbed on Liquid crystalline nanoparticles for 18 hours)	14	Free	Free	Cyclic (C3-C14)	L	None	Somatostatin adsorbed on Liquid crystalline nanoparticles	Neurotransmitter	Not reported	1.8 mg/ml	0.79 ±0.17	Rat blood proteases	ELISA	Rat plasma (Intravenous injection)	in vivo	None	None	Not available
2052	19836183	2010	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	BNP	32	Free	Free	Linear	L	None	Porcine brain	Vasodilator	Not reported	31.2ng/ml	3.1	Mouse plasma proteases	ELISA	Mouse plasma	in vivo	None	None	Not mentioned
2053	21329733	2011	L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-Lthreonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]	Octreotide acetate	8	Free	Free	Cyclic (C2-C7)	Mix	2-hydroxy-1-(hydroxymethyl)	Synthetic analog of Somatostatin	Used for treatment of acromegaly	Not reported	30Î¼g/100Î¼l	52.1	Mouse blood proteases	EIA	Mice blood serum (oral delivery in 0.5% Intravail)	in vivo	None	None	Not mentioned
2054	21329733	2011	L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-Lthreonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]	Octreotide acetate	8	Free	Free	Cyclic (C2-C7)	Mix	2-hydroxy-1-(hydroxymethyl)	Synthetic analog of Somatostatin	Used for treatment of acromegaly	Not reported	30Î¼g/100Î¼l	25.8	Mouse blood proteases	EIA	Mice blood serum (oral delivery in 1.5% Intravail)	in vivo	None	None	Not mentioned
2055	21329733	2011	L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-Lthreonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]	Octreotide acetate	8	Free	Free	Cyclic (C2-C7)	Mix	2-hydroxy-1-(hydroxymethyl)	Synthetic analog of Somatostatin	Used for treatment of acromegaly	Not reported	30Î¼g/100Î¼l	23.6	Mouse blood proteases	EIA	Mice blood serum (oral delivery in 3.0% Intravail)	in vivo	None	None	Not mentioned
2056	21329733	2011	L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-Lthreonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]	Octreotide acetate	8	Free	Free	Cyclic (C2-C7)	Mix	2-hydroxy-1-(hydroxymethyl)	Synthetic analog of Somatostatin	Used for treatment of acromegaly	Not reported	30Î¼g/100Î¼l	1.3	Mouse blood proteases	EIA	Mice blood serum (Subcutaneous injection)	in vivo	None	None	Not mentioned
2062	22934681	2012	YaG-MePhe-G	DAMGO	5	Free	Free	Linear	Mix	Methylation at phenylalanine	Synthetic peptide	Opioid peptide	Not reported	5.0 mg/kg	9.2 ± 2.1	Rat blood proteases	ESI-LC ˆ’MS/MS	Rat blood plasma (Intravenous)	in vivo	None	None	Not mentioned
2068	23836030	2013	MAPRGFSCLLLLTGEIDLPVKRRA	HNG ( substitution at position 14 (Gly for Ser) in HN seq)	24	Free	Free	Linear	L	None	Synthetic peptide	Cytoprotective	Not reported	16 fold higher than original concentration	~30	Mouse plasma proteases	ELISA	Mice plasma	in vitro	15655255	None	Not available
2069	24378440	2013	YRWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK	EGFR2R-lytic peptide	32	Free	Free	Linear	Mix	None	Synthetic peptide	Cytotoxic and antitumor	Not reported	Not mentioned	9.4 ± 1.5	Not mentioned	Not mentioned	Bovine serum	in vivo	None	None	Not available
2070	24378440	2013	YRWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK	EGFR2R-lytic peptide-gelatin complex	32	Free	Free	Linear	Mix	None	Synthetic peptide	Cytotoxic and antitumor	Not reported	Not mentioned	19.3 ±2.9	Not mentioned	Not mentioned	Bovine serum	in vivo	None	None	Not available
2071	3348603	1987	N-MeVal-EtPro-N-MeThr-Leu-MePro-AMHA-Pro-N-MeLeu- Gly	DihydromycoplanecinA (DHMP A)	10	alpha-hydroxybutyric acid	Free	Cyclic	L	N-MeVal; N-methylvaline, EtPro; Ethylproline, N-MeThr; N-methylthreonine MePro; Methylproline, AMHA; 2-amino-5-methylhexanoic acid, N-MeLeu; N-methylleucine	Active metabolite in urine of mice and dogs	Antibiotic	Not reported	10 mg/kg	0.5	Mouse blood proteases	Not mentioned	Mice serum (Intravenous)	in vivo	None	None	LD50>6000mg/kg administered orally to mice
2074	6117506	1981	HSDAVFTDNYTRLRKQMAVKKYLNSILN	Vasoactive Intestinal Peptide	28	Free	Amidation	Linear	L	None	Porcine vasoactive intestinal peptide	Vasoactive intestinal peptide	Not reported	103.7 ± 14.8 ml/kg	1.80 ± 0.1	Dog blood proteases	Radioimmunoassay	Dog plasma (Intravenous)	in vivo	None	None	150-220 µci/ µg
2075	8181115	2014	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Atrial natriuretic factor (ANF)	28	Free	Free	Linear	L	None	Cardiac atria	Peptide hormone	Not reported	Not mentioned	2.5	Human blood proteases	Radioimmunoassay	Human blood plasma	in vitro	None	None	Not available
2076	8406670	2014	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Atrial natriuretic factor (ANF)	28	Free	Free	Linear	L	None	Cardiac atrium in response to myocardial stretch	Peptide hormone	Not reported	Not mentioned	20 to 180	Human blood proteases	Radioimmunoassay	Human blood plasma	in vitro	None	None	Not available
2077	8910426	1996	KPTFRRLKWK	LL:36 €“45	10	Free	Free	Linear	L	None	Analogue of Limulus anti-lipopolysaccharide factor	Antibacterial	Not reported	2.5 µg/ml	17	Proteases present in fetal calf serum	RP-HPLC	Fetal calf serum	in vitro	None	None	No cell lysis done by this peptide
2080	9067297	1996	YGGFLRRl	E-2078 [N-methyl-Tyr1, N-methyl-Arg7-D-Leu8] Dyn A (1 €“8) ethylamide]	N.A.	Methylation	Ethylamide	Linear	Mix	Methylation on Arg7 and Tyr1	Dynorphin A (1 €“ 8) analog	Analgesic	Not reported	10 mg/kg	44	Monkey blood proteases	MALDI-MS	Rhesus monkey blood plasma (Intravenous)	in vivo	7479294	None	Not available
2081	20418955	2010	HSQGTFTSDYSKYLDSRRAQDFVQWLMNT	Glucagon	29	Free	Free	Linear	L	None	Pancreas	Plays a major regulatory role in controlling hypoglycemia	Not reported	Not mentioned	<10	Human blood proteases	ELISA	Human serum	in vitro	None	None	Not available
2083	N.A.	2004	AAGIGILTV	Melan-A27-35	9	Free	Free	Linear	L	None	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	5	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 4 nM
2084	N.A.	2004	EAAGIGILTV	Melan-A26-35	10	Free	Free	Linear	L	None	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	45	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.25 nM
2085	N.A.	2004	ELAGIGILTV	Melan-A26-35 A27L	10	Free	Free	Linear	L	None	Melan peptide which binds to HLA	Immunogenic and HLA binding peptides	N.A.	25 nM	40	Human serum proteases	HPLC-ESI-MS	Serum (human)	in vitro	None	EP1395276A1	EC50= 0.01 nM
2107	N.A.	2011	FVPIFTYGELQRMQEKERNKGQ	Motilin	22	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	3.26	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2108	N.A.	2011	FVPIFTYGELQRSPEHQRVQQRKESKKPPAKLQPR	Chimeric Motilin A	35	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	11.74	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2109	N.A.	2011	FVPIFTYGELQREHQRVQQQRKESKKPPAKLQPR	Chimeric Motilin B	34	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	11.14	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2110	N.A.	2011	FVPIFTYGELQRQRVQQRKESKKPPAKLQPR	Chimeric Motilin C	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	8.9 ±0.53	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2111	N.A.	2011	FVPIFTYGELQRQRVQQRKESKKPPAKLQPR	Chimeric Motilin D	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	8.9 ±0.50	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2112	N.A.	2011	FVPIFTYGELQRQRVQQRKESKKPPAKLQPR	Chimeric Motilin E	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	8.03	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2113	N.A.	2011	FVPIFTYGELQRQRVQQRKESKKPPAKLQPR	Chimeric Motilin F	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	9.37	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2114	N.A.	2011	FVPIFTYGELQRQRVQQRKESKKPPAKLQPR	Chimeric Motilin G	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	5.25	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2115	N.A.	2011	FVPIFTYGELQRVQQRKESKKPPAKLQ	Chimeric Motilin H	27	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	10.43	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2116	N.A.	2011	FVPIFTYGELQRQRVQQRKESKKPPAK	Chimeric Motilin I	27	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	5.76	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2117	N.A.	2011	FVPIFTYGELQRQRVQQRKESKKPP	Chimeric Motilin J	25	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	6.34	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2118	N.A.	2011	FVPIFTYGELQRQRVQQRKESKK	Chimeric Motilin K	23	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	6.14	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2119	N.A.	2011	FVPIFTYGELQRQRVQQRKES	Chimeric Motilin L	21	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	4.89	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2120	N.A.	2011	FVPIFTYGELQRQRVQQRK	Chimeric Motilin M	19	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	2.39	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2121	N.A.	2011	FVPIFTYGELQRVQQRKEKKPPAKLQPR	Chimeric Motilin N	28	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	9.12	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2122	N.A.	2011	FVPIFTYGELQRVQQRKEFKKPPAKLQPR	Chimeric Motilin O	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	7.73	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2123	N.A.	2011	FVPIFTYGELQRVQQRKETKKPPAKLQPR	Chimeric Motilin P	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	9.67	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2124	N.A.	2011	FVPIFTYGELQRVQQRKEPKKPPAKLQPR	Chimeric Motilin Q	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	9.65	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2125	N.A.	2011	FVPIFTYGELQRVQQRKELKKPPAKLQPR	Chimeric Motilin R	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	9.13	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2126	N.A.	2011	FVPIFTYGELQRVQQRKEAKKPPAKLQPR	Chimeric Motilin S	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	9.29	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2127	N.A.	2011	FVPIFTYGELORVQQRKNSKKPPAKLQPR	Chimeric Motilin T	29	Free	Free	Linear	L	Ornithine	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	5.47	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2128	N.A.	2011	FVPIFTYGELQRVQQRKQSKKPPAKLQPR	Chimeric Motilin U	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	5.66	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2129	N.A.	2011	FVPIFTYGELQRVQQRKDSKKPPAKLQPR	Chimeric Motilin V	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	10.14	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2130	N.A.	2011	FVPIFTYGELQRVQQRKKKPPAKLQPR	Chimeric Motilin W	27	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	5.39	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2131	N.A.	2011	FVPIFTYGELQRVQQKRDSRRPPAKLQPR	Chimeric Motilin X	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	7.89	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2132	N.A.	2011	FVPIFTYGELQRVQQKKSEKRPPAKLQPR	Chimeric Motilin Y	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	11.6	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2133	N.A.	2011	FVPIFTYGELQRVQQRKGESKKPPAKLQPR	Chimeric Motilin Z	30	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	10.53	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2134	N.A.	2011	FVPIFTYGELQRQQRKESGKKPPAKLQPR	Chimeric Motilin-i	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	11.55	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2135	N.A.	2011	FVPIFTYGELQRVQQRKGGESKKPPAKLQPR	Chimeric Motilin-ii	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	11.5	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2136	N.A.	2011	FVPIFTYGELQRVQQRKGGESKKPPAKLQPR	Chimeric Motilin-iii	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	10.65	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2137	N.A.	2011	FVPIFTYGELQRVQQRKESKKAKLQPR	Chimeric Motilin-iv	27	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	7.73	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2138	N.A.	2011	FVPIFTYGELQRVQQRKESKKAKLAALKA	Chimeric Motilin-v	29	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	8.94	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2139	N.A.	2011	FVPIFTYGELQRVQQRKESKKPPAKLAALKA	Chimeric Motilin-vi	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	9.94	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2140	N.A.	2011	FVPIFTYGELQRVQQRKESKKPPAELAALEA	Chimeric Motilin-vii	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	12.78	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2141	N.A.	2011	FVPIFTYGELQRVQQRKESKKPPAELAALKA	Chimeric Motilin-viii	31	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	11.56	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2142	N.A.	2011	FVPIFTYGELQRVQQRKESKKMITIR	Chimeric Motilin-ix	26	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	4.39	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2143	N.A.	2011	FVPIFTYGELQRVQQRKESKKPPMITIR	Chimeric Motilin-x	28	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	5.25	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2144	N.A.	2011	FVPIFTYGELQRKESKKPAKLAALKA	Chimeric Motilin-xi	26	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	10.29	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2145	N.A.	2011	FVPIFTYGELQRVQQKKAYSPDKERKPPALQPR	Chimeric Motilin-xii	33	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	13.03	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2146	N.A.	2011	FVPIFTYGELQRVQQKKAYSPDKERKPPAKLQPR	Chimeric Motilin-xiii	34	Free	Free	Linear	L	None	Motilin	Regulator of motility of digestive tract	N.A.	10 nM/ Kg	13.09	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2147	N.A.	2011	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP (Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	ANP (Atrial natriuretic peptide)	Regulator of sodium ions in heart	N.A.	0.1 mg/ Kg	2.88	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2148	N.A.	2011	CFGGRMDRIGAQSGLGCNSFRYVQQRKESKKPPAKLQPR	Chimeric ANP-A	39	Free	Free	Cyclic (C1-C17)	L	None	ANP (Atrial natriuretic peptide)	Regulator of sodium ions in heart	N.A.	0.1 mg/ Kg	24	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2149	N.A.	2011	VQQRKESKKPPAKLQPRCFGGRMDRIGAQSGLGCNSFRY	Chimeric ANP-B	39	Free	Free	Cyclic (C18-C34)	L	None	ANP (Atrial natriuretic peptide)	Regulator of sodium ions in heart	N.A.	0.1 mg/ Kg	40	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2150	N.A.	2011	RPQLKAPPKKSEKRQQVCFGGRMDRIGAQSGLGCNSFRY	Chimeric ANP-C	39	Free	Free	Cyclic (C18-C34)	L	None	ANP (Atrial natriuretic peptide)	Regulator of sodium ions in heart	N.A.	0.1 mg/ Kg	27.2	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2151	N.A.	2011	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP (Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	ANP (Atrial natriuretic peptide)	Regulator of sodium ions in heart	N.A.	0.1 mg/ Kg	11.2	Not mentioned	Competitive Radioimmunoassay	Rat plasma (Subcutaneous)	in vivo	None	EP2277890A1	Not mentioned
2152	N.A.	2011	CFGGRMDRIGAQSGLGCNSFRYVQQRKESKKPPAKLQPR	Chimeric ANP-A	39	Free	Free	Cyclic (C1-C17)	L	None	ANP (Atrial natriuretic peptide)	Regulator of sodium ions in heart	N.A.	0.1 mg/ Kg	46.4	Not mentioned	Competitive Radioimmunoassay	Rat plasma (Subcutaneous)	in vivo	None	EP2277890A1	Not mentioned
2153	N.A.	2011	VQQRKESKKPPAKLQPRCFGGRMDRIGAQSGLGCNSFRY	Chimeric ANP-B	39	Free	Free	Cyclic (C18-C34)	L	None	ANP (Atrial natriuretic peptide)	Regulator of sodium ions in heart	N.A.	0.1 mg/ Kg	57.3	Not mentioned	Competitive Radioimmunoassay	Rat plasma (Subcutaneous)	in vivo	None	EP2277890A1	Not mentioned
2154	N.A.	2011	RPQLKAPPKKSEKRQQVCFGGRMDRIGAQSGLGCNSFRY	Chimeric ANP-C	39	Free	Free	Cyclic (C18-C34)	L	None	ANP (Atrial natriuretic peptide)	Regulator of sodium ions in heart	N.A.	0.1 mg/ Kg	37.8	Not mentioned	Competitive Radioimmunoassay	Rat plasma (Subcutaneous)	in vivo	None	EP2277890A1	Not mentioned
2155	N.A.	2011	GLSKGCFGLKLDRIGSMSGLGC	CNP-22 (C-type natriuretic peptide)	22	Free	Free	Cyclic (C6-C22)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	0.1 mg/ Kg	7.8	Not mentioned	Competitive Radioimmunoassay	Rat plasma (Subcutaneous)	in vivo	None	EP2277890A1	Not mentioned
2156	N.A.	2011	RPQLKAPPKKSEKRQQVCFGLKLDRIGSMSGLGC	Chimeric CNP-A	34	Free	Free	Cyclic (C18-C34)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	0.1 mg/ Kg	20.7	Not mentioned	Competitive Radioimmunoassay	Rat plasma (Subcutaneous)	in vivo	None	EP2277890A1	Not mentioned
2157	N.A.	2011	CFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	Chimeric CNP-B	34	Free	Free	Cyclic (C1-C17)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	0.1 mg/ Kg	24	Not mentioned	Competitive Radioimmunoassay	Rat plasma (Subcutaneous)	in vivo	None	EP2277890A1	Not mentioned
2158	N.A.	2011	GLSKGCFGLKLDRIGSMSGLGC	CNP-22 (C-type natriuretic peptide)	22	Free	Free	Cyclic (C6-C22)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	0.1 mg/ Kg	2.93	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2159	N.A.	2011	RPQLKAPPKKSEKRQQVCFGLKLDRIGSMSGLGC	Chimeric CNP-A	34	Free	Free	Cyclic (C18-C34)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	0.1 mg/ Kg	21.7	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2161	N.A.	2011	CFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	Chimeric CNP-C	34	Free	Free	Cyclic (C1-C17)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	10 nm/ Kg	15.03	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2162	N.A.	2011	GLSKGFGLKLDRISMSGLGCVQQRKESKKPPAKLQPR	Chimeric CNP-D	37	Free	Free	Cyclic (C6-C22)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	10 nm/ Kg	20.3	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2163	N.A.	2011	CFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPRESKKPPAKLQPR	Chimeric CNP-E	46	Free	Free	Cyclic (C1-C17)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	10 nm/ Kg	18.4	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2164	N.A.	2011	RPQLKAPPKKSEKRQQVCFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	Chimeric CNP-F	51	Free	Free	Cyclic (C18-C34)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	10 nm/ Kg	17.38	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2165	N.A.	2011	VQQRKESKKPPAKLQPRCFGLKLDRIGSMSGLGC	Chimeric CNP-G	34	Free	Free	Cyclic (C18-C34)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	10 nm/ Kg	17.75	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2166	N.A.	2011	RPQLKAPPKKSEKRQQVCFGLKLDRIGSMSGLGC	Chimeric CNP-H	34	Free	Free	Cyclic (C18-C34)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	10 nm/ Kg	14.86	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2167	N.A.	2011	CFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	Chimeric CNP-I	34	Free	Amidation	Cyclic (C1-C17)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	10 nm/ Kg	14.5	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2168	N.A.	2011	GLSKGCFGLKLDRIGSMSGLGCVQQRKDSKKPPAKLQPR	Chimeric CNP-J	39	Free	Free	Cyclic (C6-C22)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	20 nm/ Kg	31.24	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2169	N.A.	2011	CFGLKLDRIGSMSGLGCAGSVDHKGKQRKWDHPKR	Chimeric CNP-K	35	Free	Free	Cyclic (C1-C17)	L	None	CNP-22 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	20 nm/ Kg	18.03	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2170	N.A.	2011	DLRVDTKSRAAWARLLQEHPNARKYKGANKKGLSKGGLSKGCFGLKLDRIGSMSGLGC	CNP-53 (C-type natriuretic peptide)	58	Free	Free	Cyclic (C42-C58)	L	None	CNP-58 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	10 nm/ Kg	15.72	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2171	N.A.	2011	GLSKGCFGLKLDRIGSMSGLGC	CNP-22 (C-type natriuretic peptide)	22	Free	Free	Cyclic (C6-C22)	L	None	CNP-58 (C-type natriuretic peptide)	Third member of natriuretic peptide family with multiple functions	N.A.	10 nm/ Kg	1.11	Rat blood proteases	Competitive Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP2277890A1	Not mentioned
2172	N.A.	2012	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exendin-4	39	Free	Amidation	Linear	L	None	Venom of Heloderma horridum	Insulinotropic peptide	N.A.	520 micro g/Kg	0.8	Not mentioned	EIA	Rat plasma (Subcutaneous)	in vivo	None	EP2423233A2	Blood glucose after 24 hour >25 mM
2175	N.A.	2006	HGDGSFSDEMNTILDNLAARDFINWLIQTLITD	Derivative of Glucagon Like Peptide-2 (GLP-2)	33	Free	Amidation	Linear	L	None	GLP-2	Intestine function modulator	N.A.	500 nM/ Kg	0.9	Not mentioned	Radioimmunoassay	Rat plasma (Subcutaneous)	in vivo	None	US7112567B2	Not mentioned
2180	N.A.	2009	YGGFLRRIRPK	Modified Dynorphin (1-13)	13	Free	Addition of hydroxyl group	Linear	L	None	Dynorphin peptide	Endogenous opioid found in CNS	N.A.	4 mg/ ml	10	Not mentioned	LC/MS	plasma	in vitro	None	US 20090175821Al	Not mentioned
2181	N.A.	2009	YGGFLRRIRPK	Modified Dynorphin(1-13)	13	Free	Amidation	Linear	L	None	Dynorphin peptide	Endogenous opioid found in CNS	N.A.	4 mg/ ml	30	Not mentioned	LC/MS	plasma	in vitro	None	US 20090175821Al	Not mentioned
2194	N.A.	2012	HVEGTFTSDVSSYLEGQAAKEFIAWLVKGRG	Val8-GLP-1-OH	31	Free	Addition of hydroxyl group	Linear	L	None	Glucagon like peptide1	Insulinotropic peptide	N.A.	10 micro g/ kg	0.05	Rat blood proteases	Radioimmunoassay	Rat plasma (Intravenous)	in vivo	None	EP1605897B1	EC50= 100% (as reference)
2197	N.A.	2012	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exendin-4	39	Free	Free	Linear	L	None	Venom of Heloderma horridum	Insulinotropic peptide	N.A.	Not mentioned	0.7	Not mentioned	Not mentioned	blood	Not mentioned	None	EP2114438B1	EC50= 100% (as reference)
2217	15369394	2004	CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	Interferon Î±2 (IFNÎ±2)	146	Free	Free	Cyclic(C1-C98, C29-138)	L	Glycosylation at Thr-105	IFNÎ±2	Antiviral and antiproliferative	0-25 hours	10 Î¼g/rat in 0.2 mL of PBS	~1	Rat blood proteases	BIAcore binding assay	Intravenously administered to wistar rats	in vivo	http://www.uniprot.org/uniprot/P01563	None	Following administration of IFNÎ±2 (100 Î¼g/rat), the circulating antiviral activity declined with a t1/2 value of ˆ¼1 h, reaching a level lower than 20 pM IFNÎ±2, 12 h after administration.
2218	730072	2001	HSDAVFTDNYTRLRKQMAVKKYLNSILN	Vasoactive intestinal peptide	28	Free	Free	Linear	L	None	Porcine VIP	Antiinflammatory and vasodilatory	0 5, 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, and 30 minutes	0.6, 1.3, and 3.3 pmol/kg/min infused over 30 minutes	~1	Human blood proteases	Radioimmunoassay	Intravenous infusion to humans	in vivo	http://www.uniprot.org/uniprot/P01282	None	Infusion of the highest dose of VIP, plasma concentrations of glucose were significantly raised from a basal level of 5.05 ± 0.29 to 5.61 ± 0.27mmol/l. Plasma levels of free fatty acids were increased from 0.40 ± 0.06 to 0.96 ± 0.09 mmol/l
2219	12954066	2003	ELYENKPRRPYIL	Neurotensin	13	Free	Free	Linear	L	None	Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	5.9 ±0.2	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2235	12954066	2003	ELYENKP-10-RPYIL	KK16	13	Free	Free	Linear	L	COOH-CH(NH2)-CH-CH-CH(NH)-C=NR(H2N) at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	14.2 ±0.3	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2236	12954066	2003	ELYENKP-11-RPYIL	KK17	13	Free	Free	Linear	L	COOH-CH(H2N)CH-CH-CH(HN)-CH(imidazole) at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	31.5 ±0.6	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2237	12954066	2003	ELYENKP-12-RPYIL	KK18	13	Free	Free	Linear	L	COOH-CH(NH2)CH-CH-CH(N-CH-CH-NH-C=NH-CH) at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	15.9 ±1.6	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2238	12954066	2003	ELYENKP-13-RPYIL	KK19	13	Free	Free	Linear	L	COOH-CH(NH2)CH-CH-CH(N-CH-CH-NH-C=NH-CH) at 8th arginine position	Derivative of Bovine hypothalamus	Induction of cyclic nucleotide production, intracellular calcium influx, Na+K+-ATPase activation, muscle relaxation, decreased food consumption, catalepsy,decreased locomotion, hypothermia, antinociception, antipsychosis	Not mentioned	1.07mM	16.5 ±0.6	Rat serum protease	MALDI-TOF-MS	Rat serum	in vitro	None	None	Biological effect of peptide is evaluated by binding to its receptor i.e hNTR. Cell membranes are tansfected with either hNTR-1 or hNTR-2 were incubated with 0.4 nM 125I-Tyr (3)-NT (2000 Ci/mmol) and various concentrations of unlabeled NT, or NT analogue.Total binding 8500 and nonspecific binding 2500 for 70 Î¼g of protein per formed on whole cells.
2239	14640680	2003	ICLKKWPWWPWRRCK	cycloCP-11	15	Free	Amidation	Cyclic (C2-C14)	L	None	Analogue of indolicidin	Antibacterial	0,5,10,20,40,60 minutes	50 µg/mL peptide and 0.2 µg/mL trypsin in 100 mM Tris buffer	18	Trypsin	HPLC and MALDI-TOF	cycloCP-11 in presence of trypsin	in vitro	None	None	MIC for E.coli=16 µg/ml
2240	14640680	2003	ILKKWPWWPWRRK	CP11	13	Free	Amidation	Linear	L	None	Indolicidin analogue	Antibacterial	0,5,10,20,40,60 minutes	50 µg/mL peptide and 0.2 µg/mL trypsin in 100 mM Tris buffer	4	Trypsin	HPLC and MALDI-TOF	CP-11 in presence of trypsin	in vitro	None	None	MIC for E.coli=8 µg/ml
2241	12220890	2002	CKAFSNSYPYDVPDYASL	Influenza hemagglutinin [(HA) 91 €“108] derivative	18	Acetylation	Amidation	Linear	L	None	Derivative of B-cell epitope hemagglutinin (HA) 91 €“108 from influenza	Modulate immune response	Not mentioned	1 mg/ml	2	Mice lung homogenate proteases	RP-HPLC	BALB/c mice lung homogenate	in vitro	None	None	IFN-y production in presence of peptide was measured. Splenocyte was collected after 12 days of immunization, cultured in presence / absence of Inactivated virus(500 HAU/well). Level of IFN-y in presence of virus is ~2500 pg/ml as measured by ELISA.
2243	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	21.2 ±1.1	Human blood plasma proteases	TLC	Human plasma mixed with drug Thioridazine	in vitro	None	None	Not mentioned
2244	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	19.6 ±1.0	Human blood plasma proteases	TLC	Human plasma mixed with drug Fluphenazine	in vitro	None	None	Not mentioned
2245	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	17.2 ±0.9	Human blood plasma proteases	TLC	Human plasma mixed with drug AS-1397	in vitro	None	None	Not mentioned
2246	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	17.1 ±1.0	Human blood plasma proteases	TLC	Human plasma mixed with drug Promethazine	in vitro	None	None	Not mentioned
2247	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	17.1 ±1.1	Human blood plasma proteases	TLC	Human plasma mixed with drug Chlorpromazine	in vitro	None	None	Not mentioned
2248	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	12.5 ±0.1	Human blood plasma proteases	TLC	Human plasma mixed with drug Methotrimeprazine	in vitro	None	None	Not mentioned
2249	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	12.1 ±0.2	Human blood plasma proteases	TLC	Human plasma mixed with drug Methotrimeprazine	in vitro	None	None	Not mentioned
2250	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	11.9 ±0.2	Human blood plasma proteases	TLC	Human plasma mixed with drug Prochlorperazine	in vitro	None	None	Not mentioned
2251	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	11.4 ±0.3	Human blood plasma proteases	TLC	Human plasma mixed with drug Trifluoperazine	in vitro	None	None	Not mentioned
2252	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	12.4 ±0.3	Human blood plasma proteases	TLC	Human plasma mixed with drug Molindone	in vitro	None	None	Not mentioned
2253	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	12.4 ±0.4	Human blood plasma proteases	TLC	Human plasma mixed with drug Loxapine	in vitro	None	None	Not mentioned
2254	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	12.1 ±0.1	Human blood plasma proteases	TLC	Human plasma mixed with drug Clozapine	in vitro	None	None	Not mentioned
2255	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	11.9 ±0.3	Human blood plasma proteases	TLC	Human plasma mixed with drug Haloperidol	in vitro	None	None	Not mentioned
2256	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	11.9 ±0.4	Human blood plasma proteases	TLC	Human plasma mixed with drug Sulpiride	in vitro	None	None	Not mentioned
2257	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	11.3 ±0.4	Human blood plasma proteases	TLC	Human plasma mixed with drug Thiothixene	in vitro	None	None	Not mentioned
2258	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	31.3 ±0.7	Human blood plasma proteases	TLC	Human plasma mixed with Bacitracin	in vitro	None	None	Not mentioned
2259	12444298	2001	YGGFL	Leucine Enkephalin	5	Free	Free	Linear	L	None	Human brain	Regulation of various physiological and behavioral processes	2, 4, 6, 10, 30, 60 and 90, 180 minutes	10 €“8 M	41.1 ±0.9	Human blood plasma proteases	TLC	Human plasma mixed with Bacitracin	in vitro	None	None	Not mentioned
2260	385880	1979	GG	5-Fluoro-4-(N-succinamoylglycylglycine benzyl ester)-2(1H)-pyrimidone (compound 11)	2	5-Fluoro-4-N-succinamoyl	Benzyl ester-2(1H)-pyrimidone	Linear	L	Conjugation of peptide C terminal carboxyl group with amino group of 5 Fluorocytosine	Synthetic	Anticandidal	Not given	Not mentioned	0.3	Sample cells proteases	Spectrophotometry	Sample cells	in vivo	None	None	5-FC peptide were tested for antifungal activity agaainst S. cerevisiae, Candida albicans and candida. The MIC was 0.62,0.62 and 20 µg/mL respectively.
2265	641324	1983	HADGVFTSDFSRLLGQLSAKKYLESLI	Peptide histidine isoleucine	27	Free	Free	Linear	L	None	Porcine intestine	Neurotransmitter	1, 2, 3, 4, 5, 10 and 15 min.	4.7 pmoles/kg	3.1 ±0.5	Human plasma proteases	Radioimmunoassay	Intravenous administration to human plasma	in vivo	None	None	PHI effect on secretion on gastrointestinal hormone and monitor its effect on gastric secretion of pepsin. PHI infused at 4.7pmoles/kg in human and gastric juice were aspirated by suction, gastric secretion was improved to be in case of PIH.
2267	3922013	1984	ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF	Calcitonin gene related peptide	37	Free	Free	Linear	L	None	Human non-thyroidal tissue	Vasoactive neuropeptide	Not given	0.32 pmol/kg	6.9 ±0.9 (first phase)	Human blood plasma proteases	Radioimmunoassay	Intravenous injection into human	in vivo	http://physrev.physiology.org/content/94/4/1099	None	CGRP infusion reduces gastric acid output as measured by plasma concentration of CGRP against time data obtained during infusion.
2268	3922013	1984	ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF	Calcitonin gene related peptide	37	Free	Free	Linear	L	None	Human non-thyroidal tissue	Vasoactive neuropeptide	Not given	2.56 pmol/kg	26.4 ±4.7 (first phase)	Human blood plasma proteases	Radioimmunoassay	Intravenous injection into human	in vivo	http://physrev.physiology.org/content/94/4/1099	None	CGRP infusion reduces gastric acid output as measured by plasma concentration of CGRP against time data obtained during infusion.
2269	4034413	1985	YGGFL	Leucine enkephalin	5	Free	Free	Linear	L	None	Human brain	Analgesic	20 minutes	0.9 nM	14.7	Human serum protease	HPLC	Human serum	in vitro	None	None	Not reported
2275	4070016	1985	GGFMTSEKSQTPLVTL	DTÎ³E( Des-Tyr1-Î³-Endorphin) (Î²-endorphin-(2-17))	16	Free	Free	Linear	L	None	CNS and piyuitary gland of Humans	Neuropeptide, non-opioid y-type endorphins	Not given	3.1-7.1 µg	5.5 (elimination phase)	Rat blood proteases	RP-HPLC	Male wistar Rats (intravenously)	in vivo	None	None	Not reported
2277	6121002	1982	PLG	PLG peptide	3	Free	Free	Linear	L	Tritium labeling at Proline	Hypothalamus and pineal gland	Interact with dopaminergic system and improve patients of parkinson disease	Not given	2 - 2.5 Î¼g	20 (t1/2 elimination)	Rat plasma proteases	Radioimmunoassay	Subcutaneously injected to rat plasma	in vivo	None	None	Radiolabelled peptide was administered in rats and blood plasma was taken and analysed by HPLC. Brain level of radioactivity increased with time.
2278	6127205	1982	AGCKNFFWKTFTSC	Somatostatin 14	14	Free	Free	Cyclic (C3-C14)	L	None	Ovine hypothalamus	Regulates the endocrine system and affects neurotransmission and cell proliferation	30-45 minute	10 µg	1.7 ±0.2	Dog blood proteases	SS Radioimmunoassay assay	Intravenous infusion in Dog plasma	in vivo	http://www.anaspec.com/products/product.asp?id=574	None	Radiolabelled peptide was administered in rats and blood plasma was taken and analysed by HPLC. Brain level of radioactivity increased with time.
2279	6127205	1982	SANSNPAMAPRERKAGCKNFFWKTFTSC	Somatostatin 28	28	Free	Free	Cyclic (C17-C28)	L	None	Ovine hypothalamus	Regulates the endocrine system and affects neurotransmission and cell proliferation	30-45 minute	20 µg	2.8 ±0.3	Dog blood plasma	SS Radioimmunoassay assay	Intravenous infusion in Dog plasma	in vivo	http://www.anaspec.com/products/product.asp?id=574	None	When 50ng of SS14 was injected there is 85.1% decreasedportal venous blood flow was observed as compared to percentage of basal flow.
2280	6128770	1982	AGCKNFFWKTFTSC	Somatostatin 14	14	Free	Free	Cyclic (C3-C14)	L	None	Ovine hypothalamus	Regulates the endocrine system and affects neurotransmission and cell proliferation	1 hour	1.7nmol	2.4	cat blood protease	Not mentioned	Intravenous infusion to cat plasma	in vivo	http://www.anaspec.com/products/product.asp?id=574	None	When 100ng of SS28 is injected there is 73% decreased portal venous blood flow as compared to basal blood flow.
2281	6128770	1982	SANSNPAMAPRERKAGCKNFFWKTFTSC	Somatostatin 28	28	Free	Free	Cyclic (C17-C28)	L	None	Ovine hypothalamus	Regulates the endocrine system and affects neurotransmission and cell proliferation	1 hour	4.8nmol	6.1	cat blood protease	Not mentioned	Intravenous infusion to cat plasma	in vivo	http://www.anaspec.com/products/product.asp?id=574	None	Gastrin exocrine inhibitor assay were performed. 80 % gastric inhibition observed at 7ug/kg of peptide.
2282	6239307	1984	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Atrial Natriuretic peptide	28	Free	Free	Cyclic (C7-C23)	L	None	Human heart	Depressor and natriuretic activity	2 hours	1nmol	30	Rat blood proteases	RP-HPLC	Intravenous administered to Rat	in vivo	None	None	Gastric exocrine inhibitory assay was performed. 80 % inhibition observed at 8ug/kg body weight of peptide
2283	6239307	1984	SSCFGGRIDRIGAQSGLGCNSFRY	Atriopeptin 3	24	Free	Free	Cyclic (C3-C19)	L	I125 radiolabeled	Human heart	Depressor and natriuretic activity	2 hours	1nmol	2.5	Rat blood proteases	RP-HPLC	Intravenous administered to Rat	in vivo	None	None	Time course depression is seen and Atropeptin 3 shows 2 time more depressor activity as compared to control alpha heart ANP.
2284	6291099	1982	WMDF	Cholecystokinin-4 (CCK4)	4	Free	Amidation	Linear	L	None	Deudenum of pig	Intestinal hormone	Not given	50 µM	13	Human plasma proteases	HPLC	Human plasma	in vitro	None	None	Not reported
2285	6291099	1982	WMDF	Cholecystokinin-4 (CCK4)	4	Free	Amidation	Linear	L	None	Deudenum of pig	Intestinal hormone	Not given	50 µM	<1	Rat plasma protease	HPLC	Rat Plasma	in vitro	None	None	Not reported
2286	6291099	1982	YMGWMDF	CCK7 (Cholecystokinin-7)	7	Free	Amidation	Linear	L	None	Deudenum of pig	Intestinal hormone	Not given	50 µM	2.5	Human blood proteases	HPLC	Human plasma	in vitro	None	None	Not reported
2287	6291099	1982	DYMGWMDF	CCK8 (Cholecystokinin-8)	8	Free	Amidation	Linear	L	None	Deudenum of pig	Intestinal hormone	Not given	50 µM	18	Human plasma proteases	HPLC	Human plasma	in vitro	None	None	Not reported
2288	6291099	1982	DYMGWMDF	CCK8 (Cholecystokinin-8)	8	Free	Amidation	Linear	L	Sulphation of Tyrosine residue at position 2	Derivative of natural cholecytokinin	Intestinal hormone	Not given	50 µM	50	Human plasma proteases	HPLC	Human plasma	in vitro	None	None	Not reported
2289	6291099	1982	DYMGWMDF	CCK8 (Cholecystokinin-8)	8	Free	Amidation	Linear	L	None	Deudenum of pig	Intestinal hormone	Not given	50 µM	5	Rat plasma protease	HPLC	Rat Plasma	in vitro	None	None	Not reported
2290	6291099	1982	DYMGWMDF	CCK8 (Cholecystokinin-8)	8	Free	Amidation	Linear	L	Sulphation of Tyrosine residue at position 2	Derivative of natural cholecytokinin	Intestinal hormone	Not given	50 µM	17	Rat plasma protease	HPLC	Rat Plasma	in vitro	None	None	Not reported
2291	6291099	1982	RDYWGWLDF	CCK9 (Cholecystokinin-9)	9	Free	Amidation	Linear	L	Sulphation of Tyrosine residue at position 3	Derivative of natural cholecytokinin	Intestinal hormone	Not given	50 µM	2.7	Human plasma proteases	HPLC	Human plasma	in vitro	None	None	Not reported
2292	6291099	1982	DRDYMGWMDF	CCK10 (Cholecystokinin-10)	10	Free	Amidation	Linear	L	Sulphation of tyrosine residue at position 4	Derivative of natural cholecytokinin	Intestinal hormone	Not given	50 µM	30	Human blood proteases	HPLC	Human plasma	in vitro	None	None	Not reported
2293	6291099	1982	DRDYMGWMDF	CCK10 (Cholecystokinin-10)	10	Free	Amidation	Linear	L	Sulphation of tyrosine residue at position 4	Derivative of natural cholecytokinin	Intestinal hormone	Not given	50 µM	45	Rat plasma protease	HPLC	Rat Plasma	in vitro	None	None	Not reported
2294	6344071	1983	MKAIFVLKGWWRTS	E.Coli leader peptide of tryptophan operon	14	Free	Free	Linear	L	None	E.coli trp operon	Regulatory peptide	Not given	Not mentioned	03-Apr	Cell-free (S-30) extracts prepared from E. coli strain W3110 trpR tnaA2 AtrpEA2 rna	Radioactivity decay assay (3H) .Leader peptide is radiolabelled and then decay in radioactivity is measured.	Not reported	in vitro	None	None	Not reported
2295	6522442	1984	YAFGYPS	Dermorphin	7	Free	Free	Linear	L	I125 radiolabeled	Frog skin	Opiod receptor agonist	60 minute	500 Î¼g/kg	1.3	Rat blood proteases	Radioimmunoassay and HPLC	Intravenous injection into tail of rats	in vivo	http://www.anaspec.com/products/product.asp?id=450	None	Not reported
2296	6605972	1984	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	Ovine corticotropic releasing factor	41	Free	Free	Linear	L	None	Paraventricular nucleus (PVN) of the hypothalamus	Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis	0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min.	76 Î¼g	16.2 (t1/2 fast)	Human blood plasma proteases	Radioimmunoassay and HPLC analysis	Intravenous administration to human plasma	in vivo	http://www.anaspec.com/products/product.asp?id=322	None	Not reported
2297	6605972	1984	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	Ovine corticotropic releasing factor	41	Free	Free	Linear	L	None	Paraventricular nucleus (PVN) of the hypothalamus	Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis	0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min.	85 Î¼g	13.3 (t1/2 fast)	Human blood plasma proteases	Radioimmunoassay and HPLC analysis	Intravenous administration to human plasma	in vivo	http://www.anaspec.com/products/product.asp?id=322	None	Not reported
2298	6605972	1984	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	Ovine corticotropic releasing factor	41	Free	Free	Linear	L	None	Paraventricular nucleus (PVN) of the hypothalamus	Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis	0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min.	75 Î¼g	12.4 (t1/2 fast)	Human blood plasma proteases	Radioimmunoassay and HPLC analysis	Intravenous administration to human plasma	in vivo	http://www.anaspec.com/products/product.asp?id=322	None	Not reported
2299	6605972	1984	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	Ovine corticotropic releasing factor	41	Free	Free	Linear	L	None	Paraventricular nucleus (PVN) of the hypothalamus	Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis	0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min.	75 Î¼g	12.7 (t1/2 fast)	Human blood plasma proteases	Radioimmunoassay and HPLC analysis	Intravenous administration to human plasma	in vivo	http://www.anaspec.com/products/product.asp?id=322	None	Not reported
2300	6605972	1984	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	Ovine corticotropic releasing factor	41	Free	Free	Linear	L	None	Paraventricular nucleus (PVN) of the hypothalamus	Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis	0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min.	90 Î¼g	5.6 (t1/2 fast)	Human blood plasma proteases	Radioimmunoassay and HPLC analysis	Intravenous administration to human plasma	in vivo	http://www.anaspec.com/products/product.asp?id=322	None	Not reported
2301	6605972	1984	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	Ovine corticotropic releasing factor	41	Free	Free	Linear	L	None	Paraventricular nucleus (PVN) of the hypothalamus	Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis	0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min.	80 Î¼g	9.4 (t1/2 fast)	Human blood plasma proteases	Radioimmunoassay and HPLC analysis	Intravenous administration to human plasma	in vivo	http://www.anaspec.com/products/product.asp?id=322	None	Not reported
2302	6605972	1984	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	Ovine corticotropic releasing factor	41	Free	Free	Linear	L	None	Paraventricular nucleus (PVN) of the hypothalamus	Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis	0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min.	80 Î¼g	11.6 (mean t1/2 fast)	Human blood plasma proteases	Radioimmunoassay and HPLC analysis	Intravenous administration to human plasma	in vivo	http://www.anaspec.com/products/product.asp?id=322	None	Not reported
2304	6605972	1984	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	Ovine corticotropic releasing factor	41	Free	Free	Linear	L	None	Paraventricular nucleus (PVN) of the hypothalamus	Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis	0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min.	85 Î¼g	49.5 (t1/2 slow)	Human blood plasma proteases	Radioimmunoassay and HPLC analysis	Intravenous administration to human plasma	in vivo	http://www.anaspec.com/products/product.asp?id=322	None	Not reported
2307	6605972	1984	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	Ovine corticotropic releasing factor	41	Free	Free	Linear	L	None	Paraventricular nucleus (PVN) of the hypothalamus	Used as a diagnostic test in disease affecting the Hypothalamic pituitary axis	0, 2, 5, 7,10,15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 min.	90 Î¼g	47.9 (t1/2 slow)	Human blood plasma proteases	Radioimmunoassay and HPLC analysis	Intravenous administration to human plasma	in vivo	http://www.anaspec.com/products/product.asp?id=322	None	Not reported
2311	6658706	1983	ADSGEGDFLAEGGGVR	125I-labeled desamino-tyrosyl (DAT-FPA) FPA	16	Free	Free	Linear	L	DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T	Desaminotyrosine Fibrinopeptide derivative	Blood clotting	6 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	7 (radioactivity)	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	http://search.anaspec.com/?keywords=fibrinopeptide	None	Not reported
2312	6658706	1983	ADSGEGDFLAEGGGVR	125I-labeled desamino-tyrosyl (DAT-FPA) FPA	16	Free	Free	Linear	L	DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T	Desaminotyrosine Fibrinopeptide derivative	Blood clotting	7 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	30 (radioactivity)	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	http://search.anaspec.com/?keywords=fibrinopeptide	None	Not reported
2315	6658706	1983	ADSGEGDFLAEGGGVR	Human Fibrinopeptide A (FPA)	16	Free	Free	Linear	L	None	N terminal end of the A-alpha chain of fibrinogen	Blood clotting	10 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	3.5	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	None	None	Not reported
2316	6658706	1983	ADSGEGDFLAEGGGVR	Human Fibrinopeptide A (FPA)	16	Free	Free	Linear	L	None	N terminal end of the A-alpha chain of fibrinogen	Blood clotting	11 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120,150,210 and 240 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	15	Normal rabbit blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of normal rabbit	in vivo	None	None	Not reported
2319	6658706	1983	ADSGEGDFLAEGGGVR	125I-labeled desamino-tyrosyl (DAT-FPA) FPA	16	Free	Free	Linear	L	DAT-FPA was labeled with 125-iodine or with 123-iodine by chloramine-T	Desaminotyrosine Fibrinopeptide derivative	Blood clotting	3 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	7 (radioactivity)	Nephrectomized rabbits blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of nephrectomized rabbits	in vivo	None	None	Not reported
2321	6658706	1983	ADSGEGDFLAEGGGVR	Human Fibrinopeptide A (FPA)	16	Free	Free	Linear	L	None	N terminal end of the A-alpha chain of fibrinogen	Blood clotting	5 sec and at 10 sec intervals upto 2 mins, then after 6,10,20,30,40,60,90,120 min	Labeled 125-I-FPA (0.1 mCi) in 1 ml of 1 µg of FPA	4	Nephrectomized rabbits blood proteases	Gel filtration chromatography of blood plasma at different time interval show that rapid clearence of peptide from blood plasma.	Intravenous injection in lateral vein of nephrectomized rabbits	in vivo	http://search.anaspec.com/?keywords=fibrinopeptide	None	Not reported
2322	6736205	1984	VPLPAGGGTVLTKMYPRGNHWAVGHLM	Gastrin releasing peptide	27	Free	Free	Linear	L	None	Porcine nonantral gastric juice	Stimulate release of gastrin	Not given	GRP I (0-30 min) bolus injection of 1.41 pmol kg-1, followed by an infusion of 0.12 pmol kg-1 x min-	2.8 ±0.4 min	Human serum proteases	Radioimmunoassay	Human serum	in vivo	http://www.anaspec.com/products/product.asp?id=301	None	Plasma gastrin concentration increased immediately after administration of peptide intravenously. After two doses of peptide(1.50pmol/kg) gastrin concentration found to be 1551pmol as compared to basal level of 370pmol.
2324	8839678	1995	HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Glucagon like peptide 1 (GLP( 7-36))	36	Free	Amidation	Linear	L	None	Human intestinal epithelium	Gastric motility	5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min	400 pmol/l	2.1 ±0.1 (for first phase)	Dog plasma proteases	Radioimmunoassay and HPLC	Intravenous injection to dogs plasma	in vitro	None	None	Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased.
2325	8839678	1995	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG	Glucagon like peptide 1 (GLP( 7-37))	37	Free	Free	Linear	L	None	Human intestinal epithelium	Gastric motility	5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min	400 pmol/l	2.4 ±0.3 (for first phase)	Dog plasma proteases	Radioimmunoassay and HPLC	Intravenous injection to dogs plasma	in vitro	http://www.anaspec.com/products/product.asp?id=324	None	Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased.
2332	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	2, 5, 15, 30, 45, and 60min	0.10mg/kg	1 (t1/2 Î±)	Rat blood plasma proteases	HPLC-MS	Intravenous administered to Rat	in vivo	None	None	Not tested
2333	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	2,5,10,20,30,45,60,90,120,180,240,300,360, 480,600, and 1440min	0.10mg/kg	13 (t1/2 Î±)	Dog blood plasma proteases	HPLC-MS	Intravenous administered to Dog	in vivo	None	None	Not tested
2334	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	2, 5, 10, 30, 60, 90, 120, 180, 240, 300, 360, 480, and 1440min	0.10mg/kg	4 (t1/2 Î±)	Rabbit blood plasma proteases	HPLC-MS	Intravenous administered to Rabbit	in vivo	None	None	Not tested
2335	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	2, 5, 10, 30, 60, 90, 120, 180, 240, 300, 360, 480, and 1440min	0.10mg/kg	5 (t1/2 Î±)	Monkey blood plasma proteases	HPLC-MS	Intravenous administered to Monkey	in vivo	None	None	Not tested
2336	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	2, 5, 15, 30, 45, and 60min	0.10mg/kg	15 (t1/2 Î²)	Rat blood plasma proteases	HPLC-MS	Intravenous administered to Rat	in vivo	None	None	Not tested
2341	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	2,5,10,20,30,45,60,90,120,180,240,300,360, 480,600, and 1440min	5 mg/kg	45 (t1/2 Î²)	Dog blood plasma proteases	HPLC-MS	Orally administered to Dog	in vivo	None	None	Not tested
2342	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	5, 10, 20, 30, 45, 60, 90, 120, 150, and 180min	5 mg/kg	51	Rat blood plasma proteases	HPLC-MS	Orally administered to Rat	in vivo	None	None	Not tested
2347	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	1 day	5 mg/kg	51	Rat blood plasma proteases	HPLC-MS	Orally administered to Rat	in vivo	None	None	Not tested
2353	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	1 day	5 mg/kg	45	Dog blood plasma proteases	HPLC-MS	Orally administered to Dog	in vivo	None	None	Not tested
2354	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	28 day	5 mg/kg	44	Dog blood plasma proteases	HPLC-MS	Orally administered to Dog	in vivo	None	None	Not tested
2355	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	1 day	50 mg/kg	48	Dog blood plasma proteases	HPLC-MS	Orally administered to Dog	in vivo	None	None	Not tested
2356	8991489	1996	RPD	IRI-695 peptide	3	Acetylation	Isobutyl citrate	Linear	L	C14 Radiolabeling	Synthetic	Anxiolytic and antidepressant	28 day	50 mg/kg	50	Dog blood plasma proteases	HPLC-MS	Orally administered to Dog	in vivo	None	None	Not tested
2359	9062685	1997	pGlu-NC(C)PRG	[pGIu4,Cyt6]AVP(4-9)	6	Free	Amidation	Linear	L	pGlu = pyroglutamate	Human kidney cells	Antidiuretic hormone	5, 10, 30, 60 and 120 min	10 ng/kg	40	Rat blood proteases	HPLC	Subcutaneously injected to rat	in vivo	None	None	Passive avoidance test to check the learning behaviour and response latency is measured of movement from light compartement to dark compartement. The peptide decreased the latency period significantly and also effective at 100 fold lower cincentration than then other drugs.
2360	9062685	1997	NCPR	[Cys6]AVP(5-8)	4	Free	Free	Linear	L	At 2 position cystine is replaced by cysteine	Human kidney cells	Antidiuretic hormone	5, 10, 30, 60 and 120 min	1 ng/kg	10	Rat blood proteases	HPLC	Subcutaneously injected to rat	in vivo	None	None	Passive avoidance test to check the learning behaviour and response latency is measured of movement from light compartement to dark compartement. The peptide decreased the latency period significantly and also effective at 100 fold lower cincentration than then other drugs.
2361	9062685	1997	pGlu-NSPRG	No.302	6	Free	Amidation	Linear	L	pGlu = pyroglutamate	Human kidney cells	Antidiuretic hormone	5, 10, 30, 60 and 120 min	0.1, 1 and 10ng/kg	9	Rat blood proteases	HPLC	Subcutaneously injected to rat	in vivo	None	None	Passive avoidance test to check the learning behaviour and response latency is measured of movement from light compartement to dark compartement. The peptide decreased the latency period significantly and also effective at 100 fold lower cincentration than then other drugs.
2363	9357069	1997	rPKPfQwFwLL	[D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P	11	Free	Amidation	Linear	Mix	None	Substance P	Neuropeptide growth factor antagonist	upto 360 minutes	12 µg/g body weight of mice	45.9 (terminal t1/2)	Mice blood proteases	RP-HPLC	Intraperitonial injection to Nu/Nu mice	in vivo	http://www.abcam.com/d-arg1d-phe5d-trp79leu11-subs	None	Not reported
2366	9421401	1998	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Atrial Natriuretic peptide	28	Free	Free	Linear	L	None	Human Heart muscle cells	Antihypertensive	0.5, 1, 1.5, 2, 3, 5, 8, 15, and 25 min	2 Î¼g	7.7 ±0.8 (t1/2 slow phase)	Rat plasma proteases	Radioimmunoassay	Exogenously administered to Male SHR-SP/Izm rats treated with carvedilol	in vivo	None	None	ANP role in antihypertension and blood pressure is determined by injecting ANP peptide(8mg/kg of body weight) in carvedilol and control group. The systolic blood pressure was decreased after 1 week of treatment in carvedilol treated group.
2367	9421401	1998	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Atrial Natriuretic peptide	28	Free	Free	Linear	L	None	Human Heart muscle cells	Antihypertensive	0.5, 1, 1.5, 2, 3, 5, 8, 15, and 25 min	2 Î¼g	4.9 ±0.5 (t1/2 slow phase)	Rat plasma proteases	Radioimmunoassay	Exogenously administered to Male SHR-SP/Izm rats	in vivo	None	None	ANP role in antihypertension and blood pressure is determined by injecting ANP peptide(8mg/kg of body weight) in carvedilol and control group. The systolic blood pressure was decreased after 1 week of treatment in carvedilol treated group.
2371	10354413	1999	YGG	Thioimreg compound 11	3	Free	Free	Linear	L	Peptide bonds at position 1,2 was replaced by thioamide linkages	Thioanalogue of natural Imreg	Immunostimulant	3.5 hours	Not given	46	Rat blood proteases	HPLC	Rat whole blood	in vitro	None	None	125 mg/kg of 11 resulted in a significant increase in activated T helper cells (CD4+CD45+, 28%, P e 0.048). This is accompanied by a significant reduction in NK cells (20-27%, P e 0.02) at 50 and 100 mg/kg
2372	10354413	1999	YGG	Imreg	3	Free	Free	Linear	L	None	Human leucocyte	Immunostimulant and in clinical trial to treat AIDS	3.5 hours	Not given	<1	Rat blood proteases	HPLC	Rat whole blood	in vitro	None	None	Immunophenotyping assay is performed to study immunological effect like stimulation of NK cells and lymphoproliferative properties. T cell proliferation was observed at even at 100mg/kg
2374	10573295	1999	DPLPEF	Enkephalin	6	Free	Amidation	Linear	L	None	Natural (Human brain)	Analgesic	0, 60, 120, 180, and 300 min	1mM	30	Mouse plasma proteases	HPLC , reverse phase HPLC, Partition coefficient	Mouse plasma	in vitro	None	None	Not tested
2386	10708307	1999	HSDAVFTDNYTRLRKQMAVKKYLNSILN	Vasoactive intestinal peptide	28	Free	Free	Linear	L	I125 radiolabeling and encapsulation of VIP in Liposome	Porcine intestine	Relaxation of the airway smooth muscle, attenuation of acute inflammation, regulation of mucus secretion	1.5, 2.5, 5, 10, 15, 20, 30, 40, and 60 min	0.33 nM	5.29 ±0.62 (t1/2 elimination)	Rat plasma proteases	Not mentioned	Intravenously administration to rat plasma	in vivo	PMID 5450698	None	Not tested
2388	10708307	1999	HSDAVFTDNYTRLRKQMAVKKYLNSILN	Vasoactive intestinal peptide	28	Free	Free	Linear	L	I125 radiolabeling and encapsulation of VIP in Liposome	Porcine intestine	Relaxation of the airway smooth muscle, attenuation of acute inflammation, regulation of mucus secretion	1.5, 2.5, 5, 10, 15, 20, 30, 40, and 60 min	0.33 nM	9.28 ±0.76 (t1/2 elimination)	Rat lung proteases	Not mentioned	Intravenously administration to rat lung	in vitro	PMID 5450698	None	Not tested
2389	10708307	1999	HSDAVFTDNYTRLRKQMAVKKYLNSILN	Vasoactive intestinal peptide	28	Free	Free	Linear	L	I125 radiolabeling	Porcine intestine	Relaxation of the airway smooth muscle, attenuation of acute inflammation, regulation of mucus secretion	1.5, 2.5, 5, 10, 15, 20, 30, 40, and 60 min	0.33 nM	3.18 ±0.22 (t1/2 elimination)	Rat lung proteases	Not mentioned	Intravenously administration to rat lung	in vitro	PMID 5450698	None	Not tested
2390	10973845	2000	MEPLGWQLTSGPNQEQVSPLTLLK	Alpha 2-antiplasmin (Î±2AP )	24	Free	Free	Linear	L	I125 radiolabeling	Human SERPINF2 gene	Clotting factor	2 hours	2 mg/ml	19	Mouse blood proteases	Not mentioned	Mouse blood fibrin clots	in vitro	None	None	Immunoblotting assay was done by taking 50 µL of fibrin clots with 2mg/ml of alpha2 AP and alpha2 AP peptide and cross linking was determined by electroblotting to PVDF membrane and detected by streptavidin-peroxidase.
2391	10973845	2000	NQEQVSPLTLLK	Alpha 2-antiplasmin peptide (Î±2AP13-24 )	12	Free	Free	Linear	L	Biotinylation at lysine residue(position 24)	Human SERPINF2 gene	Clotting factor	2 hours	0.5mMol/L	21	Mouse blood proteases	Not mentioned	Mouse blood fibrin clots	in vitro	None	None	Immunoblotting assay was done by taking 50 µL of fibrin clots with 2mg/ml of alpha2 AP and alpha2 AP peptide and cross linking was determined by electroblotting to PVDF membrane and detected by streptavidin-peroxidase.
2392	11145579	2001	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin like growth factor 1 (IGF-1)	70	Free	Free	Linear	L	I125 radiolabeling	Human IGF-1	Regulate somatic growth and cellular proliferation	1, 5, 15, and 30 min and at 1, 2, 4, 8, and 24 h	15 Î¼Ci(0.2 ml)	0.033 ±0.004 (t1/2 Î±)	Rat blood proteases	TCA precipitation	Intravenous injection into rat	in vivo	PMID:7758431	None	Human articular cartilage explant is taken and cultured in humidified environment, explant is treated with 40ng/ml of IGF-1, E3A,F49A for 5 days. Proteoglycan synthesis(matrix) synthesis is increased ~ 3 times in E3A/F49A treated sampleas compare to control as measured by scientillation counter.
2395	11145579	2001	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Analogue of Insulin like growth factor 1 (F49A)	70	Free	Free	Linear	L	I125 radiolabeling	Human IGF-1	Regulate somatic growth and cellular proliferation	1, 5, 15, and 30 min and at 1, 2, 4, 8, and 24 h	15 Î¼Ci(0.2 ml)	0.064 ±0.052 (t1/2 Î±)	Rat blood proteases	TCA precipitation	Intravenous injection into rat	in vivo	PMID:7758431	None	Human articular cartilage explant is taken and cultured in humidified environment, explant is treated with 40ng/ml of IGF-1, E3A,F49A for 5 days. Proteoglycan synthesis(matrix) synthesis is increased ~ 3 times in E3A/F49A treated sampleas compare to control as measured by scientillation counter.
2396	11145579	2001	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Analogue of Insulin like growth factor 1 (F49A)	70	Free	Free	Linear	L	I125 radiolabeling	Human IGF-1	Regulate somatic growth and cellular proliferation	1, 5, 15, and 30 min and at 1, 2, 4, 8, and 24 h	15 Î¼Ci(0.2 ml)	0.971 ±0.336 (t1/2 Î²)	Rat blood proteases	TCA precipitation	Intravenous injection into rat	in vivo	PMID:7758431	None	Human articular cartilage explant is taken and cultured in humidified environment, explant is treated with 40ng/ml of IGF-1, E3A,F49A for 5 days. Proteoglycan synthesis(matrix) synthesis is increased ~ 3 times in E3A/F49A treated sampleas compare to control as measured by scientillation counter.
2398	11145579	2001	GPATLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Analogue of Insulin like growth factor 1 (E3A/F49A)	70	Free	Free	Linear	L	I125 radiolabeling	Human IGF-1	Regulate somatic growth and cellular proliferation	1, 5, 15, and 30 min and at 1, 2, 4, 8, and 24 h	15 Î¼Ci(0.2 ml)	0.032 ±0.005 (t1/2 Î±)	Rat blood proteases	TCA precipitation	Intravenous injection into rat	in vivo	PMID:7758431	None	Human articular cartilage explant is taken and cultured in humidified environment, explant is treated with 40ng/ml of IGF-1, E3A,F49A for 5 days. Proteoglycan synthesis(matrix) synthesis is increased ~ 3 times in E3A/F49A treated sampleas compare to control as measured by scientillation counter.
2399	11145579	2001	GPATLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Analogue of Insulin like growth factor 1 (E3A/F49A)	70	Free	Free	Linear	L	I125 radiolabeling	Human IGF-1	Regulate somatic growth and cellular proliferation	1, 5, 15, and 30 min and at 1, 2, 4, 8, and 24 h	15 Î¼Ci(0.2 ml)	0.321 ±0.0.091 (t1/2 Î²)	Rat blood proteases	TCA precipitation	Intravenous injection into rat	in vivo	PMID:7758431	None	Human articular cartilage explant is taken and cultured in humidified environment, explant is treated with 40ng/ml of IGF-1, E3A,F49A for 5 days. Proteoglycan synthesis(matrix) synthesis is increased ~ 3 times in E3A/F49A treated sampleas compare to control as measured by scientillation counter.
2404	4572061	1972	pGlu-HWSTGLRPG	Luteinizing Hormone Releasing Hormone(LHRH)	10	Free	Amidation	Linear	L	pGlu=pyroglutamic acid, Tritium labeling	Gonadotropic cells in the anterior pituitary gland	Behavior influencing hormones	2 minutes	1 .0 Î¼Ci	6.97 ±0.4	Female Sprague Dawley rats blood protease	Radioimmunoassay	Intarvenous administration to Female Sprague Dawley rats	in vivo	None	None	LH-RH acts on the anterior pituitary to evoke the release of LH
2414	9040091	1997	pGlu-HWSYwLRP	Meterelin	9	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid	Gonadotropic cells in the anterior pituitary gland	Behavior influencing hormones	5, 1, 3, 5, 7, 10, 15, 20, 30, 45, 60, 75, and 90 min, then every 30 min until 3 h postinjection, an	10 Î¼g/kg	5.9 ±2.5 (t1/2 Î±)	New Zeland female rabbits blood protease	Radioimmunoassay	Intravenous injected in New Zeland female rabbits	in vivo	None	None	Castrate levels of testosterone were attained 10 days after sc administration of the implant, lasted for up to 247 days
2416	9040091	1997	pGlu-HWSYwLRP	Meterelin	9	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid	Gonadotropic cells in the anterior pituitary gland	Behavior influencing hormones	5, 1, 3, 5, 7, 10, 15, 20, 30, 45, 60, 75, and 90 min, then every 30 min until 3 h postinjection, an	1 Î¼g/kg	6.6 ±2.7 (t1/2 Î±)	New Zeland female rabbits blood protease	Radioimmunoassay	Subcutaneous injected in New Zeland female rabbits	in vivo	None	None	Castrate levels of testosterone were attained 10 days after sc administration of the implant, lasted for up to 247 days
2418	9040091	1997	pGlu-HWSYwLRP	Meterelin	9	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid	Gonadotropic cells in the anterior pituitary gland	Behavior influencing hormones	5, 1, 3, 5, 7, 10, 15, 20, 30, 45, 60, 75, and 90 min, then every 30 min until 3 h postinjection, an	10 Î¼g/kg	5.3 ±1.1 (t1/2 Î±)	New Zeland female rabbits blood protease	Radioimmunoassay	Subcutaneous injected in New Zeland female rabbits	in vivo	None	None	Castrate levels of testosterone were attained 10 days after sc administration of the implant, lasted for up to 247 days
2420	9040091	1997	pGlu-HWSYwLRP	Meterelin	9	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid	Gonadotropic cells in the anterior pituitary gland	Behavior influencing hormones	5, 1, 3, 5, 7, 10, 15, 20, 30, 45, 60, 75, and 90 min, then every 30 min until 3 h postinjection, an	100 Î¼g/kg	7.8 ±2.0 (t1/2 Î±)	New Zeland female rabbits blood protease	Radioimmunoassay	Subcutaneous injected in New Zeland female rabbits	in vivo	None	None	Castrate levels of testosterone were attained 10 days after sc administration of the implant, lasted for up to 247 days
2424	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	5, 10, 20, 30 or 60 min	8.6ng	8	Rat Stomach luminal flushing proteases	TCA precipitation	Rat Stomach luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2425	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	5, 10, 20, 30 or 60 min	8.6ng	5	Rat Stomach luminal flushing proteases	Antibody assay	Rat Stomach luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2426	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	5, 10, 20, 30 or 60 min	8.6ng	2.5	Rat Stomach luminal flushing proteases	Receptor-precipitable radioactivity	Rat Stomach luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2427	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	2-5, 5, 7-5, 10 or 20min	8.6ng	2	Rat Duodenum luminal flushing proteases	TCA precipitation	Rat Duodenum luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2428	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	2-5, 5, 7-5, 10 or 20min	8.6ng	2	Rat Duodenum luminal flushing proteases	Antibody assay	Rat Duodenum luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2429	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	2-5, 5, 7-5, 10 or 20min	8.6ng	2	Rat Duodenum luminal flushing proteases	Receptor-precipitable radioactivity	Rat Duodenum luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2430	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	2-5, 5, 7-5, 10 or 20min	8.6ng	2	Rat Ileum luminal flushing proteases	TCA precipitation	Rat Ileum luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2431	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	2-5, 5, 7-5, 10 or 20min	8.6ng	2	Rat Ileum luminal flushing proteases	Antibody assay	Rat Ileum luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2432	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	2-5, 5, 7-5, 10 or 20min	8.6ng	2	Rat Ileum luminal flushing proteases	Receptor-precipitable radioactivity	Rat Ileum luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2433	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	5, 10, 20, 30 or 60 min	8.6ng	38	Rat Colon luminal flushing proteases	TCA precipitation	Rat Colon luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2434	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	5, 10, 20, 30 or 60 min	8.6ng	33	Rat Colon luminal flushing proteases	Antibody assay	Rat Colon luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2435	7561632	1995	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Growth Hormone	5, 10, 20, 30 or 60 min	8.6ng	16	Rat Colon luminal flushing proteases	Receptor-precipitable radioactivity	Rat Colon luminal flushing	in vitro	632300	None	Stimulate gut growth and repair
2436	7561632	1995	MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	LR(3) insulin-like growth factor-I (IGF-I)	83	13 amino acid extension peptide at the N-terminus of IGF-I	Free	Linear	L	I125 labeling	Analogue of IGF-I	Growth Hormone	5, 10, 20, 30 or 60 min	8.6ng	50	Rat Stomach luminal flushing proteases	TCA precipitation	Rat Stomach luminal flushing	in vivo	http://www.cellsciences.com/content/p-detail.asp?r	None	Protect the growth factor by steric hindrance of cleavage sites.
2437	7561632	1995	MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	LR(3) insulin-like growth factor-I (IGF-I)	83	13 amino acid extension peptide at the N-terminus of IGF-I	Free	Linear	L	I125 labeling	Analogue of IGF-I	Growth Hormone	2-5, 5, 7-5, 10 or 20min	8.6ng	2	Rat Duodenum luminal flushing proteases	TCA precipitation	Rat Duodenum luminal flushing	in vivo	http://www.cellsciences.com/content/p-detail.asp?r	None	Protect the growth factor by steric hindrance of cleavage sites.
2438	7561632	1995	MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	LR(3) insulin-like growth factor-I (IGF-I)	83	13 amino acid extension peptide at the N-terminus of IGF-I	Free	Linear	L	I125 labeling	Analogue of IGF-I	Growth Hormone	2-5, 5, 7-5, 10 or 20min	8.6ng	2	Rat Ileum luminal flushing proteases	TCA precipitation	Rat Ileum luminal flushing	in vivo	http://www.cellsciences.com/content/p-detail.asp?r	None	Protect the growth factor by steric hindrance of cleavage sites.
2439	7561632	1995	MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	LR(3) insulin-like growth factor-I (IGF-I)	83	13 amino acid extension peptide at the N-terminus of IGF-I	Free	Linear	L	I125 labeling	Analogue of IGF-I	Growth Hormone	5, 10, 20, 30 or 60 min	8.6ng	60	Rat Colon luminal flushing proteases	TCA precipitation	Rat Colon luminal flushing	in vivo	http://www.cellsciences.com/content/p-detail.asp?r	None	Protect the growth factor by steric hindrance of cleavage sites.
2451	7529108	1994	CSCSSLMDKECVYFCHLDIIW	Human endothelin-1 (Human ET-1)	21	Free	Free	Linear	L	None	Human Endothelin-1	Vasoconstricting peptide	180 minute	3 nmol of peptide with 200 ng of enzyme	37 (t1/2 of hydrolysis)	Endopeptidase-24.11(E-24.11)	Radioimmunoassay and RP-HPLC	Purified ET-1 protein sample	in vitro	8269939	None	Not reported
2452	7529108	1994	VNTPEHVVPYGLGSPRS	C-terminal fragment of Human Endothelin-1 (CTF)	17	Free	Free	Linear	L	None	Human Endothelin-1	Vasoconstricting peptide	180 minute	3 nmol of peptide with 200 ng of enzyme	57 (t1/2 of hydrolysis)	Endopeptidase-24.11(E-24.11)	Radioimmunoassay and RP-HPLC	Purified ET-1 protein sample	in vitro	8269939	None	Not reported
2453	7529108	1994	CSCSSLMDKECVYFCHLDIIWVNTPERVVPYGLGSPSRS	Porcine big endothelin-1 (Porcine big-ET-1)	39	Free	Free	Linear	L	None	Porcine Endothelin-1	Vasoconstricting peptide	80 minute	3 nmol of peptide with 50 ng of enzyme	25 (t1/2 of hydrolysis)	Thermolysin	Radioimmunoassay and RP-HPLC	Purified ET-1 protein sample	in vitro	8269939	None	Not reported
2454	7529108	1994	CSCSSLMDKECVYFCHLDIIW	Porcine endothelin-1 (Porcine ET-1)	21	Free	Free	Linear	L	None	Porcine Endothelin-1	Vasoconstricting peptide	80 minute	3 nmol of peptide with 50 ng of enzyme	56 (t1/2 of hydrolysis)	Thermolysin	Radioimmunoassay and RP-HPLC	Purified ET-1 protein sample	in vitro	8269939	None	Not reported
2455	7529108	1994	VNTPERVVPYGLGSPSRS	C-terminal fragment of Porcine Endothelin-1 (Porcine CTF)	18	Free	Free	Linear	L	None	Porcine Endothelin-1	Vasoconstricting peptide	80 minute	3 nmol of peptide with 50 ng of enzyme	47 (t1/2 of hydrolysis)	Thermolysin	Radioimmunoassay and RP-HPLC	Purified ET-1 protein sample	in vitro	8269939	None	Not reported
2456	7529108	1994	RPKPQQFFGLM	Substance P	11	Free	Free	Linear	L	None	Spinal cord	Vasoconstricting peptide	180 minute	3 nmol of peptide with 200 ng of enzyme	2.1 (t1/2 of hydrolysis)	Endopeptidase-24.11(E-24.11)	Radioimmunoassay and RP-HPLC	Purified ET-1 protein sample	in vitro	None	None	Not reported
2457	7689499	1993	GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS	Galanin	30	Free	Free	Linear	L	None	Human tissue	Neuropeptide	60 minutes	74 pmol/kg	3.7 ±0.4	Human serum proteases	Radioimmunoassay	Human serum	in vivo	1370155	None	Growth hormone concentrations increased markedly during galanin infusion reaching a plateau value eight times the pre-infusion concentrations after 40-min infusion p < 0.01
2458	7714746	1994	YGGFL	Leu-enkephalin	5	Free	Free	Linear	L	None	Opoid	Nociception regulating peptide	Not mentioned	0.10mM, 10 mL	17.7	Aminopeptidases present in nasal mucosa of rat	HPLC	Nasal administration to Male Sprague Dawley derived rats	in vivo	None	None	Not reported
2459	7714746	1994	YGGFL	Leu-enkephalin	5	Free	Free	Linear	L	None	Opoid	Nociception regulating peptide	Not mentioned	0.10mM, 10 mL	23.9	Aminopeptidases present in nasal mucosa of rat	HPLC	Nasal administration to Male Sprague Dawley derived rats	in vivo	None	None	Not reported
2460	7714746	1994	DGGFL	Leu-enkephalin analogue	5	Free	Free	Linear	L	None	Opoid	Nociception regulating peptide	Not mentioned	0.10mM, 10 mL	21.2	Aminopeptidases present in nasal mucosa of rat	HPLC	Nasal administration to Male Sprague Dawley derived rats	in vivo	None	None	Not reported
2461	7957536	1994	HwAWfK	Hexarelin	6	Free	Amidation	Linear	Mix	Trp methylated at position 2	Growth hormone-releasing hormone-6	Growth hormone-releasing peptide	24 hours	0.5 Î¼g/kg	50	Human serum proteases	Chemiluminescence immunometric assay	Twelve adult male volunteers	in vivo	None	None	Mean ED50 values were 0.50 Î¼g/kg and Emax values were 55.1 Î¼g/kg
2462	7957536	1994	HwAWfK	Hexarelin	6	Free	Amidation	Linear	Mix	Trp methylated at position 2	Growth hormone-releasing hormone-6	Growth hormone-releasing peptide	24 hours	1 Î¼g/kg	51	Human serum proteases	Chemiluminescence immunometric assay	Twelve adult male volunteers	in vivo	None	None	Mean ED50 values were 0.50 Î¼g/kg and Emax values were 55.1 Î¼g/kg
2463	7957536	1994	HwAWfK	Hexarelin	6	Free	Amidation	Linear	Mix	Trp methylated at position 2	Growth hormone-releasing hormone-6	Growth hormone-releasing peptide	24 hours	2 Î¼g/kg	58	Human serum proteases	Chemiluminescence immunometric assay	Twelve adult male volunteers	in vivo	None	None	Mean ED50 values were 0.50 Î¼g/kg and Emax values were 55.1 Î¼g/kg
2464	7991443	1994	YEPGKSSILQHERPVTKPQA	C-20 Sorbin	20	Free	Amidation	Linear	L	None	Derived from Sorbin	Electrolyte absorbing peptide	1, 2, 4, 8, 16, and 32 min	200 Î¼g/kg/h	9.5 ±1.8	Rat blood proteases	Radioimmunoassay	Male Sprague-Dawley rats blood	in vivo	None	None	Increases absorption of water and ions
2465	7991443	1994	YEPGKSS	C-7 Sorbin	7	Free	Amidation	Linear	L	None	Derived from Sorbin	Electrolyte absorbing peptide	1, 2, 4, 8, 16, and 32 min	200 Î¼g/kg/h	7.5 ±1.5	Rat blood proteases	Radioimmunoassay	Male Sprague-Dawley rats blood	in vivo	None	None	Increases absorption of water and ions
2466	7991443	1994	YEPGKSS	Tritiated C-7 Sorbin	7	Free	Amidation	Linear	L	[2-dehydro-Pro1.5]C is attached and tritiated	Derived from Sorbin	Electrolyte absorbing peptide	1, 2, 4, 8, 16, 32, and 64 min	2.8 MBq	17.9 ±1.5	Rat blood proteases	Radioimmunoassay	Male Sprague-Dawley rats blood	in vivo	None	None	Increases absorption of water and ions
2469	8076909	1994	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	Human BNP (Brain natriuretic Peptide)	32	Free	Free	Linear	L	None	Human BNP (Brain Natriuretic Peptide)	Diuretic,natriuretic and vasodilatory peptide	Not mentioned	Not mentioned	20.7 (slow component)	None	Not mentioned	None	in vitro	2136732	None	Not reported
2470	8076909	1994	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	Human BNP (Brain natriuretic Peptide)	32	Free	Free	Linear	L	None	Human BNP (Brain Natriuretic Peptide)	Diuretic,natriuretic and vasodilatory peptide	Not mentioned	Not mentioned	3.9 (fast component)	None	Not mentioned	None	in vitro	2136732	None	Not reported
2471	8076909	1994	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Human BNP (Brain natriuretic Peptide)	28	Free	Free	Linear	L	None	Human BNP (Brain Natriuretic Peptide)	Diuretic,natriuretic and vasodilatory peptide	Not mentioned	Not mentioned	13.3 (slow component)	None	Not mentioned	None	in vitro	6223192	None	Not reported
2472	8076909	1994	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Human BNP (Brain natriuretic Peptide)	28	Free	Free	Linear	L	None	Human BNP (Brain Natriuretic Peptide)	Diuretic,natriuretic and vasodilatory peptide	Not mentioned	Not mentioned	1.7 (fast component)	None	Not mentioned	None	in vitro	6223192	None	Not reported
2473	8082705	1994	EAKSQGGSN	Facteur thymique serique	9	Free	Free	Linear	L	None	Thymic peptide hormone	Thymic hormone used to treat autoimmune disorder	5 minutes	300-500 kBq/kg	02-Mar	Rats blood proteases	Radioimmunoassay	Intravenouly injected in male Wistar rats	in vivo	7011613	None	The basal IRI level at 24 h after alloxan injection was significantly lower in alloxan-treated samples than in controls (12.1 + 5.2 vs. 28.7 + 6.3/zU/ml, P < 0.05)
2474	8194082	1993	NSDSECPLSHDGYCLHDGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELR	Epidermal Growth Factor (EGF)	53	Free	Free	Linear	L	I125 labeling	Epidermal Growth Factor	Growth factor	135 minutes	1420 Ci/mmol	12.4 (dissociation t1/2)	Proteases present in human meningioma	Autoradiography	Fresh surgically excised human meningioma specimens	in vitro	4636327	None	High concentrations (10-4-10 -2 M) of suramin inhibited 125I-EGF binding to meningioma sections with ICs0's of 3.2 + 0.4 Ã— 1 0 - 4 M
2477	8542672	1995	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Adrenomedullin (AM)	50	Free	Amidation	Linear	L	None	Human pheochromocytoma	Hypotensive peptide	30 minutes	1.0 nmol/kg, dissolved in saline	1.05 ±0.04	Rat blood proteases	Radioimmunoassay	Spontaneously hypertensive rats (SHR)	in vivo	None	None	The mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg.
2478	8542672	1995	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Adrenomedullin (AM)	51	Free	Amidation	Linear	L	None	Human pheochromocytoma	Hypotensive peptide	30 minutes	1.0 nmol/kg, dissolved in saline	1.19 ±0.09	Rat blood proteases	Radioimmunoassay	Wistar-Kyoto rats	in vivo	None	None	The mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were - 12.4, -46.6, -61.6 mmHg.
2479	8542672	1995	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Adrenomedullin (AM)	52	Free	Amidation	Linear	L	None	Human pheochromocytoma	Hypotensive peptide	30 minutes	1.0 nmol/kg, dissolved in saline	18.1 ±1.4	Rat blood proteases	Radioimmunoassay	Spontaneously hypertensive rats (SHR)	in vivo	None	None	The mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg.
2480	8542672	1995	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Adrenomedullin (AM)	53	Free	Amidation	Linear	L	None	Human pheochromocytoma	Hypotensive peptide	30 minutes	1.0 nmol/kg, dissolved in saline	16.3 ±1.2	Rat blood proteases	Radioimmunoassay	Wistar-Kyoto rats	in vivo	None	None	The mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were - 12.4, -46.6, -61.6 mmHg.
2481	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-1	17	Free	Free	Linear	L	None	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	42	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2483	8545241	1995	YGGFLRRIRPKLKWDN	Dynorphin A (DYN A) analog-3	17	Free	Free	Linear	L	The reduced bond psi [CH,-NH] was introduced at position 3-4	Opoid	Physiological effect regulating peptide	0-60 minutes	100 Î¼M peptide solution to 0.18-ml portions of brain membranes	43	Endopeptidase 24-11 (enkephalinase), mouse brain proteases	HPLC	Mouse brain homogenates	in vitro	None	None	Not reported
2491	8545255	1995	HwAWfK	Hexarelin	6	Free	Free	Linear	Mix	Methylated at position 2 of D-trp	Growth hormone-releasing hormone-6	Growth hormone-releasing peptide	1, 3, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 120, 150, 180, 240, 300, 360, and 420 min postdose.	1 Î¼g/kg	25 ±5.02	Dog blood proteases	Radioimmunoassay	Subcutaneous injection to male and female dogs	in vivo	None	None	Not reported
2492	8545255	1995	HwAWfK	Hexarelin	6	Free	Free	Linear	Mix	Methylated at position 2 of D-trp	Growth hormone-releasing hormone-6	Growth hormone-releasing peptide	1, 3, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 120, 150, 180, 240, 300, 360, and 420 min postdose.	10 Î¼g/kg	33.3 ±8.83	Dog blood proteases	Radioimmunoassay	Subcutaneous injection to male and female dogs	in vivo	None	None	Not reported
2493	8545255	1995	HwAWfK	Hexarelin	6	Free	Free	Linear	Mix	Methylated at position 2 of D-trp	Growth hormone-releasing hormone-6	Growth hormone-releasing peptide	1, 3, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 120, 150, 180, 240, 300, 360, and 420 min postdose.	100 Î¼g/kg	36.7 ±12.01	Dog blood proteases	Radioimmunoassay	Subcutaneous injection to male and female dogs	in vivo	None	None	Not reported
2495	9234336	1993	HSDAVFTDNYTRLRKQMAVKKYLNSILN	Vasoactive intestinal peptide (VIP)	28	Free	Free	Linear	L	None	Small intestinal mucosa	Vasoactive peptide	2,3,6,10,20,40,60 minutes	250 Î¼g	2.3 ±0.8	Rat blood proteases	Radioimmunoassay	Intravenous injection to Rat blood	in vivo	http://www.sigmaaldrich.com/catalog/product/sigma/	None	Regulate of blood flow and smooth muscle relaxation in specific mammalian organs
2507	12852770	2003	pGlu-LYENKPRRPYIL	Neurotensin	13	Free	Free	Linear	L	Post translationaly modified Glu residue at first position	Bovine hypothalamus	Neuromodulator peptide	24 hour	50 Î¼g/well	1.5	Mice blood proteases	HPLC	NTR-positive HT29 tumor- bearing SCID mice	in vivo	None	None	IC50 value reported was 0.2 nM
2511	15740458	2005	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Rat AM (Adrenomedullin)	50	Free	Free	Linear	L	None	Human pheochromocytoma	Hypotensive peptide	30 minutes	200 Î¼l	2 (distribution t1/2)	Rat blood proteases	Competitive Radioimmunoassay	Intravenous administration in Rat	in vivo	http://www.anaspec.com/products/product.asp?id=304	None	Not reported
2512	15740458	2005	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Rat AM (Adrenomedullin)	50	Free	Free	Linear	L	None	Human pheochromocytoma	Hypotensive peptide	30 minutes	200 Î¼l	15.9 (elimination t1/2)	Rat blood proteases	Competitive Radioimmunoassay	Intravenous administration in Rat	in vivo	http://www.anaspec.com/products/product.asp?id=304	None	Not reported
2513	16302271	2006	GKAFRR	Human Glandular Kallikrein 2 (hK2)-activated thapsigargin prodrug	6	Acetylation	Free	Linear	L	Ligated with potent cytotoxin thapsigargin, L12ADT	Human glandular kallikrein 2 (hK2)	Antitumor peptide	24 hours	6 mg/kg	40	Mice blood proteases	Not mentioned	Balb-C mice	in vivo	None	None	Intratumoral concentrations reached levels comparable to the in vitro IC50 of the prodrug with concentrations of 1.25 mM seen at 1 and 4 hr.
2514	17065394	2006	AKPEAPGEDASPEELSRYYASLRHYLNLVTRQRY	Porcine PYY (Peptide YY)	34	Free	Amidation	Linear	L	None	Porcine intestine	Neuropeptide	120 minutes	25 mg/kg BW per min	15	Pigs blood proteases	Double-antibody Radioimmunoassay	Intravenously administred to Crossbred (Large White!Landrace!Duroc) castrated male pigs	in vivo	http://www.genscript.com/peptide/RP10354-Peptide_Y	None	Plasma GH levels significantly increased 30 min after PYY3 €“36 injection compared with the saline-injected group (7.8 ± 2.1 vs 3.0 ± 0.6 ng/ml, P<0.05)
2515	17583927	2007	RXRRXRRXRRXRXB	Cell penetrating peptides-Phosphorodiamidate morpholino oligomers (CPP-PMO)	34	Free	PMO (5'-ACGTTGAIIIGCATCGTCGC-3')	Linear	L	X = 6-aminohexanoic acid, B = beta-alanine, I = inosine	Cell penetrating peptides-Phosphorodiamidate morpholino oligomers	Cell penetrating peptide	24 hours	15 mg/kg	0.40 ±0.05 (t1/2 Î±)	Rat plasma proteases	MALDI-TOF-MS	Intravenous administration in Rat	in vitro	None	None	LD50 of the conjugate administered iv in rats was between 210 and 250 mg/kg
2516	17583927	2007	RXRRXRRXRRXRXB	Cell penetrating peptides-Phosphorodiamidate morpholino oligomers (CPP-PMO)	34	Free	PMO (5'-ACGTTGAIIIGCATCGTCGC-3')	Linear	L	X = 6-aminohexanoic acid, B = beta-alanine, I = inosine	Cell penetrating peptides-Phosphorodiamidate morpholino oligomers	Cell penetrating peptide	24 hours	30 mg/kg	0.63 ±0.02 (t1/2 Î±)	Rat plasma proteases	MALDI-TOF-MS	Intravenous administration in Rat	in vitro	None	None	LD50 of the conjugate administered iv in rats was between 210 and 250 mg/kg
2524	8388403	1993	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP (Atrial natriuretic Peptide)	28	Free	Free	Linear	L	None	Human Heart	Diuretic,natriuretic and vasodilatory peptide	2 hours	1.5 pmol/lg/min	4.1 ±0.4	Human serum proteases	Radioimmunoassay	Human serum	in vivo	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No significant differences in systolic blood pressure, diastolic blood pressure or pulse rate were observed when values on active and placebo infusions were compared (P = 0.85)
2526	3871610	1985	PSSSLHLHRRITHHRRLGCFRSSGSLLNNAMKGGVDDEITLSAYITMALLESSLPDTDP	Rat Î±1- proteinase inhibitor	60	Free	Free	Linear	L	None	Rat serum	Protelytic activities regulating peptide	5 minutes, 30 minutes, 1 hour, 4 hour and 7 hour	Not mentioned	30 (for unglycosylated Î±1- proteinase inhibitor)	Rat serum proteases	Radioimmunoassay	Wistar rats	in vivo	http://www.uniprot.org/uniprot/Q9JMK6	None	Protect tissue against proteolytic attack by leukocyte elastase
2527	6433008	1984	pGlu-HYSTlLAP-des-Gly	TAP-144	10	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid, des-Gly	LHRH derivative	Gonadotrophins secreting hormone	10 days	10Î¼g/100g body wt	32 (t1/2 terminal phase)	Rat serum proteases	Not mentioned	Subcutaneous administration to Sprague-Dawley rats	in vivo	None	None	Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration
2530	6433008	1984	pGlu-HYSTlLAP-des-Gly	TAP-144	10	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid, des-Gly	LHRH derivative	Gonadotrophins secreting hormone	10 days	100Î¼g/100g body wt	55.5 (t1/2 terminal phase)	Rat serum proteases	Not mentioned	Rectal administration to Sprague-Dawley rats	in vivo	None	None	Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration
2531	6433008	1984	pGlu-HYSTlLAP-des-Gly	TAP-144	10	Free	Ethylamide	Linear	Mix	pGlu=pyroglutamic acid, des-Gly	LHRH derivative	Gonadotrophins secreting hormone	10 days	100Î¼g/100g body wt	43.7 (t1/2 terminal phase)	Rat serum proteases	Not mentioned	Nasal administration to Sprague-Dawley rats	in vivo	None	None	Serum LH and FSH concentrations declined to about the same low level by 8 h after the TAP- 144 administration
2533	10607940	2000	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Promotes formation and repair of bone, stimulates body protein and glucose metabolism and increases glomerular filtration rate and renal plasma flow	5, 30, 120 and 240 min	100 Î¼l	3.2 ±0.1 (t1/2Î±)	Rat blood proteases	Radioimmunoassay and bi-exponential equation that describes a two-compartment model	Intravenous bolus administration in Rat	in vivo	632300	None	infusion of 125I-IGF-I into rats, 0 ·003 ±0 ·001% (mean ±S.E.M, n=6) of total infused, intact 125I-IGF-I had appeared per milliliter of wound fluid.
2534	10607940	2000	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Insulin-like growth factor-I (IGF-I)	70	Free	Free	Linear	L	I125 labeling	Human IGF-1	Promotes formation and repair of bone, stimulates body protein and glucose metabolism and increases glomerular filtration rate and renal plasma flow	5, 30, 120 and 240 min	100 Î¼l	4.9 ±0.02 (t1/2Î±)	Rat blood proteases	Radioimmunoassay and bi-exponential equation that describes a two-compartment model	Intravenous bolus administration in Rat	in vivo	632300	None	infusion of 125I-IGF-I into rats, 0 ·003 ±0 ·001% (mean ±S.E.M, n=6) of total infused, intact 125I-IGF-I had appeared per milliliter of wound fluid.
2535	10607940	2000	MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	LR(3) insulin-like growth factor-I (IGF-I)	83	Free	Free	Linear	L	I125 labeling	Analogue of IGF-I	Promotes formation and repair of bone, stimulates body protein and glucose metabolism and increases glomerular filtration rate and renal plasma flow	5, 30, 120 and 240 min	100 Î¼l	2.8 ±0.1 (t1/2Î±)	Rat blood proteases	Radioimmunoassay and bi-exponential equation that describes a two-compartment model	Intravenous bolus administration in Rat	in vivo	http://www.cellsciences.com/content/p-detail.asp?r	None	At 5 min 0 ·01 ± 0 ·001% (mean ± S.E.M, n = 6, P < 0 ·001) of total infused intact 125I-LR3IGF-I had appeared per milliliter of wound fluid.
2536	10607940	2000	MFPAMPLSSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	LR(3) insulin-like growth factor-I (IGF-I)	83	Free	Free	Linear	L	I125 labeling	Analogue of IGF-I	Promotes formation and repair of bone, stimulates body protein and glucose metabolism and increases glomerular filtration rate and renal plasma flow	5, 30, 120 and 240 min	100 Î¼l	4.6 ±0.5 (t1/2Î±)	Rat blood proteases	Radioimmunoassay and bi-exponential equation that describes a two-compartment model	Intravenous bolus administration in Rat	in vivo	http://www.cellsciences.com/content/p-detail.asp?r	None	At 5 min 0 ·01 ± 0 ·001% (mean ± S.E.M, n = 6, P < 0 ·001) of total infused intact 125I-LR3IGF-I had appeared per milliliter of wound fluid.
2541	4327730	1971	SYSMEHFRWGKPVGKKRRPVKVYPAGEDDEASEAFPLEF	Purified Sheep Adrenocorticotropic Hormone (ACTH)	39	Free	Free	Linear	L	None	Sheep Adrenocorticotropic Hormone (ACTH)	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	2U	7.32 (steriodigenic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	http://www.genscript.com/peptide/RP11304-ACTH_1-39	None	Shows activity of 80~180USP Units/mg
2542	4327730	1971	GYSMEHFRYGKPVGKKRR	ACTH analogue- 3	18	Free	Amidation	Linear	L	None	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	5 Î¼g	2.6 (steriodigenic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	No odification in the activity of ACTH analog-2 peptide
2543	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKRR	ACTH analogue- 4	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	7.32 (steriodigenic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Showed higher potencies than Native ACTH in all the method tested
2544	4327730	1971	Ibu-YSMEHFRYGKPVGKKRR	ACTH analogue- 5	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	9.6 (steriodigenic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	The intravenous and intramuscular potencies of peptide V, Ibu1 ACTH (1-18) amide were 480-757U/mg, 4-5 times higher than the values for native hormone but subcutaneous potency was rather low (264U/mg) and in vitro potency was much lower (83U/mg) than the intravenous and intramuscular potencies.
2545	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 6	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine, Orn = Ornithine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	10.06 (steriodigenic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Showed an activity about 2/3 of that of the original Lys15 peptides IV
2546	4327730	1971	SYSMEHFRWGKPVGKKRRPVKVYPAGEDDEASEAFPLEF	Purified Sheep Adrenocorticotropic Hormone (ACTH)	39	Free	Free	Linear	L	None	Sheep Adrenocorticotropic Hormone (ACTH)	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	4.43 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	http://www.genscript.com/peptide/RP11304-ACTH_1-39	None	Shows activity of 80~180USP Units/mg
2547	4327730	1971	GYSMEHFRYGKPVGKKRR	ACTH analogue- 3	18	Free	Amidation	Linear	L	None	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	1.95 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity less than ACTH
2548	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKRR	ACTH analogue- 4	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	3.08 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity less than ACTH
2549	4327730	1971	Ibu-YSMEHFRYGKPVGKKRR	ACTH analogue- 5	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	3.32 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity less than ACTH
2550	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 6	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine, Orn = Ornithine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	4.53 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity less than ACTH
2551	4327730	1971	Ibu-YSMEHFRYGKPVGKKR-Orn	ACTH analogue- 7	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1/2, 1, 2, 4, 8, and 16min	Not mentioned	6 (lipolytic activity t1/2)	Rat blood proteases	Not mentioned	Intravenously injected to rat	in vivo	4286483	None	Shows activity more than ACTH
2552	4327730	1971	SYSMEHFRWGKPVGKKRRPVKVYPAGEDDEASEAFPLEF	Purified Sheep Adrenocorticotropic Hormone (ACTH)	39	Free	Free	Linear	L	None	Sheep Adrenocorticotropic Hormone (ACTH)	Steroidogenic peptides	1,2,3 and 4 hours	200 mU	59.22 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	http://www.genscript.com/peptide/RP11304-ACTH_1-39	None	Not mentionedtive ACTH shows similar activity to rat and rabbit fats when compared in terms of the minimal effective dose (rat = 610-6mg/50mg tissue and rabbit = 510-6mg/50mg tissue)
2553	4327730	1971	GYSMEHFRYGKPVGKKRR	ACTH analogue- 3	18	Free	Amidation	Linear	L	None	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	Not mentioned	30 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 610-6mg/50mg tissue and rabbit = 0.410-6mg/50mg tissue)
2554	4327730	1971	Î²Ala-YSMEHFRYGKPVGKKRR	ACTH analogue- 4	18	Free	Amidation	Linear	L	Î²Ala = Beta alanine	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	20 Î¼g	35.4 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 0.610-6mg/50mg tissue and rabbit = 0.0710-6mg/50mg tissue)
2555	4327730	1971	Ibu-YSMEHFRYGKPVGKKRR	ACTH analogue- 5	18	Free	Amidation	Linear	L	Ibu = Î±-aminoisobutyric acid	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	20 Î¼g	32.43 (lipolytic activity t1/2)	Rat plasma proteases	Not mentioned	Rat plasma	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 0.210-6mg/50mg tissue and rabbit = 0.00210-6mg/50mg tissue)
2560	4327730	1971	GYSMEHFRYGKPVGKKRR	ACTH analogue- 3	18	Free	Amidation	Linear	L	None	Octadecapeptide analogues of ACTH	Steroidogenic peptides	1,2,3 and 4 hours	Not mentioned	42.6 (lipolytic activity t1/2)	Rat muscle proteases	Not mentioned	Rat muscle slices	in vitro	4286483	None	Showed much higher activity in rabbit fat than in rat fat (rat = 610-6mg/50mg tissue and rabbit = 0.410-6mg/50mg tissue)
2567	17283237	2007	HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG	Glucagon like peptide-1 (GLP-1)	37	Free	Free	Linear	L	None	Human GLP-1	Growth Hormone	3 hours	100 Î¼g/kg peptide in mice	<5	Mice blood proteases	Radioimmunoassay	Subcutaneously injected in mice	in vivo	http://www.uniprot.org/blast/?about=P01275[92-128]	None	Promotes glucose-depen- dent insulin secretion from the pancreas
2570	8218482	1993	YRGDS	RGD containing peptide	5	Free	Free	Linear	L	I125 radiolabeling, covalently attached to an isocyanate-containing poly urethane prepolymer	Extra Cellular Matrix proteins	Antitumor peptide	Not mentioned	0.2 mL	0.5 (t1/2 first phase)	Mice blood proteases	Radioimmunoassay	Intravenously injected to C57BL6 mice	in vivo	None	None	Less effective in in blocking peptide-mediated attachment of B16-FlO melanoma cells to a surface.
2573	17258819	2007	CYFQNCPRG	Vasopressin, 8-L-Arginine	9	Free	Free	Cyclic (C1-C6)	L	I125 labeling	Human Vasopressin	Anti-diuretic peptide	20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min	15 Î¼Ci (555 kBq)	1.06 ±0.19 (fast phase)	Rat blood proteases	Radioimmunoassay	Female homozygous Brattleboro rats and male Wistar rats	in vivo	http://www.polypeptide.com/vasopressin-8-l-arginin	None	antidiuretic activity 408 IU/mg
2574	17258819	2007	CYFQNCPRG	Vasopressin, 8-L-Arginine	9	Free	Free	Cyclic (C1-C6)	L	I125 labeling	Human Vasopressin	Anti-diuretic peptide	20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min	15 Î¼Ci (555 kBq)	5.96 ±0.58 (slow phase)	Rat blood proteases	Radioimmunoassay	Female homozygous Brattleboro rats and male Wistar rats	in vivo	http://www.polypeptide.com/vasopressin-8-l-arginin	None	antidiuretic activity 408 IU/mg
2575	17258819	2007	CYFQNCPRG	Vasopressin, 8-L-Arginine	9	Free	Free	Cyclic (C1-C6)	L	I125 labeling	Human Vasopressin	Anti-diuretic peptide	20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min	15 Î¼Ci (555 kBq)	1.00 ±0.15 (fast phase)	Rat blood proteases	Radioimmunoassay	Female homozygous Brattleboro rats and male Wistar rats along with OPC-31260	in vivo	http://www.polypeptide.com/vasopressin-8-l-arginin	None	antidiuretic activity 408 IU/mg
2576	17258819	2007	CYFQNCPRG	Vasopressin, 8-L-Arginine	9	Free	Free	Cyclic (C1-C6)	L	I125 labeling	Human Vasopressin	Anti-diuretic peptide	20, 40 seconds and1, 2, 4, 8, 16, 32 and 60 min	15 Î¼Ci (555 kBq)	8.90 ±0.37 (slow phase)	Rat blood proteases	Radioimmunoassay	Female homozygous Brattleboro rats and male Wistar rats along with OPC-31261	in vivo	http://www.polypeptide.com/vasopressin-8-l-arginin	None	antidiuretic activity 408 IU/mg
2577	17684103	2007	CYFQNCPRG	125I-vasopressin	9	Free	Free	Cyclic (C1-C6)	L	I125 labeling	Human Vasopressin	Anti-diuretic peptide	1,2 and 3 minutes	50 or 0.4 pmol of vasopressin with 33 kBq	~ 1.5	Mice blood proteases	Radioimmunoassay	Saline treated IRAP+/+ mice	in vivo	http://www.polypeptide.com/vasopressin-8-l-arginin	None	antiduretic activity
2578	17684103	2007	CYFQNCPRG	125I-vasopressin	9	Free	Free	Cyclic (C1-C6)	L	I125 labeling	Human Vasopressin	Anti-diuretic peptide	1,2 and 3 minutes	50 or 0.4 pmol of vasopressin with 33 kBq	1	Mice blood proteases	Radioimmunoassay	Insulin-treated IRAP+/+ mice	in vivo	http://www.polypeptide.com/vasopressin-8-l-arginin	None	antiduretic activity
2579	17684103	2007	CYFQNCPRG	125I-vasopressin	9	Free	Free	Cyclic (C1-C6)	L	I125 labeling	Human Vasopressin	Anti-diuretic peptide	1,2 and 3 minutes	50 or 0.4 pmol of vasopressin with 33 kBq	3	Mice blood proteases	Radioimmunoassay	Insulin-treated IRAP-/- mice.	in vivo	http://www.polypeptide.com/vasopressin-8-l-arginin	None	antiduretic activity
2580	15828822	2005	GViTRIR	Peptide1	7	Acetylation	N-Ethylmaleimidation	Linear	Mix	None	Second type 1 repeat of thrombospondin-1	Antiangiogenic activity	Not mentioned	5mg/kg	<1	Rat plasma proteases	Not mentioned	Rat plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 = >100nM
2581	15828822	2005	Sar-GViTXIRP	Compond 5 (ABT-526)	9	Acetylation	N-Ethylmaleimidation	Linear	Mix	Sar- Sarcosine	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.2	Rat plasma proteases	Not mentioned	Rat plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 = 0.03 ± 0.015 nM, Inhibition of HMVEC tube formation with IC50 = 200-100nM
2583	15828822	2005	Sar-GViTXIRP	Compond 5 (ABT-526)	9	Acetylation	N-Ethylmaleimidation	Linear	Mix	Sar- Sarcosine	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.5	Monkey plasma proteases	Not mentioned	Monkey plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 = 0.03 ± 0.015 nM, Inhibition of HMVEC tube formation with IC50 = 200-100nM
2584	15828822	2005	Sar-GViTXIRP	Compond 5 (ABT-526)	9	Acetylation	N-Ethylmaleimidation	Linear	Mix	Sar- Sarcosine	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.5	Proteases from dog plasma	Not mentioned	Dog plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 = 0.03 ± 0.015 nM, Inhibition of HMVEC tube formation with IC50 = 200-100nM
2585	15828822	2005	Sar-GViT-(Dallo-Ile)-IRP	Compond 6 (ABT-510)	9	Acetylation	N-Ethylmaleimidation	Linear	Mix	4th AA is D isoform of allo- Ile, Sar- Sarcosine	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.2	Rat plasma proteases	Not mentioned	Rat plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 = 0.89 ± 0.029 nM, Inhibition of HMVEC tube formation with IC50 = 10-50nM
2586	15828822	2005	Sar-GViT-(Dallo-Ile)-IRP	Compond 6 (ABT-510)	9	Acetylation	N-Ethylmaleimidation	Linear	Mix	4th AA is D isoform of allo- Ile, Sar- Sarcosine	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.15	Mouse plasma proteases	Not mentioned	Mouse plamsa	in vivo	None	None	Inhibition of HMVEC migration with IC50 = 0.89 ± 0.029 nM, Inhibition of HMVEC tube formation with IC50 = 10-50nM
2588	15828822	2005	Sar-GViT-(Dallo-Ile)-IRP	Compond 6 (ABT-510)	9	Acetylation	N-Ethylmaleimidation	Linear	Mix	4th AA is D isoform of allo- Ile, Sar- Sarcosine	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.8	Rat plasma proteases	Not mentioned	Rat plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 = 0.89 ± 0.029 nM, Inhibition of HMVEC tube formation with IC50 = 10-50nM
2589	15828822	2005	GViT-(Nva)-IRP	Compund 4	8	Acetylation	N-Ethylmaleimidation	Linear	Mix	Sar- Sarcosine, Nva-Norvaline	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.3	Rat plasma proteases	Not mentioned	Rat plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 = 0.07 ± 0.004 nM,
2590	15828822	2005	Sar-GViT-(Nva)-IRP	Compound 7	9	NHIsp	N-Ethylmaleimidation	Linear	Mix	Sar- Sarcosine , Nva-Norvaline	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.9	Rat plasma proteases	Not mentioned	Rat plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 =29 ± 0.003 nM, Inhibition of HMVEC tube formation with IC50 = >1000nM
2591	15828822	2005	Sar-GViT-(Nva)-IRP	Compound 8	9	Succinylation	N-Ethylmaleimidation	Linear	Mix	Sar- Sarcosine ,Nva-norvaline	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.2	Rat plasma proteases	Not mentioned	Rat plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 =0.26 ± 0.110 nM, Inhibition of HMVEC tube formation with IC50 = 10-5nM
2592	15828822	2005	Sar-GViT-(NMeNva)-IRP	Compound 9	9	Acetylation	N-Ethylmaleimidation	Linear	Mix	Sar- Sarcosine , NMeNva- N-methyl-norvaline	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	1	Rat plasma proteases	Not mentioned	Rat plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 =0.54 ± 0.150 nM, Inhibition of HMVEC tube formation with IC50 = 50-25nM
2594	15828822	2005	Sar-GViT-NMeNva-IRP	Compound 11	9	Succinylation	N-Ethylmaleimidation	Linear	Mix	Sar- Sarcosine , NMeNva- N-methyl-norvaline	Synthetic (derived from peptide 1)	Antiangiogenic activity	Not mentioned	5mg/kg	0.3	Rat plasma proteases	Not mentioned	Rat plasma	in vivo	None	None	Inhibition of HMVEC migration with IC50 =0.06 ± 0.030 nM, Inhibition of HMVEC tube formation with IC50 = 0.25- 0.10nM
2606	17408666	2007	ARPYSFGL	Cydiastatin 4	8	Free	Amidation	Linear	L	None	Synthetic	Neuropeptides	30 °C for 20 minutes	1nmol	16.5	M. sexta larval midgut tissue proteases	RP-HPLC	Midgut tissues of M. sexta	in vitro	None	None	Not reported
2607	17408666	2007	ARPYSFGL	Cydiastatin 5	8	Free	Amidation	Linear	L	None	Synthetic	Neuropeptides	30 °C for 20 minutes	1nmol	2.5	M. sexta larval midgut lumen proteases	RP-HPLC	Midgut Lumen of M. sexta	in vitro	None	None	Not reported
2609	17408666	2007	PPPPPARPYSFGL	Cydiastatin 4-alpha	13	Free	Amidation	Linear	L	None	Synthetic	Neuropeptides	30 °C for 20 minutes	1nmol	4.5	M. sexta larval midgut lumen proteases	RP-HPLC	Midgut lumen of M. sexta	in vitro	None	None	Not reported
2610	17408666	2007	PPPPPARPYSFGL	Cydiastatin 4-alpha	13	Free	Amidation	Linear	L	None	Synthetic	Neuropeptides	31 °C for 20 minutes	1nmol	52	M. sexta haemolymph proteases	RP-HPLC	Haemolymph of M. sexta	in vitro	None	None	Not reported
2612	17408666	2007	PPPPPARPYSF-(Acpc)	Cydiastatin 4-alpha	12	Free	Amidation	Linear	L	Acpc=cyclopropylalanine	Synthetic	Neuropeptides	30 °C for 20 minutes	1nmol	7.5	M. sexta larval midgut lumen proteases	RP-HPLC	Midgut lumen	in vitro	None	None	Not reported
2613	17498958	2007	Pyr-HP	Thyrotropin-releasing hormone (TRH)	3	Free	Amidation	Linear	L	Pyr=pyroglutamic acid	Hypothalamus	Stimulates the release TSH(thyroid-stimulating hormone) by pitutiary gland	37 °C for 1-120 minutes	200Î¼M	~3	Homogenate of Caco-2 cells proteases	LC-MS	Homogenate of Caco-2 cells	in vitro	None	None	Not reported
2614	17498958	2007	Pyr-HP	Peptide1 (Thyrotropin-releasing hormone (TRH) analogue)	3	Free	D-glucopyranuronamide	Linear	L	Pyr=pyroglutamic acid	Synthetic derived from TRH	Stimulates the release TSH(thyroid-stimulating hormone) by pitutiary gland	37 °C for 1-120 minutes	200Î¼M	~20	Homogenate of Caco-2 cells proteases	LC-MS	Homogenate of Caco-2 cells	in vitro	None	None	Not reported
2615	17498958	2007	QHP	Peptide2 (Thyrotropin-releasing hormone (TRH) analogue)	3	2-aminooctanoic acid	D-glucopyranuronamide	Linear	L	None	Synthetic derived from TRH	Stimulates the release TSH(thyroid-stimulating hormone) by pitutiary gland	37 °C for 1-120 minutes	200Î¼M	~20	Homogenate of Caco-2 cells proteases	LC-MS	Homogenate of Caco-2 cells	in vitro	None	None	Not reported
2616	18049308	2007	FPESKATNATLDPRPGGGGNGDFEEIPEEYLQ	HLP(Hirulog-like peptide)	32	Free	Free	Linear	L	I125 labeling	Synthetic	Thrombin inhibitor	Blood collected after 2-120 minutes after i/v injection of peptide	3.2mg/kg	8.15 ±1.97 ( alpha or distribution half life)	Rat plasma proteases	Radioisotopic tracing method	Rat plasma	in vivo	None	None	Platelet aggregation %age = 24.33 ± 8.12, 25.67 ± 10.01 , 30.17 ± 1.13 for 3.2mg/kg/h . 2.3mg/kg/h 1.6 mg/kg/h respectively as compre to control which 36.67 ± 3.44 %; Therefore, bleeding time was significantly longer in rats received 1.6, 2.3, or 3.2 mg/kg/h of HLP compared to control
2617	18049308	2007	FPESKATNATLDPRPGGGGNGDFEEIPEEYLQ	HLP(Hirulog-like peptide)	32	Free	Free	Linear	L	I125 labeling	Synthetic	Thrombin inhibitor	Blood collected after 2-120 minutes after i/v injection of peptide	6.4mg/kg	9.69 ±1.5 ( alpha or distribution half life)	Rat plasma proteases	Radioisotopic tracing method	Rat plasma	in vivo	None	None	Platelet aggregation %age = 24.33 ± 8.12, 25.67 ± 10.01 , 30.17 ± 1.13 for 3.2mg/kg/h . 2.3mg/kg/h 1.6 mg/kg/h respectively as compre to control which 36.67 ± 3.44 %; Therefore, bleeding time was significantly longer in rats received 1.6, 2.3, or 3.2 mg/kg/h of HLP compared to control
2618	18049308	2007	FPESKATNATLDPRPGGGGNGDFEEIPEEYLQ	HLP(Hirulog-like peptide)	32	Free	Free	Linear	L	I125 labeling	Synthetic	Thrombin inhibitor	Blood collected after 2-120 minutes after i/v injection of peptide	12.8mg/kg	8.56 ±2.01 ( alpha or distribution half life)	Rat plasma proteases	Radioisotopic tracing method	Rat plasma	in vivo	None	None	Platelet aggregation %age = 24.33 ± 8.12, 25.67 ± 10.01 , 30.17 ± 1.13 for 3.2mg/kg/h . 2.3mg/kg/h 1.6 mg/kg/h respectively as compre to control which 36.67 ± 3.44 %; Therefore, bleeding time was significantly longer in rats received 1.6, 2.3, or 3.2 mg/kg/h of HLP compared to control
2619	18049308	2007	FPESKATNATLDPRPGGGGNGDFEEIPEEYLQ	HLP(Hirulog-like peptide)	32	Free	Free	Linear	L	I125 labeling	Synthetic	Thrombin inhibitor	Blood collected after 2-120 minutes after i/v injection of peptide	3.2mg/kg	24.74 ±8.30 ( beta or elimination half life)	Rat plasma proteases	Radioisotopic tracing method	Rat plasma	in vivo	None	None	Platelet aggregation %age = 24.33 ± 8.12, 25.67 ± 10.01 , 30.17 ± 1.13 for 3.2mg/kg/h . 2.3mg/kg/h 1.6 mg/kg/h respectively as compre to control which 36.67 ± 3.44 %; Therefore, bleeding time was significantly longer in rats received 1.6, 2.3, or 3.2 mg/kg/h of HLP compared to control
2620	18049308	2007	FPESKATNATLDPRPGGGGNGDFEEIPEEYLQ	HLP(Hirulog-like peptide)	32	Free	Free	Linear	L	I125 labeling	Synthetic	Thrombin inhibitor	Blood collected after 2-120 minutes after i/v injection of peptide	6.4mg/kg	27.38 ±11.52 ( beta or elimination half life)	Rat plasma proteases	Radioisotopic tracing method	Rat plasma	in vivo	None	None	Platelet aggregation %age = 24.33 ± 8.12, 25.67 ± 10.01 , 30.17 ± 1.13 for 3.2mg/kg/h . 2.3mg/kg/h 1.6 mg/kg/h respectively as compre to control which 36.67 ± 3.44 %; Therefore, bleeding time was significantly longer in rats received 1.6, 2.3, or 3.2 mg/kg/h of HLP compared to control
2621	18049308	2007	FPESKATNATLDPRPGGGGNGDFEEIPEEYLQ	HLP(Hirulog-like peptide)	32	Free	Free	Linear	L	I125 labeling	Synthetic	Thrombin inhibitor	Blood collected after 2-120 minutes after i/v injection of peptide	12.8mg/kg	30.49 ±10.24 ( beta or elimination half life)	Rat plasma proteases	Radioisotopic tracing method	Rat plasma	in vivo	None	None	Platelet aggregation %age = 24.33 ± 8.12, 25.67 ± 10.01 , 30.17 ± 1.13 for 3.2mg/kg/h . 2.3mg/kg/h 1.6 mg/kg/h respectively as compre to control which 36.67 ± 3.44 %; Therefore, bleeding time was significantly longer in rats received 1.6, 2.3, or 3.2 mg/kg/h of HLP compared to control
2622	18049308	2007	FPESKATNATLDPRPGGGGNGDFEEIPEEYLQ	HLP(Hirulog-like peptide)	32	Free	Free	Linear	L	I125 labeling	Synthetic	Thrombin inhibitor	Blood collected after 2-120 minutes after i/v injection of peptide	3.2mg/kg	1.45 ±0.53(gamma or termination elimination half life)	Rat plasma proteases	Radioisotopic tracing method	Rat plasma	in vivo	None	None	Platelet aggregation %age = 24.33 ± 8.12, 25.67 ± 10.01 , 30.17 ± 1.13 for 3.2mg/kg/h . 2.3mg/kg/h 1.6 mg/kg/h respectively as compre to control which 36.67 ± 3.44 %; Therefore, bleeding time was significantly longer in rats received 1.6, 2.3, or 3.2 mg/kg/h of HLP compared to control
2623	18049308	2007	FPESKATNATLDPRPGGGGNGDFEEIPEEYLQ	HLP(Hirulog-like peptide)	32	Free	Free	Linear	L	I125 labeling	Synthetic	Thrombin inhibitor	Blood collected after 2-120 minutes after i/v injection of peptide	6.4mg/kg	1.30 ±0.27 (gamma or termination elimination half life)	Rat plasma proteases	Radioisotopic tracing method	Rat plasma	in vivo	None	None	Platelet aggregation %age = 24.33 ± 8.12, 25.67 ± 10.01 , 30.17 ± 1.13 for 3.2mg/kg/h . 2.3mg/kg/h 1.6 mg/kg/h respectively as compre to control which 36.67 ± 3.44 %; Therefore, bleeding time was significantly longer in rats received 1.6, 2.3, or 3.2 mg/kg/h of HLP compared to control
2624	18049308	2007	FPESKATNATLDPRPGGGGNGDFEEIPEEYLQ	HLP(Hirulog-like peptide)	32	Free	Free	Linear	L	I125 labeling	Synthetic	Thrombin inhibitor	Blood collected after 2-120 minutes after i/v injection of peptide	12.8mg/kg	1.24 ±0.44 (gamma or termination elimination half life)	Rat plasma proteases	Radioisotopic tracing method	Rat plasma	in vivo	None	None	Platelet aggregation %age = 24.33 ± 8.12, 25.67 ± 10.01 , 30.17 ± 1.13 for 3.2mg/kg/h . 2.3mg/kg/h 1.6 mg/kg/h respectively as compre to control which 36.67 ± 3.44 %; Therefore, bleeding time was significantly longer in rats received 1.6, 2.3, or 3.2 mg/kg/h of HLP compared to control
2626	17532097	2007	FGGFTGARKSARKLANQ	N/OFQ (Nociceptin/Orphanin FQ peptide receptor)	17	Free	Free	Linear	L	None	Derived from the prepronociceptin protein	NOP-Receptor ligands	37 °C for 240 min	6 Î¼g/Î¼l	3.2 ±1.8	Mouse brain homogenate proteases	RP-HPLC	Mouse brain homogenate	in vitro	None	None	Hypotensive and bradycardic effects evoked by N/OFQ after i.v. administration in rats, was lasting (about 10 min)
2627	17532097	2007	FGG-(pF)F-TG-Aib-RKSARKRKNQ	UFP-112 (Nociceptin/Orphanin FQ receptor antagonist)	17	Free	Amidation	Linear	L	(pF)F = p-flouro Phenylalanine; Aib= 2-Aminoisobutyric acid	Synthetic	NOP-Receptor ligands	37 °C for 240 min	6 Î¼g/Î¼l	11.3 ±1.4	Mouse brain homogenate proteases	RP-HPLC	Mouse brain homogenate	in vitro	20497197	None	Hypotensive and bradycardic effects evoked by UFP-112 after i.v. administration in rats wast lasting for (i.e. 80 min
2633	18697865	2008	GSSFLSPEHQRVQQRKESKKPPAKLQPR	Ghrelin	28	Free	Free	Linear	L	n-octanoyl group at ser 3	Secreted by stomach P/D1-type cells	Stimulates apetite and GH secretion	Blood collected after 20 minutes to 2200 h after i/v injection of peptide	1 µg/kg i/v injected	21 ±3.0	Human plasma proteases	Competitive Radioimmunoassay	Human plasma	in vivo	15788704	None	Not reported
2634	18697865	2008	GSSFLSPEHQRVQQRKESKKPPAKLQPR	Ghrelin	28	Free	Free	Linear	L	n-octanoyl group at ser 3	Secreted by stomach P/D1-type cells	Stimulates apetite and GH secretion	Blood collected after 20 minutes to 2200 h after i/v injection of peptide	3 µg/kg i/v injected	45	Human plasma proteases	Competitive Radioimmunoassay	Human plasma	in vivo	15788704	None	Not reported
2635	18972837	2008	CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP	sCT (Salmon calcitonin)	32	Free	Free	Cyclic (C1-C7)	L	None	Hormone secreted by the parafollicular cells of thethyroid gland	Calcitropic Hormone, reduce blood calcium	5-360minutes	10 µM	13.18	Rat kidney homogenates proteases	LC-ESI-MS	Rat kidney homogenates	in vitro	None	None	Not reported
2636	18972837	2008	CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP	sCT (Salmon calcitonin)	32	Free	Free	Cyclic (C1-C7)	L	None	Hormone secreted by the parafollicular cells of thethyroid gland	Calcitropic Hormone, reduce blood calcium	5-360minutes	10 µM	43.07	Rat kidney homogenates proteases	LC-ESI-MS	Rat Liver homogenates	in vitro	None	None	Not reported
2637	19770015	2009	AEIYNKDGNKLDLYG	VrAPI (Aspartic protease inhibitor in seeds of V. radiata)	15	Free	Free	Linear	L	None	From plant Vigna radiata	Protease inhibitor	pH 2-10, Temp 20-100 °C	2mg -5mg at pH 3 and temperature 100	~30	None	Bradford assay	Buffer	in vitro	None	None	Total (aspartic protease) activity 2516 U
2639	21185160	2011	VDKPPYLPRPRPPRRIYNR	O-1(Oncocin)	19	Free	Amidation	Linear	L	None	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	25 ±4	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 8 Î¼g/mL M.luteus
2652	21185160	2011	VDKPPYLPRPRPPRrIYNR	O-16 (Oncocin)	19	Free	Amidation	Linear	Mix	D-Arg at 15th position	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	58 ±2	Mouse serum proteases	MALDI-TOF-MS	25% mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 4 Î¼g/mL M.luteus
2653	21185160	2011	VDKPPYLPRPRPPR-Har-IYN-Har	O-17 (Oncocin)	19	Free	Amidation	Linear	L	Har=Homoarginine	2kDa Oncopeltus peptide derivatives	Antimicrobial	30-480 Minutes	7.5 Î¼g/100Î¼l	55	Mouse serum proteases	MALDI-TOF-MS	Full mouse serum	in vivo	None	None	MIC = 4 Î¼g/mL in E.coli BL21A1 and 4 Î¼g/mL M.luteus
2662	22186872	2011	DRVYIHPFHL	Angiotensin I	10	Free	Free	Linear	L	None	Derived from angiotensinogen	Precursor of angiotensin-II	Room Temperature	1mg/mL	1	Hydolytic activity of bacterial strain B-9	HPLC and LC/ITMS	Bacterial strain B-9 cell culture	in vitro	None	None	Not reported
2663	22186872	2011	RPPGFSPFR	Bradykinin	9	Free	Free	Linear	L	None	Endogenous peptide of kinin family	Vasodilator, Inflammatory mediator	Room Temperature	1mg/mL	<5	Hydolytic activity of bacterial strain B-9	HPLC and LC/ITMS	Bacterial strain B-9 cell culture	in vitro	None	None	Not reported
2664	22186872	2011	YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE	Î²-Endorphin	31	Free	Free	Linear	L	None	Endogenous opioid neuropeptide in neurons of both the central and peripheral nervous system.	Agonist of the opioid receptors	Room Temperature	1mg/mL	<5	Hydolytic activity of bacterial strain B-9	HPLC and LC/ITMS	Bacterial strain B-9 cell culture	in vitro	None	None	Not reported
2665	22186872	2011	YGGFL	[Leu5]Enkephalin	5	Free	Free	Linear	L	None	Endogenous opioid neuropeptide in neurons of both the central and peripheral nervous system.	Neurotransmitter	Room Temperature	1mg/mL	<5	Hydolytic activity of bacterial strain B-9	HPLC and LC/ITMS	Bacterial strain B-9 cell culture	in vitro	None	None	Not reported
2666	22186872	2011	RPKPQQFFGLM	Substance P	11	Free	Amidation	Linear	L	None	Member of the tachykinin neuropeptide family.	Neurotransmitter	Room Temperature	1mg/mL	10	Hydolytic activity of bacterial strain B-9	HPLC and LC/ITMS	Bacterial strain B-9 cell culture	in vitro	None	None	Not reported
2668	22186872	2011	AGCKNFFWKTFTSC	Somatostatin	14	Free	Free	Cyclic (C3-C14)	L	None	Neuropeptide secreted by Hypothalamus	Inhibits insulin and glucagon secretion.	Room Temperature	1mg/mL	10	Hydolytic activity of bacterial strain B-9	HPLC and LC/ITMS	Bacterial strain B-9 cell culture	in vitro	None	None	Not reported
2670	22263969	2012	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP-Fc (Atrial natriuretic peptide- Fc)	28	Free	Free	Cyclic (C7-C23)	L	None	Synthetic ANP peptides linked to the N-terminus of recombinantly expressed Fc using native chemical ligation.	Natriuretic and vasodilator	4-72 hours	0.5mg/kg of protein	2 to 5	Rat plasma proteases	ELISA	Female Wistar rats Plasma	in vivo	None	None	Not reported
2675	23318502	2013	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1(7 €“36)NH2 [Glucagon-like peptide-1]	30	Free	Amidation	Linear	L	None	GLP-1	Regulate blood glucose	Blood sample collected after 32-60 minutes after the infusion of peptide	20pmol/kg	4.8 ±0.8	Pig kidneys proteases	Radioactivity measurement	Pig kidney	in vivo	None	None	Not reported
2676	23318502	2013	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Ex-4 (Exendin-4)	39	Free	Free	Linear	L	None	Derived from Saliva of Gila monster	GLP-1 receptor agonist	Blood sample collected after 50-130 minutes after the infusion of peptide	10 pmol/kg	32.8 ±4.1	Pig kidneys proteases	Radioactivity measurement	(Bolus injection)Pig kidney	in vivo	None	None	Not reported
2677	23318502	2013	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Ex(1 €“30) or Exendin(1 €“30)	30	Free	Free	Linear	L	None	Synthetic derived from Exendin 4	GLP-1 receptor agonist	Blood sample collected after 42-130 minutes after the infusion of peptide	20 pmol/kg	28.4 ±1.7	Pig kidneys proteases	Radioactivity measurement	(Bolus injection)Pig kidney	in vivo	None	None	Not reported
2678	23318502	2013	HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRPSSGAPPPS	GLP-1Arg34(7 €“36), Ex(31 €“39) or [GLP-Ex]	39	Free	Free	Linear	L	None	Synthetic	GLP-1 receptor agonist	Blood sample collected after 42-130 minutes after the infusion of peptide	20 pmol/kg	19.5 ±3.3	Pig kidneys proteases	Radioactivity measurement	(Bolus injection)Pig kidney	in vivo	None	None	Not reported
2679	23813302	2013	Sar-RVYIHPa	TRV027	8	Sar=Sarcosine	Free	Linear	Mix	D-Ala at 8th position	Synthetic Î²-arrestin-biased agonist	Beta €arrestin €biased AT1R(Angiotensin type 1 Receptor) ligand, antagonize G-protein signaling & stimulates beta-arrestin recruitment	Not mentioned	0.01 - 20 Î¼g/kg/min dose	<2 (intial half life)	Human plasma proteases	LC/MS/MS	Human plasma	in vivo	None	None	Not reported
2680	23813302	2013	Sar-RVYIHPa	TRV027	8	Sar=Sarcosine	Free	Linear	Mix	D-Ala at 8th position	Synthetic Î²-arrestin-biased agonist	Beta €arrestin €biased AT1R(Angiotensin type 1 Receptor) ligand, antagonize G-protein signaling & stimulates beta-arrestin recruitment	Not mentioned	0.01 - 20 Î¼g/kg/min dose	~ 10 (Terminal half life)	Human plasma proteases	LC/MS/MS	Human plasma	in vivo	None	None	Not reported
2683	24588343	2014	EGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1(9-36)(Glucagon Like protein-1)	28	Free	Amidation	Linear	L	None	Glucagon Like protein-1 (GLP-1)	Vasodialator	2-120 minutes	20Î¼g/Kg	0.05	Dog hepatocyte proteases	LC-MS	Male beagle dog plasma (Dose i/v injected)	in vivo	None	None	Not reported
2684	24588343	2014	EGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1(9-36)(Glucagon Like protein-1)	28	Free	Amidation	Linear	L	None	Glucagon Like protein-1 (GLP-1)	Vasodialator	3-120 minutes	50Î¼g/Kg	0.54	Dog hepatocyte proteases	LC-MS	Male beagle dog plasma (Dose s/c injected)	in vivo	None	None	Not reported
2685	24588343	2014	EGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1(7-36)(Glucagon Like protein-1)	28	Free	Amidation	Linear	L	None	Glucagon Like protein-1 (GLP-1)	Vasodialator	4-120 minutes	50Î¼g/Kg	2.1	Dog hepatocyte proteases	LC-MS	Male beagle dog plasma (Dose s/c injected)	in vivo	None	None	Not reported
2686	25025626	2014	MKFTLFSVLVVLLIATFVAADDCPRICTADFRPVCGTPSGGRRSANRTFGNQCSLDSHNCLNKGDTYDKLHDGECK	Vasotab TY	76	Free	Free	Linear	L	None	Salivary glands of the horsefly ofTabanus yao	Vasodialator and anti-thrombic	1-480 minutes	5mg/kg	>1	Mouse plasma proteases	ELISA	Kunming Mouse plasma (Dose i/v injected)	in vivo	None	None	At the dosages of 5,10, and 20 nmol/kg, vasotab TY inhibited thrombus formation by47.2, 72.2, and 86.1%, respectively.
2687	25025626	2014	MKFTLFSVLVVLLIATFVAADDCPRICTADFRPVCGTPSGGRRSANRTFGNQCSLDSHNCLNKGDTYDKLHDGECK	Vasotab TY	76	Free	Free	Linear	L	None	Salivary glands of the horsefly ofTabanus yao	Vasodialator and anti-thrombic	1-480 minutes	5mg/kg	50	Mouse lungs proteases	ELISA	Kunming Mouse lungs (Dose i/v injected)	in vivo	None	None	At the dosages of 5,10, and 20 nmol/kg, vasotab TY inhibited thrombus formation by47.2, 72.2, and 86.1%, respectively.
2688	25039358	2014	EGTFTSDVSSYLEGQAAKEFIAWLVKGR	Gly8-GLP-1(7-36)(Glucagon Like protein-1)	30	Free	Amidation	Linear	L	None	Glucagon Like protein-1 (GLP-1)	Vasodialator	37 °C for 2-72 hours	1000ng/ml	0.6	Rat plasma proteases	LC-MS/MS	Rat Plasma	in vitro	None	None	GLP-1 receptor Activation potency with EC50 = 8.3 ± 0.4 pM in HEK-293 cells
2707	25243635	2014	HAEGTFTSDVSCYLEGQAACEFIAWLVKGRG	GLP-1(Glucagon Like protein-1)	31	Free	Free	Linear	L	None	Glucagon Like protein-1 (GLP-1)	Antihyperglycemic	5-90 hours	500Î¼g	<2	DPP IV	ELISA	DPP IV	in vitro	None	None	The insulin levels were increased dramatically to 806.74 ± 30.60 pmol/L within 15 min after GLP-1 administration
2715	25771000	2015	HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY	BAY55-9837 (VPAC2 receptor agonist)	31	Free	Free	Linear	L	None	Pituitary adenylate cyclase-activating peptides (PACAPs) derived peptide	Insulin secretion stimulant	37 C, 48 Hours	10 µM	4.18	Fxa(Facor Xa) and DPP-IV	HPLC-ESI/MS/MS	Protein Sample +HAS + Fxa +DPP IV	in vitro	None	None	AUC for glucose -stimulated 1st phase insulin secretion in BAY55-9837-treated mice (20nmol/kg) is 0.79 fold higher than control
2716	25771000	2015	HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY	BAY55-9837 (VPAC2 receptor agonist)	31	Free	Free	Linear	L	None	Pituitary adenylate cyclase-activating peptides (PACAPs) derived peptide	Insulin secretion stimulant	0.5-24 hours	0.5 mg/kg	~ 5	db/db mice plasma proteases	LC-MS/MS	db/db Mice plasma (Dose i/v injected)	in vivo	None	None	AUC for glucose -stimulated 1st phase insulin secretion in BAY55-9837-treated mice (20nmol/kg) is 0.79 fold higher than control
2717	25771000	2015	HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY	BAY55-9837 (VPAC2 receptor agonist)	31	Free	Free	Linear	L	None	Pituitary adenylate cyclase-activating peptides (PACAPs) derived peptide	Insulin secretion stimulant	0.5-24 hours	0.5 mg/kg	~ 5	Rabbit plasma proteases	LC-MS/MS	New Zealand White Rabbit plasma (Dose i/v injected)	in vivo	None	None	AUC for glucose -stimulated 1st phase insulin secretion in BAY55-9837-treated mice (20nmol/kg) is 0.79 fold higher than control
2735	26197931	2015	YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY	PYY(3-34) [Peptide YY]	34	Free	Free	Linear	L	None	Synthetic peptide hormone released from enteroendocrine cells	Antihyperglycemic or incretin effect(Stimulate Insulin release in glucose dependent manner)	Blood sample collected after 15minutes of the infusion of peptide	100 pmol/kg	3.6 ±0.5	Pig blood proteases	Radioimmunoassay	Female pigs blood	in vivo	None	None	Porcine PYY 3 €“36 signaled through the Y-2 receptor in COS-7 cells with potency with EC50 = 3.9nmol/L
2736	26197931	2015	YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY	PYY(1-36) [Peptide YY]	36	Free	Free	Linear	L	None	Synthetic peptide hormone released from enteroendocrine cells	Antihyperglycemic or incretin effect(Stimulate Insulin release in glucose dependent manner)	Blood sample collected after 15minutes of the infusion of peptide	100 pmol/kg	7.3 ±0.8	Pig blood proteases	Radioimmunoassay	Female pigs blood	in vivo	None	None	Not reported
2751	26222180	2015	HA/EGTFTSDVSSYLEGQAAKEFIAWLVKGRG	G 37 or [GLP-1(7 €“37)]	31	Free	Free	Linear	L	None	Glucagon-like peptide 1 (GLP-1)	Antihyperglycemic or incretin effect(Stimulate Insulin release in glucose dependent manner)	Room Temp	0.4 µM	1 ±0.3	Human blood proteases + DPP IV	MS	EDTA whole blood	in vitro	None	None	Not reported
2763	26308095	2015	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	Saliva of Gila monster	Regulates blood glucose by upregulating the insulin secretion	Blood sample collected after 1-96 hours after the injection of peptide	5nmol/Kg	30	Rat plasma proteases	ELISA, LC/MS	Rat Plasma (Dose i/v injected)	in vivo	None	None	Not reported
2768	26325323	2015	pGlu-HWSYGLRPG	Endogenous LHRH	10	Free	Amidation	Linear	L	Pyro-Glutamate at 1st position	Hypothalamus	Stimulates pitutiary gland to secretes to release gonadotropins(LH, FSH)	Blood sample collected after0.5-24 hours after the injection of peptide	2.5mg/Kg	4-8min	Human plasma proteases	LC/MS	Human plasma (Dose s/c injected)	in vivo	None	None	Not reported
2771	26337231	2015	LLTHTISRIAVSYQTKVNLL	P16 [TNF Î± (75 €“94)]	20	Free	Free	Linear	L	None	Tumor necrosis factor-derived (TNF)	Tumor growth inhibitor and anti-angiogenic	Blood sample collected after0.5-24 hours after the injection of peptide	5mg/kg	0.096 ±0.008	BALB/c mice plasma proteases	LC/MS	BALB/c mice plasma (Dose i/v injected)	in vivo	None	None	Growth inhibition effect of RMP16 was observed in DU145 cells (IC50 = 17.20 ± 1.95 nM, Tumor inhibition rates of P16-treated mice was 21.81%
2773	26400022	2015	fPRPGGGGQGDFEEIPEEYL	Hirulog-1	20	Free	Free	Linear	Mix	None	Hirudin derived	Anti-coagulant	Not mentioned	1.0Î¼M/Kg	20-25	Human plasma proteases	HPLC, MS-MS	Human plasma (Dose i/v injected)	in vivo	None	None	Inhibition constant for peptides (Ki, nM) in rat thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 20.50 ± 0.62nM; Inhibition constant for peptides (Ki, nM) in human thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 11.77 ± 0.09nM
2774	26400022	2015	fPRPGGGGQGDFEEIPEEYL	Hirulog-1	20	Free	Free	Linear	Mix	None	Hirudin derived	Anti-coagulant	Not mentioned	1.0Î¼M/Kg	15 ±1.3	Rat plasma proteases	HPLC, MS-MS	Sprague-Dawley (SD) rats plasma (Dose i/v injected)	in vivo	None	None	Inhibition constant for peptides (Ki, nM) in rat thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 20.50 ± 0.62nM; Inhibition constant for peptides (Ki, nM) in human thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 11.77 ± 0.09nM
2775	26400022	2015	fPRPGGGGQGDFEPIPEDAYDE	Peptide 1 (Hirudin mimetic peptide)	22	Free	Amidation	Linear	Mix	None	Hirudin derived	Anti-coagulant	Not mentioned	1.0Î¼M/Kg	13+-2.6	Rat plasma proteases	HPLC, MS-MS	Sprague-Dawley (SD) rats plasma (Dose i/v injected)	in vivo	None	None	Inhibition constant for peptides (Ki, nM) in rat thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 13.40 ± 0.46 nM; Inhibition constant for peptides (Ki, nM) in human thrombin €“catalyzed hydrolysis of Chromozym TH with Ki 5.80 ± 0.55nM
2777	18632826	2008	CKQSCSFGPFTFVCDGNTK	99m Tc-Duramycin	19	Free	Free	Linear	L	Succinimidyl 6-hydrazinonicotinate acetone hydrazone (HYNIC) derivatized, HYNIC conjugated at either at Cys -1 or Amine group Of Lys-2	Phosphatidylethanolamine binding probe and employed in In Vivo Imaging of Acute Cardiac Cell Death	Molecular probe for imaging PtdE	Blood sample collected at 1-60 minutes	2.3nmol	<4	Rat blood proteases	HPLC radiodetection (radio-HPLC)	Healthy Sprague €“Dawley rats blood	in vivo	None	None	Binding of 99mTc-duramycin to apoptotic cells was elevated by a factor of 32 ± 6
2778	21459096	2011	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP (Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Derived from parotid gland	Vasorelaxing	37 °C for 0-125 minutes	Not mentioned	1.3	Human kidney proteases	Not mentioned	Human kidney membrane extract	in vitro	None	None	Not reported
2779	21459096	2011	SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH	BNP(B-type natriuretic peptide)	32	Free	Free	Cyclic (C10-C26)	L	None	Brain natriuretic peptide	Cardiac fibrosis Inhibitor	37 °C for 0-125 minutes	Not mentioned	8	Human kidney proteases	Not mentioned	Human kidney membrane extract	in vitro	None	None	Not reported
2780	21459096	2011	GLSKGCFGLKLDRIGSMSGLGC	CNP(C-type natriuretic peptide)	22	Free	Free	Cyclic (C6-C22)	L	None	Secreted from vascular endothelium	Vasodialator	37 °C for 0-125 minutes	Not mentioned	4.3	Human kidney proteases	Not mentioned	Human kidney membrane extract	in vitro	19395584	None	Not reported
2782	21459096	2011	GLSKGCFGLKLDRIGSMSGLGCPSLRDPRPNAPSTSA	CD-NP (C-terminal tail of DNP)	37	Free	Free	Cyclic (C6-C22)	L	None	Chimeric peptide derived from CNP and DNP	Natriuretic and aldosterone suppressor	37 °C for 0-125 minutes	Not mentioned	17-22.9	Human kidney proteases	Not mentioned	Human kidney membrane extract	in vitro	None	None	Not reported
2784	19344673	2009	SCSlPQT	Mouse [D-Leu-4]OB3	7	Free	Free	Linear	Mix	None	Synthetic peptide amide with leptin-like activity	Regulate energy balance by inhibiting hunger	Blood collected after 5-120 minutes after peptide delivery	1mg/200ul	30	Mice serum proteases	Competitive ELISA	Male Swiss Webster mice serum (Intraperitoneal route of delivery)	in vivo	11495687	None	Not reported
2785	19344673	2009	SCSlPQT	Mouse [D-Leu-4]OB3	7	Free	Free	Linear	Mix	None	Synthetic peptide amide with leptin-like activity	Regulate energy balance by inhibiting hunger	Blood collected after 5-120 minutes after peptide delivery	1mg/200ul	35	Mice serum proteases	Competitive ELISA	Male Swiss Webster mice serum (Subcutaneous Route of delivery)	in vivo	11495687	None	Not reported
2786	19344673	2009	SCSlPQT	Mouse [D-Leu-4]OB3	7	Free	Free	Linear	Mix	None	Synthetic peptide amide with leptin-like activity	Regulate energy balance by inhibiting hunger	Blood collected after 5-120 minutes after peptide delivery	1mg/200ul	42	Mice serum proteases	Competitive ELISA	Male Swiss Webster mice serum (Intra-muscular route of delivery)	in vivo	11495687	None	Not reported
2787	19344673	2009	SCSlPQT	Mouse [D-Leu-4]OB3	7	Free	Free	Linear	Mix	None	Synthetic peptide amide with leptin-like activity	Regulate energy balance by inhibiting hunger	Blood collected after 5-120 minutes after peptide delivery	1mg/200ul	41.1	Mice serum proteases	Competitive ELISA	Male Swiss Webster mice serum (Intranasal route of delivery)	in vivo	11495687	None	Not reported
2788	19157421	2009	GPE	Glypromate	3	Free	Free	Linear	L	None	N-terminal cleavage product of human insulin-like growth factor-1 (IGF-1) in the brain	Neuroprotective	Blood collected after 0.5-12 hours after peptide delivery	3 -10 mg/kg/h dose	5	Rat plasma proteases	LC-MS	Sprague-Dawley rats plasma (Dose i/v injected)	in vivo	None	None	Not reported
2789	19157421	2009	GPE	NNZ-2566 (Glycyl-L-2-methylprolyl-L- glutamic acid)	3	Free	Free	Linear	L	Methylation of alpha-C of Pro	Glypromate analogue	Neuroprotective	Blood collected after 0.5-12 hours after peptide delivery	3 -10 mg/kg/h dose	49	Rat blood proteases	LC-MS	Sprague-Dawley rats brain (Dose i/v injected)	in vivo	None	None	NNZ-2566-treated animals(i/v) exhibited an average infarct area of 79.8 ±10.4 mm2 (3 mg/kg/h, pb0.01) and 21.3 ±7.5 mm2 (10 mg/kg/h) as compare to ET-1 induced an infarct area of 153.1 ±20.1 mm2 (mean ±s.e.m) in saline-treated rat; Total injury size was 22.2 ±5.7 mm2 following 30 mg/kg (76% protection; Dunnett's multiple comparison test) and only 4.6 ±2.3 mm2 following 60 mg/kg (95% protection; Dunnett's multiple comparison test).
2797	24139844	2013	Hyp-AS-Chg-Q	Conjuagte 3(conjugates of 4-aminocyclophosphamide (4-NH2-CPA))	5	Bn-glutarylation	Amidated CPA	Linear	L	None	Synthetic peptide derived from conjugates of 4-aminocyclophosphamide (4-NH2-CPA)	Anti-cancer	Not mentioned	Not mentioned	55	PSA(Prostate-specific antigen )	HPLC	Conjuagte 3+PSA(Prostate-specific antigen)	in vitro	None	None	pEC50-8.19 ±1.0minutes, Emax 9.44 ±0.3 nmol/well
2799	24874704	2014	YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY	AM(adrenomedullin)	52	Free	Amidation	Cyclic (Ringed structure formed by C16-C21)	L	None	Isolated from Human pheochromocytoma	Vasodilator and cardiovascular protection	Not mentioned	3nmol/kg Dose	15.2 ±1.9 min (2nd plasma half life)	Rat plasma proteases	ELISA	Male Wistar rats plasma	in vivo	http://www.genscript.com/peptide/RP11288-Adrenomed	None	Native human AM peptide elevated intracellular cAMP levels in a dose-dependent manner with pEC50 and Emax values of 8.59 ± 0.90 and9.30 ± 0.26 nmol/well
2800	24874704	2014	YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY	PEGylated AM	52	Pegylation	Amidation	Cyclic (Ringed structure formed by C16-C21)	L	None	Isolated from Human pheochromocytoma	Vasodilator and cardiovascular protection	Not mentioned	3nmol/kg Dose	4.87 ±0.68(1st plasma half life)	Rat plasma proteases	ELISA	Male Wistar rats plasma	in vivo	http://www.genscript.com/peptide/RP11288-Adrenomed	None	PEGylated AM peptide elevated intracellular cAMP levels in a dose-dependent manner with pEC50 and Emax values of 8.519 ± 0.10 and9.44 ± 0.30 nmol/well
2807	25453979	2014	SCSlPQT	(D-Leu-4)OB3	7	Free	Free	Linear	Mix	None	Synthetic peptide amide with leptin-like activity	Regulate energy balance by inhibiting hunger	Not mentioned	Peptide was dissolved in 0.3% Intravail ® reconstituted in sterile deion-ized water at a concentratio	34	Mice serum proteases	Competitive ELISA	Male Swiss Webster mice serum(Subcutaneous Route of delivery)	in vivo	None	None	Efficacy of MA-[D-Leu-4]-OB3 on blood glucose levels in db/dbmice following oral delivery in 0.3% DDM
2808	25453979	2014	SCSlPQT	(D-Leu-4)OB3	7	Free	Free	Linear	Mix	None	Synthetic peptide amide with leptin-like activity	Regulate energy balance by inhibiting hunger	Not mentioned	Peptide was dissolved in 0.3% Intravail ® reconstituted in sterile deion-ized water at a concentratio	49	Mice serum proteases	Competitive ELISA	Male Swiss Webster mice serum (Intraperitoneal route of delivery)	in vivo	None	None	Efficacy of MA-[D-Leu-4]-OB3 on blood glucose levels in db/dbmice following oral delivery in 0.3% DDM
2809	25453979	2014	SCSlPQT	(D-Leu-4)OB3	7	Free	Free	Linear	Mix	None	Synthetic peptide amide with leptin-like activity	Regulate energy balance by inhibiting hunger	Not mentioned	Peptide was dissolved in 0.3% Intravail ® reconstituted in sterile deion-ized water at a concentratio	36	Mice serum proteases	Competitive ELISA	Male Swiss Webster mice serum (Intra-muscular route of delivery)	in vivo	None	None	Efficacy of MA-[D-Leu-4]-OB3 on blood glucose levels in db/dbmice following oral delivery in 0.3% DDM
2810	25453979	2014	SCSlPQT	(D-Leu-4)OB3	7	Free	Free	Linear	Mix	None	Synthetic peptide amide with leptin-like activity	Regulate energy balance by inhibiting hunger	Not mentioned	Peptide was dissolved in 0.3% Intravail ® reconstituted in sterile deion-ized water at a concentratio	20	Mice serum proteases	Competitive ELISA	Male Swiss Webster mice serum (Oral route of delivery)	in vivo	None	None	Efficacy of MA-[D-Leu-4]-OB3 on blood glucose levels in db/dbmice following oral delivery in 0.3% DDM
2811	25453979	2014	SCSlPQT	(D-Leu-4)OB3	7	Free	Free	Linear	Mix	None	Synthetic peptide amide with leptin-like activity	Regulate energy balance by inhibiting hunger	Not mentioned	Peptide was dissolved in 0.3% Intravail ® reconstituted in sterile deion-ized water at a concentratio	41	Mice serum proteases	Competitive ELISA	Male Swiss Webster mice serum (Intranasal route of delivery)	in vivo	None	None	Stimulates TLR3 signaling and Inhibits TLR4 signaling by seqsteting LPS
2812	24462899	2014	CSSPIQGSWTWENGK(propargylglycine)WTWKGIIRLEQ	APTEDB-DTX (Fibronectin extra domain B (EDB)-specific aptide docetaxel conjugate)	27	Free	Free	Linear	L	Modified Gly at 16th postion i.e. propargylglycine and peptide conjugated with drug DTX at this position	Fibronectin extra domain B (EDB)-specific aptide docetaxel conjugate	Drug(anticancer agent i.e. DTX) Delivery vehicle	Not mentioned	5 mg DTX/kg Dose	0.491	Mice serum proteases	HPLC	C57BL6 mice Serum	in vivo	None	None	Stimulates TLR3 signaling and Inhibits TLR4 signaling by seqsteting LPS
2813	5092290	2014	LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES	LL-37 (Antimicrobial Peptide)	37	Free	Free	Linear	L	None	Human epithelial cells(proteolytic cleavage of c-ter portion of hCAP-18 protein)	Antimicrobial	15-720 minutes hour	3 µM	~1	Cathepsin	Proteolysis assay, (confirmed by Western blotting)	Western Blotting	in vitro	16716248	None	Not reported
2816	1319455	1992	SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII	hCRH(Human Corticotropin Releasing Hormone)	41	Free	Free	Linear	L	None	Derived from Pre-hormone	Hormone causes Adrenocorticotropin secrection and neurotransmitter	2.5-180 minutes	100Î¼g	30.5 ±3.3	Human plasma proteases	IRM(Immunoradiometric assays)	Human plasma	in vivo	12379493	None	22.4 ± 8.1 ng/hour (ACTH response)
2817	1319455	1992	SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII	hCRH(Human Corticotropin Releasing Hormone)	41	Free	Free	Linear	L	None	Derived from Pre-hormone	Hormone causes Adrenocorticotropin secrection and neurotransmitter	2.5-180 minutes	100Î¼g	46.5 ±7.2	Sheep plasma proteases	IRM(Immunoradiometric assays)	Human plasma	in vivo	12379493	None	46.5 ± 6.4 ng/hour (ACTH response)
2818	1319455	1992	SQEPPISLVLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	oCRH(Ovine Corticotropin Releasing Hormone)	41	Free	Free	Linear	L	None	Derived from Pre-hormone	Hormone causes Adrenocorticotropin secrection and neurotransmitter	2.5-180 minutes	100Î¼g	42.8 ±6.4	Human plasma proteases	IRM(Immunoradiometric assays)	Sheep plasma	in vivo	6603620	None	39.9 ± 11.7 ng/hour (ACTH response)
2819	1319455	1992	SQEPPISLVLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	oCRH(Ovine Corticotropin Releasing Hormone)	41	Free	Free	Linear	L	None	Derived from Pre-hormone	Hormone causes Adrenocorticotropin secrection and neurotransmitter	2.5-180 minutes	100Î¼g	39.8 ±10.1	Sheep plasma proteases	IRM(Immunoradiometric assays)	Sheep plasma	in vivo	6603620	None	40.2 ± 8.4 ng/hour (ACTH response)
2826	1387608	1992	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP (Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Hormone secreted by heart muscle cells	Natriuretic and vasodilator	Blood collected 1-60 minutes after peptide infused	2Î¼g/min	12.5 (Terminal half life)	Human plasma proteases	IRM(Immunoradiometric assays)	Young Human plasma (average age 23.3) (Dose i/v injected)	in vivo	None	None	Not reported
2827	1387608	1992	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP (Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Hormone secreted by heart muscle cells	Natriuretic and vasodilator	Blood collected 1-60 minutes after peptide infused	2Î¼g/min	9.6 (Terminal half life)	Human plasma proteases	IRM(Immunoradiometric assays)	Older Human plasma(average age 75.3) (Dose i/v injected)	in vivo	None	None	Not reported
2835	1646465	1991	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	rANP(99-126) (Recombinant atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Derived from ANP (Atrial natriuretic peptide)	Natriuretic and vasodilator	Blood samples collected at 5-1800 seconds after peptide injecteion	Not mentioned	114 ±38.6	Rat plasma proteases	Radioimmunoassay	Male Wistar rats plasma	in vivo	None	None	Not reported
2836	1646465	1991	SQDSAERIQERLRNSKMAHSSSCFGQKIDRIGAVSRLGCDGLRQF	iso-rANP(1-45) (Recombinant atrial natriuretic peptide)	45	Free	Free	Cyclic (C23-C39)	L	None	Derived from ANP (Atrial natriuretic peptide)	Natriuretic and vasodilator	Blood samples collected at 5-1800 seconds after peptide injecteion	1 x 106 cpm	130 ±13	Rat plasma proteases	Radioimmunoassay	Male Wistar rats plasma (Dose i/p injected)	in vivo	None	None	Not reported
2838	1646465	1991	SQDSAERIQERLRNSKMAHSSSCFGQKIDRIGAVSRLGCDGLRQF	iso-rANP(1-45) (Recombinant atrial natriuretic peptide)	45	Free	Free	Cyclic (C23-C39)	L	None	Derived from ANP (Atrial natriuretic peptide)	Natriuretic and vasodilator	Blood samples collected at 5-1800 seconds after peptide injecteion	1x 106 cpm	164.3 ±9.0(Î²- t1/2)	Rat plasma proteases	Radioimmunoassay	Male Wistar rats plasma (Dose i/p injected)	in vivo	None	None	Not reported
2841	1649728	1991	HSDAVFTDNYTRLRKQMAVKKYLNSILN	VIP(Vasoactive intestinal peptide)	28	Free	Amidation	Linear	L	None	Peptide hormone secreted by Intestine	Stimulates the secretion of electrolytes and water	Sample collected at 40-50 minutes	10pmol min-1 kg -1 peptide infused	1.27 ±0.20	Rabbit plasma proteases	Radioimmunoassay	New Zealand White rabbits plasma(have normal sodium diet i.e. 29.35 k 4.02 pmol/l)	in vivo	None	None	Not reported
2843	1723638	1991	GWTLNSAGYLLGPHAI	Galanin(1-16)	16	Free	Free	Linear	L	None	High affinity synthetic agonist	Neuroendocrine activities, stimulates growth hormone secretion	37 °C	2 Î¼M	28	Hypothalamic membrane protaeses	HPLC	Hypothalamic membranes of Male Sprague-Dawley rats	in vitro	None	None	Not reported
2844	1730807	1992	HwAWfK	GHRP (Growth Hormone releasing peptide)	6	Free	Amidation	Linear	Mix	None	Growth Hormone releasing peptide	Release growth hormone	Not mentioned	100Î¼g/kg	20	Human serum proteases	Radioimmunoassay	Human serum	in vivo	None	None	GH response elicited by 300 Î¼g/kg on oral administeration of peptide
2845	1763193	1991	aSTTTNYT	Peptide T (Dala1-peptide T-NH2)	8	Free	Amidation	Linear	Mix	None	Synthetic derived from the external envelope protein of HIV IIIB	HIV-entry inhibitor	Not mentioned	Intravenous test dose of 0.033 mg/Kg of peptide T	30-60	AIDS patient plasma proteases	Radioimmunoassay , HPLC	AIDS patient plasma	in vivo	None	None	Not reported
2846	1826667	1991	YADAIFTNSYRKVLGQLSARKLLQDIMSR	GRF(1-29)-NH2 (Growth hormone-releasing factor (GRF- Growth regulating factor))	29	Free	Amidation	Linear	L	None	Growth regulating factor (GRF)	Release growth hormone	Not mentioned	100 µg/ml	0.25	Porcine plasma proteases	HPLC	Porcine plasma	in vitro	None	None	Not reported
2847	1826667	1991	YADAIFTNSYRKVLGQLSARKLLQDIMSR	[Ala15]GRF(1-29)-NH2	29	Free	Amidation	Linear	L	None	Synthetic(GRF-1 analogs)	Release growth hormone	Not mentioned	100 µg/ml	0.3	Porcine plasma proteases	HPLC	Porcine plasma	in vitro	None	None	Not reported
2848	1826667	1991	YADAIFTNSYRKVLGQLSARKLLQDIMSR	[DesNH2-Tyr1,Ala15]GRF(1-29)-NH2	29	Chlorpheniramine M	Amidation	Linear	L	None	Synthetic(GRF-1 analogs)	Release growth hormone	Not mentioned	100 µg/ml	1	Porcine plasma proteases	HPLC	Porcine plasma	in vitro	None	None	Not reported
2849	1826667	1991	YaDAIFTNSYRKVLAQLSARKLLQDIMSR	[DesNH2-Tyr1,D-Ala2,Ala15]GRF(1-29)-NH2	29	Chlorpheniramine M	Amidation	Linear	Mix	None	Synthetic(GRF-1 analogs)	Release growth hormone	Not mentioned	100 µg/ml	1	Porcine plasma proteases	HPLC	Porcine plasma	in vitro	None	None	Not reported
2855	1889124	1991	AQKVNSGEPRAHLGALLARYIQQARKAPSGRMSVIKNLQNLDPSHRISDRDYMGWMDF	CCK58 (Cholecystokinin 58)	58	Free	Amidation	Linear	L	None	Peptide hormone of the gastrointestinal system	Stimulates digestion of fat & protein	37 °C for 30-180 minutes	1.6pmol	45 ±5	Normal Human plasma proteases	Radioimmunoassay and HPLC	Normal Human plasma	in vitro	None	None	Not reported
2857	1889124	1991	AQKVNSGEPRAHLGALLARYIQQARKAPSGRMSVIKNLQNLDPSHRISDRDYMGWMDF	CCK58 (Cholecystokinin 58)	58	Free	Amidation	Linear	L	None	Peptide hormone of the gastrointestinal system	Stimulates digestion of fat & protein	37 °C for 30-180 minutes	1.6pmol	10.4 ±1.1	Pancreatitis patients blood proteases	Radioimmunoassay and HPLC	Pancreatitis patient plasma	in vitro	None	None	Not reported
2858	1889124	1991	AQKVNSGEPRAHLGALLARYIQQARKAPSGRMSVIKNLQNLDPSHRISDRDYMGWMDF	CCK58 (Cholecystokinin 58)	58	Free	Amidation	Linear	L	None	Peptide hormone of the gastrointestinal system	Stimulates digestion of fat & protein	37 °C for 30-180 minutes	1.6pmol	11.1 ±1	Pancreatitis patients plasma proteases	Radioimmunoassay and HPLC	Pancreatitis patient blood	in vitro	None	None	Not reported
2864	2162275	1990	HADGVFTSDFSKLLGQLSAKKYLESLM	PHM (Peptide histidine methionine)	27	Free	Amidation	Linear	L	None	Peptide derived from Prepro-VIP	Vasodilator	Not mentioned	5 pmol min-1 kg-1	6.5	Human plasma proteases	Radioimmunoassay	Human plasma	in vivo	None	None	It increase heart rate
2865	2162275	1990	HADGVFTSDFSKLLGQLSAKKYLESLMGKRVSSNISEDPVPV	PHV (Peptide histidine valine)	42	Free	Free	Linear	L	None	Peptide derived from Prepro-VIP	Vasodilator	Not mentioned	5 pmol min-1 kg-1	37.5	Human plasma proteases	Radioimmunoassay	Human plasma	in vivo	None	None	It increases heart rate but not significantly
2866	2896343	1988	YADAIFTNSYRKVLGQLSARKLLQDIMSR	GRF(1-29)-NH2 (Growth regulating factor)	29	Free	Amidation	Linear	L	None	Growth regulating factor	Release growth hormone	Blood collected 1-90 minutes after peptide injection	20Î¼g/200Î¼l	6.2 ±0.7	Rat plasma proteases	Radioimmunoassay	Rat plasma (i/v and s/c route of injection)	in vivo	None	None	Relative potency for GH releasing activity = 100%
2867	2896343	1988	YaDAIFTNSYRKVLGQLSARKLLQDIMSR	[D-Ala2]-GRF(1-29)-NH2 (Growth regulating factor)	29	Free	Amidation	Linear	Mix	None	GRF-1 analogs	Release growth hormone	Blood collected 1-90 minutes after peptide injection	20Î¼g/200Î¼l	6.6 ±0.4	Rat plasma proteases	Radioimmunoassay	Rat plasma (i/v and s/c route of injection)	in vivo	None	None	Relative potency for GH releasing activity = 5146%
2868	2896343	1988	YAdAIFTNSYRKVLGQLSARKLLQDIMSR	[D-Asp3]-GRF(1-29)-NH2 (Growth regulating factor)	29	Free	Amidation	Linear	Mix	None	GRF-1 analogs	Release growth hormone	Blood collected 1-90 minutes after peptide injection	20Î¼g/200Î¼l	5.9 ±0.8	Rat plasma proteases	Radioimmunoassay	Rat plasma (i/v and s/c route of injection)	in vivo	None	None	Relative potency for GH releasing activity = 670%
2869	2896343	1988	YADAIFTnSYRKVLGQLSARKLLQDIMSR	lD-Asn8]-GRF(1-29)-NH2 (Growth regulating factor)	29	Free	Amidation	Linear	Mix	None	GRF-1 analogs	Release growth hormone	Blood collected 1-90 minutes after peptide injection	20Î¼g/200Î¼l	6.9 ±0.5	Rat plasma proteases	Radioimmunoassay	Rat plasma (i/v and s/c route of injection)	in vivo	None	None	Relative potency for GH releasing activity = 221%
2870	2896343	1988	YADAIFTNSyRKVLGQLSARKLLQDIMSR	[D-Tyr10]-GRF(1-29)-NH2 (Growth regulating factor)	29	Free	Amidation	Linear	Mix	None	GRF-1 analogs	Release growth hormone	Blood collected 1-90 minutes after peptide injection	20Î¼g/200Î¼l	4.7 ±0.8	Rat plasma proteases	Radioimmunoassay	Rat plasma (i/v and s/c route of injection)	in vivo	None	None	Relative potency for GH releasing activity = 230%
2871	2896343	1988	yaDAIFTNSYRKVLGQLSARKLLQDIMSR	Ac-[D-Tyr1,D-AIa2]GRF(1-29)-NH2 (Growth regulating factor)	29	Acetylation	Amidation	Linear	Mix	None	GRF-1 analogs	Release growth hormone	Blood collected 1-90 minutes after peptide injection	20Î¼g/200Î¼l	7.4 ±0.5	Rat plasma proteases	Radioimmunoassay	Rat plasma (i/v and s/c route of injection)	in vivo	None	None	Relative potency for GH releasing activity = 2817%
2872	2940625	1986	pyr-EHWSYwLRPG	[D-Trp6]-LHRH (Luteinizing hormone-releasing hormone)	10	Free	Amidation	Linear	Mix	Pyr=Pyro-glutamic acid	LHRH (Luteinizing hormone-releasing hormone) derivative	Release Luteinizing hormone	Blood collected 1-240 minutes after peptide infused	100 µg/ml	>10 (alpha t1/2)	Dog plasma proteases	HPLC	Two male Beagle dogs plasma (Dose s/c injected)	in vivo	None	None	Not reported
2880	2953516	1987	RRSSCFGGRMDRIGAQSGLGCNSFRY	rANP (Recombinant Atrial natriuretic peptide )	26	Free	Free	Cyclic (C5-C21)	L	None	Atrial natriuretic factor	Natriuretic, diuretic and vasorelaxant peptide	Blood collected 0.2-2 hours after peptide injection	1 Î¼g/min dose	4.5	Human plasma proteases	Radioimmunoassay	Human plasma	in vivo	None	None	ANP induced dose-related effects on systemic and renal hemodynamic, as well as electrolyte excretion
2881	2966345	1988	NPVYSAVSNTDLMDFKNLLDHLEEKMPVEDEVMPPQALSEQTDEAGAALSSLSEVPPWTGEVNPSQRDGGALGRGPWDPSDRSALLKSKLRALLAGPR	rANF(Asn1-Arg98) [Rat atrial natriuretic factor]	98	Free	Free	Linear	L	Radioiodinated peptide at Tyr-4	Rat ANF derivative [Rat atrial natriuretic factor]	Natriuretic, diuretic and vasorelaxant peptide	Not mentioned	10 X106 CPM	54.8 ±3.9(2nd component)	Rat plasma proteases	Radioimmunoassay	Male Sprague-Dawley rats plasma	in vivo	http://www.uniprot.org/uniprot/P01161	None	Not reported
2882	2966345	1988	NPVYSAVSNTDLMDFKNLLDHLEEKMPVEDEVMPPQALSEQTDEAGAALSSLSEVPPWTGEVNPSQRDGGALGRGPWDPSDRSALLKSKLRALLAGPR	rANF(Asn1-Arg98) [Rat atrial natriuretic factor]	98	Free	Free	Linear	L	Radioiodinated peptide at Tyr-4	Rat ANF derivative [Rat atrial natriuretic factor]	Natriuretic, diuretic and vasorelaxant peptide	Not mentioned	10 X106 CPM	2.5 ±0.3(1st compent)	Rat plasma proteases	Radioimmunoassay	Male Sprague-Dawley rats plasma	in vivo	http://www.uniprot.org/uniprot/P01162	None	Not reported
2883	2988919	1985	SQEPPISLVLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	r/hCRF(Human/rat corticotropin-releasing factor)	41	Free	Free	Linear	L	None	Peptide hormone secreted by hypothalamus	Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH)	Blood samples collected at 1-180 minutes after peptide injection	10 µg/kg peptide injected to rhesus monkey	4.0 ±1.2 (t1/2fast)	Rhesus monkey proteases	Radioimmunoassay	Rhesus monkey plasma	in vivo	None	None	ACTH increased by 1035 ± 226 %, cortisol increased by 123 ± 34% on 10 µg/kg dose
2884	2988919	1985	SQEPPISLVLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	r/hCRF(Human/rat corticotropin-releasing factor)	41	Free	Free	Linear	L	None	Peptide hormone secreted by hypothalamus	Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH)	Blood samples collected at 1-180 minutes after peptide injection	100 µg/kg peptide injected to rhesus monkey	1.5 ±0.5 (t1/2fast)	Rhesus monkey proteases	Radioimmunoassay	Rhesus monkey plasma	in vivo	None	None	ACTH increased by 1858 ± 452 %, cortisol increased by 231 ± 28% on 10 µg/kg dose
2885	2988919	1985	SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII	oCRF(Ovine corticotropin-releasing factor)	41	Free	Free	Linear	L	None	Peptide hormone secreted by hypothalamus	Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH)	Blood samples collected at 1-180 minutes after peptide injection	1 µg/kg peptide injected to rhesus monkey	3.6 ±1.1 (t1/2 fast)	Rhesus monkey proteases	Radioimmunoassay	Rhesus monkey plasma	in vivo	None	None	ACTH increased by 161 ± 40 %, cortisol increased by 78 ± 22 % on 10 µg/kg dose
2886	2988919	1985	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	r/hCRF(Human/rat corticotropin-releasing factor)	41	Free	Free	Linear	L	None	Peptide hormone secreted by hypothalamus	Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH)	Blood samples collected at 1-180 minutes after peptide injection	10 µg/kg peptide injected to rhesus monkey	29.0 ±2.0(t1/2 slow)	Rhesus monkey proteases	Radioimmunoassay	Rhesus monkey plasma	in vivo	None	None	ACTH increased by 1858 ± 452 %, cortisol increased by 123 ± 28% on 10 µg/kg dose
2887	2988919	1985	SQEPPISLDLTFHLLREVLEMTKADQLAQQAHSNRKLLDIA	r/hCRF(Human/rat corticotropin-releasing factor)	41	Free	Free	Linear	L	None	Peptide hormone secreted by hypothalamus	Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH)	Blood samples collected at 1-180 minutes after peptide injection	100 µg/kg peptide injected to rhesus monkey	32.7 ±10.1 (t1/2 slow)	Rhesus monkey proteases	Radioimmunoassay	Rhesus monkey plasma	in vivo	None	None	ACTH increased by 1858 ± 452 %, cortisol increased by 231 ± 28% on 10 µg/kg dose
2888	2988919	1985	SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII	oCRF(Ovine corticotropin-releasing factor)	41	Free	Free	Linear	L	None	Peptide hormone secreted by hypothalamus	Stimulates corticotropes to secrete adrenocorticotropic hormone (ACTH)	Blood samples collected at 1-180 minutes after peptide injection	1 µg/kg peptide injected to rhesus monkey	44.3 +/= 6.7 (t1/2 slow)	Rhesus monkey proteases	Radioimmunoassay	Rhesus monkey plasma	in vivo	None	None	ACTH increased by 161 ± 40 %, cortisol increased by 78 ± 22 % on 10 µg/kg dose
2891	3147901	1988	HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNKNNIA	Oxyntomodulin	37	Free	Free	Linear	L	None	Synthetic derived from proglucagon, identified in extracts from porcine small intestinal mucosa	GLP-1-GCGR (glucagon) agonist	Blood samples collected at 1-5 hourss after peptide injection	100- 400ng/kg/h	12 ±1	Human plasma proteases	Radioimmunoassay	Human plasma (Dose i/v injected)	in vivo	http://www.glucagon.com/oxyntomodulin.html	None	The acid secretion increased during the first 90 rnin of pentagastrin infusion from 1 - 2 meq H+/15 rnin to a plateau of 5-6 meq H+/15 min
2892	3215483	1988	YGGFM	MET-enkephalin (Methionine-enkephalin)	5	Free	Free	Linear	L	None	Enkephalin	Neurotransmitter	37 °C for 1-180 minutes	300pg (pooled platelet-poor plasma)	12.8	Human plasma proteases	TLC (Thin-layer chromatography)	Human plasma	in vitro	None	None	Not reported
2893	3215483	1988	YGGFL	LEU-enkephalin (Leucine-enkephalin)	5	Free	Free	Linear	L	None	Enkephalin	Neurotransmitter	37 °C for 1-180 minutes	300pg (pooled platelet-poor plasma)	7	Human plasma proteases	TLC (Thin-layer chromatography)	Human plasma	in vitro	None	None	Not reported
2894	3261772	1988	ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF	hCGRP(Human Calcitonin gene-related peptide)	37	Free	Amidation	Cyclic (C2-C7)	L	None	Alernative spliced product of calcitonon produced by thyroid gland	Vasodilator and cause tumor hypoxia	Blood collected-10 to 90 minutes after peptide infusion	5pmol/kg	3.6 ±0.3 (Half life of 1st phase)	Sheep plasma proteases	Radioimmunoassay, RP-HPLC	Merino-Corriedale cross ewes (sheep) plasma	in vivo	None	None	Not reported
2895	3261772	1988	ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF	hCGRP(Human Calcitonin gene-related peptide)	37	Free	Amidation	Cyclic (C2-C7)	L	None	Alernative spliced product of calcitonon produced by thyroid gland	Vasodilator and cause tumor hypoxia	Blood collected-10 to 90 minutes after peptide infusion	5pmol/kg	13.6 ±1.0(Half life of 1st phase)	Sheep plasma proteases	Radioimmunoassay, RP-HPLC	Merino-Corriedale cross ewes (sheep) plasma	in vivo	None	None	Not reported
2898	3379352	1988	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	Reduced IGF-1(Free form) (Insulin-like growth factor-I)	70	Free	Free	Linear	L	Labelled with 125I, Disulphide bond is reduced	Bovine IGF-1	Mediates growth and development	Blood collected 10 minutes to 30 hours after peptide infusion	10mM/L	0.8	Lamb plasma proteases	Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity	Eight merino lambs plasma	in vivo	None	None	Not reported
2900	3379352	1988	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	S-CM IGF-1 (Insulin-like growth factor-I)	70	Free	Free	Linear	L	S-CM=S-carboxymethylated	Bovine IGF-1	Mediates growth and development	Blood collected 10 minutes to 30 hours after peptide infusion	10mM/L	0.8-0.9	Lamb plasma proteases	Radioimmunoassay, Binding protein radioactivity assay and IGF-region radioactivity	Eight merino lambs plasma	in vivo	None	None	Not reported
2901	3601235	1987	YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY	Porcine NPY (Neuropeptide Y)	36	Free	Amidation	Linear	L	None	Neuropeptide	Acts as a neurotransmitter	Blood collected 1 to 90 minutes after peptide infusion	06-10nM/kg	~ 20 (20-28)	Dog plasma proteases	Radioimmunoassay	Six mongrel dogs plasma (Dose i/v injected)	in vivo	None	None	Not reported
2902	3492729	1986	YGGFM	MET-enkephalin (Methionine-enkephalin)	5	Free	Free	Linear	L	None	Enkephalin	Neurotransmitter	Blood collected 5-60 minutes after peptide infused	1-20mM	<2	Proteases from rhesus monkey plasma	RP-HPLC	Rhesus monkey plasma	in vitro	None	None	Not reported
2903	3768731	1986	WAGGDASGE	DSIP (Delta sleep inducing peptide)	9	Free	Free	Linear	L	None	Neuropeptide secreted from hypothamus	Stress reliever, stimulates LH, somatostatin	Blood collected 2-60 minutes after peptide injected	0.1mg/Kg	7.24 ±0.77	Proteases from dog plasma	Radioimmunoassay	Mongrel dog plasma(Dose i/v injected)	in vivo	None	None	Not reported
2904	3768731	1986	AGGDASGE	des-Trp-DSIP	8	Free	Free	Linear	L	None	DSIP analogue	Anticarcinogenic	Blood collected 2-60 minutes after peptide injected	0.1mg/Kg	7.55 ±0.52	Proteases from dog plasma	Radioimmunoassay	Mongrel dog plasma(Dose i/v injected)	in vivo	None	None	Not reported
2905	3768731	1986	WAaGDASGE	D-Ala3-DSIP	9	Free	Free	Linear	Mix	None	DSIP analogue	Anticarcinogenic	Blood collected 2-60 minutes after peptide injected	0.1mg/Kg	8.19 ±0.30	Proteases from dog plasma	Radioimmunoassay	Mongrel dog plasma(Dose i/v injected)	in vivo	None	None	Not reported
2906	3768731	1986	WAGaDASGE	D-Ala4-DSIP	9	Free	Free	Linear	Mix	None	DSIP analogue	Anticarcinogenic	Blood collected 2-60 minutes after peptide injected	0.1mg/Kg	12.9 ±0.83	Proteases from dog plasma	Radioimmunoassay	Mongrel dog plasma(Dose i/v injected)	in vivo	None	None	Not reported
2907	3768731	1986	WAGaDASGE	D-Ala4-DSIP-NH2	9	Free	Amidation	Linear	Mix	None	DSIP analogue	Anticarcinogenic	Blood collected 2-60 minutes after peptide injected	0.1mg/Kg	10.2 ±0.69	Proteases from dog plasma	Radioimmunoassay	Mongrel dog plasma(Dose i/v injected)	in vivo	None	None	Not reported
2908	3924685	1985	YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGA	hGRF-1(1-40) (Human growth regulating factor)	40	Free	Amidation	Linear	L	None	Human growth regulating factor	Release growth hormone	Blood collected 60-240 minutes after peptide injection	5 µg/200ul	57.3 ±1.5 (beta or elimination half life)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	None	None	Not reported
2909	3924685	1985	YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGA	hGRF-1(1-40) (Human growth regulating factor)	40	Free	Amidation	Linear	L	None	Human growth regulating factor	Release growth hormone	Blood collected 60-240 minutes after peptide injection	5 µg/200ul	3.2 ±0.2 (alpha or distribution half life)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	None	None	Not reported
2910	1551497	1992	EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ	C-peptide (Connecting peptide)	31	Free	Free	Linear	L	None	Pro-insulin derivative	Connect A- and B-chains of insulin and regulates Ca-dependent cell signaling	Blood collected 2-180 minutes after peptide injection	150 µg of peptide injected	4.95 ±1.04(short half life or initial decay)	Proteases from Human plasma	Radioimmunoassay	Human plasma	in vivo	None	None	Insulin secretion rates can be accurately estimated from plasma levels of C-peptide
2911	1551497	1992	EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ	C-peptide (Connecting peptide)	31	Free	Free	Linear	L	None	Pro-insulin derivative	Connect A- and B-chains of insulin and regulates Ca-dependent cell signaling	Blood collected 2-180 minutes after peptide injection	150 µg of peptide injected	32.4 ±5(long half life)	Proteases from Human plasma	Radioimmunoassay	Human plasma	in vivo	None	None	Insulin secretion rates can be accurately estimated from plasma levels of C-peptide
2912	1551497	1992	EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ	C-peptide (Connecting peptide)	31	Free	Free	Linear	L	None	Pro-insulin derivative	Connect A- and B-chains of insulin and regulates Ca-dependent cell signaling	Blood collected 2-180 minutes after peptide injection	150 µg of peptide injected	4.55 ±1.23 (short half life or initial decay)	Proteases from Human(obese) plasma	Radioimmunoassay	Human(obese) plasma	in vivo	None	None	Insulin secretion rates can be accurately estimated from plasma levels of C-peptide
2913	1551497	1992	EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ	C-peptide (Connecting peptide)	31	Free	Free	Linear	L	None	Pro-insulin derivative	Connect A- and B-chains of insulin and regulates Ca-dependent cell signaling	Blood collected 2-180 minutes after peptide injection	150 µg of peptide injected	32.4 ±5(long half life)	Proteases from Human(obese) plasma	Radioimmunoassay	Human(obese) plasma	in vivo	None	None	Insulin secretion rates can be accurately estimated from plasma levels of C-peptide
2914	1651738	1991	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	alpha-ANP (alpha-atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	alpha-atrial natriuretic peptide	Natriuretic and vasodilator	Blood collected 30-60 minutes during and 5-20 minutes after peptide injection	0.005 - 0.05 µg/kg/min in 25 mL normal saline infused over 1 h	4.3 ±0.6	Proteases from Human plasma(younger, 20-39 years old)	Radioimmunoassay	Human plasma(younger, 20-39 years old)	in vivo	None	None	Natriuresis (145 ±36 Î½ 142 ± 28 µMol/min) and urinary cGMP excretion (40.9 ± 6.7 nmol/h)
2915	1651738	1991	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	alpha-ANP (alpha-atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	alpha-atrial natriuretic peptide	Natriuretic and vasodilator	Blood collected 30-60 minutes during and 5-20 minutes after peptide injection	0.005 - 0.05 µg/kg/min in 25 mL normal saline infused over 1 h	7.8 ±0.6	Proteases from Human plasma(older, 65-83 years old)	Radioimmunoassay	Human plasma(older, 65-83 years old)	in vivo	None	None	Natriuresis 142 ± 28 µMol/min and urinary cGMP excretion 35.3 ± 4.1
2916	1777964	1991	APGPR	CLAP(Prpcolipase activation peptide)	5	Free	Free	Linear	L	None	Derived from colipase	Procolipase activation peptide	Room Temperature(25C)	500nM/L	5	Proteases from Human serum	ELISA	Human Serum	in vitro	None	None	Not reported
2918	1831249	1991	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP(99-126) (Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Hormone secreted by heart muscle cells	Natriuretic and vasodilator	Blood collected 2-20 minutes after peptide infused	5pmol/kg	4.8 ±0.8	Proteases from Human plasma (Chronic renal diseases)	Radioimmunoassay	Human plasma (Chronic renal diseases)	in vivo	None	None	GFR and ERPF increased by a mean value of 23% and 27% respectively
2919	1882091	1991	PGlu-HWSYGLRPG	GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	L	pGlu= Pyro-glutamate	Hormone secreted by Hypothalamus	Stimulates the release of the gonadotropins from the pituitary.	37 °C	40mg/ml	10.5	Proteases from Rat ovary tissues	Radioimmunoassay	Rat ovary tissues	in vitro	1631133	None	Not reported
2920	1882091	1991	PGlu-HWSYGLRPG	GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	L	pGlu= Pyro-glutamate	Hormone secreted by Hypothalamus	Stimulates the release of the gonadotropins from the pituitary.	37 °C	40mg/ml	45	Proteases from Rat Lung tissues	Radioimmunoassay	Rat lung tissues	in vitro	1631133	None	Not reported
2921	1882091	1991	PGlu-HWSYGLRPG	GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	L	pGlu= Pyro-glutamate	Hormone secreted by Hypothalamus	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	2.66 (t1/2 alpha)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	1631133	None	Not reported
2922	1882091	1991	PGlu-HWSYGLRPG	GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	L	pGlu= Pyro-glutamate	Hormone secreted by Hypothalamus	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	12.16 (t1/2 beta)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	1631133	None	Not reported
2924	1882091	1991	PGlu-HWSYfLRPG	D-Phe-6-GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	Mix	None	GnRH derivative	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	14.53	Rat plasma proteases	Radioimmunoassay	(Dose i/m injected)Rat plasma	in vivo	1631133	None	Not reported
2926	1882091	1991	PGlu-HwSYfLRPG	D-Trp3-D-Phe-6-GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	Mix	None	GnRH derivative	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	25.8 (t1/2 beta)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	1631133	None	Not reported
2927	1882091	1991	PGlu-HwSYfLRPG	D-Trp3-D-Phe-6-GnRH (Gonadotropin releasing hormone)	10	Free	Amidation	Linear	Mix	None	GnRH derivative	Stimulates the release of the gonadotropins from the pituitary.	Blood collected 30-300 minutes after peptide injection	24 µg/kg	36.4	Rat plasma proteases	Radioimmunoassay	(Dose i/m injected)Rat plasma	in vivo	1631133	None	Not reported
2928	2156886	1990	DSGCFGRRLDRIGSLSGLGCNVLRRY	Porcine 125I-BNP(1-26)	26	Free	Free	Cyclic (C4-C20)	L	Tyr is Iodinated (125I)	Porcine brain and heart	Natriuretic and vasodilator	Blood collected 2-270 minutes after peptide injection	2 pmol/kg peptide infused	3.1	Proteases from Human plasma	Radioimmunoassay	Human plasma	in vivo	None	None	PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP
2929	2175178	1990	DSGCFGRRLDRIGSLSGLGCNVLRRY	Porcine 125I-BNP(1-26)	26	Free	Free	Cyclic (C4-C20)	L	Tyr is Iodinated (125I)	Porcine brain and heart	Natriuretic and vasodilator	Blood collected 2-270 minutes after peptide injection	0.17-0.25 Mbeq peptide infused	1.23 ±0.35	Rat plasma proteases	HPLC	Rat plasma	in vivo	None	None	PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP
2930	2175178	1990	DSGCFGRRLDRIGSLSGLGCNVLRRY	Porcine 125I-BNP(1-26)	26	Free	Free	Cyclic (C4-C20)	L	Tyr is Iodinated (125I)	Porcine brain and heart	Natriuretic and vasodilator	Blood collected 2-270 minutes after peptide injection	0.17-0.25 Mbeq peptide+ captoril(ACE inhibitor) infused	6.99 ±0.34	Rat plasma proteases	HPLC	Rat plasma	in vivo	None	None	PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP
2931	2175178	1990	DSGCFGRRLDRIGSLSGLGCNVLRRY	Porcine 125I-BNP(1-26)	26	Free	Free	Cyclic (C4-C20)	L	Tyr is Iodinated (125I)	Porcine brain and heart	Natriuretic and vasodilator	Blood collected 2-270 minutes after peptide injection	0.17-0.25 Mbeq peptide+phosphoramidon, a specific E-24.11 inhibitor infused	11.8 ±0.49	Rat plasma proteases	HPLC	Rat plasma	in vivo	None	None	PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP
2932	2175178	1990	DSGCFGRRLDRIGSLSGLGCNVLRRY	Porcine 125I-BNP(1-26)	26	Free	Free	Cyclic (C4-C20)	L	Tyr is Iodinated (125I)	Porcine brain and heart	Natriuretic and vasodilator	Blood collected 2-270 minutes after peptide injection	0.17-0.25 Mbeq peptide+phosphoramidon, a specific E-24.11 inhibitor +captoril(ACE inhibitor infused	14.3 ±0.48	Rat plasma proteases	HPLC	Rat plasma	in vivo	None	None	PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP
2933	2175178	1990	DSGCFGRRLDRIGSLSGLGCNVLRRY	Porcine 125I-BNP(1-26)	26	Free	Free	Cyclic (C4-C20)	L	Tyr is Iodinated (125I)	Porcine brain and heart	Natriuretic and vasodilator	Blood collected 2-270 minutes after peptide injection	1.5 Kbeq peptide	4.6 ±0.1	Proteases from Rat serum	HPLC	Rat Serum	in vitro	None	None	PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP
2934	2175178	1990	DSGCFGRRLDRIGSLSGLGCNVLRRY	Porcine 125I-BNP(1-26)	26	Free	Free	Cyclic (C4-C20)	L	Tyr is Iodinated (125I)	Porcine brain and heart	Natriuretic and vasodilator	Blood collected 2-270 minutes after peptide injection	1.5 Kbeq peptide+ captoril(ACE inhibitor	8.3 ±0.3	Proteases from Rat serum	HPLC	Rat Serum	in vitro	None	None	PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP
2935	2175178	1990	DSGCFGRRLDRIGSLSGLGCNVLRRY	Porcine 125I-BNP(1-26)	26	Free	Free	Cyclic (C4-C20)	L	Tyr is Iodinated (125I)	Porcine brain and heart	Natriuretic and vasodilator	Blood collected 2-270 minutes after peptide injection	1.5 Kbeq peptide+phosphoramidon, a specific E-24.11 inhibitor infuse	5.6 ±0.2	Proteases from Rat serum	HPLC	Rat Serum	in vitro	None	None	PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP
2936	2175178	1990	DSGCFGRRLDRIGSLSGLGCNVLRRY	Porcine 125I-BNP(1-26)	26	Free	Free	Cyclic (C4-C20)	L	Tyr is Iodinated (125I)	Porcine brain and heart	Natriuretic and vasodilator	Blood collected 2-270 minutes after peptide injection	1.5 Kbeq peptide+phosphoramidon, a specific E-24.11 inhibitor +captoril(ACE inhibitor infused	9.9 ±0.4	Proteases from Rat serum	HPLC	Rat Serum	in vitro	None	None	PRA and Plasma aldosterone concentrations were suppressed 50 % and 30 % respectively by 2pmol/kg BNP
2939	2454805	1988	FVNQHLCGSHVDELQYLCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	[125I]B-chain mutant IGF-1	71	Free	Free	Linear	L	None	Human Recombinant peptide	Stmulates glycogen synthesis	Blood collected 10 minutes to 6 hours after peptide injection	2 µCi peptide injected to rhesus monkey	27.5	Proteases from Rat serum	Radioimmunoassay	Rat Serum	in vivo	None	None	Stimulates glycogen synthesis by the incorporation of [14C]glucose into glycogen in rat diaphragm
2940	2454805	1988	GPQALCGAELVDALYLVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	[125I] [Gln3,Ala4,Tyr15,Leu16]IGF-1	70	Free	Free	Linear	L	None	Human Recombinant peptide	Stmulates glycogen synthesis	Blood collected 10 minutes to 6 hours after peptide injection	3 µCi peptide injected to rhesus monkey	26.9	Proteases from Rat serum	Radioimmunoassay	Rat Serum	in vivo	None	None	Stimulates glycogen synthesis by the incorporation of [14C]glucose into glycogen in rat diaphragm
2941	2498387	1989	p-Glu-HWSYsLRP	Buserelin	9	Free	Ethylamide	Linear	Mix	D-Ser(tBu) at 6th position, Pglu=pyr- Glutamate	Analogue of LHRH (Luteinizing hormone-releasing hormone)	Stimulates release of LH, FSH and estradiol	Blood collected 0-6 hours after peptide injection	500 µg/kg	11.2 (elimination t1/2 after 10-60 min of i/v injection)	Proteases from serum of women with endometriosis	Radioimmunoassay, HPLC	(Dose i/v injected)Serum of women with endometriosis	in vivo	None	None	Serum LH, FSH, and estradiol concentrations increased acutely up to 10-fold above basal values
2942	2498387	1989	p-Glu-HWSYsLRP	Buserelin	9	Free	Ethylamide	Linear	Mix	D-Ser(tBu) at 6th position	Analogue of LHRH (Luteinizing hormone-releasing hormone)	Stimulates release of LH, FSH and estradiol	Blood collected 0-6 hours after peptide injection	500 µg/kg	50.4 (elimination t1/2 after 60-120 mins of i/v injection)	Proteases from serum of women with endometriosis	Radioimmunoassay, HPLC	(Dose i/v injected)Serum of women with endometriosis	in vivo	None	None	Serum LH, FSH, and estradiol concentrations increased acutely up to 10-fold above basal values
2946	2521208	1989	CYFQNCPRG	VP (Vasopressin)	9	Free	Amidation	Cyclic (C1-C6)	L	None	Anti-diuretic hormone secreted by pitutiary gland	Anti-diuretic and regulates retention of water	Not mentioned	Exogenously administered	5.4(lower phase)	Proteases from Rabbit plasma	Radioimmunoassay	Rabbit plasma	in vivo	None	None	Not mentioned
2947	2521208	1989	CYFQNCPRG	VP (Vasopressin)	9	Free	Amidation	Cyclic (C1-C6)	L	None	Anti-diuretic hormone secreted by pitutiary gland	Anti-diuretic and regulates retention of water	Not mentioned	Endogenously administered	1.3	Proteases from Rabbit plasma	Radioimmunoassay	Rabbit plasma	in vivo	None	None	Not mentioned
2948	2521208	1989	SLRRSSCFGGRIDRIGAQSGLGCNSFRY	ANP (Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Synthetic	Natriuretic and vasodilator	Not mentioned	Exogenously administered	1.2	Proteases from Rabbit plasma	Radioimmunoassay	Rabbit plasma	in vivo	None	None	Not mentioned
2949	2521208	1989	SLRRSSCFGGRIDRIGAQSGLGCNSFRY	ANP (Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Synthetic	Natriuretic and vasodilator	Not mentioned	Endoogenously administered	3.2	Proteases from Rabbit plasma	Radioimmunoassay	Rabbit plasma	in vivo	None	None	Not mentioned
2951	2866222	1985	YADAIFTNSYRKVLGQLSARKLLQDIMSR	hGRF-1(1-29) (Human growth hormone-releasing factor)	29	Free	Amidation	Linear	L	None	Human growth hormone-releasing factor	Stimulates growth hormone release	Blood collected 2-60 minutes after peptide injection	10 µg/200Î¼1 0.9% NaCl/0.5% Human Serum albumin,	1.9 ±0.2 (alpha half life)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	None	None	Not reported
2952	2866222	1985	YADAIFTNSYRKVLGQLSARKLLQDIMSR	hGRF-1(1-29) (Human growth hormone-releasing factor)	29	Free	Amidation	Linear	L	None	Human growth hormone-releasing factor	Stimulates growth hormone release	Blood collected 2-60 minutes after peptide injection	10 µg/200Î¼1 0.9% NaCl/0.5% Human Serum albumin,	10.4 ±0.2 (beta or elimination half life)	Rat plasma proteases	Radioimmunoassay	(Dose i/v injected)Rat plasma	in vivo	None	None	Not reported
2953	2868381	1986	AGCKNFFWKTFTSC	Somatostatin	14	Free	Free	Cyclic (C3-C14)	L	None	Growth hormone €“inhibiting hormone (GHIH)	Inhibitor of Growth hormone secretion	Blood sample collected after 10 minutes in 5 minutes interval, followed by 30 minutes thricely at 1	250 µg peptide infused	1.2-3.6	Proteases from plasma of healthy Human	Radioimmunoassay	Human plasma	in vivo	None	None	Not reported
2954	2868381	1986	AGCKNFFWKTFTSC	Somatostatin	14	Free	Free	Cyclic (C3-C14)	L	None	Growth hormone €“inhibiting hormone (GHIH)	Inhibitor of Growth hormone secretion	Blood sample collected after 10 minutes in 5 minutes interval, followed by 30 minutes thricely at 1	250 µg peptide infused	1.4-4.1	Proteases from plasma of Human patient (cirrhotic subjects)	Radioimmunoassay	Plasma of Human patient (cirrhotic subjects)	in vivo	None	None	Not reported
2955	3108068	1987	GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA	IGF-1 (Insulin-like growth factor-I)	70	Free	Free	Linear	L	None	Purified from bovine colostrum	Mediates growth and development	Blood collected 12hours after peptide injection	6 - 10 µg/Kg	<15	Proteases from chicken plasma	Radioimmunoassay	(Dose i/v injected)Chicken plasma	in vivo	None	None	GH concentrations subsequent to TRH injection were significantly depressed45.1 and 48.2% in IGF-l-treated as compared with control chicks; and GRF-stimulated GH secretion was significantly decreased by IGF-I administration in (41.3%)
2957	1664804	1991	SQDSAFRIQERLRNSKMAHSSSCFGQKIDRIGAVSRLGCDGLRLF	Rat BNP-45 ( Brain natriuretic peptide-45)	45	Free	Free	Cyclic (C23-C39)	L	None	Isolated from rat heart and shown to be a circulating form of rat BNP	Cardiac Natriuretic Peptide	Blood samples collected at 0.5-10 minutes post peptide injection	2 µg/150ul saline	6.95 (t 1/2 beta or 2nd phase t1/2)	Proteases from Mice (WKY)plasma	Radioimmunoassay	(Dose i/v injected)Mice (WKY) plasma	in vivo	None	None	Urinary sodi µM excretion (uEq/min per kg)= 0.43 ± 0.13, mean arterial pressure (mmHg) = 129 ± 1, Urinary cGMP excretion (pmol/min) = 27.0 ± 3.2
2959	1664804	1991	SLRRSSCFGGRIDRIGAQSGLGCNSFRY	Rat alpha-ANP (Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Atrial natriuretic peptide	Natriuretic and vasodilator	Blood samples collected at 0.5-10 minutes post peptide injection	2 µg/150ul saline	4.03 (t 1/2 beta or 2nd phase t1/2)	Proteases from Mice (WKY)plasma	Radioimmunoassay	(Dose i/v injected)Mice (WKY) plasma	in vivo	None	None	Urinary sodi µM excretion (uEq/min per kg)= 0.43 ± 0.13, mean arterial pressure (mmHg) = 129 ± 1, Urinary cGMP excretion (pmol/min) = 27.0 ± 3.4
2960	2524034	1989	GGFMTSEKSQTPLVTL	[Leu5]Enkephalin	18	Free	Free	Linear	L	None	Somatostatin	Inhibitor of Growth hormone secretion	Not mentioned	Peptide 0.04 w/v in 154mM KCl	33 ±7	Proteases from rat rectal proteases	HPLC	Rat rectal lumen	in vitro	None	None	Not mentioned
2962	2524034	1989	GGFMTSEKSQTPLVTL	[3H-Lys9]DE-gamma-E	18	Free	Free	Linear	L	None	Neuroleptic peptide	Neuroregulator	Not mentioned	6 µg or 200uCi	1.2 ±0.6	Proteases from rat blood	HPLC	Rat blood	in vivo	None	None	Not mentioned
2966	2556215	1989	DRVYIHPFHL	Angiotensin I (AI)	10	Free	Free	Linear	L	None	Derived from angiotensin	Precusor of angiotensin- II (AII)	37 °C	100 - 2000 ng/ml	0.6	Fetal calf serum proteases	Radioimmunoassay	Primary endothelial cells + Fetal calf Serum (20%)	in vitro	None	None	Not mentioned
2974	2714145	1989	HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1(72-107) (Glucagon-like peptide-1)	36	Free	Amidation	Linear	L	None	Glucagon-like peptide-1 derivative	Regulates glycemic index, inhibits gastric acid secretion	Not mentioned	14.4ng/kg peptide infused from 45 min as priming dose, followed by 100 - 400 ng/kg/h dose for 45 m	17.2 ±2	Proteases from Human plasma	Radioimmunoassay	Human plasma	in vivo	None	None	200pmol/L and 600pmol/L cause 16% and 23% Inhibition of pentagastrin-stimulated acid secretion respectively
2975	2714145	1989	HDEFERHAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	Truncated GLP-1(78-107)	31	Free	Amidation	Linear	L	None	Glucagon-like peptide-1 derivative	Regulates glycemic index, inhibits gastric acid secretion	Not mentioned	4.8 -14.4ng/kg peptide infused from 45 min as priming dose, followed by 12.5 - 50 ng/kg/h dose for	11.4 ±2.1	Proteases from Human plasma	Radioimmunoassay	Human plasma	in vivo	None	None	200pmol/L of peptide causes 36% Inhibition of pentagastrin-stimulated acid secretion respectively
2976	8147781	1994	ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF	CGRP(Calcitonin gene related peptide)	37	Free	Free	Linear	L	None	Alernative spliced product of calcitonon produced by thyroid gland	Vasodilator and cause tumor hypoxia	37 °C for 5-60 minutes	60 µL of 1 nmol/L CGRP	4.3 ±0.2	Proteases from sheep plasma	Radioimmunoassay	Sheep plasma before nephrectomy	in vitro	None	None	Not reported
2977	8147781	1994	ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF	CGRP(Calcitonin gene related peptide)	37	Free	Free	Linear	L	None	Alernative spliced product of calcitonon produced by thyroid gland	Vasodilator and cause tumor hypoxia	37 °C for 5-60 minutes	60 µL of 1 nmol/L CGRP	7.6 ±0.8	Proteases from sheep plasma	Radioimmunoassay	Sheep plasma after 2 days nephrectomy	in vitro	None	None	Not reported
2978	8147781	1994	ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF	CGRP(Calcitonin gene related peptide)	37	Free	Free	Linear	L	None	Alernative spliced product of calcitonon produced by thyroid gland	Vasodilator and cause tumor hypoxia	37 °C for 5-60 minutes	60 µL of 1 nmol/L CGRP	7.3 ±0.4	Proteases from sheep plasma	Radioimmunoassay	Sheep plasma after 5 days nephrectomy	in vitro	None	None	Not reported
2979	8217216	1993	SDKP	AcSDKP (Acetyl-SDKP)	4	Acetylation	Free	Linear	L	None	Isolated from fetal calf bone marrow	Natural hemoregulatory	37 °C for 24 hours	4 X lO-7M, 10 µCi	0.75	Proteases from Human serum	HPLC	Human serum	in vitro	None	None	Not reported
2982	8217216	1993	SDKP	AcSDKP (Acetyl-SDKP)	4	Acetylation	Free	Linear	L	None	Isolated from fetal calf bone marrow	Natural hemoregulatory	37 °C for 24 hours	4 X lO-7M, 10 µCi	0.5	Proteases from Horse serum	HPLC	Horse serum	in vitro	None	None	Not reported
2993	8218482	1993	YRGDS	YRGDS-polymer conj µgate(Isocyanate containing polyurethane prepolymer)	5	Free	Free	Linear	L	Peptide covalently attached to Isocyanate containing polyurethane prepolymer	Synthetic RGD containing peptide	Cell attachment property	Not mentioned	Not mentioned	0.5 (Half life of 1st phase)	Proteases from mouse bood	HPLC	Mouse blood	in vivo	None	None	Not reported
3000	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 1 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	42	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3002	8545241	1995	YGGFLRRIRPK	Dynorphin A(1-11)-NH2 analogue 3 (DYN A analogue)	11	Free	Amidation	Linear	L	None	Human placenta Dynorphin A derivative	Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates.	37 °C	100 µM	43	Proteases from mouse brain tissues	HPLC	Mouse brain homogenate	in vitro	None	None	Not reported
3011	9234336	1994	HSDAVFTDNYTRLRKQMAVKKYLNSILN	131I-VIP (Vasoactive intestinal peptide)	28	Free	Amidation	Linear	L	Iodinated at Tyr	Neuropeptide	Anti-inflammatory neuropeptide	Organs are collected at 2-60 minutes after administration of drug (by killing organism)	250 µg (6MBq in 0.2mL)	2.3 ±0.8 (elimination half life)	Proteases from rat lung tissues	HPLC	(Dose i/v injected)Rat lung tissues	in vivo	None	None	Not reported
3012	8542672	1995	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Rat adrenomedullin (AM)	50	Free	Amidation	Cyclic (C14-C19)	L	None	Member of the calcitonin family of peptides	Hypotensive effect	Blood sample collected after 0.5-20 minutes after drug administration	1.0nmol/Kg	1.05 ±0.04 (1st phase elimination life)	Proteases from SHR rat plasma	Radioimmunoassay	Rat(SHR) plasma	in vivo	None	None	Mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg for SHR, and - 12.4, -46.6, -61.6 mmHgfor WKY, respectively
3013	8542672	1995	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Rat adrenomedullin (AM)	50	Free	Amidation	Cyclic (C14-C19)	L	None	Member of the calcitonin family of peptides	Hypotensive effect	Blood sample collected after 0.5-20 minutes after drug administration	1.0nmol/Kg	1.19 ±0.09 (1st phase elimination life)	Proteases from WKY rat plasma	Radioimmunoassay	Rat(WKY) plasma	in vivo	None	None	Mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg for SHR, and - 12.4, -46.6, -61.6 mmHgfor WKY, respectively
3014	8542672	1995	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Rat adrenomedullin (AM)	50	Free	Amidation	Cyclic (C14-C19)	L	None	Member of the calcitonin family of peptides	Hypotensive effect	Blood sample collected after 0.5-20 minutes after drug administration	1.0nmol/Kg	18.1 ±1.4 (2nd phase elimination life)	Proteases from SHR rat plasma	Radioimmunoassay	Rat(SHR) plasma	in vivo	None	None	Mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg for SHR, and - 12.4, -46.6, -61.6 mmHgfor WKY, respectively
3015	8542672	1995	YRQSMNQGSRSTGCRFGTCTMQKLAHQIYQFTDKDKDGMAPRNKISPQGY	Rat adrenomedullin (AM)	50	Free	Amidation	Cyclic (C14-C19)	L	None	Member of the calcitonin family of peptides	Hypotensive effect	Blood sample collected after 0.5-20 minutes after drug administration	1.0nmol/Kg	16.3 ±1.2 (2nd phase elimination life)	Proteases from WKY rat plasma	Radioimmunoassay	Rat(WKY) plasma	in vivo	None	None	Mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg for SHR, and - 12.4, -46.6, -61.6 mmHgfor WKY, respectively
3016	8395230	1993	RPPGFSPFR	Bradykinin	9	Free	Free	Linear	L	None	Endogenous peptide of kinin family	Vasodilator, Inflammatory mediator	37 °C for 15-60 minutes	10 µg/L of peptide	29 ±1	Neutral endopeptides in Human umbilical vein endothelial cells	Radioimmunoassay	Human umbilical vein endithelial cells	in vitro	None	None	Not reported
3018	8395230	1993	RPPGFSPFR	Bradykinin	9	Free	Free	Linear	L	None	Endogenous peptide of kinin family	Vasodilator, Inflammatory mediator	37 °C for 15-60 minutes	10 µg/L of peptide	46 ±2	Neutral endopeptides in Human umbilical vein endothelial cells	Radioimmunoassay	Human umbilical vein endithelial cells+ phosphoramidon	in vitro	None	None	Not reported
3022	8388403	1993	RRSSCFGGRIDIIGAQSGLGCNSFRY	ile 12-ANP (Atrial natriuretic peptide)	26	Free	Free	Cyclic (C5-C21)	L	None	Infusions of atrial natriuretic peptide	Natriuretic and vasodilator	Blood sample collected after 15-240 minutes after peptide administration	1.5pmol/Kg/min dose of peptide	4.1 ±0.4	Proteases from Human plasma	Radioimmunoassay	Human plasma(elder men)	in vivo	None	None	It increases the cGMP approx 3 fold
3025	2945560	1986	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	hANP (Human Atrial Natriuretic Peptide)	28	Free	Amidation	Cyclic (C7-C23)	L	None	Hormone secreted by heart muscle cells	Natriuretic and vasodilator	Not mentioned	98.3 ± 44.6pg/ml	5.65	Proteases from Human plasma	Radioimmunoassay	Human plasma(bolus injection)	in vivo	None	None	Not reported
3027	18424366	2008	HAEGTFTSDVSSYLEGQAAKEFIAWLVK	GLP(7-34) (Glucagon like peptide)	28	Acetylation	Amidation	Linear	L	None	GLP-1 (Glucagon like peptide-1) analogue	Antihyperglycemic or incretin effect (Stimulate Insulin release in glucose dependent manner)	37C for 2 hours	200 µg/ml	~34	DPP IV	MALDI-TOF-MS	Peptide in 0.01 M Na2HPO4 buffer	in vitro	None	None	In the DPP-IV-free rat pancreatic beta cell line RINm5F GLP-1-(7-34)-amide elevated cAMP production with an EC50 of about 40 nM
3028	1911217	1991	SCNTATCVTHRLAGLLSRSGGVVKDNFVPTNVGSEAF	CGRP (Calcitonin gene-related peptide)	37	Free	Amidation	Cyclic (C2-C7)	L	None	Alernative spliced product of calcitonon produced by thyroid gland	Vasodilator and cause tumor hypoxia	Not mentioned	300-600pmol	9.00 (plasma half-life)	Proteases from Human plasma	Not mentioned	Human Plasma	in vivo	None	None	Not reported
3030	2991517	1985	(Cbc)KFAP	Compound 16 (Ketomethylene pentapeptide analogue)	4	Cbc=Cyclobutanecarboxylic acid	Free	Linear	L	Proline ring is tritiated	Pentapeptide analogue of the ketomethylene-containing angiotensin converting enzyme (ACE) inhibitor	Angiotensin converting enzyme (ACE) inhibitor and anti-hypertensive	Not mentioned	2mg	24.4	Proteases from rat blood	Liquid scintillation spectrometer	(Dose i/v injected) Rat blood	in vivo	None	None	Potent ACE-inhibitor with I50 =7.0nM
3031	2991517	1985	5(S)-benzamido-4-oxo-6-phenylhexanoyl-P	Compound 1 (Ketomethylene pentapeptide analogue)	1	5(S)-benzamido-4-oxo-6-phenylhexanoyl	Free	Linear	L	Proline ring is tritiated	Pentapeptide analogue of the ketomethylene-containing angiotensin converting enzyme (ACE) inhibitor	Angiotensin converting enzyme (ACE) inhibitor and anti-hypertensive	Not mentioned	2mg	11.6	Proteases from rat blood	Liquid scintillation spectrometer	(Dose i/v injected) Rat blood	in vivo	None	None	Potent ACE-inhibitor with I50 =70nM
3032	16197609	2005	PGDSTRKCMDLKGNK	PCK3145 (Prostate secretory protein 94 derived peptide)	15	Free	Free	Linear	L	None	Prostate secretory protein 94 (PSP94) derivative	Anti cancer	Not mentioned	5-80mg/m2	Mean Elimination half life: 0.35-1.45 (Mean Elimination half life)	Proteases from Human plasma	Not mentioned	Human plamsa	in vivo	http://www.drugbank.ca/drugs/DB04985	None	Not reported
3034	20158487	2010	DRDYMGWMDF	PEG10kDa-[(123)I]-CCK-10	10	Free	Amidation	Linear	L	SO3H Group at Tyr-4, Coupled to PEG(10KDa), PEG=Polyethylene glycol, CCK-10=Cholecystokinin	Peptide Hormone produced by small intestine	Stimulates the digestion of fat and protein	Not mentioned	Not available	15	Rat blood proteases	HPLC	Rat blood	in vivo	None	None	Not reported
3037	20221650	2010	NHHGRRRRRRRRRRR	R1(NH2GR11) (An arginine-rich cell permeable peptide)	15	Cu-DOTA (DOTA=1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid)	Free	Linear	L	Cu-labelled	Derived from prostate cancer cell lines, an arginine-rich cell permeable peptide	Cell permeable peptide	Not mentioned	Not available	10.7	Proteases from mouse blood	Fluorescence Imaging	Mouse blood	in vivo	None	None	In PC3, LNCaP, PZ-HPV-7, DU145 and DU145, FITC-NHGR11 displayed much higher uptake efficiency
3038	20221650	2010	NHHGRRRRRRRRRRR	R1(NH2GR11) (An arginine-rich cell permeable peptide)	15	Cu-DOTA (DOTA=1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid)	Free	Linear	L	Cu-labelled	Derived from prostate cancer cell lines, an arginine-rich cell permeable peptide	Cell permeable peptide	Not mentioned	Not available	17.2 (Elimination half life)	Proteases from mouse blood	Fluorescence Imaging	Mouse blood	in vivo	None	None	In PC3, LNCaP, PZ-HPV-7, DU145 and DU145, FITC-NHGR11 displayed much higher uptake efficiency
3039	2624887	1989	pyr-Glu-LTFTPNW	CC-2 (Corpora cardiaca)	8	Free	Amidation	Linear	L	pyr-Glu= Pyro-Glutamic acid	Hypertrehalosaemic hormone in cockroaches	Activate fat body glycogen phosphorylase and increase haemolymph trehalose	2 hours	1-2pmol	13.2	Proteases from Haemolymph of american cockroach	Not mentioned	Haemolymph of american cockroach	in vivo	None	None	Increase in carbohydrates in haemolymph; simulates activation of glycogen phosphorylase and induction of trehalose synthesis
3040	1490668	1992	FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	rhGH(Recombinant DNA derived human growth hormone)	191	Free	Free	Linear	L	None	Recombinant DNA derived human growth hormone	Promotes growth and development	Not mentioned	4 IU rhGH/m2 BSA	18	Proteases from Human serum	Radioimmunoassay	(Intravenous route of injection) human serum	in vivo	None	None	In a GH-deficient child, hGH serum levels between 10 and 20 ng/ml were demonstrated for a period of 8 h after s.c. administration of 0.07 IU rhGH/kg body weight.
3041	1490668	1992	FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	rhGH(Recombinant DNA derived human growth hormone)	191	Free	Free	Linear	L	None	Recombinant DNA derived human growth hormone	Promotes growth and development	Not mentioned	4 IU rhGH/m2 BSA	2.59 ±1.32	Proteases from Human serum	Radioimmunoassay	(Subcutaneous route of injection) human serum	in vivo	None	None	In a GH-deficient child, hGH serum levels between 10 and 20 ng/ml were demonstrated for a period of 8 h after s.c. administration of 0.07 IU rhGH/kg body weight.
3042	1490668	1992	FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	rhGH(Recombinant DNA derived human growth hormone)	191	Free	Free	Linear	L	None	Recombinant DNA derived human growth hormone	Promotes growth and development	Not mentioned	10 IU rhGH/m2 BSA	4.29 ±1.89	Proteases from Human serum	Radioimmunoassay	(Subcutaneous route of injection) human serum	in vivo	None	None	In a GH-deficient child, hGH serum levels between 10 and 20 ng/ml were demonstrated for a period of 8 h after s.c. administration of 0.07 IU rhGH/kg body weight.
3043	1490668	1992	FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	rhGH(Recombinant DNA derived human growth hormone)	191	Free	Free	Linear	L	None	Recombinant DNA derived human growth hormone	Promotes growth and development	Not mentioned	4 IU rhGH/m2 BSA	6.06 ±2.64	Proteases from Human serum	Radioimmunoassay	(Intramuscular route of injection)human serum	in vivo	None	None	In a GH-deficient child, hGH serum levels between 10 and 20 ng/ml were demonstrated for a period of 8 h after s.c. administration of 0.07 IU rhGH/kg body weight.
3044	6361234	1983	Pyr-QRLGNQWAVGHLM	Amphibian bombesin	14	Free	Amidation	Linear	L	Pyr=Pyro-glutamine	Skin of the frog Bombina bombina	Insulinotropic agent	Not reported	5 pmol/kg . min for 30 min and a volume of 1 ml/min.	3	Calf blood proteases	Radioimmunoassay	Arterial blood sample of pedigree jersey calves	in vivo	18185064	None	Not mentioned
3045	6361234	1983	VPLPAGGGTVLTKMYPRGNHWAVGHLM	Porcine gastrin releasing peptide	27	Free	Amidation	Linear	L	None	Gastrin releasing peptide	Stimulates the release of Gastrin	Not reported	5 pmol/kg . min for 30 min and a volume of 1 ml/min.	3	Calf blood proteases	Radioimmunoassay	Arterial blood sample of pedigree jersey calves	in vivo	18185064	None	Not mentioned
3047	10377427	1999	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP ( Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Cardiac atria	cardiovascular homeostasis	Blood was collected after 0.5, 1.5,2.5, 4, 8, and 16 min after administration of the labeled peptide	0.2 µci/mouse of [125I]ANP	1.44 ±0.05	Npr3+/+ mice blood proteases	Radioimmunoassay	Npr3+/+ mice blood sample	in vivo	6230082	None	Blood pressure=118.7 ±1.9 mmHg
3048	10377427	2000	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	ANP ( Atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Cardiac atria	cardiovascular homeostasis	Blood was collected after 0.5, 1.5,2.5, 4, 8, and 16 min after administration of the labeled peptide	0.2 µci/mouse of [125I]ANP	2.4 ±0.08	Npr3-/- mice blood proteases	Radioimmunoassay	Npr3-/- mice blood sample	in vivo	6230082	None	Blood pressure=110.4 ±2.3 mmHg
3049	2939312	1986	SLRRSSCFGGRMDRIGAQSGLGCNSFRY	Î±-hANP (Alpha human atrial natriuretic peptide)	28	Free	Free	Cyclic (C7-C23)	L	None	Human atrial extracts	Natriuretic and hypotensive actions	Venous samples were drawn at 1 mln intervals for 10 mlns after injectlon and then at 15 and 30 mlns.	100 µg	2.5	Human blood proteases	Radioimmunoassay	Intravenous bolus injection of 100Î¼g alpha human atrial natriuretic factor in human	in vivo	None	None	Not mentioned
3075	12083977	2002	PHWSYlLRP	Leuprorelin	9	5-oxo	Ethylacetate	Linear	Mix	None	Synthetic agonist analogue of gonadotropin-releasing hormone	Suppression of gonadal steroid synthesis, resulting in pharmacological castration	Not mentioned	100Î¼g/kg	8.4 ±4(t1/2Î±)	Diestrous female rats blood proteases	Radioimmunoassay	Intravenous injection in diestrous female rats	in vivo	None	None	Not mentioned
3076	12083977	2002	PHWSYlLRP	Leuprorelin	9	5-oxo	Ethylacetate	Linear	Mix	None	Synthetic agonist analogue of gonadotropin-releasing hormone	Suppression of gonadal steroid synthesis, resulting in pharmacological castration	Not mentioned	100Î¼g/kg	33.2 ±6.8(t1/2Î²)	Diestrous female rats blood proteases	Radioimmunoassay	Intravenous injection in diestrous female rats	in vivo	None	None	Not mentioned
3079	12083977	2002	PHWSYlLRP	Leuprorelin	9	5-oxo	Ethylacetate	Linear	Mix	None	Synthetic agonist analogue of gonadotropin-releasing hormone	Suppression of gonadal steroid synthesis, resulting in pharmacological castration	Not mentioned	10 µg	32(t1/2Î²)	Pregnant female rats blood proteases	Radioimmunoassay	Subcutaneous injection in pregnant rats	in vivo	3083092	None	Not mentioned
3080	12083977	2002	pGlu-HWSYGLRPG	GnRH (Gonadotropin-releasing hormone)	10	PyroGlu=Pyroglutamic acid	Free	Linear	L	pGlu=pyroglutamic acid	Hypothalamic neurons	Regulating the synthesis and secretion of the gonadotropins luteinising hormone (LH) and follicle-stimulating hormone (FSH).	Not mentioned	Not mentioned	less than 15	Human plasma proteases	Radioimmunoassay	Human blood	in vivo	None	None	Not mentioned
3081	15452596	2004	YGGFL	Leu-enkephalin	5	Free	Free	Linear	L	None	Endogenous opioid ligand	Indicator of Endogenous opioid system which is characterized by biological effects, including adaptogenic and antinociceptive activity, regulation of the emotional sphere, behavior research,learning and memory.	Not mentioned	Not mentioned	2.17 ±0.05	Enkephalin-degrading enzymes present in blood serum	Accumulation of radioactive 3H-leu-enkephalin degradation products ,Thin layer chromatography	Breast fed healthy infants(0-1years)serum sample	in vivo	O. Yu. Sokolov, M. V. Gabaeva, K. G. Gurevich, et	None	Not mentioned
3082	15452596	2004	YGGFL	Leu-enkephalin	5	Free	Free	Linear	L	None	Endogenous opioid ligand	Indicator of Endogenous opioid system which is characterized by biological effects, including adaptogenic and antinociceptive activity, regulation of the emotional sphere, behavior research,learning and memory.	Not mentioned	Not mentioned	2.48 ±0.007	Enkephalin-degrading enzymes present in blood serum	Accumulation of radioactive 3H-leu-enkephalin degradation products ,Thin layer chromatography	Formula fed healthy infants(0-1years)serum sample	in vivo	O. Yu. Sokolov, M. V. Gabaeva, K. G. Gurevich, et	None	Not mentioned
3083	15452596	2004	YGGFL	Leu-enkephalin	5	Free	Free	Linear	L	None	Endogenous opioid ligand	Indicator of Endogenous opioid system which is characterized by biological effects, including adaptogenic and antinociceptive activity, regulation of the emotional sphere, behavior research,learning and memory.	Not mentioned	Not mentioned	2.26 ±0.06	Enkephalin-degrading enzymes present in blood serum	Accumulation of radioactive 3H-leu-enkephalin degradation products ,Thin layer chromatography	Serum sample of healthy infant boys(0-1 years)	in vivo	O. Yu. Sokolov, M. V. Gabaeva, K. G. Gurevich, et	None	Not mentioned
3084	15452596	2004	YGGFL	Leu-enkephalin	5	Free	Free	Linear	L	None	Endogenous opioid ligand	Indicator of Endogenous opioid system which is characterized by biological effects, including adaptogenic and antinociceptive activity, regulation of the emotional sphere, behavior research,learning and memory.	Not mentioned	Not mentioned	2.51 ±0.08	Enkephalin-degrading enzymes present in blood serum	Accumulation of radioactive 3H-leu-enkephalin degradation products ,Thin layer chromatography	Serum sample of healthy infant girls(0-1 years)	in vivo	O. Yu. Sokolov, M. V. Gabaeva, K. G. Gurevich, et	None	Not mentioned
3085	15452596	2004	YGGFL	Leu-enkephalin	5	Free	Free	Linear	L	None	Endogenous opioid ligand	Indicator of Endogenous opioid system which is characterized by biological effects, including adaptogenic and antinociceptive activity, regulation of the emotional sphere, behavior research,learning and memory.	Not mentioned	Not mentioned	2.37 ±0.05	Enkephalin-degrading enzymes present in blood serum	Accumulation of radioactive 3H-leu-enkephalin degradation products ,Thin layer chromatography	Serum sample of children(0-1 years)	in vivo	O. Yu. Sokolov, M. V. Gabaeva, K. G. Gurevich, et	None	Not mentioned
3086	15452596	2004	YGGFL	Leu-enkephalin	5	Free	Free	Linear	L	None	Endogenous opioid ligand	Indicator of Endogenous opioid system which is characterized by biological effects, including adaptogenic and antinociceptive activity, regulation of the emotional sphere, behavior research,learning and memory.	Not mentioned	Not mentioned	3.10 ±0.05	Enkephalin-degrading enzymes present in blood serum	Accumulation of radioactive 3H-leu-enkephalin degradation products ,Thin layer chromatography	Serum sample of adults	in vivo	O. Yu. Sokolov, M. V. Gabaeva, K. G. Gurevich, et	None	Not mentioned
3093	19023544	2008	RKDVY	TP5 (Thymopentin)	5	Free	Free	Linear	L	None	Synthetic peptide of thymic hormone	Immunomodulator	Not mentioned	Not mentioned	5.6 ±0.7	Rabbit plasma proteases	HPLC	heparinized rabbit plasma	in vitro	http://www.drugbank.ca/drugs/DB00112	None	IL2 concentration in mouse serum:0.65pg/ml,macrophage clearance index(K value)=0.0132 ±0.0008,phagocytic index(Î± value=3.43 ±0.29.
3094	20382695	2010	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	hGLP-1[7-36] (Human glucagon like peptide-1)	30	Free	Amidation	Linear	L	None	Incretin released by intestinal L cells	Metabolism regulation	1 hour	40 nm(1Î¼g/Î¼l upto 500Î¼l)	50	Rat blood proteases	HPLC	Rat blood plasma	in vitro	http://www.drugbank.ca/drugs/DB00113	None	cAMP stimulation,EC50=0.08nM
3119	21036718	2010	QWAVGHLM	177Lu-AMBA	9	177Lu,DO3A-CH2CO-G-(4-aminobenzoyl)	Amidation	Linear	L	None	Synthetic Bombesin like peptide	Clinical trials for use as systemic radiotherapy for hormone refractory prostate cancer (HRPC) patients.	Not mentioned	10Î¼g/mouse	0.52 ±0.05(t1/2Î±)	Mice plasma proteases	Radio-HPLC	Intravenous injection in PC-3M-luc-C6 tumour-bearing mice	in vivo	http://www.drugbank.ca/drugs/DB00138	None	In vitro stability =24.3 ±21.9% after 48 hours
3123	21986100	2011	YaGFlC	DALCE [(D-Ala2, Leu5, Cys6)-enkephalin]	6	Free	Free	Linear	Mix	None	Enkephalin derative	Treatment of ischemia	Not mentioned	1mg/Kg	9.1 ±2.4	Rats plasma proteases	LC-MS	Intravenous injection in male Sprague €“Dawley rats	in vivo	http://www.drugbank.ca/drugs/DB00142	None	Not mentioned
3124	21986100	2011	YaGFl	DADLE [(D-Ala2, Leu5)-enkephalin]	5	Free	Free	Linear	Mix	None	Opoid peptide	Neuromodulator	Not mentioned	1mg/Kg(200-250Î¼l)	4.6	Rats plasma proteases	HPLC with tandem LC/MS/MS	Rat plasma	in vivo	http://www.drugbank.ca/drugs/DB00143	None	Not mentioned
3125	21986100	2011	YaGFlC	CMD-Cys-DALCE	6	Free	Thiolated carboxymethyl dextran(CMD) cysteine conjugated via disulfide bond	Linear	Mix	None	Enkephalin derative	Treatment of ischemia	Not mentioned	4.5 mg/kg corresponding to 1 mg/kg of DALCE	56 ±6.0	Rats plasma proteases	LC-MS	Intravenous injection in male Sprague €“Dawley rats	in vivo	http://www.drugbank.ca/drugs/DB00144	None	Not mentioned
3126	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	HR2 (wild type) [HR2 regions of the HIV-1 envelope glycoprotein gp41]	41	Free	Free	Linear	L	None	HR2 regions of the HIV-1 envelope glycoprotein gp41	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	37.2	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00145	None	Cell ˆ’Cell Fusion Inhibition Efficacy (IC50)=1.5 ± 0.1nM
3127	22770564	2012	CEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW	N-terminus of HR2	42	Free	Free	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	38.6	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00146	None	Not mentioned
3128	22770564	2012	CEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW	N-terminus-PEG750 of HR2	42	Pegylation-PEG750	Free	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	40	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00147	None	Cell ˆ’Cell Fusion Inhibition Efficacy (IC50)=7.2 ± 0.7nM
3130	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	R4C derivative of HR2	41	Free	Free	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	37.4	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00149	None	Not mentioned
3131	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	R4C-PEG750 derivative of HR2	41	Free	Free	Linear	L	Pegylation-PEG750 of cysteine at 4th position	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	44.1	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00150	None	Cell ˆ’Cell Fusion Inhibition Efficacy (IC50)=5.1 ± 1.1nM
3133	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	S11C derivative of HR2	41	Free	Free	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	38.9	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00152	None	Not mentioned
3134	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	S11C-PEG750 derivative of HR2	41	Free	Free	Linear	L	Pegylation-PEG750 of cysteine at 11th position	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	50.2	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00153	None	Cell ˆ’Cell Fusion Inhibition Efficacy (IC50)=4.4 ± 0.8nM
3136	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	S15C derivative of HR2	41	Free	Free	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	39.9	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00155	None	Not mentioned
3137	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	S15C-PEG750 derivative of HR2	41	Free	Free	Linear	L	Pegylation-PEG750 of cysteine at 15th position	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	53.7	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00156	None	Cell ˆ’Cell Fusion Inhibition Efficacy (IC50)=4.1 ± 1.0nM
3139	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	E18C derivative of HR2	41	Free	Free	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	38.4	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00158	None	Not mentioned
3140	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	E18C-PEG750 derivative of HR2	41	Free	Free	Linear	L	Pegylation-PEG750 of cysteine at 18th position	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	50.3	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00159	None	Cell ˆ’Cell Fusion Inhibition Efficacy (IC50)=4.5 ± 1.0nM
3142	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	N22C derivative of HR2	41	Free	Free	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	38.9	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00161	None	Not mentioned
3143	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	N22C-PEG750 derivative of HR2	41	Free	Free	Linear	L	Pegylation-PEG750 of cysteine at 22nd position	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	51.8	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00162	None	Cell ˆ’Cell Fusion Inhibition Efficacy (IC50)=4.2 ± 0.9nM
3145	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	Q29C derivative of HR2	41	Free	Free	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	38.6	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00164	None	Not mentioned
3146	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNECELLELDKWASLW	Q29C-PEG750 derivative of HR2	41	Free	Free	Linear	L	Pegylation-PEG750 of cysteine at 29th position	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	58.1	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00165	None	Cell ˆ’Cell Fusion Inhibition Efficacy (IC50)=5.2 ± 0.8nM
3148	22770564	2012	EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWC	C terminus derivative of HR2	42	Free	Free	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	39	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00167	None	Not mentioned
3151	22770564	2012	EWDREINNYTSLIHSLIEECQNQQEKNEQELLELDKWASLW	S20C derivative of HR2	41	Free	Pegylation (PEG2000)	Linear	L	None	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	38.6	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00170	None	Not mentioned
3152	22770564	2012	EWDREINNYTSLIHSLIEECQNQQEKNEQELLELDKWASLW	S20C-PEG750 derivative of HR2	41	Free	Free	Linear	L	Pegylation-PEG750 of cysteine at 20th position	Modified HR2 wild type peptide	Inhibitor to prevent virus ˆ’host cell membrane fusion	Not mentioned	20Î¼M	42	Bovine Trypsin	Trypsin degradation assay, Analytical reverse phase HPLC	Solutions of bovine trypsin and the peptide or PEG ˆ’peptide conjugate in 10 mM PBS (pH 7.4)	in vitro	http://www.drugbank.ca/drugs/DB00171	None	Cell ˆ’Cell Fusion Inhibition Efficacy (IC50)>400
3154	23099431	2012	HwAWfK	GHRP-6 (Growth Hormone-Releasing Peptide-6)	6	Free	Amidation	Linear	Mix	None	Synthetic molecule structurally related to Met-enkephalin	Cytoprotective,antioxidant in nature	Not mentioned	100 Î¼g/kg of the body weight	0.14 ±0.03(t1/2Î±)	human plasma proteases	LC-MS	Intravenous bolus administartion in 9 healthy male subjects	in vivo	http://www.drugbank.ca/drugs/DB00173	None	Not mentioned
3156	23099431	2012	HwAWfK	GHRP-6 (Growth Hormone-Releasing Peptide-6)	8	Free	Amidation	Linear	Mix	None	Synthetic molecule structurally related to Met-enkephalin	Cytoprotective,antioxidant in nature	Not mentioned	200 Î¼g/kg of the body weight	0.15 ±0.06(t1/2Î±)	human plasma proteases	LC-MS	Intravenous bolus administartion in 9 healthy male subjects	in vivo	http://www.drugbank.ca/drugs/DB00175	None	Not mentioned
3158	23099431	2012	HwAWfK	GHRP-6 (Growth Hormone-Releasing Peptide-6)	10	Free	Amidation	Linear	Mix	None	Synthetic molecule structurally related to Met-enkephalin	Cytoprotective,antioxidant in nature	Not mentioned	400 Î¼g/kg of the body weight	0.09 ±0.01(t1/2Î±)	human plasma proteases	LC-MS	Intravenous bolus administartion in 9 healthy male subjects	in vivo	http://www.drugbank.ca/drugs/DB00177	None	Not mentioned
3160	23196806	2012	YGRKKRRQRRR	TAMRA-TAT [5-(and-6)-carboxytetramethylrhodamine labeled HIV transactivator protein TAT]	11	5-(and-6)-carboxytetramethylrhodamine(TAMRA)	Free	Linear	L	None	HIV	Cell penetrating peptide	Not mentioned	60 Î¼g/g	6.7	Modified simulated intestinal fluid with pancreatic enzymes	HPLC with fluorescence detection	Modified simulated intestinal fluid	in vitro	http://www.drugbank.ca/drugs/DB00179	None	Fluorescence intensity (intestinal delivery)=4.0Ã—105 in Duodenum, 6.0Ã—105 in Jejunum, 4.0Ã—105 in Ileum, 1Ã—105 in Colon
3161	23196806	2012	YGRKKRRQRRR	TAMRA-TAT microemulsion	11	5-(and-6)-carboxytetramethylrhodamine(TAMRA)	Free	Linear	L	None	HIV	Cell penetrating peptide	Not mentioned	Microemulsion composition: Miglyol 812/Capmul MCM/Tween 80/TAMRA-TAT solution at the weight ratio of	19.4	Modified simulated intestinal fluid with pancreatic enzymes	HPLC with fluorescence detection	Modified simulated intestinal fluid	in vitro	http://www.drugbank.ca/drugs/DB00180	None	Fluorescence I ntensity (intestinal delivery)< 1.0Ã—105 in Duodenum, Jejunum, Ileum, Colon
3167	1213660	1975	FVNQHLCGSHLVEALYLVCGERGFFYTPKARREAQNPQAGAVELGGGLGGLNALALEGPPQKRGIVEQCCTSICSLYQLENYCN	Procine Proinsulin	84	Free	Free	Cyclic (C7-C70,C19-C83,C69-C74)	L	None	Proinsulin	Not mentioned	Not reported	5-8.6 µg/kg were injected.	8.2 ±0.3	Porcine blood proteases	Radioimmunoassay	Porcine blood	in vivo	http://www.drugbank.ca/drugs/DB00186	None	Not reported
3168	1213660	1975	RREAQNPQAGAVELGGGLGGLNALALEGPPQKRG	Procine C-Peptide	34	Free	Free	Linear	L	None	Proinsulin	Not mentioned	Not reported	5-8.6 µg/kg were injected.	9.9 ±0.5	Porcine blood proteases	Radioimmunoassay	Porcine blood	in vivo	http://www.drugbank.ca/drugs/DB00187	None	Not reported
3169	7787827	1994	SSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFFETKCRDPNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSRKAVRRA	125I-Î²-NGF	120	Free	Free	Cyclic (3 disulphide bonds between C15-C80, C58-C108, C68-C110)	L	None	Î²-nerve growth factor	Nerve growth promoting peptide	Blood samples (250 µl) were obtained from the catheterized carotid artery 15, 30, 45 and 60 min afte	800 000 cpm of 125I-7S-NGF or 125I-Î²-NGF (diluted in 200 µl of saline)	36.3 + 2.20	Rats blood proteases	Column chromatography	Intravenouly injected in adult male Wistar rats	in vivo	http://www.drugbank.ca/drugs/DB00188	None	Not reported
3170	7962302	1994	YADAIFTNSYRKVLGQLSARKLLQDIMSR	GHRH	29	Free	Amidation	Linear	L	None	Synthetic	Growth hormone-releasing hormone (GHRH) stimulates growth hormone (GH) gene transcription, synthesis, and secretion of growth hormone via growth hormone-releasing hormone receptor (GHRH-R)	Blood samples were obtained at 5 min intervals for measurement of serum GH concentrations and at the	Intravenous dose of 1 µg/kg followed by a 15 min infusion of saline in human subjects.	18.5 ±0.8	Human blood proteases	Immunoradiometric assay (IRMA)	Human blood	in vivo	http://www.drugbank.ca/drugs/DB00189	None	Not reported
3171	7899230	1994	YGGFL	Leucine enkephalin	5	Free	Free	Linear	L	None	Leucine enkephalin	Opioid peptide	Not reported	0.63 mg/ml	40	Sheep nasal wash fluid proteases	HPLC	Sheep nasal wash fluid	in vitro	http://www.drugbank.ca/drugs/DB00190	None	Not reported
3172	7899230	1994	YGGFL	Leucine enkephalin	5	Free	Free	Linear	L	None	Leucine enkephalin	Opioid peptide	Not reported	20 µg/ml	12	Sheep nasal mucosal proteases	HPLC	Sheep nasal mucosal tissue homogenate	in vitro	http://www.drugbank.ca/drugs/DB00191	None	Not reported
3173	7899230	1994	GGFL	des-tyrosine leucine enkephalin	4	Free	Free	Linear	L	None	des-tyrosine leucine enkephalin	Opioid peptide	Not reported	0.63 mg/ml	13	Sheep nasal wash fluid proteases	HPLC	Sheep nasal wash fluid	in vitro	http://www.drugbank.ca/drugs/DB00192	None	Not reported
3174	7899230	1994	GGFL	des-tyrosine leucine enkephalin	4	Free	Free	Linear	L	None	des-tyrosine leucine enkephalin	Opioid peptide	Not reported	20 µg/ml	7	Sheep nasal mucosal proteases	HPLC	Sheep nasal mucosal tissue homogenate	in vitro	http://www.drugbank.ca/drugs/DB00193	None	Not reported
3175	8100840	1993	AGCKNFFWKTFTSC	Somatostatin (SOM)	14	Free	Free	Cyclic (C3-C14)	L	None	Synthetic	Growth hormone inhibiting hormone (GHIH)	Not reported	Not reported	<5	Rats blood proteases	Not mentioned	Rats plasma	in vivo	http://www.drugbank.ca/drugs/DB00194	None	Not reported
3176	8100840	1993	YPSKPDNPGEDAPAEDLARYYSALRHYINLITRQRY	Neuropeptide Y	36	Free	Amidation	Linear	L	None	Neuropeptide	Stimulation of the right cardiac sympathetic nerve	Not reported	Not reported	21	Dogs blood proteases	Not mentioned	Dogs plasma	in vivo	http://www.drugbank.ca/drugs/DB00195	None	Not reported
3177	8082705	1994	EAKSQGGSN	Facteur thymique serique (FTS)	9	Free	Free	Linear	L	None	Thymic peptide hormone	Suppressed hyperglycemia	Not reported	Not reported	2 to 3	Rats blood proteases	Radioimmunoassay	Intravenouly injected in male Wistar rats	in vivo	http://www.drugbank.ca/drugs/DB00196	None	Plasma glucose in FTS-treated group=15.7 ± 1.8 (mmol/l)while in control Plasma glucose=28.3 ±2.1 ( µmol/l)
3178	8035644	1994	YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY	Adrenomedullin (ADM)	52	Free	Free	Linear	L	None	Synthetic	Hormone in circulation control	Not reported	Intraarterial doses of 0.01-0.3 nmol	55 to 80	Cat blood proteases	HPLC	Hind limb vascular bed of the cat	in vivo	http://www.drugbank.ca/drugs/DB00197	None	Not reported
3179	8035644	1994	GCRFGTCT	ADM 15-22	8	Free	Free	Linear	L	None	Carboxy terminal 15-52 fragment of adrenomedullin	An inhibitor of the cellular actions of adrenomedullin	Not reported	Intraarterial doses of 0.01-0.3 nmol	55 to 80	Cat blood proteases	HPLC	Hind limb vascular bed of the cat	in vivo	http://www.drugbank.ca/drugs/DB00198	None	Not reported
3181	17204551	2007	FNAPFDVGIKLSGAQYQQHGRAL	Rat Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin frpm human	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	0 - 60 minutes	10 Î¼g	22 ±2	Protease from rat plasma	Radioimmunoassay	Intravenous injection of peptide into Sprague Dawley rats	in vivo	None	None	Co-administration of obestatin with ghrelin inhibited food intake.
3182	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	19	Proteases from Crude brain homogenate of mouse	HPLC	Crude brain homogenate of mouse	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3183	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	53	Proteases from Crude brain homogenate of mouse	HPLC	Crude brain homogenate of mouse + P8340 protease inhibitor cocktail	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3184	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	39	Proteases from Crude brain homogenate of mouse	HPLC	Crude brain homogenate of mouse + EDTA	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3185	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	20.5	Proteases from Crude brain homogenate of mouse	HPLC	Crude brain homogenate of mouse + Soybean trypsin inhibitor	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3186	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	20.5	Proteases from Crude brain homogenate of mouse	HPLC	Crude brain homogenate of mouse + APMSF	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3187	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	24	Proteases from Crude brain homogenate of mouse	HPLC	Crude brain homogenate of mouse + 1,10-Phenanthrolin	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3188	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	20	Proteases from Crude brain homogenate of mouse	HPLC	Crude brain homogenate of mouse + Captopril	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3189	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	17	Proteases from Crude brain homogenate of mouse	HPLC	Crude brain homogenate of mouse + Chymostatin	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3190	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	27	Proteases from Membrane brain Homogenate	HPLC	Membrane brain Homogenate	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3193	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	38.5	Proteases from Membrane brain Homogenate	HPLC	Membrane brain Homogenate + Soybean trypsin inhibitor	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3194	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	16	Proteases from Membrane brain Homogenate	HPLC	Membrane brain Homogenate+ APMSF	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3195	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	28	Proteases from Membrane brain Homogenate	HPLC	Membrane brain Homogenate + 1,10-Phenanthrolin	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3196	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	28	Proteases from Membrane brain Homogenate	HPLC	Membrane brain Homogenate + Captopril	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3197	19422857	2009	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 120 minutes	90 Î¼g	29.5	Proteases from Membrane brain Homogenate	HPLC	Membrane brain Homogenate+ Chymostatin	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	No suppressive effects of obestatin on food or water intake were observed
3198	18602197	2008	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 60 minutes, pH 7.4	90 Î¼g	42.2 [40.5, 44.0]	Proteases from mouse plasma	HPLC, LC-UV/MS	Mouse plasma	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	Not reported
3199	18602197	2008	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 60 minutes, pH 7.5	90 Î¼g	12.6 [11.4, 14.1]	Proteases from Mouse liver homogenate	HPLC, LC-UV/MS	Mouse liver homogenate	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	Not reported
3200	18602197	2008	FNAPFDVGIKLSGAQYQQHGRAL	Mouse Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin from mouse	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 60 minutes, pH 7.6	90 Î¼g	30.0 [27.8, 32.6]	Proteases from Mouse stomach homogenate	HPLC, LC-UV/MS	Mouse stomach homogenate	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	Not reported
3204	18602197	2008	FNAPFDVGIKLSGVQYQQHSQAL	Human Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin frpm human	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 60 minutes, pH 7.10	90 Î¼g	13.3 [12.7, 14.0]	Proteases from mouse liver homogenate	HPLC, LC-UV/MS	Mouse liver homogenate	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	Not reported
3205	18602197	2008	FNAPFDVGIKLSGVQYQQHSQAL	Human Obestatin	23	Free	Amidation	Linear	L	None	Proghrelin frpm human	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 60 minutes, pH 7.11	90 Î¼g	28.0 [25.8, 30.5]	Proteases from mouse liver homogenate+protease inhibitor cocktai	HPLC, LC-UV/MS	Mouse liver homogenate with protease inhibitor cocktail	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	Not reported
3207	18602197	2008	FNAPFDVGIKLSGVQYQQHSQAL	Mono-iodinated human obestatin	23	Free	Amidation	Linear	L	Iodination at tyr16	Proghrelin frpm human	Energy balance, Inhibit Ghrelin-induced Growth Hormone secretion	37 °C for 0 - 60 minutes, pH 7.12	90 Î¼g	15.1 [9.1, 45.0]	Proteases from Mouse liver homogenate	HPLC, LC-UV/MS	Mouse liver homogenate	in vitro	http://www.sigmaaldrich.com/catalog/product/sigma/	None	Not reported
3208	8353280	1993	ASISGRDTHRLTRTLNCSSIVKEIIGKLPEPELKTDDEGPSLRNKSFRRVNLSKFVESQGEVDPEDRYVIKSNLQKLNCCLPTSANDSALPGVFIRDLDDFRKKLRFYMVHLNDLETVLTSRPPQPASGSVSPNRGTVEC	Interleukin-3 (IL-3)	140	Free	Free	Cyclic (C17-C80,C79-C140)	L	Glycosylation at 84thand 112th position	IL3 is produced by activated T lymphocytes, activated mast cells, and eosinophils and neutrophils	Hematopoietic growth factor	Not mentioned	1,000 biologic units	2.1 (Î± half life)	Balb/c mice blood proteases	ELISA	Injected intravenously in Balb/c mice blood	in vivo	http://www.uniprot.org/uniprot/P01586	None	Mice treated with IL3 had megakaryocyte frequency=0.9 ±0.21 per high-power field while saline control had 1.4 ±0.33 per high-power field
3209	8353280	1993	ASISGRDTHRLTRTLNCSSIVKEIIGKLPEPELKTDDEGPSLRNKSFRRVNLSKFVESQGEVDPEDRYVIKSNLQKLNCCLPTSANDSALPGVFIRDLDDFRKKLRFYMVHLNDLETVLTSRPPQPASGSVSPNRGTVEC	Interleukin-3 (IL-3)	140	Free	Free	Cyclic (C17-C80,C79-C140)	L	Glycosylation at 84thand 112th position	IL3 is produced by activated T lymphocytes, activated mast cells, and eosinophils and neutrophils	Hematopoietic growth factor	Not mentioned	1,000 biologic units	10.0 (Î² half life)	Balb/c mice blood proteases	ELISA	Injected intravenously in Balb/c mice blood	in vivo	http://www.uniprot.org/uniprot/P01586	None	Mice treated with IL3 had megakaryocyte frequency=0.9 ±0.21 per high-power field while saline control had 1.4 ±0.33 per high-power field
3210	8353280	1993	ASISGRDTHRLTRTLNCSSIVKEIIGKLPEPELKTDDEGPSLRNKSFRRVNLSKFVESQGEVDPEDRYVIKSNLQKLNCCLPTSANDSALPGVFIRDLDDFRKKLRFYMVHLNDLETVLTSRPPQPASGSVSPNRGTVEC	Interleukin-3 (IL-3)	140	Free	Free	Cyclic (C17-C80,C79-C140)	L	Glycosylation at 84thand 112th position	IL3 is produced by activated T lymphocytes, activated mast cells, and eosinophils and neutrophils	Hematopoietic growth factor	Not mentioned	1,000 biologic units	3.6 (Î± half-life)	Balb/c mice blood proteases	ELISA	Injected intravenously in Balb/c mice blood	in vivo	http://www.uniprot.org/uniprot/P01586	None	Mice treated with IL3 had megakaryocyte frequency=0.9 ±0.21 per high-power field while saline control had 1.4 ±0.33 per high-power field
3211	8353280	1993	ASISGRDTHRLTRTLNCSSIVKEIIGKLPEPELKTDDEGPSLRNKSFRRVNLSKFVESQGEVDPEDRYVIKSNLQKLNCCLPTSANDSALPGVFIRDLDDFRKKLRFYMVHLNDLETVLTSRPPQPASGSVSPNRGTVEC	Interleukin-3 (IL-3)	140	Free	Free	Cyclic (C17-C80,C79-C140)	L	Glycosylation at 84thand 112th position	IL3 is produced by activated T lymphocytes, activated mast cells, and eosinophils and neutrophils	Hematopoietic growth factor	Not mentioned	1,000 biologic units	30.8 (Î² half life)	Balb/c mice blood proteases	ELISA	Injected intravenously in Balb/c mice blood	in vivo	http://www.uniprot.org/uniprot/P01586	None	Mice treated with IL3 had megakaryocyte frequency=0.9 ±0.21 per high-power field while saline control had 1.4 ±0.33 per high-power field
3212	19115392	2009	HPAGKRPCKMQAFRIWDTNQKTFYLRNNQLIAGYLQGPNTKLEEKIDMVPIDFRNVFLGIHGGKLCLSCVKSGDDTKLQLEEVNITDLNKNKEEDKRFTFIRSETGPTTSFESLACPGWFLCTTLEADHPVSLTNTPKEPCTVTKFYFQEDQ	Interleukin-1 Receptor Antagonist (IL-1ra)	152	Free	Free	Cyclic(66-116)	L	Glycosylation at 84th position	Interleukin-1 Receptor Antagonist	The natural specific receptor antagonist (IL-1ra) binds to IL-1RI but does not initiate signaling as it does not engage the IL1R accessory protein and therefore acts as a receptor antagonist.	Not mentioned	Not mentioned	6 to 15	Rats blood proteases	Not mentioned	Rat blood	in vivo	http://www.uniprot.org/uniprot/P25086	None	Significant depression of LTP in the group of animals that received intracerebroventricular injection of AÎ²-peptide (1 €“40) compared with control animals injected with vehicle.
4006	38789061	2024	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	Exendin-4 analogs	Antidiabetes	Blood sample was collected for IV-dosed rats, time points were pre-dose, 1 min, 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr, 8 hr, 10 hr, and 24 hr	1 mg/kg	0.5 ± 0.1	Male SD rats plasma protease	UHPLC	Male SD rats plasma	In Vivo	PDB id: 7MLL	None	N.A.
4019	38737283	2024	LAEAKVLANRELDKYGVSDFYKRLINKAKTVEGVEALKLHILAALP-FRRG-(E5C3)-(GN)	ABD035-immunoGN	N.A.	P1h3	His-tag	Linear	L	Humanized anti-HER2 scFv P1h3, albumin-binding peptides (ABD035 or dAb7h8), cathepsin B-cleavable peptide B2, endosome-disruptive peptide E5C3 fusion protein, GN= Gasdermin-N	Synthetic	Antitumor	Blood samples were promptly collected at 5, 10, 30, 60, 360, and 720 min	0.1 μmol/kg	35.22	BALB/c mice serum protease	ELISA	BALB/c mice serum	In Vivo	None	None	Cytotoxicity of ABD035-immunoGN in N87 cells reached as high as 62 %, compared to 38 % for immunotBid after 24 h of incubation
4020	38737283	2024	FRRG-(E5C3)-(GN)	immunoGN	N.A.	P1h3	His-tag	Linear	L	Humanized anti-HER2 scFv P1h3, albumin-binding peptides (ABD035 or dAb7h8), cathepsin B-cleavable peptide B2, endosome-disruptive peptide E5C3 fusion protein, GN= Gasdermin-N	Synthetic	Antitumor	Blood samples were promptly collected at 5, 10, 30, 60, 360, and 720 min	0.1 μmol/kg	4.599	BALB/c mice serum protease	ELISA	BALB/c mice serum	In Vivo	None	None	Cytotoxicity of ABD035-immunoGN in N87 cells reached as high as 62 %, compared to 38 % for immunotBid after 24 h of incubation
4021	38737283	2024	DIQMTQSPSSLSAVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYRNSPLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYRVPPTFGQGTKVEIKR-FRRG-(E5C3)-(GN)	dAb7h8-immunoGN	N.A.	P1h3	His-tag	Linear	L	Humanized anti-HER2 scFv P1h3, albumin-binding peptides (ABD035 or dAb7h8), cathepsin B-cleavable peptide B2, endosome-disruptive peptide E5C3 fusion protein, GN= Gasdermin-N	Synthetic	Antitumor	Blood samples were promptly collected at 5, 10, 30, 60, 360, and 720 min	0.1 μmol/kg	31.25	BALB/c mice serum protease	ELISA	BALB/c mice serum	In Vivo	None	None	Cytotoxicity of ABD035-immunoGN in N87 cells reached as high as 62 %, compared to 38 % for immunotBid after 24 h of incubation
4031	38613996	2024	AGILKRW	PepH3	7	Free	Amidation	Linear	L	None	Synthetic	Anticancer	At different time points (0, 1, 5, 10, 30, 60, 120, and 360 min), 120 µL aliquots were collected and incubated with equal volume of 96% ethanol for 30 min at 4⁰C	1 mM	21.00 ± 2.91	Human serum protease	RP-HPLC	Human serum	In Vitro	None	None	IC50 > 100.0 for TNBC MDA-MB-231 Monolayer
4041	38493673	2024	ALWPPNLHAWVP	Peptide ALW	12	Free	Free	Linear	L	None	Synthetic	Alleviating Lupus Nephritis	N.A.	12.5 mg/kg	0.315 (Elimination Half Life)	Cd1 mice plasma protease	N.A.	CD1 mice plasma	In Vivo	None	None	KD(M) = 1.99*10-4 (Binding affinity of peptides to anti-dsDNA IgG3)
4057	38312052	2024	KXCRGDCFCX	Maraciclatide (99mTc)	7	Acetylation	Free	Cyclic(Ac-Cys8 Bond, Cys2-Cys6 Disulfide Bond)	L	Radiolabelled with technetium, X= Unknown Structure	synthetic	Novel Diagnostic Imaging Agent For A Range Of Pathological Conditions	Blood and plasma samples were collected at 10 min, 30 min, 1 h, 2 h, 4 h, 8 h, 24 h, 48 h, 72 h, and 7 days post-administration	The data acquired from all participants who received 99mTc-maraciclatide within the expected clinical range (15, 75 µg, 150) were pooled	1 (Terminal Elimination Half Life)	Human Plasma Protease	Gamma counter	Human plasma	In Vivo	https://pubchem.ncbi.nlm.nih.gov/compound/73050806	None	N.A.
4061	38104907	2024	Y-(d-Dab)-RFFwKTF	[Al18F]NODA-MPAA-HTA	8	Conjugating 18F nuclide with a modified KE108 peptide, MPAA modification at N terminal	The amino group of KE108 peptide conjugated with the carboxyl group of NODA	Cyclic(d-Dab2-Phe8)	Mix	D-Tryp amino acid substituition, d-Dab = Diaminobutyric acid	18F-radiolabeled somatostatin analogue	Used for PET imaging of Neuroendocrine tumors (NETs)	Blood samples were collected from the retroorbital plexus into capillary at 5, 10, 15, 30,60 and 120 min	N.A.	37.63 ± 13.05 (Elimination Half Life)	BALB/c mice blood protease	Gamma counter	BALB/c mice blood sample	In Vivo	None	None	Affinity of [Al18F]NODA-MPAA-HTA (Kd = 8.77 ± 1.14 nM, n = 4)
4079	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood sample were collected at 2,5,10,20,40,60 Minutes After Dosing And For Animals Receiving 10 Mg/Kg, Additional Samples Were Taken At 90 And 120 Minutes After Dosing	0.1 mg/kg	3.49 (Initial Elimination Phase)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rat plasma	In Vivo	None	EP 2023067975 W	N.A.
4080	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood sample were collected at 2,5,10,20,40,60 Minutes After Dosing And For Animals Receiving 10 Mg/Kg, Additional Samples Were Taken At 90 And 120 Minutes After Dosing	1 mg/kg	3.34 (Initial Elimination Phase)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rat plasma	In Vivo	None	EP 2023067975 W	N.A.
4081	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood sample were collected at 2,5,10,20,40,60 Minutes After Dosing And For Animals Receiving 10 Mg/Kg, Additional Samples Were Taken At 90 And 120 Minutes After Dosing	10 mg/kg	7.64 (Initial Elimination Phase)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rat plasma	In Vivo	None	EP 2023067975 W	N.A.
4082	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood sample were collected at 2,5,10,20,40,60 Minutes After Dosing And For Animals Receiving 10 Mg/Kg, Additional Samples Were Taken At 90 And 120 Minutes After Dosing	0.1 mg/kg	18.8 (Terminal Elimination Phase)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rat plasma	In Vivo	None	EP 2023067975 W	N.A.
4083	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood sample were collected at 2,5,10,20,40,60 Minutes After Dosing And For Animals Receiving 10 Mg/Kg, Additional Samples Were Taken At 90 And 120 Minutes After Dosing	1 mg/kg	10 (Terminal Elimination Phase)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rat plasma	In Vivo	None	EP 2023067975 W	N.A.
4084	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood sample were collected at 2,5,10,20,40,60 Minutes After Dosing And For Animals Receiving 10 Mg/Kg, Additional Samples Were Taken At 90 And 120 Minutes After Dosing	10 mg/kg	10.2 (Terminal Elimination Phase)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rat plasma	In Vivo	None	EP 2023067975 W	N.A.
4085	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples were collected at 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	1 mg/kg	8.4 (Elimination Half Life)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rats plasma after day 1 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4086	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples were collected at 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	1 mg/kg	7.33 (Elimination Half Life)	Female wistar rats plasma protease	LC-MS/MS	Female wistar rats plasma after day 1 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4087	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples were collected at 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	1 mg/kg	7.66 (Elimination Half Life)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rats plasma after day 14 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4088	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples were collected at 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	1 mg/kg	7.11 (Elimination Half Life)	Female wistar rats plasma protease	LC-MS/MS	Female wistar rats plasma after day 14 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4089	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples were collected at 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	3 mg/kg	7 (Elimination Half Life)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rats plasma after day 1 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4090	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples were collected at 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	3 mg/kg	8 (Elimination Half Life)	Female wistar rats plasma protease	LC-MS/MS	Female wistar rats plasma after day 1 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4091	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples were collected at 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	3 mg/kg	6.67 (Elimination Half Life)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rats plasma after Day 14 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4092	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples were collected at 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	3 mg/kg	6.85 (Elimination Half Life)	Female wistar rats plasma protease	LC-MS/MS	Female wistar rats plasma After Day 14 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4093	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	10 mg/kg	7.8 (Elimination Half Life)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rats plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4094	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	10 mg/kg	7.16 (Elimination Half Life)	Female wistar rats plasma protease	LC-MS/MS	Female wistar rats plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4095	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	10 mg/kg	7.31 (Elimination Half Life)	Male wistar rats plasma protease	LC-MS/MS	Male wistar rats plasma After Day 14 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4096	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	10 mg/kg	7.04 (Elimination Half Life)	Female wistar rats plasma protease	LC-MS/MS	Female wistar rats plasma After Day 14 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4097	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	1 mg/kg	4.68 (Elimination Half Life)	Male dogs plasma protease	LC-MS/MS	Male dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4098	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	1 mg/kg	4.83 (Elimination Half Life)	Female dogs plasma protease	LC-MS/MS	Female dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4099	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	1 mg/kg	6.59 (Elimination Half Life)	Male dogs plasma protease	LC-MS/MS	Male dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4100	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	1 mg/kg	4.66 (Elimination Half Life)	Female dogs plasma protease	LC-MS/MS	Female dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4101	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	3 mg/kg	6.01 (Elimination Half Life)	Male dogs plasma protease	LC-MS/MS	Male dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4102	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	3 mg/kg	5.7(Elimination Half Life)	Female dogs plasma protease	LC-MS/MS	Female dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4103	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	3 mg/kg	6.05 (Elimination Half Life)	Male dogs plasma protease	LC-MS/MS	Male dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4104	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	3 mg/kg	6.13 (Elimination Half Life)	Female dogs plasma protease	LC-MS/MS	Female dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4105	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	10 mg/kg	5.09 (Elimination Half Life)	Male dogs plasma protease	LC-MS/MS	Male dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4106	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	10 mg/kg	5.41 (Elimination Half Life)	Female dogs plasma protease	LC-MS/MS	Female dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4107	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	10 mg/kg	6 (Elimination Half Life)	Male dogs plasma protease	LC-MS/MS	Male dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4108	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Samples Were Collected At 2,5,10,20,40 Minutes After Dosing On Days 1 Or 14	10 mg/kg	5.9 (Elimination Half Life)	Female dogs plasma protease	LC-MS/MS	Female dogs plasma After Day 1 Repeated Dose	In Vivo	None	EP 2023067975 W	N.A.
4111	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood Samples Were Collected At The Following Time Points: Pre-Dose, Then, 10 Min,20 Min,30Min,0.75,1,1.5,2,2.5,3,4,6,8,12,16 And 24 H After Infusion Start	100μg/kg	1.15 (Elimination Half Life)	Human plasma protease	LC-MS/MS	Human plasma	In Vivo	None	EP 2023067975 W	N.A.
4112	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood Samples Were Collected At The Following Time Points: Pre-Dose, Then, 10 Min,20 Min,30Min,0.75,1,1.5,2,2.5,3,4,6,8,12,16 And 24 H After Infusion Start	150 μg/kg	1.15 (Elimination Half Life)	Human plasma protease	LC-MS/MS	Human plasma	In Vivo	None	EP 2023067975 W	N.A.
4113	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood Samples Were Collected For Pk Purpose For Peptide 1 Determinations On Day 1 At The Following Time Points: Pre-Dose, Then 10 Min, 20 Min, 30 Min = 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 8.16, 8.32, 8.5, 8.75, 9.0, 9.5, 10.0, 10.5, 11.0, 12.0, 14.0, 16.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 16.16, 16.32, 16.5, 16.75, 17.0, 17.5, 18.0, 18.5, 19.0, 20.0, 22.0 And 24 Hours After The First Infusion Start	50 μg/kg	1.38 (Elimination Half Life)	Human plasma protease	LC-MS/MS	Human plasma received three 8 hours apart 30-min peptide 1 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4114	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood Samples Were Collected For Pk Purpose For Peptide 1 Determinations On Day 1 At The Following Time Points: Pre-Dose, Then 10 Min, 20 Min, 30 Min = 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 8.16, 8.32, 8.5, 8.75, 9.0, 9.5, 10.0, 10.5, 11.0, 12.0, 14.0, 16.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 16.16, 16.32, 16.5, 16.75, 17.0, 17.5, 18.0, 18.5, 19.0, 20.0, 22.0 And 24 Hours After The First Infusion Start	100μg/kg	2.18 (Elimination Half Life)	Human plasma protease	LC-MS/MS	Human plasma received three 8 hours apart 30-min peptide 1 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4115	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood Samples Were Collected For Pk Purpose For Peptide 1 Determinations On Day 1 At The Following Time Points: Pre-Dose, Then 10 Min, 20 Min, 30 Min = 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 8.16, 8.32, 8.5, 8.75, 9.0, 9.5, 10.0, 10.5, 11.0, 12.0, 14.0, 16.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 16.16, 16.32, 16.5, 16.75, 17.0, 17.5, 18.0, 18.5, 19.0, 20.0, 22.0 And 24 Hours After The First Infusion Start	140 μg/kg	1.94 (Elimination Half Life)	Human plasma protease	LC-MS/MS	Human plasma received three 8 hours apart 30-min peptide 1 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4116	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood Samples Were Collected For Pk Purpose For Peptide 1 Determinations On Day 1 At The Following Time Points: Pre-Dose, Then 10 Min, 20 Min, 30 Min = 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 8.16, 8.32, 8.5, 8.75, 9.0, 9.5, 10.0, 10.5, 11.0, 12.0, 14.0, 16.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 16.16, 16.32, 16.5, 16.75, 17.0, 17.5, 18.0, 18.5, 19.0, 20.0, 22.0 And 24 Hours After The First Infusion Start	200 μg/kg	1.94 (Elimination Half Life)	Human plasma protease	LC-MS/MS	Human plasma received three 8 hours apart 30-min peptide 1 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4117	N.A.	2024	AMVSEFLKQAWFIENEEQEYVQTLKSSKGGPGSAVSPYPTFNPSSDV	Peptide 1	47	Free	Amidation	Linear	L	V24L modifications	Annexin A1 Derivative	Antiinflammatory	Blood Samples Were Collected For Pk Purpose For Peptide 1 Determinations On Day 1 At The Following Time Points: Pre-Dose, Then 10 Min, 20 Min, 30 Min = 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 8.16, 8.32, 8.5, 8.75, 9.0, 9.5, 10.0, 10.5, 11.0, 12.0, 14.0, 16.0, Then 10 Min, 20 Min, 30 Min After The Second Infusion Start, I.E. 16.16, 16.32, 16.5, 16.75, 17.0, 17.5, 18.0, 18.5, 19.0, 20.0, 22.0 And 24 Hours After The First Infusion Start	250 μg/kg	1.88 (Elimination Half Life)	Human plasma protease	LC-MS/MS	Human plasma received three 8 hours apart 30-min peptide 1 repeated dose	In Vivo	None	EP 2023067975 W	N.A.
4118	38863646	2024	N.A.	(89Zr, Mn)-WPMNs	N.A.	Free	Free	Linear	L	Mn and 89Zr labeling, MNPs modified with WL12-SH	WL12 derivative	Targets PD-L1	Blood samples were collected from orbital vein at 1, 3, 5, 10, 15, 20, 30, 45 min and 1, 1.5, 2, 3, 4, 14, 24, 48, 72, 96 h	0.5 mg/ml	0.1234 (Fast) (Metabolic Half Life)	KM mouse blood protease	Radioactivity assay using γ-counter	KM mouse blood	In Vivo	None	None	N.A.
4173	38027063	2023	QVTLKESGPGILQPSQTLSLTCSFSGFSLNTFGMGVSWIRQPSGKGLEWLAHIFWDDDKHYNPSLKSRLTISKDTSNNQVFLKITTVDTADTATYYCVRYGFDGFPYWGQGTGGGGSGGGGSGGGGSDVVMTQTPLSLPVSLGDQASISCRSNQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRPSGSGSGTDFTLKISRVEAEDLGFYFCSQSTRVPWTFGGGTKLEIKR	ScFv9	304	Free	Free	Linear	L	Biotinylation	The scFv9 sequence is derived from an antibody fragment to target amyloid beta (Aβ)	Treatment of AD and Parkinson disease	Plasma was collected at 0, 2, 4, 8, and 24 h after injection	250 μg	0.74	TgCRND8 mice plasma protease	Direct ELISA	TgCRND8 mice plasma	In Vivo	None	None	N.A.
4176	37880318	2023	VAIALKAAHYHTHKE	L3	15	Free	Amidation	Linear	L	None	Derived from calcitermin	Antimicrobial	37 °C	0.0001 M	20	Human plasma protease	HPLC	Human plasma with 1 ml of ammonium acetate buffer (pH 7.4)	In Vitro	None	None	CFU = 189 ± 23 for 0.032 mg/mL peptide concentration (0.1 mL of microbial suspension after 24 hours of incubation at 37°C) (Effect of peptide derivatives on Candida albicans (ATCC 10231) proliferation)
4177	37880318	2023	VAIALKAAHYHTHKE	Wild-type Calcitermin (WT)	15	Free	Free	Linear	L	None	C-terminal cleavage fragment of calgranulin C	Antimicrobial	37 °C	0.0001 M	18 ± 3	Human plasma protease	HPLC	Human plasma with 1 ml of ammonium acetate buffer (pH 7.4)	In Vitro	None	None	CFU = 28 ± 15 for 0.032 mg/mL peptide concentration (0.1 mL of microbial suspension after 24 hours of incubation at 37°C) (Effect of peptide derivatives on Candida albicans (ATCC 10231) proliferation)
4178	37875481	2023	N.A.	IL-15-Cy7	N.A.	Free	Free	Linear	L	Cy7	Derived from Interleukin-15	Antitumor	The blood sample was harvested at timed intervals (2 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h)	N.A.	0.69	Mice blood protease	Fluorescence spectrophotometry	Mice blood	In Vivo	None	None	Not mentioned
4189	37397495	2023	SLAFVDVLN	Peptide	9	Free	Free	Linear	L	Removing an Asp residue	Isolated from Merluccius productus fish protein hydrolysate	Inhibits BACE-1	Blood was taken after 0, 5, and 30 min and 2, 6, and 24 h after injectio	4 mg/kg	0.69	Mouse plasma protease	Mass spectrometry	Mouse plasma	In Vivo	None	None	Ki(µM)= 0.0940 BACE-1 activity with peptide which has reduced activity due to inhibition by peptide
4190	37390979	2023	H-Aib-DGTFTSELSRLREGARLQRLLQGLLQGLVGK	BI-3434	33	Free	Amidation	Linear	L	Lys33 conjuagted with HLE (fatty acid based half life extension group),Substituting Ser with 2-aminoisobutyric acid (Aib) at position 2	Lipidated secretin analog	Secretin receptor agonist	N.A.	30 nmol/kg	<15	Male NMRI mice plasma protease	Mass spectrometry	Male NMRI mice plasma (Non fasted)	In Vivo	None	None	EC50 =15.5 pM for BI-3434
4196	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	Timepoints of 0, 10, 20, 30, 60, and 120 min	2 μM	54.6	Beagle dogs plasma protease	Triple Quadrupole Mass spectrometry	Beagle dogs plasma	In Vitro	None	None	Not mentioned
4197	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	Timepoints of 0, 10, 20, 30, 60, and 120 min	2 μM	52.7	Cynomolgus monkeys plasma protease	Triple Quadrupole Mass spectrometry	Cynomolgus monkeys plasma	In Vitro	None	None	Not mentioned
4198	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	Timepoints of 0, 10, 20, 30, 60, and 120 min	2 μM	5.68	CD-1 mouse plasma protease	Triple Quadrupole Mass spectrometry	CD-1 mouse plasma	In Vitro	None	None	Not mentioned
4200	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	120 minutes	2 μM	2.72	Intestinal fluid protease	Triple Quadrupole Mass spectrometry	Simulated Intestinal Fluid (SIF) at pH = 5.5	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4204	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	32.5	CD-1 mouse Liver Microsomes protease	LC-MS/MS	CD-1 mouse Liver Microsomes	In Vitro	None	None	N.A.
4205	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	27.7	SD rats Liver Microsome Protease	LC-MS/MS	SD rats Liver Microsome	In Vitro	None	None	N.A.
4206	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	33	Beagle dogs Liver Microsome Protease	LC-MS/MS	Beagle dogs Liver Microsome	In Vitro	None	None	N.A.
4207	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	21.8	Cynomolgus monkeys Liver Microsome Protease	LC-MS/MS	Cynomolgus monkeys Liver microsome	In Vitro	None	None	N.A.
4208	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15,30, 60, 90, and 120 minutes), samples were removed for analysis	2 μM (0.5 mg protein/mL of each species pooled together)	20.3	Human Liver Microsome protease	LC-MS/MS	Human Liver Microsome	In Vitro	None	None	N.A.
4209	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	<15	CD-1 mouse Hepatocytes Lysate Protease	LC-MS/MS	CD-1 mouse Hepatocytes Lysate	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4210	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	5.81	SD rats Hepatocytes Lysates protease	LC-MS/MS	SD rats hepatocytes Lysates	In Vitro	None	None	N.A.
4211	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	10.7	Beagle dogs Hepatocytes Lysates protease	LC-MS/MS	Beagle dogs Hepatocytes Lysates	In Vitro	None	None	N.A.
4212	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	12.1	Cynomolgus monkeys Hepatocytes Lysates protease	LC-MS/MS	Cynomolgus monkeys Hepatocytes Lysates	In Vitro	None	None	N.A.
4213	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	5.28	Human Hepatocytes Lysates protease	LC-MS/MS	Human Hepatocytes	In Vitro	None	None	Enzyme Activity = 0.682 at 2 microMolar of HM1010 (Cytochrome P450 (CYP1A2) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4214	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	5.28	Human Hepatocytes Lysates protease	LC-MS/MS	Human Hepatocytes Lysates	In Vitro	None	None	Enzyme Activity = 3.18 at 2 microMolar of HM1010 (Cytochrome P450 (CYP2B6) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4215	37373203	2023	LRKLRKRLLRLVGRQLEEFL	HM-10/10	20	Free	Free	Linear	L	None	Chimeric high-density lipoprotein mimetic peptide	Anticancer	At the assay points (time zero, 15, 30, 60,120, and 180 minutes), samples were removed for analysis	2 μM (0.5 million cells/mL, of each species pooled together)	5.28	Human Hepatocytes Lysates protease	LC-MS/MS	Human Hepatocytes Lysates	In Vitro	None	None	Enzyme Activity = 2.06 at 2 microMolar of HM1010 (Cytochrome P450 (CYP3A4) Induction in Single-Donor Human Hepatocytes Lot HH1086)
4216	37094132	2023	GQWHCTTSFPHHYCLY-Bip	SNIO–CBP	16	Single nanometer iron oxide and PEG conjugation at N terminal	Amidation	Cyclic (C5-C14 Disulfide Bond)	L	None	SINO-CBP product	Used in detection of Liver Fibrosis	N.A.	2 nmol/g animal	5.7 ± 1.9 (Elimination Half Life)	Mice blood protease	Dynamic T1-weighted MRI	Mice blood	In Vivo	None	None	Kd = 18.4 µM (Binding affinity of SNIO–CBP toward human type I collagen)
4217	37073494	2023	pGlu-LTPTPNW(Man)GT	Carmo‐HrTH‐I	10	pGlu = Pyroglutamate	Amidation	Linear	L	C‐mannosylated tryptophan residue at position 8	Derived from the corpora cardiaca (CC) of the Indian stick insect Carausius morosus	Hypertrehalosemia In Ligated Stick Insects	0, 2‐, 5‐, 10‐and 30 min at Room temp	100 pmol	5	C.Morosus hemolymph protease	HPLC	C.Morosus hemolymph	In Vitro	None	None	[Lipid]T0 min(µg/µL) = 9.32 ± 1.59 for Natural Carmo‐HrTH‐I (10 pmol) (Biological activity of a crude methanolic extract of corpora cardiaca (CC) from the natural hypertrehalosemic hormones (HrTHs) extracted from the CC of the Indian stick insect(Carausius morosus) in an in vivo bioassay withL. migratoria)
4218	37047588	2023	VIKLSGRELVRAQIAISGMSTWSKRSL	B7-33	27	Free	Free	Linear	L	None	Derived as a single-chain peptidomimetic of the B-chain of H2 relaxin	Treatment of Acute Cardiac Failure	A total of 80 µL of samples was removed at various time points (0 min, 30 min, 60 min, 120 min, 240 min, and 480 min)	400 µg/mL	6	Human serum protease	RP-HPLC	Human serum	In Vitro	None	None	HEK-7BP Binding B.S.A. Free Eu-H2 pKi = 7.28 ± 0.11
4219	37047588	2023	VIKLSGRELVRAQIAISGMSTWSKRSL	AcK(PalmGlu)-PEG12-B7-33	27	Ac modifed Lysine in Palmitic fatty acid linked with B7-33 using PEG linker	Free	Linear	L	None	B7-33 analog	Treatment of Acute Cardiac Failure	A total of 80 µL of samples was removed at various time points (0 min, 30 min, 60 min, 120 min, 240 min, and 480 min)	400 µg/mL	60	Human serum protease	RP-HPLC	Human serum	In Vitro	None	None	HEK-7BP Binding B.S.A. Free Eu-H2 pKi =7.52 ± 0.13
4221	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	1.5 mg/kg	0.306	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vivo	None	None	N.A.
4222	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	4.5 mg/kg	0.344	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vivo	None	None	N.A.
4223	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	13.5 mg/kg	0.547	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vivo	None	None	N.A.
4224	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	1 mg/kg	0.805	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4225	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	1 mg/kg	0.248	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4226	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	5 mg/kg	0.46	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4227	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	5 mg/kg	0.437	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4228	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	75 mg/kg	0.341	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4229	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	75 mg/kg	0.391	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4230	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	1 mg/kg	0.665	Dogs plasma protease	LC-MS/MS	Dogs plasma	In Vivo	None	None	N.A.
4231	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	1 mg/kg	0.668	Dogs plasma protease	LC-MS/MS	Dogs plasma	In Vivo	None	None	N.A.
4232	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	5 mg/kg	0.655	Dogs plasma protease	LC-MS/MS	Dogs plasma	In Vivo	None	None	N.A.
4233	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	5 mg/kg	0.648	Dogs plasma protease	LC-MS/MS	Dogs plasma	In Vivo	None	None	N.A.
4234	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	75 mg/kg	0.615	Dogs plasma protease	LC-MS/MS	Dogs plasma	In Vivo	None	None	N.A.
4235	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	75 mg/kg	0.62	Dogs plasma protease	LC-MS/MS	Dogs plasma	In Vivo	None	None	N.A.
4236	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	5 mg/kg	0.888	Monkeys Plasma Protease	LC-MS/MS	Monkeys plasma	In Vivo	None	None	N.A.
4237	36982773	2023	CRGDKGPDC	CEND-1	9	Free	Free	Cyclic (C1-C9 Disulfide Bond)	L	None	iRGD cyclic peptide	Antitumor	Blood samples were collected for pharmacokinetic evaluations pre-dose and at 1, 5, 10, 15 and 30 min, and 1, 2 and 6 h post-dose in rats, dogs and monkeys, and 3, 10, 30 and 90 min, and 4 and 8 h post-dose in mice	50 mg/kg	0.956	Monkeys Plasma Protease	LC-MS/MS	Monkeys plasma	In Vivo	None	None	N.A.
4250	36631971	2023	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation, Orn=Ornithine at position 19	Linear	L	Orn=Ornithine at position 15	Oncocins	Antimicrobial	Prodrug and Onc72 concentrations were determined 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h postadministration	4.34 mmol/kg	43	CD-1 mice plasma protease	LC-MS	CD-1 mice plasma	In Vivo	None	None	(Onc72 in 19% MHB2 medium) MIC = 12.5 μmol L−1 (29 mg L−1) on E.coli BW25113
4251	36631971	2023	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation, Orn=Ornithine at position 19	Linear	L	Orn=Ornithine at position 15	Oncocins	Antimicrobial	Prodrug and Onc72 concentrations were determined 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h postadministration	4.34 mmol/kg	43	CD-1 mice plasma protease	LC-MS	CD-1 mice plasma	In Vivo	None	None	(Onc72 in 25% mouse serum ) MIC = 25 μmol L−1 (58 mg L−1) on E.coli BW25113
4252	36631971	2023	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation, Orn=Ornithine at position 19	Linear	L	Orn=Ornithine at position 15	Oncocins	Antimicrobial	Prodrug and Onc72 concentrations were determined 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h postadministration	4.34 mmol/kg	43	CD-1 mice plasma protease	LC-MS	CD-1 mice plasma	In Vivo	None	None	Onc72 Showed negligible hemolytic activity (below 0.2%) up to the highest tested concentration (50 μmol L−1), similar to the negative control (PBS)
4253	36631971	2023	VDKPPYLPRPRPPROIYNO	Onc72	19	Free	Amidation, Orn=Ornithine at position 19	Linear	L	Orn=Ornithine at position 15	Oncocins	Antimicrobial	Prodrug and Onc72 concentrations were determined 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h postadministration	4.34 mmol/kg	43	CD-1 mice plasma protease	LC-MS	CD-1 mice plasma	In Vivo	None	None	Onc72: Non-toxic to human HepG2 and HEK293 cell lines at 50 μmol L−1
4272	36509220	2023	KLLKINLKALAALAKKIL	KM8	18	Free	Amidation	Linear	L	None	Analogue of Mastoparan	Antitumor	N.A.	N.A.	30	Mouse plasma protease	Plasma stability assay	Mouse plasma	In Vivo	None	None	N.A.
4273	36410792	2023	HGDGSFSDEMNTILDNLAARDFINWLIQTKITD	Teduglutide	33	Free	Free	Linear	L	None	GLP-2 analogue	Small Bowel Hypertrophic Effect	Blood (0.3 ml) was then collected from the jugularvein at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours for teduglutide and 1, 4, 8, 24, 48, 72, 96, 230, 244, 268, 192, 216, 240, 264, 288, 312, and 336 hours for HM15912	670 nmol/kg	0.6 ± 0.1	SD rats serum protease	GLP-2 ELISA	SD rats serum	In Vivo	None	None	EC50 = 0.12 ± 0.056 nM for teduglutide peptide (In vitro potency of GLP-2 analogs on human GLP-2 receptor in cell-based functional assays of dose-response cAMP)
4305	N.A.	2023	GSSFLSPEHQRVQQRKESKKPPAKLQPR	SEQ ID NO 1	28	Free	Free	Linear	L	None	Human Ghrelin Analog	Ghrelin Receptor Agonist	Solutions were incubated at 37 C for 60, 120 and 180 Minutes	1 mg/ml	0.2	Plasma protease	LC-MS	Diluted plasma	In Vitro	None	EP 2023054305 W	EC50(nM) = 0.83
4388	37329900	2023	N.A.	KAN-101	N.A.	N.A.	N.A.	N.A.	N.A.	Liver-targeting glycosylation signature conjugated to a deaminated gliadin peptide	N.A.	Liver-Targeted Immune Tolerance Therapy	N.A.	0·15 mg/kg, 0·3 mg/kg, 0·6 mg/kg, 1·2 mg/kg, 1·5 mg/kg	3·72 to 31·72	Human protease	N.A.	Human	In Vivo	None	None	N.A.
4395	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration	20 μg/kg	15.2	SD rats plasma protease	LC-MS/MS	SD rats plasma	In Vivo	None	None	N.A.
4396	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	100 μg/kg	18.5	SD rats plasma protease	LC-MS/MS	SD rats plasma dosed with BPC once a day for seven consecutive days	In Vivo	None	None	N.A.
4397	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration	20 μg/kg	7.87	SD rats plasma protease	LC-MS/MS	SD rats plasma	In Vivo	None	None	N.A.
4398	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	100 μg/kg	17.1	SD rats plasma protease	LC-MS/MS	SD rats plasma dosed with BPC once a day for seven consecutive days	In Vivo	None	None	N.A.
4399	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration	500 μg/kg	29.7	SD rats plasma protease	LC-MS/MS	SD rats plasma	In Vivo	None	None	N.A.
4400	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration	6 μg/kg	5.27 ± 2.25	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma	In Vivo	None	None	N.A.
4401	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	30 μg/kg	19.6 ± 3.72	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma with repeated dose of 30 μg/kg for seven consecutive days	In Vivo	None	None	N.A.
4402	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration	6 μg/kg	20.0 ± 5.53	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma	In Vivo	None	None	N.A.
4403	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration	30 μg/kg	25.5 ± 7.08	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma	In Vivo	None	None	N.A.
4404	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Treatment of various wounds in rats and dogs	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration	150 μg/kg	29.3 ± 5.06	Beagle Dogs Plasma Protease	LC-MS/MS	beagle dogs plasma	In Vivo	None	None	N.A.
4406	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	https://pmc.ncbi.nlm.nih.gov/articles/PMC7994712/	None	IC50(nM) = 1.7 (relative affinities of CST for the different Somatostatin receptor SSTR1)
4407	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 0.09 (relative affinities of CST for the different Somatostatin receptor SSTR2)
4408	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 0.3 (relative affinities of CST for the different Somatostatin receptor SSTR3)
4409	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 0.2 (relative affinities of CST for the different Somatostatin receptor SSTR4)
4410	36559278	2022	PCKNFFWKTFSSCK	Native CST	14	Free	Free	Cyclic (C2-C13 Disulfide Linkage)	L	None	Neuropeptide	Antiinflammatory	37 °C	6 mg/mL	2	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 0.3 (relative affinities of CST for the different Somatostatin receptor SSTR1)
4411	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 47.3 (relative affinities of A5 for the different Somatostatin receptor SSTR1)
4412	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 35 (relative affinities of A5 for the different Somatostatin receptor SSTR2)
4413	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 5.1 (relative affinities of A5 for the different Somatostatin receptor SSTR3)
4414	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 4.1 (relative affinities of A5 for the different Somatostatin receptor SSTR4)
4415	36559278	2022	PCKN-Mesityl-AFwKTFSSCK	CST analogue 5	14	N-octanoyl	Free	Cyclic (C2-C13 Disulfide Linkage)	Mix	w=D-Trp,Mesityl	CST analogue	Antiinflammatory	37 °C	6 mg/mL	21	Human plasma protease	N.A.	Human plasma	In Vitro	None	None	IC50(nM) = 1.12 (relative affinities of A5 for the different Somatostatin receptor SSTR1)
4416	36557850	2022	pGlu-HWSYlLRP	Leuprolide	9	pGlu = Pyroglutamate	NHEt (Ethylamine)	Linear	Mix	d-Leucine6 substituitions	Synthetic	Anticancer (Treatment of Advanced Prostate Cancer)	Blood sample of approximately 0.3 mL was collected via femoral artery cannulation at various time points (0, 1, 3, 5, 10, 20, 30, 60, 90, 120, 180, 240, 360, 480, and 600 min)	0.1 mg/kg	38.2 ± 4.3 (Terminal Elimination Half Life)	Male SD Rats Plasma Protease	UPLC-MS/MS	Male SD rats plasma	In Vivo	None	None	N.A.
4419	36499357	2022	ILRWSRKLPCVS	JM#21	12	Free	Free	Linear	L	Cysteine was introduced at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	1.7	Human plasma protease	Flow cytometry-based functional assay and mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4421	36499357	2022	ILRWSRKLPCVS	JM#21	12	Free	Free	Linear	L	Cysteine was introduced at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	7	Human plasma protease	Antibody-competition assay	Human plasma	In Vitro	None	None	N.A.
4422	36499357	2022	IVRWSKKVPCVS	WSC02	12	Free	Free	Linear	L	Cysteine was introduced in the sequence of both peptides at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	9	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4423	36499357	2022	IVRWSKKVPCVS	WSC02	12	Free	Free	Linear	L	Cysteine was introduced in the sequence of both peptides at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	6	Human plasma protease	Functional stability assay	Human plasma after GuHCl + DTT treatment	In Vitro	None	None	N.A.
4424	36499357	2022	ILRWSRKLPCVS	JM#21	12	Free	Free	Linear	L	Cysteine was introduced at position 10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	5	Human plasma protease	Mass spectrometry	Human plasma after GuHCl + DTT treatment	In Vitro	None	None	N.A.
4425	36499357	2022	IVRWSKKVPSVS	WSC02 (C10S)	12	Free	Free	Linear	L	Cys10 replaced by Ser10	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	4	Human plasma protease	Mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4426	36499357	2022	IVRWSKKVPCVS	WSC02 (Cdm)	12	Free	Free	Linear	L	Carbamidomethylation of Cys10 residue = Cdm	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	5	Human plasma protease	Mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4427	36499357	2022	ILRWSRKLPSVS	JM#21 (C10S)	12	Free	Free	Linear	L	Cys replaced by Ser	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	4	Human plasma protease	Mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4428	36499357	2022	ILRWSRKLPCVS	JM#21 (Cdm)	12	Free	Free	Linear	L	Carbamidomethylation of Cys residue = Cdm	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	7 µM	3	Human plasma protease	Mass spectrometry	Human plasma	In Vitro	None	None	N.A.
4429	36499357	2022	IVRWSKKVPCVS	WSC02 (Cdm)	12	Free	Free	Linear	L	Carbamidomethylation of Cys residue = Cdm	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	20 µM	6	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4430	36499357	2022	IVRWSKKVPSVS	WSC02 (C10S)	12	Free	Free	Linear	L	Cys replaced by Ser	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	20 µM	7	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4431	36499357	2022	ILRWSRKLPCVS	JM#21 (Cdm)	12	Free	Free	Linear	L	Carbamidomethylation of Cys residue = Cdm	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	20 µM	3	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4432	36499357	2022	ILRWSRKLPSVS	JM#21 (C10S)	12	Free	Free	Linear	L	Cys replaced by Ser	Synthetic	Anticancer, Antiinflammatory	Five microliter aliquots were separated after 0, 5, 10, 20, 30, 45, 60, 90, and 120 min	20 µM	4	Human plasma protease	Functional stability assay	Human plasma	In Vitro	None	None	N.A.
4437	36443291	2022	FSSE	Entry 1 (aka P5779)	4	Free	Amidation	Linear	L	None	Synthetic	Inhibitor of Hmgb1/Md-2/Tlr4 Complex Formation	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	2.0 ± 0.1	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	HMGb1:MD-2 inhibition (IC50) = 68.5 nM
4440	36443291	2022	FSS-azaE	Entry 4 (Azapeptide 53)	4	Free	Aza-glutamic acid (azaE4) modification at position 4 (E4)	Linear	L	None	P5779 analogues	Inhibitor of Hmgb1/Md-2/Tlr4 Complex Formation	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	2.6 ± 0.11	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	HMGb1:MD-2 inhibition (IC50) = 396.8 nM
4442	36443291	2022	azaF-SSQ	Entry 6 (Azapeptide 55)	4	Aza-Phe at postion 1	Amidation, Q amino acid subtituition at place of E at C terminal	Linear	L	None	P5779 analogues	Inhibitor of Hmgb1/Md-2/Tlr4 Complex Formation	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	24.4 ± 1.6	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	HMGb1:MD-2 inhibition (IC50) = 159.3 nM
4445	36443291	2022	FSS-azaQ	Entry 9 (Azapeptide 58)	4	Free	Amidation, Aza-glutamine (azaQ4)	Linear	L	None	P5779 analogues	Inhibitor of Hmgb1/Md-2/Tlr4 Complex Formation	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	2.9 ± 0.20	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	HMGb1:MD-2 inhibition (IC50) = 422.9 nM
4446	36443291	2022	RPPGFSPFR	Entry 1 (Bradykinin)	9	Free	Free	Linear	L	None	Derived from kininogen	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	5.29 ± 0.5	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	EC50(nM) = 44.4 (PEG2 induction in Fibroblasts)
4447	36443291	2022	azaR-PPGFSPFR	Entry 2 (azaR1-BK)	9	Modified at position 1 with an aza-amino acid (aza-arginine)	Free	Linear	L	None	Aza-bradykinin analogues	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	2.46 ± 0.05	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	N.A.
4448	36443291	2022	R-azaP-PGFSPFR	Entry 3(azaP2-BK)	9	Free	Free	Linear	L	Modified at position 2 with an aza-amino acid (aza-proline)	Aza-bradykinin analogues	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	5.40 ± 1.1	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	EC50(nM) = 61.1 (PEG2 induction in Fibroblasts)
4449	36443291	2022	RP-azaP-GFSPFR	Entry 4 (azaP3-BK)	9	Free	Free	Linear	L	Modified at position 3 with an aza-amino acid (aza-proline)	Aza-bradykinin analogues	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	2.63 ± 0.25	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	N.A.
4450	36443291	2022	RPP-azaG-FSPFR	Entry 5 (azaG4-BK)	9	Free	Free	Linear	L	Modified at position 4 with an aza-amino acid (aza-glycine)	Aza-bradykinin analogues	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	4.33 ± 1.3	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	N.A.
4451	36443291	2022	RPPG-azaF-SPFR	Entry 6 (azaF5-BK)	9	Free	Free	Linear	L	Modified at position 5 with an aza-amino acid (aza-phenylalanine)	Aza-bradykinin analogues	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	14.7 ± 1.6	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	N.A.
4452	36443291	2022	RPPGFS-azaP-FR	Entry 7 (azaP7-BK)	9	Free	Free	Linear	L	Modified at position 7 with an aza-amino acid (aza-proline)	Aza-bradykinin analogues	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	2.38 ± 0.03	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	N.A.
4453	36443291	2022	RPPGFSP-azaF-R	Entry 8 (azaF8-BK)	9	Free	Free	Linear	L	Modified at position 8 with an aza-amino acid (aza-phenylalanine)	Aza-bradykinin analogues	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	39.3 ± 2.5	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	EC50(nM) = 99.6 (PEG2 induction in Fibroblasts)
4454	36443291	2022	RPPGFSPF-azaR	Entry 9 (azaR9-BK)	9	Free	Free	Linear	L	Modified at position 9 with an aza-amino acid (aza-arginine)	Aza-bradykinin analogues	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	42.6 ± 0.8	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	N.A.
4455	36443291	2022	R-azaP-PGFSP-azaF-R	Entry 10 ([azaP2, azaF8]-BK)	9	Free	Free	Linear	L	Modified at both positions 2 and 8 with aza-amino acids (aza-proline and aza-phenylalanine, respectively)	Aza-bradykinin analogues	Effects on Pain, Inflammation, Edema/Vasodilation and Blood Pressure	Aliquots (200 μL) were taken at each time point (0, 5, 10, 15, 20, 30, 60 and 120 minutes)	0.1 mg/ml	29.2 ± 3.8	C57Bl/6 J mouse serum protease	LC-MS/MS	C57BL/6 J male mouse serum	In Vitro	None	None	EC50(nM) = 80.6 (PEG2 induction in Fibroblasts)
4457	36380917	2022	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG	GLP-1	31	Free	Free	Linear	L	None	Glucagon	Antidiabetes	37 °C	0.3 nmol	10.2 ± 0.4	DPP-IV	RP-HPLC	50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIV	In Vitro	PDB id: 5VAI	None	BGLmax (mmol L−1) = 19.27 ± 1.41 (In vivo glucose stabilizing capability)
4458	36380917	2022	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG	GLP-1	31	Free	Free	Linear	L	None	Glucagon	Antidiabetes	37 °C	6 nmol	55.7 ± 12.1	Mouse serum protease	RP-HPLC	Mouse serum	In Vitro	PDB id: 5VAI	None	BGLmax (mmol L−1) = 19.27 ± 1.41 (In vivo glucose stabilizing capability)
4459	36380917	2022	HAEGTFTSNVSSYLEGQAAKEFIAWLVKGRG	Glc-GLP-1-1	31	Free	Free	Linear	L	Glucosylation at Asn15	GLP-1 analogs	Antidiabetes	37 °C	0.3 nmol	30.2 ± 2.4	DPP-IV	RP-HPLC	50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIV	In Vitro	None	None	N.A.
4461	36380917	2022	HAEGTFTSDVSSYLEGQAANESIAWLVKGRG	Glc-GLP-1-3	31	Free	Free	Linear	L	Glucosylation at Asn26	GLP-1 analogs	Antidiabetes	37 °C	0.3 nmol	46.1 ± 3.5	DPP-IV	RP-HPLC	50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIV	In Vitro	None	None	N.A.
4463	36380917	2022	HAEGTFTSDVSSYLEGQAAKEFIAWLVNGTG	Glc-GLP-1-5	31	Free	Free	Linear	L	Glucosylation at Asn34	GLP-1 analogs	Antidiabetes	37 °C	0.3 nmol	32.5 ± 1.4	DPP-IV	RP-HPLC	50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIV	In Vitro	None	None	N.A.
4465	36380917	2022	HAEGTFTSNVSSYLEGQAAKEFIAWLVKGRG	Glycan-GLP-1-1(G2)	31	Free	Free	Linear	L	N-glycosylation with biantennary complex-type N-glycan at Asn15 (G2 glycoform = glycan)	GLP-1 analogs	Antidiabetes	37 °C	0.3 nmol	49.1 ± 5.7	DPP-IV	RP-HPLC	50 mM Tris–HCl (pH 7.4) buffer + 10 ng μL−1 DPPIV	In Vitro	None	None	BGLmax (mmol L−1) = 24.44 ± 2.37 (In vivo glucose stabilizing capability)
4497	36135098	2022	QDTDTWA	GNRs-AAP1-Cy5	7	Free	Free	Linear	L	Cy5 conjugation	AAP1/AAP1-1/AAP1-2 modified GNRs	Antiadhesive property	At 0, 0.08, 0.16, 0.33, 0.5, 1, 2, 6, 12, 24, 48, 72 h, adding 40 μL termination solution	1 mg/ml	0.29 (T1/2 a)	Mouse serum protease	HPLC	1 mL mouse serum	In Vitro	None	None	N.A.
4499	36135098	2022	WTDAQTD	GNRs-AAP1-1-Cy5	7	Free	Free	Linear	L	Cy5 conjugation	AAP1/AAP1-1/AAP1-2 modified GNRs	Antiadhesive property	At 0, 0.08, 0.16, 0.33, 0.5, 1, 2, 6, 12, 24, 48, 72 h, adding 40 μL termination solution	1 mg/ml	0.18 (T1/2 a)	Mouse serum protease	HPLC	1 mL mouse serum	In Vitro	None	None	N.A.
4501	36135098	2022	TADWTDQ	GNRs-AAP1-2-Cy5	7	Free	Free	Linear	L	Cy5 conjugation	AAP1/AAP1-1/AAP1-2 modified GNRs	Antiadhesive property	At 0, 0.08, 0.16, 0.33, 0.5, 1, 2, 6, 12, 24, 48, 72 h, adding 40 μL termination solution	1 mg/ml	0.2 (T1/2 a)	Mouse serum protease	HPLC	1 mL mouse serum	In Vitro	None	None	N.A.
4503	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	N.A.	1 mg/kg	1	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vivo	None	None	KD(nM) = 2.9±1.1 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in Mouse)
4504	36112771	2022	CP-1Nal-dCM-HArg-DWSTP-HyP-WC	BT8009	16	Acetylation	Conjugation to MMAE cytotoxin via a valine–citrulline (V-Citr) cleavable linker,Val-Citriline linker and BTC joined by spacer Sar10	Bicyclic	Mix	cyclised on TATA (1,3,5-Triacryloylhexahydro-1,3,5-triazine), 1Nal - 3-(1-naphthyl)-L-alanine, HArg – homo-arginine, HyP – hydroxyproline, MMAE = Monomethyl auristatin E, Cys16 with amidation modification, D-Asp4 modification	BT8009 and MMAE cytotoxin hybrid	Anticancer	N.A.	1 mg/kg	0.9	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	KD(nM) = 6.0±1.2 (Binding affinity for BT8009 binding to extracellular domains of Nectin-4 in Rat)
4518	36101452	2022	YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY	AM	52	Free	Amidation	Cyclic (C16-C21 Disulfide Bond)	L	None	Isolated from Human pheochromocytoma	Vasodilator and Cardiovascular Protection	Blood was collected before injection (0 min), and then 15, 30, 60 and 120 min after administration	50 nmol/kg	32.3	Wistar rats plasma protease	ELISA (measure mAM )	Wistar rats plasma	In Vivo	None	None	After treatment with IgG4-AM (6-52), SBP (Systolic Blood Pressure) decreased significantly over time, showing reductions of 24.3 ± 4.8 mmHg on day 3, 32.2 ± 6.9 mmHg on day 6, 40.7 ± 3.1 mmHg on day 9, and 56.6 ± 4.5 mmHg on day 12, compared to the control group
4519	36101452	2022	YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY	AM	52	Free	Amidation	Cyclic (C16-C21 Disulfide Bond)	L	None	Isolated from Human pheochromocytoma	Vasodilator and Cardiovascular Protection	Blood was collected before injection (0 min), and then 15, 30, 60 and 120 min after administration	50 nmol/kg	27.5	Wistar rats plasma protease	ELISA (measure tAM )	Wistar rats plasma	In Vivo	None	None	After treatment with IgG4-AM (6-52), SBP (Systolic Blood Pressure) decreased significantly over time, showing reductions of 24.3 ± 4.8 mmHg on day 3, 32.2 ± 6.9 mmHg on day 6, 40.7 ± 3.1 mmHg on day 9, and 56.6 ± 4.5 mmHg on day 12, compared to the control group
4525	36034808	2022	MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT	uPAR	335	Free	Free	Linear	L	None	Derived from PLAUR gene	Plays role in thrombosis	N.A.	N.A.	48.2 ± 2.3	BEAS-2B cells lysate protease	Densitometry analysis using NIH Image J	BEAS-2B cells lysate with UK treatment +H/R (Hypoxia/Reoxygenation) + Cycloheximide	In Vivo	None	None	N.A.
4546	35890224	2022	K-(PEG)4-E	177Lu-Palm-3PRGD2	2	Lys1 linked with (palmitoyl-Glu-OH)	Glu3 linked with (PEG4-c(RGDfK))2	Cyclic (3PRGD2)	Mix	177Lu radiolabeling at PEG4, Lys1 and Glu2 linked with PEG4 in between	Synthetic	Antitumor	N.A.	0.74 MBq	4.49 (T1/2a)	KM mice blood protease	Gamma counter	KM mice blood sample	In Vivo	None	None	N.A.
4547	35890224	2022	E	177Lu-3PRGD2	1	PEG4	Glu linked with [PEG4-c(RGDfK)]2	Cyclic (3PRGD2)	Mix	177Lu radiolabeling at PEG4	Synthetic	Antitumor	N.A.	0.74 MBq	1.94 (T1/2a)	KM mice blood protease	Gamma counter	KM mice blood sample	In Vivo	None	None	N.A.
4549	35890224	2022	E	177Lu-3PRGD2	1	PEG4	Glu linked with [PEG4-c(RGDfK)]2	Cyclic (3PRGD2)	Mix	177Lu radiolabeling at PEG4	Synthetic	Antitumor	N.A.	0.74 MBq	11.81 (T1/2Β)	KM mice blood protease	Gamma counter	KM mice blood sample	In Vivo	None	None	N.A.
4551	35890224	2022	E	177Lu-3PRGD2	1	PEG4	Glu linked with [PEG4-c(RGDfK)]2	Cyclic (3PRGD2)	Mix	177Lu radiolabeling at PEG4	Synthetic	Antitumor	N.A.	0.74 MBq	14.54 (Slow)	C57Bl/6 mice blood protease	Gamma counter	C57BL/6 mice blood sample	In Vivo	None	None	N.A.
4552	35890224	2022	K-(PEG)4-E	177Lu-Palm-3PRGD2	2	Lys1 linked with (palmitoyl-Glu-OH)	Glu3 linked with (PEG4-c(RGDfK))2	Cyclic (3PRGD2)	Mix	177Lu radiolabeling at PEG4, Lys1 and Glu2 linked with PEG4 in between	synthetic	Antitumor	N.A.	0.74 MBq	2.08 (Fast)	C57Bl/6 mice blood protease	Gamma counter	C57BL/6 mice blood sample	In Vivo	None	None	N.A.
4553	35890224	2022	E	177Lu-3PRGD2	1	PEG4	Glu linked with [PEG4-c(RGDfK)]2	Cyclic (3PRGD2)	Mix	177Lu radiolabeling at PEG4	synthetic	Antitumor	N.A.	0.74 MBq	1.06 (Fast)	C57Bl/6 mice blood protease	Gamma counter	C57BL/6 mice blood sample	In Vivo	None	None	N.A.
4568	35807500	2022	AEWCP	TIPP	5	Free	Free	Linear	L	None	From calf thymus extracts	Treatment of Asthma	At 0.5, 1, 2, 5, 10, 15, 20, and 40 min post administration (eight mice at each time points), blood samples were taken from an inner canthus	50 mg/kg	5.99 ± 1.82	Mice plasma protease	LC-MS/MS	Mice plasma	In Vivo	None	None	TIPP inhibits degranulation and inflammation in RBL-2H3 cells and pretreatment with 200 microgram/mL of TIPP for 20 minutes reduces the level of biomarkers of allergic response and inflammation i.e β-hexosaminidase, Histamine, IL-4
4569	35779189	2022	WSGWSSCSRSCG	NX210	12	Free	Free	Linear	L	None	Derived from the subcommissural organ (SCO)-spondin	Treatment of Neurodegenerative Diseases	Blood PK samples (4 mL) for the analysis of NX210 via its metabolite NX210c were collected prior to dosing, immediately after bolus injection or termination of the infusion and at 5, 10, 15, 20, 25, 30, 70, 120, and 180 min after bolus injection or termination of infusion	2.5 mg/kg	13.3	Human plasma protease	HPLC–MS/MS	Human plasma	In Vivo	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965545/	None	N.A.
4570	35779189	2022	WSGWSSCSRSCG	NX210	12	Free	Free	Linear	L	None	Derived from the subcommissural organ (SCO)-spondin	Treatment of Neurodegenerative Diseases	Blood PK samples (4 mL) for the analysis of NX210 via its metabolite NX210c were collected prior to dosing, immediately after bolus injection or termination of the infusion and at 5, 10, 15, 20, 25, 30, 70, 120, and 180 min after bolus injection or termination of infusion	5 mg/kg	6.19	Human plasma protease	HPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4571	35779189	2022	WSGWSSCSRSCG	NX210	12	Free	Free	Linear	L	None	Derived from the subcommissural organ (SCO)-spondin	Treatment of Neurodegenerative Diseases	Blood PK samples (4 mL) for the analysis of NX210 via its metabolite NX210c were collected prior to dosing, immediately after bolus injection or termination of the infusion and at 5, 10, 15, 20, 25, 30, 70, 120, and 180 min after bolus injection or termination of infusion	10 mg/kg	20	Human plasma protease	HPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4575	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from jugular veins at predose and at 2, 5, 10, 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after dosing from group 1 to 3	0.04 mmol/kg	0.3 (Elimination Half Life)	Male SD rats plasma protease	ICP-MS	Male SD rats plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4576	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from jugular veins at predose and at 2, 5, 10, 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after dosing from group 1 to 3	0.04 mmol/kg	0.28 (Elimination Half Life)	Female SD rats plasma protease	ICP-MS	Female SD rats plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4577	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from jugular veins at predose and at 2, 5, 10, 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after dosing from group 1 to 3	0.04 mmol/kg	0.57(Elimination Half Life)	(P) SD rats plasma protease	ICP-MS	(P) SD rats plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4578	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from jugular veins at predose and at 2, 5, 10, 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after dosing from group 1 to 3	0.1 mmol/kg	0.31 (Elimination Half Life)	Male SD rats plasma protease	ICP-MS	Male SD rats plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4579	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from jugular veins at predose and at 2, 5, 10, 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after dosing from group 1 to 3	0.1 mmol/kg	0.32 (Elimination Half Life)	Female SD rats plasma protease	ICP-MS	Female SD rats plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4580	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from jugular veins at predose and at 2, 5, 10, 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after dosing from group 1 to 3	0.1 mmol/kg	0.65 (Elimination Half Life)	(P) SD rats plasma protease	ICP-MS	(P) SD rats plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4581	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from jugular veins at predose and at 2, 5, 10, 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after dosing from group 1 to 3	0.2 mmol/kg	0.3 (Elimination Half Life)	Male SD rats plasma protease	ICP-MS	Male SD rats plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4582	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from jugular veins at predose and at 2, 5, 10, 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after dosing from group 1 to 3	0.2 mmol/kg	0.32 (Elimination Half Life)	Female SD rats plasma protease	ICP-MS	Female SD rats plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4583	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from jugular veins at predose and at 2, 5, 10, 15, 30, and 45 minutes and 1, 2, 3, and 4 hours after dosing from group 1 to 3	0.2 mmol/kg	0.22 (Elimination Half Life)	(P) SD rats plasma protease	ICP-MS	(P) SD rats plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4584	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from fore limb veins at predose and at 5, 10, 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, and 6 hours after dosing from group 1 to 3.	0.04 mmol/kg	0.76 (Elimination Half Life)	Male dogs plasma protease	ICP-MS	Male dogs plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4585	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from fore limb veins at predose and at 5, 10, 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, and 6 hours after dosing from group 1 to 3.	0.04 mmol/kg	0.74 (Elimination Half Life)	Female dogs plasma protease	ICP-MS	Female dogs plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4586	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from fore limb veins at predose and at 5, 10, 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, and 6 hours after dosing from group 1 to 3.	0.04 mmol/kg	0.8 (Elimination Half Life)	(P) dogs plasma protease	ICP-MS	(P) dogs plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4587	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from fore limb veins at predose and at 5, 10, 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, and 6 hours after dosing from group 1 to 3.	0.1 mmol/kg	0.7 (Elimination Half Life)	Male dogs plasma protease	ICP-MS	Male dogs plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4588	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from fore limb veins at predose and at 5, 10, 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, and 6 hours after dosing from group 1 to 3.	0.1 mmol/kg	0.67 (Elimination Half Life)	Female dogs plasma protease	ICP-MS	Female dogs plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4589	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from fore limb veins at predose and at 5, 10, 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, and 6 hours after dosing from group 1 to 3.	0.1 mmol/kg	0.33 (Elimination Half Life)	(P) dogs plasma protease	ICP-MS	(P) dogs plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4590	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from fore limb veins at predose and at 5, 10, 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, and 6 hours after dosing from group 1 to 3.	0.2 mmol/kg	0.69 (Elimination Half Life)	Male dogs plasma protease	ICP-MS	Male dogs plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4591	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from fore limb veins at predose and at 5, 10, 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, and 6 hours after dosing from group 1 to 3.	0.2 mmol/kg	0.63 (Elimination Half Life)	Female dogs plasma protease	ICP-MS	Female dogs plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4592	35703463	2022	TVRTSAD	MT218	7	Free	ZD2 conjugated to a clinical contrast agent gadoteridol Gd(HP-DO3A) using N3 linker	Linear	L	None	ZD2 analog	Cancer targeting contrast agent	Blood samples were collected from fore limb veins at predose and at 5, 10, 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, and 6 hours after dosing from group 1 to 3.	0.2 mmol/kg	0.048 (Elimination Half Life)	(P) dogs plasma protease	ICP-MS	(P) dogs plasma	In Vivo	None	None	MT218 did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at concentrations up to 100 μM
4608	35646543	2022	HsQGTFTSDYSKYLDKRRAQDFVQWLLNTGGPSSGAPPPS	TB001	40	Free	Amidation, GGPSSGAPPPS introduced in the C-terminal	Cyclic (R17-D21 Lactam Bridge)	Mix	D serine modifcation at 2, side chain modification at Lysine (n=12, R=CH3)	GLP-1 and GCG chimera analog	Treatment of Multiple Causes of Hepatic Fibrosis	N.A.	15.3 μg/kg	0.498 ± 0.0100	Rhesus monkeys plasma protease	HPLC–MS/MS	Rhesus monkeys plasma	In Vivo	None	None	GCGR EC50(nmol/L) = 0.01, GLP-1R EC50(nmol/L) = 0.04
4631	35414877	2022	MVATKTFALLLLSLFLAVGLGEKKEGHFSALPSLPVGSHAKVSSPQPRGPRYAEGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQREARALELASQANRKEEEAVEPQSSPAKNPSDEDLLRDLLIQELLACLLDQTNLCRLRSR	Native GIP	153	Free	Free	Linear	L	None	Glucagon	Glucose dependent insulinotropic	At selected time points samples were taken: 5, 15, 30, 60, 120, 210, 300 mins	1 μM	45	Human plasma protease	LC-MS	80% pooled human Li-heparin plasma	In Vitro	None	None	N.A.
4632	35414877	2022	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG	GLP-1	31	Free	Free	Linear	L	None	Glucagon	Antidiabetes	At selected time points samples were taken: 5, 15, 30, 60, 120, 210, 300 mins	1 μM	35	Human plasma protease	LC-MS	80% pooled human Li-heparin plasma	In Vitro	PDB id: 5VAI	None	N.A.
4638	35359494	2022	EMRLSKFFRDFILQRKK	CSP1	17	Free	Free	Linear	L	None	Competence stimulating peptide	Modulates Quorum Sensing In Streptococcus Pneumoniae	Aliquots (100 μL) were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, and 24 h time points	1 mM	30	Trypsin	RP-HPLC	PBS solution	In Vitro	None	None	EC50(nM) = 10 for CSP1 against ComD1 receptor, EC50(nM) = 530 for CSP1 against ComD2 receptor
4639	35359494	2022	EMRLSKFFRDFILQRKK	CSP1	17	Free	Free	Linear	L	None	Competence stimulating peptide	Modulates Quorum Sensing In Streptococcus Pneumoniae	Aliquots (100 μL) were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, and 24 h time points	1 mM	1	Chymotrypsin	RP-HPLC	PBS solution	In Vitro	None	None	EC50(nM) = 10 for CSP1 against ComD1 receptor, EC50(nM) = 530 for CSP1 against ComD2 receptor
4644	35180646	2022	YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY	NPY1–36	36	Free	Amidation	Linear	L	None	Human derived	Vasoconstrictor	168 min for a study day	N.A.	4.66 ± 0.70	Human plasma protease	LC-MS/MS	Human plasma after Heavy exercise	In Vivo	PDB id: 7RTA	None	N.A.
4645	35180646	2022	YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY	NPY1–36	36	Free	Amidation	Linear	L	None	Human derived	Vasoconstrictor	168 min for a study day	N.A.	4.78 ± 1.07	Human plasma protease	LC-MS/MS	Human plasma with 5 mg saxagliptin after Heavy exercise	In Vivo	PDB id: 7RTA	None	N.A.
4646	35180646	2022	SKPDNPGEDAPAEDMARYYSALRHYINLITRQRY	NPY3–36	34	Free	Amidation	Linear	L	None	Human derived	Vasoconstrictor	168 min for a study day	N.A.	26.9 ± 6.2	Human plasma protease	LC-MS/MS	Human plasma after Heavy exercise	In Vivo	PDB id: 7RTA	None	N.A.
4647	35180646	2022	SKPDNPGEDAPAEDMARYYSALRHYINLITRQRY	NPY3–36	34	Free	Amidation	Linear	L	None	Human derived	Vasoconstrictor	168 min for a study day	N.A.	25.5 ± 6.2	Human plasma protease	LC-MS/MS	Human plasma with 5 mg saxagliptin after Heavy exercise	In Vivo	PDB id: 7RTA	None	N.A.
4649	35174698	2022	MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK-AANDENYALAA	GFP-Ec	250	GFP	Ec (E.coli) SsrA tag sequences conjugation	Linear	L	None	eGFP derivative	Increases Half Life	N.A.	N.A.	6	E. Coli Bl21(De3) cells lysate protease	Fluorescence assay	E. coli BL21(DE3) cells lysate after 5 h removed the inducer	In Vivo	PDB id: 4EUL	None	N.A.
4650	35174698	2022	MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK-AANKNEENTNEVPTFMLNAGQANYAFA	GFP-Mf	266	GFP	Mf (M.fluorum) SsrA tag sequences	Linear	L	None	eGFP derivative	Increases Half Life	N.A.	N.A.	56	E. Coli Bl21(De3) cells lysate protease	Fluorescence assay	E. coli BL21(DE3) cells lysate after 5 h removed the inducer	In Vivo	PDB id: 4EUL	None	N.A.
4652	35174698	2022	MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK-AANDENYALAA	GFP-Ec	250	GFP	Ec (E.coli) SsrA tag sequences	Linear	L	None	eGFP derivative	Increases Half Life	N.A.	N.A.	14	E. Coli Bl21(De3) star strain lysate protease	Fluorescence assay	E. coli BL21 (DE3) star strain lysate in which RNase E has been knocked out	In Vivo	PDB id: 4EUL	None	N.A.
4654	35150805	2022	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	GLP-1 analogs	Antidiabetes	Blood sampling was performed at 0.083, 0.5, 4, 24, 48 and 72 h after injection	1200 nmol/kg	0.137 (Terminal Half Life)	Male CDR1 mice plasma protease	ELISA	Male CDR1 mice plasma	In Vivo	PDB id: 7MLL	None	EC50 = 0.42nM ( in the classical in vitro GLP1R cell based assay based on cAMP)
4662	35113575	2022	ETVTLLVALKVRYRERIT-Ahx-CKRGARSTC	TT1-IP peptide	27	Free	Amidation	Cyclic (C-C Disulfide Bond)	L	Conjugation of TT1 and IP proteins which is linked by Ahx	TT1 and IP fusion protein	Antitumor (Effect on TPP-IPs on Cll xenograft models)	plasma collected at 10, 20, 30, 45, 60, 120 and 360 min	5 mg/kg	28 (Terminal Half Life)	BALB/c mice plasma protease	HPLC-MS	Balb/c mice plasma	In Vivo	None	None	The average survival for TT1-IP and LinTT1-IP treated groups was 19 days (the survival range for TT1-IP group was 17-23 days and for LinTT1-IP group was 13-25 days) and for the control group 16 days (range of 14-20 days)
4671	34954052	2022	KEIVSRNKRRYQEDGRKKRRQRRR	SY-007	24	Free	Free	Linear	L	None	Neuropeptide	Treatment of Ischemic Stroke	Blood samples were collected for determinationsof SY-007 at pre-dose (within 0.5 h prior to dosing) and at 5, 10, 15, 20,30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of the intravenous infusion	1 mg	0.25 ± 0.02	Human plasma protease	LC-MS	Human plasma	In Vivo	None	None	N.A.
4672	34954052	2022	KEIVSRNKRRYQEDGRKKRRQRRR	SY-007	24	Free	Free	Linear	L	None	Neuropeptide	Treatment of Ischemic Stroke	Blood samples were collected for determinationsof SY-007 at pre-dose (within 0.5 h prior to dosing) and at 5, 10, 15, 20,30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of the intravenous infusion	4 mg	0.36 ± 0.04	Human plasma protease	LC-MS	Human plasma	In Vivo	None	None	N.A.
4673	34954052	2022	KEIVSRNKRRYQEDGRKKRRQRRR	SY-007	24	Free	Free	Linear	L	None	Neuropeptide	Treatment of Ischemic Stroke	Blood samples were collected for determinationsof SY-007 at pre-dose (within 0.5 h prior to dosing) and at 5, 10, 15, 20,30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of the intravenous infusion	10 mg	0.45 ± 0.05	Human plasma protease	LC-MS	Human plasma	In Vivo	None	None	N.A.
4674	34954052	2022	KEIVSRNKRRYQEDGRKKRRQRRR	SY-007	24	Free	Free	Linear	L	None	Neuropeptide	Treatment of Ischemic Stroke	Blood samples were collected for determinationsof SY-007 at pre-dose (within 0.5 h prior to dosing) and at 5, 10, 15, 20,30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of the intravenous infusion	20 mg	0.55 ± 0.07	Human plasma protease	LC-MS	Human plasma	In Vivo	None	None	N.A.
4675	34954052	2022	KEIVSRNKRRYQEDGRKKRRQRRR	SY-007	24	Free	Free	Linear	L	None	Neuropeptide	Treatment Of Ischemic Stroke	blood samples were collected for determinationsof SY-007 at pre-dose (within 0.5 h prior to dosing) and at 5, 10, 15, 20,30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of the intravenous infusion	30 mg	0.70 ± 0.08	Human plasma protease	LC-MS	Human plasma	In Vivo	None	None	N.A.
4676	34954052	2022	KEIVSRNKRRYQEDGRKKRRQRRR	SY-007	24	Free	Free	Linear	L	None	Neuropeptide	Treatment Of Ischemic Stroke	blood samples were collected for determinationsof SY-007 at pre-dose (within 0.5 h prior to dosing) and at 5, 10, 15, 20,30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of the intravenous infusion	45 mg	0.73 ± 0.05	Human plasma protease	LC-MS	Human plasma	In Vivo	None	None	N.A.
4677	34954052	2022	KEIVSRNKRRYQEDGRKKRRQRRR	SY-007	24	Free	Free	Linear	L	None	Neuropeptide	Treatment Of Ischemic Stroke	blood samples were collected for determinationsof SY-007 at pre-dose (within 0.5 h prior to dosing) and at 5, 10, 15, 20,30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of the intravenous infusion	60 mg	0.78 ± 0.06	Human plasma protease	LC-MS	Human plasma	In Vivo	None	None	N.A.
4678	34910492	2022	SETSKSF	68Ga-DOTA-SETSKSF	7	68Ga labelled	Free	Cyclic	L	None	Synthetic	Used For Positron Emission Tomography imaging of PD-L1 expression in tumors	N.A.	N.A.	14.48 ± 3.26	N.A.	N.A.	N.A.	N.A.	None	None	N.A.
4689	34431071	2022	PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC	vosoritide	39	Free	Free	Cyclic (Cysteine (23->39)-Disulfide)	L	None	Analog of C-type natriuretic peptide	Treatment of Achondroplasia	In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30 (± 5 min), 60 (± 5 min), 90 (± 5 min), 120 (± 5 min) and 180 (± 5 min) min postdose	15 µg/kg	24.4	Human plasma protease	ELISA	Human plasma	In Vivo	https://pubchem.ncbi.nlm.nih.gov/compound/119058036#section=2D-Structure	None	N.A.
4690	34431071	2022	PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC	vosoritide	39	Free	Free	Cyclic (Cysteine (23->39)-Disulfide)	L	None	Analog of C-type natriuretic peptide	Treatment of Achondroplasia	In a phase II study, full PK sampling was performed at days 1, 10, 29, 85 and 183, during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30 (± 5 min), 60 (± 5 min), 90 (± 5 min), 120 (± 5 min) and 180 (± 5 min) min postdose	30 µg/kg	27	Human plasma protease	ELISA	Human plasma	In Vivo	https://pubchem.ncbi.nlm.nih.gov/compound/119058036#section=2D-Structure	None	N.A.
4691	34431071	2022	PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC	vosoritide	39	Free	Free	Cyclic (Cysteine (23->39)-Disulfide)	L	None	Analog of C-type natriuretic peptide	Treatment of Achondroplasia	In the phase III study, full PK sampling was performed at day 1 during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30 (± 5 min), 45 (± 5 min), 60 (± 5 min), 90 (± 5 min) and 120 (± 5 min) min postdose	15 µg/kg	21	Human plasma protease	ELISA	Human plasma	In Vivo	https://pubchem.ncbi.nlm.nih.gov/compound/119058036#section=2D-Structure	None	N.A.
4692	34431071	2022	PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC	vosoritide	39	Free	Free	Cyclic (Cysteine (23->39)-Disulfide)	L	None	Analog of C-type natriuretic peptide	Treatment of Achondroplasia	In the phase III study, full PK sampling was performed at week 26 during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30 (± 5 min), 45 (± 5 min), 60 (± 5 min), 90 (± 5 min) and 120 (± 5 min) min postdose	15 µg/kg	26.6	Human plasma protease	ELISA	Human plasma	In Vivo	https://pubchem.ncbi.nlm.nih.gov/compound/119058036#section=2D-Structure	None	N.A.
4693	34431071	2022	PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC	vosoritide	39	Free	Free	Cyclic (Cysteine (23->39)-Disulfide)	L	None	Analog of C-type natriuretic peptide	Treatment of Achondroplasia	In the phase III study, full PK sampling was performed at week 52, during which plasma samples were collected predose and at 5 (± 2 min), 15 (± 2 min), 30 (± 5 min), 45 (± 5 min), 60 (± 5 min), 90 (± 5 min) and 120 (± 5 min) min postdose	15 µg/kg	27.9	Human plasma protease	ELISA	Human plasma	In Vivo	https://pubchem.ncbi.nlm.nih.gov/compound/119058036#section=2D-Structure	None	N.A.
4694	34217775	2022	VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF	FE 992326	30	Free	Amidation	Linear	L	None	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 2, 6, 10, 15, 20, 30, 45, 60, 90, 120 min	0.3 mg/kg	6.5 ± 1.8	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 9 ± 3, Human(%Plasma Protein Binding) = 17 ± 2 for FE 205030
4695	34217775	2022	vYC-Agp-DVGPFC-3Pal	FE 992325	10	D-val at position 1	Amidation, 3-Pal modification at C terminal	Cyclic (C3-C10 disulfide bond)	Mix	Agp	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 2, 6, 10, 15, 20, 30, 45, 60, 90, 120 min	0.3 mg/kg	21 ± 2	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 50 ± 5, Human(%Plasma Protein Binding) = 46 ± 4 for FE 992325
4696	34217775	2022	vFCODVGPFC-3Pal	FE 205030	10	Oxazole-2-carbonyl, D-val at position 1	Amidation, 3-Pal modification at C terminal	Cyclic (C3-C10 disulfide bond)	Mix	Phe linked with (2-Cbm),3Pal, Orn linked with iPr	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 2, 6, 10, 15, 20, 40, 60, 90, 135, 180 min	0.2 mg/kg	25 ± 8	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 9 ± 3, Human(%Plasma Protein Binding) = 17 ± 2 for FE 205030
4697	34217775	2022	VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF	FE 992326	30	Free	Amidation	Linear	L	None	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 5, 10, 20, 30, 45, 60, 90, 120, 180, 240, 300 min	1 mg/kg	11 ± 8.4	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 9 ± 3, Human(%Plasma Protein Binding) = 17 ± 2 for FE 205030
4698	34217775	2022	vYC-Agp-DVGPFC-3Pal	FE 992325	10	D-val at position 1	Amidation, 3-Pal modification at C terminal	Cyclic (C3-C10 disulfide bond)	Mix	Agp	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 5, 10, 20, 30, 45, 60, 90, 120, 180, 240, 300 min	1 mg/kg	48 ± 11	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 50 ± 5, Human(%Plasma Protein Binding) = 46 ± 4 for FE 992325
4699	34217775	2022	vFCODVGPFC-3Pal	FE 205030	10	Oxazole-2-carbonyl, D-val at position 1	Amidation	Cyclic (C3-C10 disulfide bond)	Mix	Phe linked with (2-Cbm),3Pal, Orn linked with iPr	Derived from CGRP	Treatment of Acute Episodic Migraine	Blood sample was collected at 5, 10, 20, 40, 60, 90, 120, 180, 240, 300 min	0.6 mg/kg	23 ± 2	Male SD rats plasma protease	LC-MS/MS	Male SD rats plasma	In Vivo	None	None	Rat (%Plasma Protein Binding) = 9 ± 3, Human(%Plasma Protein Binding) = 17 ± 2 for FE 205030
4704	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration. Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	100 μg/kg	18.5	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4705	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration. Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	20 μg/kg	7.87	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4706	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration. Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	100 μg/kg	17.1	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4707	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected from rats in groups one to four at the corresponding time points before (0 h) and within 6 h after BPC157 administration. Blood samples were collected from rats in group five before the last three doses and within 6 h after the last dose	500 μg/kg	29.7	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
4708	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	6 μg/kg	5.27 ± 2.25	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4709	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	30 μg/kg	19.6 ± 3.72	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4710	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	6 μg/kg	20.0 ± 5.53	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4711	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	30 μg/kg	25.5 ± 7.08	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4712	36588717	2022	GEPPPPGKPADDAGLV	BPC157	15	Free	Free	Linear	L	None	Isolated from human gastric juice	Therapeutic Agent For Severe Trauma And Stress Damage And Can Promote The Healing Of Wounds, Ligament Injuries, Tendon Injuries, And Fractures	Blood samples were collected at the corresponding time points before (0 h) and within 6 h of a single administration. Blood samples were collected from dogs administered multiple doses at corresponding time points before the first dosing (0 h), within 6 h after dosing, before the last three doses, and at corresponding time points after the last dosing	150 μg/kg	29.3 ± 5.06	Beagle dogs plasma protease	LC-MS/MS	Beagle dogs plasma	In Vivo	None	None	N.A.
4713	N.A.	2022	eeeeeeeeeXPLGLAGrrrrrrrrrk	12kD-PEG-e9-XPLGLAG-r9-k(cy5)	25	12 KDa PEG	Cy5 linked with Lys side chain at C terminus	Linear	Mix	e=D-Glutamic acid, r=D-Aspartic acid, k=D-Lys, Cy5 = indocarbocyanine dye conjugated with Lys at C terminal, X=linker	Synthetic	Transport molecule	Blood was collected in a heparinized capillary tube at 30 minutes and 1, 2 And 6 hour time points	6 nmol	20	Mice blood plasma protease	N.A.	Mice blood plasma	In Vivo	None	US 201916457763 A	N.A.
4731	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVEQHLCGDHLVEALYLVCGERGFFETPR-OH)	Example 12	51	Free	B29R, desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)tetradecanedioyl-4×gGlu), B3E, B26E modification, A and B chain linked with disulfide bond	Insulin Derivative	Antidiabetes	Blood sample taken at the following time points: Predose (-10,0),3,6,9,12,15,20,30,45,60,90,120,150,180,240,300,360,420,480,540,600 And 720 Minutes	1 nmol/kg	46	Lyd pig plasma protease	ELISA	Lyd pig plasma	In Vivo	None	US 201615754395 A	hIGF1R 0.1% HSA (% rel to HI) Ex48 = 13
4741	N.A.	2022	(GIVEQCCTSICSLEQLENYCNK*-OH)-(FVEQHLCGDHLVEALYLVCGERGFFYEER-OH)	Example 4	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A14E, A22K(N(eps)tetradecanedioyl-4×gGlu), B3E, B27E, B28E modifications, A and B chain linked with disulfide bond	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	24	SD rats plasma protease	LC-MS	SD rats plasma	In Vivo	None	US 201615754395 A	hIGF1R 0.1% HSA (% rel to HI) Ex48 = 28.6
4742	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVEQHLCGDHLVEALYLVCGERGFFYTDR-OH)	Example 10	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)tetradecanedioyl-4×gGlu), B3E, B28D modification, A and B chain linked with disulfide bond	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	28	SD rats plasma protease	LC-MS	SD rats plasma	In Vivo	None	US 201615754395 A	hIGF1R 0.1% HSA (% rel to HI) Ex48 = 77.3
4743	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVEQHLCGDHLVEALYLVCGERGFFETER-OH)	Example 11	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)tetradecanedioyl-4×gGlu), B3E, B26E, B28E modificatino, A and B chain linked with disulfide bond	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	28	SD rats plasma protease	LC-MS	SD rats plasma	In Vivo	None	US 201615754395 A	hIGF1R 0.1% HSA (% rel to HI) Ex48 = 13.6
4744	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVEQHLCGDHLVEALYLVCGERGFFETPR-OH)	Example 12	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)tetradecanedioyl-4×gGlu), B3E, B26E modifications, A and B chain linked with disulfide bond	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	25	SD rats plasma protease	LC-MS	SD rats plasma	In Vivo	None	US 201615754395 A	hIGF1R 0.1% HSA (% rel to HI) Ex48 = 13
4745	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVNQHLCGSHLVEALYLVCGERGFFYTPR-OH)	PA2	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)tetradecanedioyl-gGlu-2×OEG) modifications	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	24	SD rats plasma protease	LC-MS	SD rats plasma with 3 Zn/Hexamer Of Insulin Derivative	In Vivo	None	US 201615754395 A	N.A.
4746	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVNQHLCGSHLVEALYLVCGERGFFYTDR-OH)	PA3	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)tetradecanedioyl-4×gGlu), B28D modifications	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	26	SD rats plasma protease	LC-MS	SD rats plasma with 3 Zn/Hexamer Of Insulin Derivative	In Vivo	None	US 201615754395 A	N.A.
4747	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVEQHLCGDHLVEALYLVCGERGFFYTDR-OH)	Example 33	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)hexadecanedioyl-gGlu-2×OEG), B3E, B28D modifications, A and B chain linked with disulfide bond	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	58	SD rats plasma protease	LC-MS	SD rats plasma with 3 Zn/Hexamer Of Insulin Derivative	In Vivo	None	US 201615754395 A	hIGF1R 0.1% HSA (% rel to HI) Ex48 = 85.1
4749	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVEQHLCGDHLVEALYLVCGERGFFETPR-OH)	Example 41	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)hexadecanedioyl-4×gGlu), B3E, B26E modifications, A and B chain linked with disulfide bond	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	57	SD rats plasma protease	LC-MS	SD rats plasma with 3 Zn/Hexamer Of Insulin Derivative	In Vivo	None	US 201615754395 A	N.A.
4750	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVEQHLCGDHLVEALYLVCGERGFFETPR-OH)	Example 42	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)hexadecanedioyl-gGlu-2×OEG), B3E, B26E modifications, A and B chain linked with disulfide bond	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	41	SD rats plasma protease	LC-MS	SD rats plasma with 3 Zn/Hexamer Of Insulin Derivative	In Vivo	None	US 201615754395 A	N.A.
4751	N.A.	2022	(GIVEQCCTSICSLYQLENYCNK*-OH)-(FVNQHLCGSHLVEALYLVCGERGFFYTPR-OH)	PA1	51	Free	B29R, desB30 modification	Cyclic (C7-C12 disulfide bond in A chain)	L	A22K(N(eps)hexadecanedioyl-gGlu-2×OEG) modification	Insulin Derivative	Antidiabetes	Plasma collected at time points 0,3,7,15,30,60,120,180 Minutes After Dosing	25 nmol/kg	41	SD rats plasma protease	LC-MS	SD rats plasma with 3 Zn/Hexamer Of Insulin Derivative	In Vivo	None	US 201615754395 A	N.A.
4771	35177945	2022	RPRLSHKGPMPF	pE13F	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin Analog	Diuretic and Cardiovascular effects	Incubated at 37°C for various times, from T0 to T4 h	5 μM	7.2	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	Ki(nM) = 0.56 ± 0.07
4773	35177945	2022	KFRRQRPRLSHKGPMPF	K17F	17	Free	Free	Linear	L	None	Apelin Analog	Diuretic and Cardiovascular effects	Incubated at 37°C for various times, from T0 to T4 h	5 μM	4.6	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	Ki(nM) = 0.06 ± 0.01
4774	35177945	2022	KFrRqRPRlS-Aib-kaP-Nle-P	P92	16	Lys1 acetylation	Free	Linear	Mix	D-Arg = r, D-Gln = q, D-Leu = l, D-ala = a, Proline side chain linked with (4Br-Phe) at C terminus	Apelin Analog	Diuretic and Cardiovascular effects	Incubated at 37°C for various times, from T0 to T4 h	5 μM	24	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/29412822/, https://pubmed.ncbi.nlm.nih.gov/27815337/	None	Ki(nM) = 0.09 ± 0.02
4820	35259149	2022	RKDVY	TP5	5	Free	Free	Linear	L	None	Synthetic	Treatment Of Patients With Immunodeficiency Diseases, Such As Rheumatoid Arthritis, Cancers, Hepatitis B Virus Infection, And Acquired Immunodeficiency Syndrome (Aids)	One hundred microliter plasma samples were collected at the following time intervals: 0.5, 5, 10, 20, 30, and 45 min and 1, 2, 3, 4, 6, 8,and 10 h after peptide administration.	1 mg/kg	0.022 ± 0.004	Wistar rats plasma protease	LC-MS/MS	Wistar rats plasma	In Vivo	https://pubs.acs.org/doi/10.1021/acsomega.9b00059, https://pubmed.ncbi.nlm.nih.gov/28365509/	None	The cytotoxicity of TP5-MA was evaluated in mice spleen lymphocytes. Cytotoxicity was not detected after treatment with different concentrations of TP5-MA and TP5
4843	35807558	2022	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG	GLP-1	31	Free	Free	Linear	L	None	Glucagon	Treatment Of Type 2 Diabetes	The reaction was stopped at selected time points (5, 15, 30, 60, 90, 120, 150, 180, 210, 240, 270, and 300 min)	1 μM	46	Minipigs plasma protease	LC-MS	Minipigs plasma	In Vitro	https://pubmed.ncbi.nlm.nih.gov/34647404/, https://pubmed.ncbi.nlm.nih.gov/30399314/, PDB id: 5VAI	None	N.A.
4844	35059568	2021	Hoo-FOP-hle-Pff-F	JPE-1375	7	Hoo = L-hydroorotic acid	Amidation	Linear	Mix	hle5 = D-homoleucine, Pff6 = Phe(4-F), Orn = Ornithine,Replaces the C-terminal Arg of PMX53 with a hydrophobic amino acid	Peptidomimetic C5a receptor antagonists	C5Ar1 Antagonists	Serial blood samples were collected at 10, 15, 30, 45, and 60 min, and at 2, 4, 6, and 24 h via a tail vein	1 mg/kg	0.13 (Elimination Half Life)	Mice plasma protease	LC-MS	Mice plasma	In Vivo	None	None	The inhibition of TNF levels also presented a similar median effective concentration (EC50) for PMX53 (5.9 μM)
4846	35056979	2021	FRRG	Al-ProD	4	Maleimide	DOX	Linear	L	None	Albumin-binding maleimide and cathepsin B-cleavable peptide conjugate	Antitumor	blood samples were collected from mice at pre-determined times (0, 3 h, 6 h, 9 h, 12 h, 24 h, 48 h, 72 h, 96 h, 120 h, and 144 h)	3 mg/kg	3.1	BALB/C nude mice plasma protease	Fluorescence assay	BALB/c nude mice plasma	In Vivo	None	None	The IC50 value of HSA-bound Al-ProD in MDA-MB231 breast cancer cells is 7.33 µM, On day 20, the tumor volume in the Al-ProD-treated group was 347.42 ± 25.9 mm³, significantly smaller than the free DOX group (580.25 ± 139.92 mm³) and saline group (1810.98 ± 544.56 mm³)
4880	34707178	2021	IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY	PYY3-36 analogues 44	34	Free	Amidation	Linear	L	Fatty acid conjugation at position 30	Derived from PYY	Antiobesity	N.A.	15 nmol/kg	0.5	Male göttingen minipigs plasma protease	LC-MS	Male göttingen minipigs plasma	In Vivo	None	None	N.A.
4889	34661390	2021	VVGSPSAQDEASPLS	VVGS peptide	15	Free	Free	Linear	L	None	Synthetic	Targets tropoelastin	Aliquots (6 μL) taken after 0, 35, and 120 min	0.6 mM which is diluted in water at a final concentration of 0.06 mM when aliquoting	45	Pooled serum protease from human male AB plasma	RP-HPLC	50% pooled serum from human male AB plasma	In Vitro	None	None	KD (μM) = 41 ± 12 ( Interaction between Immobilized Human Recombinant Tropoelastin and Gd4TESMA)
4892	34630378	2021	GPVEDAITAAIGRVADTVGTGPTNSEAIPALTAAETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLCRSACVYFTEYENSGAKRYAEWVLTPRQAAQLRRKLEFFTYVRFDLELTFVITSTQQPSTTQNQDAQILTHQIMYVPPGGPVPDKVDSYVWQTSTNPSVFWTEGNAPPRMSIPFLSIGNAYSNFYDGWSEFSRNGVYGINTLNNMGTLYARHVNAGSTGPIKSTIRIYFKPKHVKAWIPRPPRLCQYEKAKNVNFQPSGVTTTRQSITTMTNTGAF	VP1 vaccine	284	Free	Free	Linear	L	None	Synthetic	Treatment of Coxsackievirus B3 (Cvb3)-Induced Viral Myocarditis	1h at RT	0.25 μg/μL	<15	Murine serum protease	ELISA	Murine serum	In Vivo	None	None	ABD-VP1 increased the 28-day survival rate from about 40% (VP1) to 73%
4893	34575581	2021	OP-(d-Cha)-WR	C5a receptor 1 antagonist (PMX205)	5	HC = Hydrocinnamate, O1: ornithine	Free	Cyclic	Mix	D-Cha3: cyclohexylalanine	Lipophilic analogue of PMX53	Treatment of Inflammatory Bowel Disease, Amyotrophic Lateral Sclerosis, Allergic Asthma, And Spinal Cord Injury	Blood samples were collected at 0.04, 0.25, 0.5, 0.75, 1, 1.5, 1, 4, 6, and 24 h for both groups and then 48, 72, 96, and 120 h	1 mg/kg	0.84 (Terminal Elmination Half Life)	Mice plasma protease	LC-MS/MS	Mice plasma	In Vivo	None	None	IC50 = 31 nM for PMX205
4894	34575581	2021	OP-(d-Cha)-WR	C5a receptor 1 antagonist (PMX205)	5	HC = Hydrocinnamate, O1: ornithine	Free	Cyclic	Mix	D-Cha3: cyclohexylalanine	Lipophilic analogue of PMX53	Treatment of Inflammatory Bowel Disease, Amyotrophic Lateral Sclerosis, Allergic Asthma, And Spinal Cord Injury	Samples (n = 4) were quenched at regular intervals of 5 min, 10 min, 15 min, 30 min and 60 min	1 µg/ml	0.17 (Elimination Half Life)	Mice plasma protease	LC-MS/MS	Mice plasma	In Vivo	None	None	IC50 = 31 nM for PMX205
4895	34575581	2021	OP-(d-Cha)-WR	C5a receptor 1 antagonist (PMX205)	5	HC = Hydrocinnamate, O1: ornithine	Free	Cyclic	Mix	D-Cha3: cyclohexylalanine	Lipophilic analogue of PMX53	Treatment of Inflammatory Bowel Disease, Amyotrophic Lateral Sclerosis, Allergic Asthma, And Spinal Cord Injury	Blood sample was collected at 2.5, 5, 10, 15, 30, 45, 60, and 90 min	1 μg/mL	0.33 (Elimination Half Life)	Mice spinal cord homogenate protease	LC-MS/MS	Mice spinal cord homogenate	In Vivo	None	None	IC50 = 31 nM for PMX205
4899	34455010	2021	pGlu-RPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP	ELA-32	32	pGlu = Pyroglutamate	Free	Cyclic (Cys-Cys Disulfide Bond)	L	None	Derived from Zebrafish	Anticancer, Treatment of Cardiovascular Disease	Blood sample were withdrawn at time points: 0, 2, 5, 10, 15, 30, 60, 120, 240 min	5 μg/mL	47.2 ± 5.7	Human plasma protease	LC–MS/MS	Human plasma	In Vitro	None	None	N.A.
4905	34402197	2021	HGDGSFSDEMNTILDNLAARDFINWLIQTKITD	Teduglutide	33	Free	Free	Linear	L	None	GLP-2 analogue	Treatment of Short Bowel Syndrome	N.A.	0.05 mg/kg	0.89	Human plasma protease	N.A.	Human pediatrics plasma (in Japanese patients with SBS)	In Vivo	DB id: DB08900	None	N.A.
4906	34402197	2021	HGDGSFSDEMNTILDNLAARDFINWLIQTKITD	Teduglutide	33	Free	Free	Linear	L	None	GLP-2 analogue	Treatment of Short Bowel Syndrome	N.A.	0.05 mg/kg	1	Human plasma protease	N.A.	Human pediatrics plasma (in non - Japanese patients with SBS)	In Vivo	DB id: DB08900	None	N.A.
4909	34393794	2021	KFRRQRPRLSHLGPMPF	LIT01-196	17	Fluorocarbon chain (CF3(CF2)7(CH2)2C(O)) to the N-terminal part of K17F	Free	Linear	L	None	Apelin-17 Analog	Treatment of Hypertension	N.A.	900 nmol/kg	28	Rats plasma protease	RIA	Rats plasma	In Vivo	Pubchem CID Apelin: 56841713	None	IC50 = 0.56 ± 0.04 nmol/l for LIT01-196
4912	34206631	2021	YGGFL	Leu-ENK	5	Free	Free	Linear	L	None	Opioid peptide	Analgesic	Aliquot (95 µL) was taken at 0, 5, 15, 60, and 300 min	315 µmol/L	25	Mice plasma protease	UPLC	Mice dipotassium ethylenediaminetetraacetic acid containing pooled plasma	In Vitro	None	None	N.A.
4916	34201398	2021	KRRVRWIIW	optP7	9	Free	Free	Linear	L	None	Synthetic	Antimicrobial	For 0, 0.5, 1, 3, 6, and 24 h at 37 °C	100 μM	13	Human serum protease	UPLC-MS	Human serum	In Vitro	None	None	MIC(µM) = 3 for Pseudomonas aeruginosa in growth media MH,MIC(µM) = 0.8 for E.coli in growth media MH,MIC(µM) = 1.5 for K. pneumoniae in growth media MH,MIC(µM) = 1.5 for A. baumannii in growth media MH,MIC(µM) = 0.8 for VRE in growth media MH,MIC(µM) = 6 for MRSA in growth media MH
4917	34201398	2021	CAAKRRVRWIIWAAC	c-optP7	15	Free	Free	Cyclic(Cys1-Cys15)	L	All Alanine replaced by β-alanine	Synthetic	Antimicrobial	For 0, 0.5, 1, 3, 6, and 24 h at 37 °C	100 μM	9	Human serum protease	UPLC-MS	Human serum	In Vitro	None	None	MIC(µM) = 142 for Pseudomonas aeruginosa in growth media MH,MIC(µM) = 71 for E.coli in growth media MH,MIC(µM) > 142 for K. pneumoniae in growth media MH,MIC(µM) = ND for A. baumannii in growth media MH,MIC(µM) > 142 for VRE in growth media MH,MIC(µM) = 142 for MRSA in growth media MH
4919	34163352	2021	YHPYKEIEQLIELANYQVLS	OPT	20	Free	Free	Linear	L	None	Derived from the QKHPD-containing region of NCX1	Binds To Pser68-Plm	Aliquots of 50 μl were collected at different time points (0–48 h)	300 μM	0.86	Human serum protease	Mass spectrometry	Human serum	In Vitro	None	None	N.A.
4922	34122400	2021	RKDVY	TP5	5	Free	Free	Linear	L	None	derived from thymopoietin	Immunomodulatory	15 min at 37°C	10 µg/mL	3.2 ± 0.5	Human serum protease	HPLC	Human serum	In Vitro	None	None	The cytotoxicity of CbTP was lower than that of parental peptide CATH2
4927	36133017	2021	KGSGSGCPRILMRCKQDSDCLAGCVCGPNGFCG	CKP-NLP	30	Free	Free	Linear	L	AF488 labeled , Lys1 fatty acid conjugation (Palm)	Synthetic	Platform for potential delivery of peptide like drug candidates	37 °C	N.A.	1	N.A.	SEC	N.A.	In Vitro	None	None	N.A.
4928	34048741	2021	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exendin-4	39	Free	Amidation	Linear	L	None	Salivary gland of the lizard Heloderma suspectum	Antidiabetes	Blood samples were collected from the lateral tail vein at 0, 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 10 h	0.07 mg/kg	0.32 ± 0.04	Male SD rats plasma protease	ELISA	Male SD rats plasma	In Vivo	PDB id: 7MLL	None	EC50(nM) = 1.79 ± 0.47 (EC50 values represent the concentration (nM) of agonists to simulate half-maximum GLP-1 receptor cAMP activation)
4932	33940058	2021	gqsehhmrvysf	OPBP-1	12	Free	Free	Linear	D	Substituition of A with Y at position 10	Derived from H12	Anticancer	Co-incubation of OPBP-1 with 10% human serum for 0 h, 1 h, 2 h, 4 h, 8 h, 16 h, 24 h, 32 h and 48 h.	8 mg/kg	0.33 ± 0.01	Male SD rats plasma protease	RP-HPLC	Male SD rats plasma	In Vivo	None	None	After 2 weeks of daily administration of 0.5 mg/kg OPBP-1, the tumor growth was significantly inhibited in CT26 and B16-OVA models.
4941	33825469	2021	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Native Ex4	39	Free	Amidation	Linear	L	None	GLP-1 analogs	Antidiabetes	Blood sample (20 μL) was obtained from the leg veins and using a pipette added into 80 μL of PBS solution (containing EDTA) at 40 s, 25 min, 50 min, 1.2 h, 1.6 h, 2 h, 4.8 h, 6.5 h, 8.5 h, 10 h, and 24 h after injection.	75 nmol/kg	0.72 ± 0.07	C57Bl/6 mice plasma protease	Fluorescence assay	C57BL/6 mice plasma	In Vivo	None	None	EC50 values = 0.99 nM for Ex4 (GLP-1 Receptor Activation Potency)
4953	33813091	2021	SGQYASHCWCWRDPGRSGGSK	FITC-TPP1	21	FITC labelled	Free	Linear	L	None	Synthetic	Anticancer	Blood samples (20μL) were obtained at different points (0, 5, 30 min, 1,2, 4, 6, 9, 24 h) via tail bleeding	4 mg/kg	<10 (Blood Clearance Half Life)	Mice blood plasma protease	Fluorescence spectrometry	Mice blood plasma	In Vivo	None	None	N.A.
4955	33791863	2021	DRVYIHP	125I-Ang1–7	7	Free	Free	Linear	L	125I labeled	Synthetic	Role in Renal and Cardiovascular Homeostasis	Blood samples (∼200 µL) were collected from the cannula into heparinized tubes before dosing and 5, 10, 15, 30, and 45 min and 1, 1.5, 2, and 3 h after administration	4.5 mM	0.6	Rats plasma protease	Radioactivity assay	Rats plasma	In Vivo	None	None	Ang1–7 exhibited 4.2±0.1%, 3.7±0.6%, 4.4±0.2%, and 2.6±0.4% binding capacity in D.D. water, PBS 50 mM, PBS10mM, and acetate bufer, respectively
4973	33656323	2021	PTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFSQSIISTLT	IL-2	132	Free	Free	Cyclic (C57-C104 Disulfide Bond)	L	None	Synthetic	Anticancer, Autoimmune diseases treatment	Serum samples were collected at 10 min and 2, 6, 12, 20, and 36 h for group I and 1, 4, 8, 16, 24, and 48 h for group II by retro-orbital bleeding, . Serum samples were collected at 0, 2, 5, 20, 30, and 45 min for group I and 10 min and 1, 2, 4, 6, and 8 h for group II by retro-orbital bleeding	0.6 mg/kg	0.041 ± 0.006 (T1/2a )	Mouse plasma protease	Sandwich ELISA	Mouse plasma	In Vivo	pdb id: 5LQB and https://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.1c00062/suppl_file/bc1c00062_si_001.pdf	None	KD (M) = (1.952 ± 0.130) × 10−8 for IL-2
4974	33656323	2021	PTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT-(ED)6-LPETGGGK	B6	146	Free	Lys146 contains Fatty acid moiety which introduces 8-amino-3,6-dioxaoctanoic acid (AEEA) and glutamic acid	Cyclic (C57-C104 Disulfide Bond) In IL-2	L	None	Synthetic	Anticancer, Autoimmune diseases treatment	Serum samples were collected at 10 min and 2, 6, 12, 20, and 36 h for group I and 1, 4, 8, 16, 24, and 48 h for group II by retro-orbital bleeding, . Serum samples were collected at 0, 2, 5, 20, 30, and 45 min for group I and 10 min and 1, 2, 4, 6, and 8 h for group II by retro-orbital bleeding	0.6 mg/kg	0.613 ± 0.063(T1/2a )	Mouse plasma protease	Sandwich ELISA	Mouse plasma	In Vivo	pdb id: 5LQB and https://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.1c00062/suppl_file/bc1c00062_si_001.pdf	None	KD (M) = (1.952 ± 0.130) × 10−8 for IL-2
4975	33656323	2021	PTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT-(ED)6-LPETGGGK	B6 control	146	Free	Lys146 contains Fatty acid moiety which introduces 8-amino-3,6-dioxaoctanoic acid (AEEA) and glutamic acid	Cyclic (C57-C104 Disulfide Bond) In IL-2	L	None	Synthetic	Anticancer, Autoimmune diseases treatment	Serum samples were collected at 0, 5, and 30 min and 2, 6, and 12 h for group I and 2, 10, and 60 min and 4, 8, and 24 h for group II by retro-orbital bleeding	0.6 mg/kg	0.035 ± 0.014(T1/2a )	Mouse plasma protease	Sandwich ELISA	Mouse plasma	In Vivo	pdb id: 5LQB and https://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.1c00062/suppl_file/bc1c00062_si_001.pdf	None	KD (M) = (1.952 ± 0.130) × 10−8 for IL-2
4976	33656323	2021	PTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFSQSIISTLT	IL-2	132	Free	Free	Cyclic (C57-C104 Disulfide Bond)	L	None	Synthetic	Anticancer, Autoimmune diseases treatment	Serum samples were collected at 10 min and 2, 6, 12, 20, and 36 h for group I and 1, 4, 8, 16, 24, and 48 h for group II by retro-orbital bleeding, . Serum samples were collected at 0, 2, 5, 20, 30, and 45 min for group I and 10 min and 1, 2, 4, 6, and 8 h for group II by retro-orbital bleeding	0.6 mg/kg	0.273 ± 0.040(T1/2b)	Mouse plasma protease	Sandwich ELISA	Mouse plasma	In Vivo	pdb id: 5LQB and https://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.1c00062/suppl_file/bc1c00062_si_001.pdf	None	KD (M) = (1.952 ± 0.130) × 10−8 for IL-2
4978	33656323	2021	PTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT-(ED)6-LPETGGGK	B6 control	146	Free	Lys146 contains Fatty acid moiety which introduces 8-amino-3,6-dioxaoctanoic acid (AEEA) and glutamic acid	Cyclic (C57-C104 Disulfide Bond) In IL-2	L	None	Synthetic	Anticancer, Autoimmune diseases treatment	Serum samples were collected at 0, 5, and 30 min and 2, 6, and 12 h for group I and 2, 10, and 60 min and 4, 8, and 24 h for group II by retro-orbital bleeding	0.6 mg/kg	0.196 ± 0.114(T1/2b)	Mouse plasma protease	Sandwich ELISA	Mouse plasma	In Vivo	pdb id: 5LQB and https://pubs.acs.org/doi/suppl/10.1021/acs.bioconjchem.1c00062/suppl_file/bc1c00062_si_001.pdf	None	KD (M) = (1.952 ± 0.130) × 10−8 for IL-2
4981	33607700	2021	KEIVSRNKRRYQEDGRKKRRQRRR	Tat-K13	24	Free	Free	Linear	L	None	Synthetic	Treatment of Ischemic Stroke	Plasma samples were taken at pre-dose, 5, 10, 15, 20, 30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of intravenous infusion	1 mg	0.26 ± 0.02	Human plasma protease	UPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4982	33607700	2021	KEIVSRNKRRYQEDGRKKRRQRRR	Tat-K13	24	Free	Free	Linear	L	None	Synthetic	Treatment of Ischemic Stroke	Plasma samples were taken at pre-dose, 5, 10, 15, 20, 30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of intravenous infusion	4 mg	0.36 ± 0.04	Human plasma protease	UPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4983	33607700	2021	KEIVSRNKRRYQEDGRKKRRQRRR	Tat-K13	24	Free	Free	Linear	L	None	Synthetic	Treatment of Ischemic Stroke	Plasma samples were taken at pre-dose, 5, 10, 15, 20, 30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of intravenous infusion	10 mg	0.45 ± 0.05	Human plasma protease	UPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4984	33607700	2021	KEIVSRNKRRYQEDGRKKRRQRRR	Tat-K13	24	Free	Free	Linear	L	None	Synthetic	Treatment of Ischemic Stroke	Plasma samples were taken at pre-dose, 5, 10, 15, 20, 30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of intravenous infusion	20 mg	0.55 ± 0.07	Human plasma protease	UPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4985	33607700	2021	KEIVSRNKRRYQEDGRKKRRQRRR	Tat-K13	24	Free	Free	Linear	L	None	Synthetic	Treatment of Ischemic Stroke	Plasma samples were taken at pre-dose, 5, 10, 15, 20, 30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of intravenous infusion	30 mg	0.70 ± 0.08	Human plasma protease	UPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4986	33607700	2021	KEIVSRNKRRYQEDGRKKRRQRRR	Tat-K13	24	Free	Free	Linear	L	None	Synthetic	Treatment of Ischemic Stroke	plasma samples were taken at pre-dose, 5, 10, 15, 20, 30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of intravenous infusion	45 mg	0.73 ± 0.05	Human plasma protease	UPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4987	33607700	2021	KEIVSRNKRRYQEDGRKKRRQRRR	Tat-K13	24	Free	Free	Linear	L	None	Synthetic	Treatment of Ischemic Stroke	plasma samples were taken at pre-dose, 5, 10, 15, 20, 30, 45 min, and 1, 1.5, 2, 3, 4, 5, 6 h after the beginning of intravenous infusion	60 mg	0.78 ± 0.06	Human plasma protease	UPLC–MS/MS	Human plasma	In Vivo	None	None	N.A.
4989	33607165	2021	KKPYIL	JMV438	6	Both Arg residues in positions 1 and 2 were replaced by two Lys	Free	Linear	L	None	Derived from NT	Analgesic without hypothermia	Plasma collected at 0, 1, 2, 5, 10, 30 and 60 min	0.156 mM	1.57 ± 0.27	Rats plasma protease	UPLC-MS	Rats plasma	In Vivo	None	None	(Binding) Ki (nM) = 4.00 ± 0.35 for hNTS1
4990	33607165	2021	KΨ[CH2NH]KPYIL	JMV449	6	Free	Free	Linear	L	Arg8-Arg9 was replaced by a reduced amine bond (Ψ[CH2NH]) between Lys8-Lys9	Derived from NT	Analgesic without hypothermia	Plasma collected at 0, 1, 2, 5, 10, 30 and 60 min	0.156 mM	8.37 ± 2.02	Rats plasma protease	UPLC-MS	Rats plasma	In Vivo	None	None	(Binding) Ki (nM) = 2.02 ± 0.80 for hNTS1
5006	33387593	2021	CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	Wild-type (IFN)	165	Free	Free	Linear	L	None	Human derived	Antiviral, Antiproliferative	Blood samples were taken at different times post-injection	100000 U	0.9 ± 0.1 (T1/2 Elimination)	Rats plasma protease	Sandwich ELISA	Rats plasma	In Vivo	PDB id: 1ITF	None	Antiviral SBA (IU/ng) = 201 ± 9 in wild-type IFN, Antiproliferative SBA (IU/ng) = 240 ± 50
5010	33245951	2021	YAEGTFISDYSIAMDKIRQQNFVNWLLAQKGKKSDWKHNITQ	GIP(1–42)	42	Free	Free	Linear	L	None	Secreted by entero-endocrine K cells located in the proximal intestine	Insulinotrophic Effect	Blood samples (50 μL) were drawn from the retro-orbital plexus at t = 0, 1, 3, 5, 10 and 20 min and then co-incubation with Val-Pyr	25 nmol/kg	5 ± 0.6	Mouse plasma protease	RIA	Mouse plasma	In Vivo	https://pdf.sciencedirectassets.com/271102/1-s2.0-S0014579300X09702/1-s2.0-0014579381802888/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEIr%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIQD62SR4A%2B4hs8dyDimRd8i4eqjFdUt5lDROOjPQfQfVdAIgCzazhyIQYpOf0Ptr2TaxQcJ0gfc0tFJSvp00rqp72KMqsgUIExAFGgwwNTkwMDM1NDY4NjUiDFKOQuOPiilKRo0IGiqPBYnEsqS8aZVPDGyG07f6LcX2zV6C1BU1jQ%2BiYzudplRLnaMGn2dzKqD0IgA3jsmhp7CPygQevWTs4Ed1E%2FEvWjuhN8AOvlXEs2Af0t7zL6%2Ba6LtjwN7ZRUIgQGtEhxXKjkWXm9SbXNXu%2FW%2B0ZCHb36rhKfxxcw6e3m0TTTQ5VBU5YtjFRc9KPiAZsUvrVg42y6wbkYdoImtbRueY2e67MmEBizqQ12ayvDeaiudwbYmOGBGr%2BGvimIbEui5OYl1NgebT3Q8%2F%2F5MQ6z0bJxhTQQvplmdG7ymlRrCWfaYdi6ama4%2FpLbZKNVGuU9hscZNpcQUayR82zK3CBh9HRLr%2BTXe6OyFGBRn56BpJ1b%2Bh7qQZYMWBDZGMQdNungv743HpUHMuIxKAt3%2B8SEJ1WkfsIsptsTXEJ%2Fe5Pe2WTSkejT7b9WNpvYncidJCF2lT8NW9RfAw8mc7boYYiFuzqfjULjJV2W6KiXDtf%2F3yQmIV8VRa6hHVovZEQlYpMNpkWgqXznwKL5Lf%2FVUx09SOMK8MoHIWUbF8kgKRM9zGxSs3lPKU7g5gnTqcLwgUKBTnYjjS%2Bm0kz5A4Y4PRE0NI5L4Uy4iF0moVtD6fcXJ7uceU5ofMjnk4jTbla86W0LkLEI6VxBLN2vyWJ%2BkiKXE0GmT7xerhOiY%2FJt74ImPgZVDf6nKzoNAKgoEW5yIBW8X8eRQhNQgbPrCSTSwcAW%2BCoULg4xS3aG87frYuj3ZSUb1DOHzkIRq5G9yj7EjgVbroxu2hh3g9YytLb2PpbvOVSTe%2B%2F2zm04ZibPDOd9UEZQPhgDMGQLnEQ0oKpHU3xaThRzRdTnF%2B6Va%2F7nTk9HXfj3MLfKH3vRbkHVcuODJZVomDO2Awq9mnuQY6sQFg6uBpRDSJbdGuJM4MBWHMJAuiWcghOQq8RAfYeWwCKcdeeLjIPYYpXygg22s0S36%2BiClhIk6QXuPZWihQ%2BbG2PEAcUOIXqLpPHTWwmjGIGrKcTPHPEJKRYKb6HCmW5yCqSEXiKCKgJXX2OzfABfGdtJxraYtj94rVu3tUZ2J1%2Bp4icKKPMKSJaHNBTuKzqNmpvnDyVRDiT0L2iJhacy9SB9TOXT9U0gMzOfOZeQk%2Famo%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20241105T104258Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY7EKIR4FY%2F20241105%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=da086866fd5ae7aa1850a8ed33269fdcc94d601135b6ec16e293756e1d2b3045&hash=fbb1651e9188cb1c761d3e5215af03584aadf82583c0ccbb7e874e4504a450ee&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=0014579381802888&tid=spdf-dbd1ce2d-f820-4e78-8534-eac97584de70&sid=5ffdcf685136184f4559b673ec8c38454df3gxrqb&type=	None	N.A.
5011	33135460	2021	HSQGTFTSDYSKYLDSRRAQDFVQWLMNT	Glucagon	29	Free	Free	Linear	L	None	Produced by the alpha cells of the pancreas	Antidiabetes	1 day	0.65 ng/kg/min from 1100 (120 min) till the end of the study at 1400 (300 min)	4.01 ± 1.19	Human male blood protease	Two site ELISA	Human male blood sample	In Vivo	pdb id: 1GCN	None	N.A.
5012	33135460	2021	HSQGTFTSDYSKYLDSRRAQDFVQWLMNT	Glucagon	29	Free	Free	Linear	L	None	Produced by the alpha cells of the pancreas	Antidiabetes	1 day	0.65 ng/kg/min from 1100 (120 min) till the end of the study at 1400 (300 min)	3.94 ± 1.10	Human female blood protease	Two site ELISA	Human female blood sample	In Vivo	pdb id: 1GCN	None	N.A.
5013	33135460	2021	HSQGTFTSDYSKYLDSRRAQDFVQWLMNT	Glucagon	29	Free	Free	Linear	L	None	Produced by the alpha cells of the pancreas	Antidiabetes	1 day	0.65 ng/kg/min from 1100 (120 min) till the end of the study at 1400 (300 min)	3.96 ± 1.12	Human blood protease (All)	Two site ELISA	Human blood sample (All)	In Vivo	pdb id: 1GCN	None	N.A.
5014	33129837	2021	VDKPPYLPRPRPIRrPGGr	OM19r-8	19	Free	Amidation	Linear	Mix	replacing L-Arg15,19 with D-Arg15,19	Derived from the antibacterial peptide OM19R	Antibacterial	Blood samples were collected in 1.5 mL capacity disposable tubes at 0.125, 0.25, 0.5, 0.75, 1, 5, 10, 15, 30, 45, 60 and 75min	1 mg/ml	1.632 ± 0.34 (Elimination Half Life)	Wistar rats blood protease	N.A.	Wistar rats blood sample	In Vivo	None	None	MIC(μM) = 1 for OM19r -8 in E. coli ATCC25922, OM19r-8 and 250 mPEG5-OM19r-8 showed no cytotoxicity at the concentration up to 32 µM, hemolytic activity of OM19r-8 and mPEG5-OM19r-8 was < 10% at the determined concentration (1-128 μM), which was obviously superior to the control peptide melittin
5015	33129837	2021	VDKPPYLPRPRPIRrPGGr	mPEG5- OM19r-8	19	mPEG5	Amidation	Linear	Mix	replacing L-Arg15,19 with D-Arg15,19	Derived from the antibacterial peptide OM19R	Antibacterial	Blood samples were collected in 1.5 mL capacity disposable tubes at 0.125, 0.25, 0.5, 0.75, 1, 5, 10, 15, 30, 45, 60 and 75min	1 mg/ml	28.09 ± 2.81 (Elimination Half Life)	Wistar rats blood protease	N.A.	Wistar rats blood sample	In Vivo	None	None	MIC(μM) = 1 for OM19r -8 in E. coli ATCC25922, OM19r-8 and 250 mPEG5-OM19r-8 showed no cytotoxicity at the concentration up to 32 µM, hemolytic activity of OM19r-8 and mPEG5-OM19r-8 was < 10% at the determined concentration (1-128 μM), which was obviously superior to the control peptide melittin
5042	32078672	2020	KTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLYDKTHTCPPCPAPELL	rFVIII	654	Free	Free	Linear	L	None	Synthetic	Role In Clotting	N.A.	150 IU/kg	0.23	DKO mice plasma protease	chromogenic activity assays	DKO mice plasma	In Vivo	PDB id : 5K8D, https://pmc.ncbi.nlm.nih.gov/articles/instance/7180082/bin/bloodBLD2019001292-suppl1.pdf	None	ED50 values for BIVV001 (7.5 IU/kg) and rFVIII (7.9 IU/kg) were similar
5057	33203916	2020	VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG	Native TRAIL	168	Free	Free	Linear	L	None	Synthetic	Anticancer	Blood samples (25–30 μL) were collected at 5, 15, 30, 60, 180, 360, 720 min, and 24 h	0.01 mg/mL	3.4 ± 1.1	BALB/c wild type mice plasma protease	Western blotting	BALB/c wild type mice plasma	In Vivo	PDB id: 1D0G	None	KD (M) = (6.02 ± 1.99) × 10–8 (Binding kinetics of TRAIL-ATNC and TRAIL against TRAIL receptor DR5.)
5058	33203916	2020	VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG-GSGGGSG	TRAIL-ATNC	168	Free	TRAIL joined with ATNC using flexible linkers consisting of small amino acids (GSGGGSG) that could form a bridge between the C-terminal of TRAIL and the triple helix	Linear	L	None	Synthetic	Anticancer	Blood samples (25–30 μL) were collected at 5, 15, 30, 60, 180, 360, 720 min, and 24 h	1 mg/mL	56.1 ± 5.8	BALB/c wild type mice plasma protease	Western blotting	BALB/c wild type mice plasma	In Vivo	PDB id: 1D0G	None	KD (M) = (2.56 ± 2.58) × 10–10 (Binding kinetics of TRAIL-ATNC and TRAIL against TRAIL receptor DR5.)
5059	33203916	2020	VRERGPQRVAAHITGTRGRSNTLSSPNSKNEKALGRKINSWESSRSGHSFLSNLHLRNGELVIHEKGFYYIYSQTYFRFQEEIKENTKNDKQMVQYIYKYTSYPDPILLMKSARNSCWSKDAEYGLYSIYQGGIFELKENDRIFVSVTNEHLIDMDHEASFFGAFLVG-GSGGGSG	TRAIL-ATNCIL4rP	168	Free	TRAIL joined with ATNC using flexible linkers consisting of small amino acids (GSGGGSG) that could form a bridge between the C-terminal of TRAIL and the triple helix followed by (MMP2) cleavage site (GPLGLAG) then IL4rP (CRKRLDRNC)	Linear	L	None	Synthetic	Anticancer	Blood samples (25–30 μL) were collected at 5, 15, 30, 60, 180, 360, 720 min, and 24 h	1 mg/mL	53.6 ± 5.8	BALB/c wild type mice plasma protease	Western blotting	BALB/c wild type mice plasma	In Vivo	PDB id: 1D0G	None	IC50 value of 0.48 nM for TRAIL-ATNCIL4rP
5072	32888078	2020	QHSQITKV	Mouse Lau- PTEN-PDZ	8	N-Lauryl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.3	Simulated intestinal fluid protease	HPLC	Simulated intestinal fluid	In Vitro	None	None	N.A.
5075	32888078	2020	QHTQITKV	Human Lau-PTEN-PDZ	8	N-Lauryl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.6	50% W/V liver homogenate protease	HPLC	50% w/v liver homogenate	In Vitro	None	None	N.A.
5076	32888078	2020	QHSQITKV	Mouse Lau- PTEN-PDZ	8	N-Lauryl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.95	50% W/V liver homogenate protease	HPLC	50% w/v liver homogenate	In Vitro	None	None	N.A.
5079	32888078	2020	QHTQITKV	Human Lau-PTEN-PDZ	8	N-Lauryl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.15	50% V/V mouse plasma protease	HPLC	50% v/v mouse plasma	In Vitro	None	None	N.A.
5081	32888078	2020	QHTQITKV	Human Myr-PTEN-PDZ	8	N-myristoyl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.11	50% V/V Mouse Plasma Protease	HPLC	50% v/v Mouse plasma	In Vitro	None	None	N.A.
5082	32888078	2020	QHSQITKV	Mouse Myr-PTEN-PDZ	8	N-myristoyl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.87	50% V/V Mouse Plasma Protease	HPLC	50% v/v Mouse plasma	In Vitro	None	None	N.A.
5083	32888078	2020	QHTQITKV	Human Lau-PTEN-PDZ	8	N-Lauryl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.36	50% W/V Brain Homogenate Protease	HPLC	50% w/v Brain Homogenate	In Vitro	None	None	N.A.
5084	32888078	2020	QHSQITKV	Mouse Lau- PTEN-PDZ	8	N-Lauryl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.2	50% W/V Brain Homogenate Protease	HPLC	50% w/v Brain Homogenate	In Vitro	None	None	N.A.
5085	32888078	2020	QHTQITKV	Human Myr-PTEN-PDZ	8	N-myristoyl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.16	50% W/V Brain Homogenate Protease	HPLC	50% w/v Brain Homogenate	In Vitro	None	None	N.A.
5086	32888078	2020	QHSQITKV	Mouse Myr-PTEN-PDZ	8	N-myristoyl	Free	Linear	L	Lipidation	Synthetic	Treatment of Alzheimer's diseases	Samples (80 μL) were taken at 0, 3, 6,9, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 1440 min	Peptide stock solutions (120 μL) were added to pre-warmed diluted plasma (50% v/v, 1080 μL)	0.25	50% W/V Brain Homogenate Protease	HPLC	50% w/v Brain Homogenate	In Vitro	None	None	N.A.
5087	32858124	2020	hArg-rQ-hArg-Pr-NMeLeu-SHKG-Oic-pIPhe-P-DBip	Cmpd# 3	16	Acetylation	Free	Linear	Mix	hArg = Homo-Arginine, NMeLeu, Oic = Unnatural amino acid	Derived from pyr-apelin-13	Treatment of Chronic Hepatic Failure	N.A.	0.1 mg/kg	0.362	Male SD rats plasma protease	Scintillation proximity assay	Male SD rats plasma	In Vivo	None	None	Rat GTPγS (nM) EC50 ± SE = 1.95 ± 1.16
5111	32812282	2020	SYSMEHFRWGKPVG	α-MSH	14	Free	Free	Linear	L	None	Deriving from the pro-opimelanocortin (POMC)	Stimulates The Production And Release Of Melanin By Melanocytes	4 ◦C for 15 min	40 μM	7.4	Human plasma protease	RP-HPLC	Human plasma	In Vitro	None	None	N.A.
5114	32808659	2020	LRKHNCLQRRCMPLHSRVPFP	ELA-21	21	Free	Free	Linear	L	None	produced endogenously in the body	Anti-Heart Failure Activity	Blood was collected at time points of 0, 3, 10, 30 and 90 mins, and 4.5, 12 and 24 h	100 mg/kg	∼13	Mice plasma protease	Western blotting	Mice plasma	In Vivo	https://sci-hub.se/10.1016/j.ijcard.2019.04.089	None	EC50 = 0.6 nM (cAMP supression)
5116	32803073	2020	GSLTSSERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLNLPKMAEKDGCFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQARAVQMSTKVLIQFLQKKAKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTHLILRSFKEFLQSSLRALRQM	WT-Rb	168	Free	Free	Linear	L	Biotinylation	Synthetic	Antitumor	Blood was collected in predetermined time points postinjection (n = 5; 0.05, 0.5, 1, 2, 4, 6, 12 and 24 h	10 mg/kg	20 (Initial Half-Life)	Mice plasma protease	Sandwich ELISA	Mice plasma	In Vivo	PDB ID: 4J4L	None	The tumor size remained around 200 mm3 until 27 days when Pal-Rb was administered (p < 0.01), whereas tumor continued to grow over 600 mm3 when WT-Rb and PBS were injected.
5118	32759365	2020	MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGR	hAβ40	40	Free	Free	Linear	L	None	Synthesized in neurons and degraded in the brain and liver	Treatment of Alzheimer's diseases	Serial blood sampling (0.15 mL) was performed after IV injections via the carotid artery catheter at times 0, 0.5, 1, 2, 5, 10, 15, 30, 45, 60, 90, 120, 150, and 180 min post-dose	68.5 ± 12.0 µg/kg	16.8±5.66 (Terminal Half Life)	(IP) corn oil treated rats plasma protease	ELISA	Corn oil treated rat plasma	In Vivo	pdb id: 8KEW	None	N.A.
5119	32759365	2020	MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGR	hAβ40	40	Free	Free	Linear	L	None	Synthesized in neurons and degraded in the brain and liver	Treatment of Alzheimer's diseases	Serial blood sampling (0.15 mL) was performed after IV injections via the carotid artery catheter at times 0, 0.5, 1, 2, 5, 10, 15, 30, 45, 60, 90, 120, 150, and 180 min post-dose	64.5 ± 13.2 µg/kg	24.5±0.05 (Terminal Half Life)	Untreated rats plasma protease	ELISA	untreated rats plasma	In Vivo	pdb id: 8KEW	None	N.A.
5121	32759365	2020	MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGR	hAβ40	40	Free	Free	Linear	L	None	Synthesized in neurons and degraded in the brain and liver	Treatment of Alzheimer's diseases	Serial blood sampling (0.15 mL) was performed after IV injections via the carotid artery catheter at times 0, 0.5, 1, 2, 5, 10, 15, 30, 45, 60, 90, 120, 150, and 180 min post-dose	68.5 ± 12.0 µg/kg	47.9 ± 20.9 (Terminal Half Life)	(IP) corn oil treated rats CSF protease	ELISA	Corn oil treated rat CSF	In Vivo	pdb id: 8KEW	None	N.A.
5122	32736262	2020	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	EX	39	Free	Amidation	Linear	L	None	Produced by the salivary glands of Gila monster	Antiobesity	Blood was withdrawn at 0, 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 8 h post-administratio	50 nmol/kg	0.69	ICR mice plasma protease	ELISA	ICR mice plasma	In Vivo	None	None	Kd(M) = 6.97 * 10-8(binding affinities of EX-ABD-AFF to glucagon-like peptide-1 receptor (GLP-1))
5128	32603666	2020	V	V-Gem	1	Free	Gemicitabine	Linear	L	None	Derived from Gemcitabine	Anticancer	2, 5, 15, 30, 45, 60, 90, 120, 180, 240, 300, and 360 min	76 nmol/g	46.2	Mice blood plasma protease	LC-MS/MS	Mice blood plasma (analyte = Gemcitabine)	In Vivo	None	None	N.A.
5130	32603666	2020	V	V-Gem	1	Free	Gemicitabine	Linear	L	None	Derived from Gemcitabine	Anticancer	2, 5, 15, 30, 45, 60, 90, 120, 180, 240, 300, and 360 min	76 nmol/g	3.7	Mice blood plasma protease	LC-MS/MS	Mice blood plasma (analyte = Prodrug)	In Vivo	None	None	N.A.
5131	32603666	2020	V	V-Gem	1	Free	Gemicitabine	Linear	L	None	Derived from Gemcitabine	Anticancer	2, 5, 15, 30, 45, 60, 90, 120, 180, 240, 300, and 360 min	228 nmol/g	39.1	Mice blood plasma protease	LC-MS/MS	Mice blood plasma (analyte = Gemcitabine)	In Vivo	None	None	N.A.
5133	32582624	2020	RRPYIL	NT(8-13)	6	Free	Free	Linear	L	None	Derived from NT	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	1.0 ± 0.1	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 1.5 ± 0.03 for hNTS1
5134	32582624	2020	KKPYIL	Entry 1	6	KK amino acid substiuitions	Free	Linear	L	None	NT(8-13) analogs	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	1.6 ± 0.3	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 4.0 ± 0.4 for hNTS1
5135	32582624	2020	Kψ(CH2NH)KPYIL	Entry 2	6	Kψ[CH2NH]K substiuition at position 1	Free	Linear	L	None	NT(8-13) analogs	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	8.4 ± 2.0	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 2.0 ± 0.8 for hNTS1
5136	32582624	2020	KKPYI	Entry 3	5	KK amino acid substiuitions	TMSAla conjugation	Linear	L	None	NT(8-13) analogs	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	1.6 ± 0.3	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 0.018 ± 0.004 for hNTS1
5138	32582624	2020	KK-Sip-YIL	Entry 5	6	KK amino acid substiuitions	Free	Linear	L	Sip amino acid substiution	NT(8-13) analogs	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	4.5 ± 0.8	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 14 ± 11 for hNTS1
5140	32582624	2020	KK-Sip-YI	Entry 7	5	Kψ[CH2NH]K substiuition	TMSAla conjugation	Linear	L	Sip amino acid substiution, TMSAla substuition	NT(8-13) analogs	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	3.5 ± 0.1	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 55 ± 5 for hNTS1
5142	32582624	2020	KKPKIL	Entry 9	6	KK amino acid substiuitions	Free	Linear	L	Substiution of Y amino acid with K	NT(8-13) analogs	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	2.9 ± 0.2	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 7 600 ± 1 000 for hNTS1
5144	32582624	2020	KKPKI	Entry 11	5	KK amino acid substiuitions	TMSAla-OH conjugation	Linear	L	Substiution of Y amino acid with K	NT(8-13) analogs	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	2.8 ± 0.1	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 710 ± 100 for hNTS1
5146	32582624	2020	KKPwI	Entry 13	5	KK amino acid substiuitions	TMSAla-OH conjugation	Linear	Mix	Substiution of Y amino acid with d-W	NT(8-13) analogs	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	10 ± 2	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 3 600 ± 600 for hNTS1
5148	32582624	2020	KKP-Dmt-Tle-L	Entry 15	6	KK amino acid substiuitions	Free	Linear	L	Substiution of Y, I amino acid with Dmt, Tle	NT(8-13) analogs	Improve Nts1-Induced Protective Hypothermia	NT(8-13) and compounds without reduced amine bounds were incubated during short incubation times (0, 1, 2, 5, 10, and 30 min), whereas all analogs with reduced amine bounds, except compound 2, were tested during longer incubation times (0, 1, 2, 4, 8, 16, and 24 h) at 37°C	0.156 mM	4.6 ± 0.6	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Binding, Ki (nM) = 57 ± 6 for hNTS1
5150	32512181	2020	LEDGPKFL	[3H]-THF	8	Free	Free	Linear	L	3H labeling at proline5 residue	Isolated from calf thymus	Antiviral, Anticancer (As an adjunct to chemotherapy in cancer treatment)	Samples were taken for analysis after 0, 1, 2, 5, 10, 15, 20, 30, 45 and 60 min	93 nmol/mL	3.7 ± 0.2	Rats blood protease	N.A.	Rats blood sample	In Vitro	None	None	N.A.
5151	32512181	2020	LEDGPKFL	[3H]-THF	8	Free	Free	Linear	L	3H labeling at proline5 residue	Isolated from calf thymus	Antiviral, Anticancer (As an adjunct to chemotherapy in cancer treatment)	Samples were taken for analysis after 0, 1, 2, 5, 10, 15, 20, 30, 45 and 60 min	93 nmol/mL	5.6 ± 0.2	Mouse blood protease	N.A.	Mouse blood sample	In Vitro	None	None	N.A.
5152	32512181	2020	LEDGPKFL	[3H]-THF	8	Free	Free	Linear	L	3H labeling at proline5 residue	Isolated from calf thymus	Antiviral, Anticancer (As an adjunct to chemotherapy in cancer treatment)	Samples were taken for analysis after 0, 1, 2, 5, 10, 15, 20, 30, 45 and 60 min	93 nmol/mL	5.2 ± 0.4	Human blood protease	N.A.	Human blood sample	In Vitro	None	None	N.A.
5153	32506501	2020	SYSMEHFRWGKPVG	des-Ac-a-MSH	14	Free	Amidation	Linear	L	None	Derived from POMC	Antiinflammatory, Antipyretic	37 °C	2 µM	0.21	Human plasma protease	Glo-sensor transfected cell-based luminescence assay	Human plasma	In Vitro	None	None	EC50 (M) = 1.667E-09 for MC1R-des-Ac-a-MSH
5155	32506501	2020	YVMGHFRWDRFG	gamma2-MSH	12	Free	Amidation	Linear	L	None	Derived from POMC	Antiobesity	37 °C	2 µM	0.028	Human plasma protease	Glo-sensor transfected cell-based luminescence assay	Human plasma	In Vitro	None	None	EC50 (M) = 7.749E-10 for MC1R-g2-MSH
5162	32404523	2020	WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL	C34	34	Free	Free	Linear	L	None	Derived from the gp41 CHR	Therapeutic Efficacy In Simian-Human Immunodeficiency Virus-Acutely Infected Rhesus Monkeys	Blood samples (300 μl) were collected from the tail vein before administration and at different intervals after injection (3, 6, 9, 20, 23, 29, 48, 72, and 96 h)	1.7 μmol/kg	0.6	Rats plasma protease	HIV inhibition assay	Rats plasma	In Vivo	None	None	[EC50] = 18.51 nM for PEG40-NC (antiviral activity)
5168	32348108	2020	Aib-EGTFTSDVSSYLEG-(Bis-pentenyl glycine)-AAKEFI-(S-octenyl alanine)-WLVKGR	SAH-GLP-1-A8J(23,30)	28	Aminoisobutyric acid	Free	Linear	L	Modifications include (S-octenyl alanine) and (Bis-pentenyl glycine)	Single-stapled analogs of GLP-1	Antidiabetes	20 μl aliquots were removed at 0, 5, 15, 30, 60, 120 and 200 min	1 mM	30	Proteinase K	LC-MS/MS	DMSO + buffer consisting of 50 mM Tris HCl, pH 7.4	In Vitro	PDB:3IOL	None	EC50 = 160 pM for SAH-GLP-1(16, 23, 30)
5170	32348108	2020	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Free	Linear	L	None	Unstapled GLP-1 analogs	Antidiabetes	20 μl aliquots were removed at 0, 5, 15, 30, 60, 120 and 200 min	1 mM	<10	Proteinase K	LC-MS/MS	DMSO + buffer consisting of 50 mM Tris HCl, pH 7.4	In Vitro	None	None	EC50 = 160 pM for SAH-GLP-1(16, 23, 30)
5171	32348108	2020	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR	GLP-1	30	Free	Free	Linear	L	None	Unstapled GLP-1 analogs	Antidiabetes	20 μl aliquots were removed at 0, 5, 15, 30, 60, 120 and 200 min	10 μM	14	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vitro	None	None	EC50 = 160 pM for SAH-GLP-1(16, 23, 30)
5174	32332143	2020	fQWAVGH	68Ga‐NeoBOMB1	7	68Ga-DOTA-(p-aminomethylaniline)-(diglycolic acid), D-Phe at position 1	NH-CH[CH2-CH(CH3)2]2 chemical group attached at C terminal	Linear	L	None	Synthetic	DOTA‐coupled GRPR‐antagonist	2, 5, 10, 30 and 45 min and at 1, 2 and 3 h p.i	50 µg	27.3	Human plasma protease	RP-HPLC	Human plasma	In Vivo	None	None	N.A.
5175	32332143	2020	fQWAVGH	68Ga‐NeoBOMB1	7	68Ga-DOTA-(p-aminomethylaniline)-(diglycolic acid), D-Phe at position 1	NH-CH[CH2-CH(CH3)2]2 chemical group attached at C terminal	Linear	L	None	Synthetic	DOTA‐coupled GRPR‐antagonist	2, 5, 10, 30 and 45 min and at 1, 2 and 3 h p.i	50 µg	35	Human blood protease	RP-HPLC	Human blood sample	In Vivo	None	None	N.A.
5182	32243137	2020	HsQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA	OXM-1	37	Free	Free	Linear	Mix	Incorporation of D-ser in place of L-ser at 2nd position	Derived from proglucagon	Antiobesity, Antisteatotic	N.A.	40 μg/kg	6 (Terminal Half Life)	Mice plasma protease	In vitro cell based activity assay	Mice plasma	In Vivo	None	None	EC50(nM) = 10 for OXM-1 (in Vitro Potency of Stapled Peptides in Human GLP-1R- and GCGR-Mediated CRE-Luc Reporter Assays)
5205	32133341	2020	RAAPYGVRLCGREFIRAVIFTCGGSRW	R3 B1-27	27	Free	Free	Linear	L	None	Native relaxin-3	Roles in metabolism, arousal, learning and memory	N.A.	0.05 μg/μl	3.1	Human serum protease	LC-MS	Human serum	In Vitro	None	None	Binding affinity pKi ± SEM [logM] = 5.91 ± 0.21
5206	32133341	2020	RAAPYGVRLSGREFIRAVIFTSR	R3 B1-22R	23	Free	Amidation	Linear	L	None	Synthetic	Relaxin-3 antagonist	N.A.	0.05 μg/μl	4	Human serum protease	LC-MS	Human serum	In Vitro	None	None	Binding affinity pKi ± SEM [logM] = 6.76 ± 0.03
5213	32075870	2020	HADGSFSDEMNTILDNLAARDFINWLIQTKITD	hGLP-2	33	Free	Free	Linear	L	None	Derived from hGLP-2	Treatment of Short Bowel Syndrome	Blood samples were collected at multiple time points up to 6 h post injection	1 mg/kg	6.4 ± 0.2 (Elimination Half Life)	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	EC50(nM) = 0.07 for hGLP-2 receptor
5214	32075870	2020	FGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK	Glepaglutide	39	Free	KKKKKK amino acids substiuitions at C terminal	Linear	L	G,E,T,S,L,A,A,A,A amino acid substuitions at positions 2,3,5,8,10,11,16,24,28 respectively	Derived from hGLP-2	Treatment of Short Bowel Syndrome	Blood samples were collected at multiple time points up to 6 h post injection	0.2 mg/kg	19 ± 1.9 (Elimination Half Life)	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	EC50(nM) = 0.03 for hGLP-2 receptor
5215	32075870	2020	HGDGSFSDEMNTILDNLAARDFINWLIQTKITD	Teduglutide	33	Free	Free	Linear	L	G amino acid substituition at position 2	Derived from hGLP-2	Treatment of Short Bowel Syndrome	Blood samples were collected at multiple time points up to 6 h post injection	0.2 mg/kg	16 ± 0.8 (Elimination Half Life)	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	EC50(nM) = 0.09 for hGLP-2 receptor
5219	32075870	2020	HGDGSFSDE-Nle-fTILDLLAARDFINWLIQTKITD	Apraglutide	33	Free	Amidation	Linear	L	Gly2, Nle10, D-Phe11, Leu16 modification	Derived from hGLP-2	Treatment of Short Bowel Syndrome	Blood samples were collected at multiple time points up to 6 h post injection	0.100 mg/kg	43 ± 4 (Elimination Half Life)	Male cynomolgus monkeys plasma protease	LC-MS/MS	Male cynomolgus monkeys	In Vivo	None	None	EC50(nM) = 0.09 for hGLP-2 receptor
5223	32075870	2020	HGDGSFSDEMNTILDNLAARDFINWLIQTKITD	Teduglutide	33	Free	Free	Linear	L	G amino acid substituition at position 2	Derived from hGLP-2	Treatment of Short Bowel Syndrome	Blood samples were collected at multiple time points up to 169 h post injection	1 mg/kg	0.5 ± 0.1 (Terminal Half Life)	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	EC50(nM) = 0.09 for hGLP-2 receptor
5224	32075870	2020	HGDGSFSDEMNTILDNLAARDFINWLIQTKITD	Teduglutide	33	Free	Free	Linear	L	G amino acid substituition at position 2	Derived from hGLP-2	Treatment of Short Bowel Syndrome	Blood samples were collected at multiple time points up to 169 h post injection	5 mg/kg	0.5 ± 0.0 (Terminal Half Life)	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	EC50(nM) = 0.09 for hGLP-2 receptor
5227	32075870	2020	HGDGSFSDEMNTILDNLAARDFINWLIQTKITD	Teduglutide	33	Free	Free	Linear	L	G amino acid substituition at position 2	Derived from hGLP-2	Treatment of Short Bowel Syndrome	Blood samples were collected at multiple time points up to 169 h post injection	0.25 mg/kg	0.9 ± 0.1 (Terminal Half Life)	Male cynomolgus monkeys plasma protease	LC-MS/MS	Male cynomolgus monkeys plasma	In Vivo	None	None	EC50(nM) = 0.09 for hGLP-2 receptor
5234	31926774	2020	QHWSYLLRP	Leuprolide	10	Free	NHEt (Ethylamine)	Linear	L	None	Synthetic	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	0.43 ± 0.025	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The administration of same dose of PEGylated leuprolides also results in an initial testosterone surge. In addition, the extent of the testosterone surge is almost the same for all three peptides, either PEGylated or not
5235	31926774	2020	QHWSYLLRP	Leuprolide	10	Free	NHEt (Ethylamine)	Linear	L	None	(GnRH) agonist	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	0.43 ± 0.06	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The administration of same dose of PEGylated leuprolides also results in an initial testosterone surge. In addition, the extent of the testosterone surge is almost the same for all three peptides, either PEGylated or not
5236	31926774	2020	QHWSYLLRPX	PEG2K-LEU	10	Free	Free	Linear	L	PEGylation at His2	Derived from leuprolide	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	0.53 ± 0.032	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The weight of testis of the rats received unmodified leuprolide, PEG2K-LEU and PEG5K-LEU decreases to be ~57%, ~58%, and ~52% of the untreated group
5237	31926774	2020	QHWSYLLRPX	PEG2K-LEU	10	Free	Free	Linear	L	PEGylation at His2	Derived from leuprolide	Anticancer (Treatment of Advanced Prostate Cancer)	Blood samples were collected from rats orbit at predetermined time interval	1.0 mg/kg	0.59 ± 0.023	SD rats serum protease	UPLC–MS/MS	SD rats serum	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/PMC6017563/	None	The weight of testis of the rats received unmodified leuprolide, PEG2K-LEU and PEG5K-LEU decreases to be ~57%, ~58%, and ~52% of the untreated group
5241	31866565	2020	YSNSG	YSNSG peptide	5	Free	Free	Cyclic	L	None	Synthetic	Antitumor	Blood samples from blood vessel in the tail were taken at the following time intervals: 15, 30, 60, 90 and 120 min	20 mg/kg	25.8 ± 8.2	B16F1 melanoma mice plasma protease	UPLC-MS/MS	B16F1 melanoma mice plasma	In Vivo	None	None	The relative recoveries of the microdialysis probes of YSNSG peptide in mice using the reverse dialysis method were 79.3 ± 6.6% in the region 1 of the tumor and 79.1 ± 7.4% in the region 2 of the tumor
5255	31529097	2020	FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	GH	191	Free	Free	Linear	L	None	Produced by the somatotroph cells in the anterior pituitary gland	Involved in the regulation of growth and metabolism	N.A.	N.A.	13.9 ± 3.6	Human blood plasma protease	2-site immunoassay	Human blood plasma	In Vivo	pdb id: 1HWG	None	N.A.
5256	31529097	2020	FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	GH	191	Free	Free	Linear	L	None	Produced by the somatotroph cells in the anterior pituitary gland	Involved in the regulation of growth and metabolism	N.A.	N.A.	17.0 ± 6.8	Human blood plasma protease	2-site immunoassay	Human blood plasma after Sitagliptin	In Vivo	pdb id: 1HWG	None	N.A.
5257	31529097	2020	FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	GH	191	Free	Free	Linear	L	None	Produced by the somatotroph cells in the anterior pituitary gland	Involved in the regulation of growth and metabolism	GH levels were obtained every 10 minutes from 8 PM until 8 AM	N.A.	13.9	Human blood plasma protease	2-site immunoassay	Human blood plasma	In Vivo	pdb id: 1HWG	None	N.A.
5258	31529097	2020	FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF	GH	191	Free	Free	Linear	L	None	Produced by the somatotroph cells in the anterior pituitary gland	Involved in the regulation of growth and metabolism	GH levels were obtained every 10 minutes from 8 PM until 8 AM	N.A.	14.5	Human blood plasma protease	2-site immunoassay	Human blood plasma after 1month of Sitagliptin	In Vivo	pdb id: 1HWG	None	N.A.
5259	31479925	2020	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	GLP-1 analogs	Antidiabetes	Blood samples (w1.5 mL) were drawn before dosing and at 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, and 180 min after dosing from the jugular vein	10 mg/kg	43 (T1/2, b)	Cat plasma protease	LC-MS/MS	Cat plasma (Diabetic)	In Vivo	PDB id: 7MLL	None	N.A.
5260	31479925	2020	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	GLP-1 analogs	Antidiabetes	Blood samples (w1.5 mL) were drawn before dosing and at 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, and 180 min after dosing from the jugular vein	10 mg/kg	9.9 (T1/2, a)	Cat plasma protease	LC-MS/MS	Cat plasma (Diabetic)	In Vivo	PDB id: 7MLL	None	N.A.
5261	31479925	2020	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	GLP-1 analogs	Antidiabetes	Blood samples (w1.5 mL) were drawn before dosing and at 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, and 180 min after dosing from the jugular vein	5 mg/kg	52 (T1/2, b)	Cat plasma protease	LC-MS/MS	Cat plasma (Diabetic)	In Vivo	PDB id: 7MLL	None	N.A.
5262	31479925	2020	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	GLP-1 analogs	Antidiabetes	Blood samples (w1.5 mL) were drawn before dosing and at 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, and 180 min after dosing from the jugular vein	5 mg/kg	12 (T1/2, a)	Cat plasma protease	LC-MS/MS	Cat plasma (Diabetic)	In Vivo	PDB id: 7MLL	None	N.A.
5263	31479925	2020	HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSSGAPPPS	[Gln28]exenatide	39	Free	Amidation	Linear	L	Gln28 modifcations	Exenatide analogs	Antidiabetes	Blood samples (w1.5 mL) were drawn before dosing and at 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, and 180 min after dosing from the jugular vein	10 mg/kg	32 (T1/2, b)	Cat plasma protease	LC-MS/MS	Cat plasma (Diabetic)	In Vivo	PDB id: 7MLL	None	N.A.
5264	31479925	2020	HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSSGAPPPS	[Gln28]exenatide	39	Free	Amidation	Linear	L	Gln28 modifcations	Exenatide analogs	Antidiabetes	Blood samples (w1.5 mL) were drawn before dosing and at 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, and 180 min after dosing from the jugular vein	10 mg/kg	8.3 (T1/2, a)	Cat plasma protease	LC-MS/MS	Cat plasma (Diabetic)	In Vivo	PDB id: 7MLL	None	N.A.
5265	31479925	2020	HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSSGAPPPS	[Gln28]exenatide	39	Free	Amidation	Linear	L	Gln28 modifcations	Exenatide analogs	Antidiabetes	Blood samples (w1.5 mL) were drawn before dosing and at 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, and 180 min after dosing from the jugular vein	5 mg/kg	38 (T1/2, b)	Cat plasma protease	LC-MS/MS	Cat plasma (Diabetic)	In Vivo	PDB id: 7MLL	None	N.A.
5266	31479925	2020	HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSSGAPPPS	[Gln28]exenatide	39	Free	Amidation	Linear	L	Gln28 modifcations	Exenatide analogs	Antidiabetes	Blood samples (w1.5 mL) were drawn before dosing and at 10, 20, 30, 40, 50, 60, 80, 100, 120, 150, and 180 min after dosing from the jugular vein	5 mg/kg	13 (T1/2, a)	Cat plasma protease	LC-MS/MS	Cat plasma (Diabetic)	In Vivo	PDB id: 7MLL	None	N.A.
5274	N.A.	2020	CSFPYRCLHQDLC	Ac-(06-34-18) Phe2 Tyr4	12	Acetylation	Free	Linear	L	Tryptophan (W) at position 3 is replaced with Phe, alanine (A) at position 5 is replaced with Tyr	Synthetic	Targets plasma kallikrein	N.A.	5 uM	0.9	Rats plasma protease	Waters Xevo TQ-MS	Rats plasma	In Vitro	None	US 201214350192 A	IC50(nM)(rat kallikrein) = 13.8
5306	31774631	2019	HSDAVFDTNYTRLRKQVAAKKYLQSIKNKRY	BAY55-9837	31	Free	Free	Linear	L	None	Synthetic	Antidiabetes	N.A.	5 mg/kg	0.31	Kunming mice plasma protease	ELISA	Kunming mice plasma	In Vivo	https://sci-hub.se/10.2337/diabetes.51.5.1453	None	N.A.
5312	31632382	2019	Gu-ONNRPVYIPRPRPPHPRL	Api137	18	Gu: N,N,N',N' tetramethylguanidino	Free	Linear	L	O: L-ornithine at position 2	Apidaecin analog	Antimicrobial	N.A.	20 mg/kg	< 30	Mice plasma protease	RP-HPLC	Mice plasma	In Vivo	None	None	N.A.
5340	31443263	2019	RKDVY	TP5	5	Free	Free	Linear	L	None	Arg32–Tyr36 fragment derived from thymopoietin	Antiinflammatory (Treatment of Several Intestinal Inflammation Conditions)	37 °C	N.A.	1.32 ± 0.24	Rats plasma proteaes	HPLC	10 μg/mL rats plasma	In Vitro	None	None	Among the peptides, LTP exhibited a lower cytotoxicity than LL-37 and TP5. In addition, LTP exhibited no significant cytotoxicity towards RAW264.7 cells, even at the highest concentration of 60 µg/mL
5351	31277465	2019	CGFLG-C6-KTVRTSADE	Dox-peptide conjugate 13	14	DOX	Free	Cyclic (Lys6-Glu14 bond)	L	C6 fatty acid linked between	Synthetic	Anticancer	Several aliquots (55 µL) were removed at 2, 5, 10, 15, 30, 60, 90, and 120 min	125 µM	11.8	Human serum protease	HPLC	25% human serum	In Vitro	None	None	Dox conjugate 13 was moderately toxic with a reduced cell proliferation to a range of 25–35% as compared to Dox which reduced cell proliferation in the range of 20–34% for all selected four cell lines
5353	31276085	2019	RWVRWIOQVRpG	S-RWRWR peptide	12	Acetylation	Amidation	Linear	Mix	R amino acid substituition at 1,4, 11, FAM denotes 5,6-carboxyfluorescein conjugated with Orn,p=D-Proline11,O=Ornithine7	scrambled version of the RWRWR peptide	Cell penetrating peptide	37°C	2 mg/ml	30	HeLa lysates protease	RP-HPLC	HeLa lysates + Assay buffer(10 mM Tris-HCl, pH 7.6)	In Vitro	None	None	N.A.
5354	31276085	2019	GGAYAAPFKKKA	III-67B	12	FAM denotes 5,6-carboxyfluorescein	Amidation	Linear	L	None	Synthetic	Cell penetrating peptide	37°C	2 mg/ml	9.5	HeLa lysates protease	RP-HPLC	HeLa lysates + Assay buffer(10 mM Tris-HCl, pH 7.6)	In Vitro	None	None	N.A.
5355	31235532	2019	PGQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC	CNP-39	39	Proline substituition (amino acid 1)	Free	Cyclic (1 Disulfide Bond)	L	Glycine (amino acid 2) modifcation	CNP derivative	Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3–related Skeletal Dysplasias	Samples from animals treated with the daily CNP-39 molecule were also obtained after the 1st and the 26th dose: at pre-dose, 0.08, 0.25, 0.5, 1, 2, and 4 hours postdose	20 μg/kg per day for 26 weeks	0.35	Cynomolgus monkeys plasma protease	competitive radioimmunoassay	Cynomolgus monkeys plasma	In Vivo	None	None	Ratio IC50 CNP-38/IC50 CNP-38 conjugate = <1 for TransCon CNP (NPR-C Affinity)
5362	31194563	2019	CARSKNKDC	Fasudil in CAR-liposome	9	Conjugation of amino groups of the lipids of liposomes with CAR peptide at N terminal Cys	Amidation	Linear	L	None	Synthetic	Treatment of Pulmonary Arterial Hypertension	N.A.	3 mg/kg	0.7 ± 0.3	Sham rats plasma protease	LC–MS/MS	Sham rats plasma	In Vivo	None	None	N.A.
5370	31156041	2019	LQVDIVPSQGEISVGESKFFLCQVAGDAKDKDISWFSPNGEKLTPNQQRISVVWNDDSSSTLTIYNANIDDAGIYKCVVTGEDGSESEATVNVKIFQAAADYKDDDDKAADYKDDDDK	AD-114-Im7-FH	118	Free	lm7-FH fusion	Linear	L	None	Fusion protein of AD-114 with lm7 and FH	Attenuates Renal fibrosis through blockade Of CXCR	Blood samples were collected 5 min, 2, 6, 12, 24, 72 h post dosing	3 mg/kg	0.18	Mouse plasma protease	LC–MS/MS	Mouse plasma	In Vivo	PDB id: >5AEA_1	None	Kd(nM) = 9.1 (Human CXCR4 affinity)
5371	31156041	2019	LQVDIVPSQGEISVGESKFFLCQVAGDAKDKDISWFSPNGEKLTPNQQRISVVWNDDSSSTLTIYNANIDDAGIYKCVVTGEDGSESEATVNVKIFQAAADYKDDDDKAADYKDDDDK	AD-114-Im7-FH-SA21	118	Free	lm7-FH-SA21	Linear	L	None	Fusion protein of AD-114 with lm7 and FH, SA21	Attenuates Renal fibrosis through blockade Of CXCR	Blood samples were collected 5 min, 2, 6, 12, 24, 72 h post dosing	2 mg/kg	0.95	Mouse plasma protease	LC–MS/MS	Mouse plasma	In Vivo	PDB id: >5AEA_1	None	Kd(nM) = 9.2 (Human CXCR4 affinity)
5386	31100806	2019	MAATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSAGYGKAGGTVTPTPNTGWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQDGHVWVGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIKLEHHHHHH	lysostaphin	255	Free	Free	Linear	L	None	Produced by Staphylococcus simulans	Anti-Staphylococcal lysin	Blood was collected by orbital bleeding at 1, 4, 7, and 24 h postadministration	40 mg/kg	<1	Mice serum protease	ELISA	Mice serum	In Vivo	None	None	Unconjugated lysostaphin shows a standard antibody binding response from 0.3 to 20 ng/ml.
5387	31100806	2019	MTCYYAGDFETTTNEEETEVWLSCFAKVIDYDKLDTFKVNTSLEDFLKSLYLDLDKTYTETGEDEFIIFFHNLKFDGSFLLSFFLNNDIECTYFINDMGVWYSITLEFPDFTLTFRDSLKILNFSIATMAGLFKMPIAKGTTPLLKHKPEVIKPEWIDYIHVDVAILARGIFAMYYEENFTKYTSASEALTEFKRIFRKSKRKFRDFFPILDEKVDDFCRKHIVGAGRLPTLKHRGRTLNQLIDIYDINSMYPATMLQNALPIGIPKRYKGKPKEIKEDHYYIYHIKADFDLKRGYLPTIQIKKKLDALRIGVRTSDYVTTSKNEVIDLYLTNFDLDLFLKHYDATIMYVETLEFQTESDLFDDYITTYRYKKENAQSPAEKQKAKIMLNSLYGKFGAKIISVKKLAYLDDKGILRFKNDDEEEVQPVYAPVALFVTSIARHFIISNAQENYDNFLYADTDSLHLFHSDSLVLDIDPSEFGKWAHEGRAVKAKYLRSKLYIEELIQEDGTTHLDVKGAGMTPEIKEKITFENFVIGATFEGKRASKQIKGGTLIYETTFKIRETDYLV	Cpl-1	568	Free	Free	Linear	L	None	Lytic enzyme of a pneumococcal bacteriophage	Antimicrobial for Pneumococcal Bacteremia	Blood was collected after 5, 10, and15 min from three animals and after 30, 60, and 120 min from the other three animals	1.6 mg	20.5	Mice plasma protease	Western blotting and spot densitometry	Mice serum	In Vivo	None	None	MICs of Cpl-1 = 32 μg/ml
5388	31100806	2019	MEINVSKLRTDLPQVGVQPYRQVHAHSTGNPHSTVQNEADYHWRKDPELGFFSHIVGNGCIMQVGPVDNGAWDVGGGWNAETYAAVELIESHSTKEEFMTDYRLYIELLRNLADEAGLPKTLDTGSLAGIKTHEYCTNNQPNNHSDHVDPYPYLAKWGISREQFKHDIENGLTIETGWQKNDTGYWYVHSDGSYPKDKFEKINGTWYYFDSSGYMLADRWRKHTDGNWYWFDNSGEMATGWKKIADKWYYFNEEGAMKTGWVKYKDTWYYLDAKEGAMVSNAFIQSADGTGWYYLKPDGTLADRPEFTVEPDGLITVK	LytA	318	Free	Free	Linear	L	None	Derived from Streptococcus pneumoniae	Therapeutic agent in experimental peritonitis sepsis caused by highly Β-lactam resistant Streptococcus Pneumoniae	Blood samples were obtained from three animals per group, which were killed at 5, 15, 60, and 120 min	3.1 mg/ml	22.5	Adult swiss mice plasma protease	N.A.	Adult swiss mice plasma	In Vivo	None	None	MICs of LytA = 16 μg/ml
5401	31069381	2019	MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR	Tozuleristide	36	Free	Free	Cyclic (C2-C19, C5-C28, C16-C33, C20-C35 Disulfide Linkage)	L	Fluorophore indocyanine green (ICG) at Lysine27	Derived from chlorotoxin	Used for fluorescence imaging of tozuleristide in adult subjects with gliomas	Collected before dosing at 1, 5, 15,30, 60, and 120 min postdose, presurgery, and 24 h after surgery	3 mg	0.242	Human serum protease	LC-MS/MS	Human serum	In Vivo	PubChem id: 121488172	None	N.A.
5402	31069381	2019	MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR	Tozuleristide	36	Free	Free	Cyclic (C2-C19, C5-C28, C16-C33, C20-C35 Disulfide Linkage)	L	Fluorophore indocyanine green (ICG) at Lysine27	Derived from chlorotoxin	Used for fluorescence imaging of tozuleristide in adult subjects with gliomas	Collected before dosing at 1, 5, 15,30, 60, and 120 min postdose, presurgery, and 24 h after surgery	9 mg	0.326	Human serum protease	LC-MS/MS	Human serum	In Vivo	PubChem id: 121488172	None	N.A.
5403	31069381	2019	MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR	Tozuleristide	36	Free	Free	Cyclic (C2-C19, C5-C28, C16-C33, C20-C35 Disulfide Linkage)	L	Fluorophore indocyanine green (ICG) at Lysine27	Derived from chlorotoxin	Used for fluorescence imaging of tozuleristide in adult subjects with gliomas	Collected before dosing at 1, 5, 15,30, 60, and 120 min postdose, presurgery, and 24 h after surgery	18 mg	0.392	Human serum protease	LC-MS/MS	Human serum	In Vivo	PubChem id: 121488172	None	N.A.
5404	31069381	2019	MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR	Tozuleristide	36	Free	Free	Cyclic (C2-C19, C5-C28, C16-C33, C20-C35 Disulfide Linkage)	L	Fluorophore indocyanine green (ICG) at Lysine27	Derived from chlorotoxin	Used for fluorescence imaging of tozuleristide in adult subjects with gliomas	Collected before dosing at 1, 5, 15,30, 60, and 120 min postdose, presurgery, and 24 h after surgery	24 mg	0.521	Human serum protease	LC-MS/MS	Human serum	In Vivo	PubChem id: 121488172	None	N.A.
5405	31069381	2019	MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR	Tozuleristide	36	Free	Free	Cyclic (C2-C19, C5-C28, C16-C33, C20-C35 Disulfide Linkage)	L	Fluorophore indocyanine green (ICG) at Lysine27	Derived from chlorotoxin	Used for fluorescence imaging of tozuleristide in adult subjects with gliomas	Collected before dosing at 1, 5, 15,30, 60, and 120 min postdose, presurgery, and 24 h after surgery	30 mg	0.485	Human serum protease	LC-MS/MS	Human serum	In Vivo	PubChem id: 121488172	None	N.A.
5410	31064153	2019	KPA	Lys(Har)-PA	3	Side chain of the Lys residue in the first position was extended by attaching additional homoarginine (Har)	Free	Linear	L	None	KPPR analogs	Peptidic inhibitor of the VEGF165/NRP-1 interaction	100 µL of aliquots were withdrawn at different time intervals (for 8 and 10: 0 min, 2h, 4h, 6h, 10h, 12h, 24h, 48h, 72h, 96h)	1.1 µmol/mL	39	Human plasma protease	HPLC-MS/MS	Human plasma	In Vitro	None	None	IC50 = 0.2μM
5411	31064153	2019	Dab-R	Dab-R	2	Dab (2,4-diaminobutyric acid) substiuition at 1st position	Free	Linear	L	None	KPPR analogs	Peptidic inhibitor of the VEGF165/NRP-1 interaction	100 µL of aliquots were withdrawn at different time intervals (for 8 and 10: 0 min, 2h, 4h, 6h, 10h, 12h, 24h, 48h, 72h, 96h)	1.1 µmol/mL	44	Human plasma protease	HPLC-MS/MS	Human plasma	In Vitro	None	None	IC50 = 0.3 μM
5414	31038930	2019	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	Synthetic	Antidiabetes	Blood samples (ca. 0.6 mL) were collected from the posterior aorta 1, 2, 8, 24, 48, 72, 96, 120, and 168 h after administration	25 nmol/kg	0.9	Mice plasma protease	ELISA	Mice plasma	In Vivo	PDB id: 7MLL	None	Exenatide presented similar GLP-1 activities with EC50 values of 1.1
5418	30986342	2019	NLLMAAS	T4-Cy5.5	7	Free	Conjugated with Cy5.5	Linear	L	None	Synthetic	Antitumor	N.A.	N.A.	1	Mice plasma protease	Fluorescence assay	Mice plasma	In Vivo	None	None	Free T4 or P-T4 slowed tumor regrowth after chemotherapy, whereas the P-T4 treatment group exhibited a better suppressive effect
5423	30973007	2019	QNSPNIFGQWM	GBAP	11	Free	Free	Cyclic (Ser3-Met11 bond)	L	None	Produced by Enterococcus faecalis	Antibacterial	Time points were taken at 0 min, 30 min, 1 hr, 2 hr, 4 hr, 8hr, and 24 hr	0.28 mM	<30	Human plasma protease	HPLC	Human plasma	In Vitro	None	None	EC50 (nM) = 1.15 for GBAP
5424	30973007	2019	QNSPNI-NMeF-GQWM	GBAP 11	14	Free	Free	Cyclic (Ser3-Met11 bond)	L	N-methylation at Phe7	GBAP analogs	Antibacterial	Time points were taken at 0 min, 30 min, 1 hr, 2 hr, 4 hr, 8hr, and 24 hr	0.28 mM	<30	Human plasma protease	HPLC	Human plasma	In Vitro	None	None	EC50(nM) = 6.3 for GBAP-[N-MeF7]
5432	30901967	2019	EMTWEEWEKKIEEYTKKIEEILKKSQNQQIDL	HP23-E6-IDL	32	Free	Free	Linear	L	None	Synthetic	Antiviral (Anti-Hiv Activity)	Mouse serum samples were collected before (0 h) and after injection (0.5, 1, 2, 4, and 6 h for peptides HP23-E6-IDL	5 mg/kg	1	Mice serum protease	N.A.	Mice serum	In Vivo	None	None	IC50(pM) = 912 ± 29 in HIV-1 NL4-3 D36G (WT)(Inhibitory activities of HP23-E6-IDL against infection by HIV-1 mutants resistant to T20)
5433	30900390	2019	SDKP	Ac-SDKP	4	Acetylation	Free	Linear	L	None	Synthetic	Antifibrotic effects on Hepatic Fibrosis	At 2, 4, 6, 8, 10, 18, 30, 120, 360, 480, and 540 min after the injection, 50 μL of blood was sampled from each animal through the caudal vein	1 mg/kg	9.65 ± 1.78	Rats serum protease	RP-HPLC	Rats serum	In Vivo	None	None	Ac-SD(d)K(d)P and Ac-SDKP exhibited similar antifibrotic effects in vitro
5435	30900390	2019	SDKP	Ac-SDKP	4	Acetylation	Free	Linear	L	None	synthetic	Antifibrotic Effects On Hepatic Fibrosis	9 h at 37 C	100 μM	6.47 ± 1.53	Human Serum Protease	HPLC	human serum	In Vitro	None	None	Ac-SD(d)K(d)P and Ac-SDKP exhibited similar antifibrotic effects in vitro
5438	30817059	2019	EAENPQAGAVELGGGLGGLQALALEGPPQ	Porcine C‐Peptide	29	Free	Free	Linear	L	None	Released from the pancreatic beta cells when proinsulin is processed into insulin and C-peptide	Used as marker of insulin production	Blood samples (200 μL each) were collected through the catheter at 1, 2, 5, 15, 30, 60, 90, and 120 minutes	200 pmol/kg	4.3 ± 1.2 (Terminal Elimination Half Life)	Rats plasma protease	ELISA	Rats plasma	In Vivo	https://www.jbc.org/article/S0021-9258(19)41064-8/pdf	None	N.A.
5440	30817059	2019	EAENPQAGAVELGGGLGGLQALALEGPPQ	Porcine C‐Peptide	29	Free	Free	Linear	L	None	Released from the pancreatic beta cells when proinsulin is processed into insulin and C-peptide	Used as marker of insulin production	Blood samples (200 μL each) were collected through the catheter at 1, 2, 5, 15, 30, 60, 90, and 120 minutes	2000 pmol/kg	6.9 ± 2.5 (Terminal Elimination Half Life)	Rats plasma protease	ELISA	Rats plasma	In Vivo	https://www.jbc.org/article/S0021-9258(19)41064-8/pdf	None	N.A.
5441	30817059	2019	EAENPQAGAVELGGGLGGLQALALEGPPQ	Porcine C‐Peptide	29	Free	Free	Linear	L	None	Released from the pancreatic beta cells when proinsulin is processed into insulin and C-peptide	Used as marker of insulin production	Blood samples (200 μL each) were collected through the catheter at 5, 15, 30, 60, 90 and 120 minutes after intraperitoneal injection	2000 pmol/kg	53 ± 14 (Terminal Elimination Half Life)	Rats plasma protease	ELISA	Rats plasma	In Vivo	https://www.jbc.org/article/S0021-9258(19)41064-8/pdf	None	N.A.
5442	30814652	2019	ASPAAPAPASPAAPAPSAPA	Adnectin C	20	Free	Free	Linear	L	None	Derived from the tenth domain of fibronectin type III (10thFn3)	Anticancer	Blood samples were taken after 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, and 96 h	5 mg/kg	49.41	Mice plasma protease	ELISA	Mice plasma	In Vivo	None	None	Kd(1/s) = 5.643E − 5
5446	30794654	2019	GLSKGCFGLKLDRIGSMSGLGC	CNP(1–22)	22	Free	Free	Cyclic (C6-C22 Disulfide Bond)	L	None	CNP C terminal cleavage	Improved endochondral ossification and accelerated bone growth in mice	N.A.	20 nmol/kg	1.42 ± 0.45	Rats plasma protease	ELISA	Rats plasma	In Vivo	None	None	N.A.
5447	30794654	2019	GLSKGCFGLKLDRIGSMSGLGCVQQRKDSKKPPAKLQPR	ASB20123	39	Free	Free	Cyclic (C6-C22 Disulfide Bond)	L	None	C-type natriuretic peptide derivative	Treatment of Growth failure and Dwarfism	N.A.	20 nmol/kg	31.3 ± 4.8	Rats plasma protease	ELISA	Rats plasma	In Vivo	None	None	N.A.
5448	30794654	2019	GLSKGCFGLKLDRIGSMSGLGC	CNP(1–22)	22	Free	Free	Cyclic (C6-C22 Disulfide Bond)	L	None	CNP C terminal cleavage	Improved Endochondral Ossification And Accelerated Bone Growth In Mice	N.A.	50 nmol/kg	10.0 ± 5.0	Rats plasma protease	ELISA	Rats plasma	In Vivo	None	None	N.A.
5449	30794654	2019	GLSKGCFGLKLDRIGSMSGLGCVQQRKDSKKPPAKLQPR	ASB20123	39	Free	Free	Cyclic (C6-C22 Disulfide Bond)	L	None	C-type natriuretic peptide derivative	Treatment Of Growth Failure And Dwarfism	N.A.	50 nmol/kg	32.1	Rats plasma protease	ELISA	Rats plasma	In Vivo	None	None	N.A.
5450	30756483	2019	GLAEAKVLANRELDKYGVSDYYKNLINNAKTVEGVKALIDEILAALP	ABD–Dox	47	Free	Dox conjugation	Linear	L	None	Derived from streptococcal protein G	Anticancer	Blood samples were collected at 40 s, 15 and 30 min, and 2, 4, 8, 24, 48, 72, and 96 h post injection	5 mg/kg	29.4 ± 0.8 (Elimination Half Life)	Mice plasma protease	Flurorescence assay	Mice plasma	In Vivo	None	None	(IC50) of ABD–Dox was 6.4 × 10−6 for C26 cell
5452	30742145	2019	MAQAKHKQRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR	Native BMP-2	116	Free	Free	Linear	L	None	Synthetic	Promotes Bone repair	N.A.	0.5 mg/kg	<30	N.A.	Fluorescence spectrometry	Rats	In Vivo	PDB id: 1ES7	None	n(BMP-2) did not enhance ALP expression in MSCs compared with native BMP-2 unless pretreated with IV collagenase, which significantly enhanced ALP expression and calcium deposition
5453	30709867	2019	DRVYIHS	PNA5	7	Free	Replaces the seventh residue (proline) with a serine, and has a glucose sugar moiety attached to the serine and is amidated on the C terminus	Linear	L	None	Ang-(1-7) analogs	Treating Vascular Cognitive Impairment and Inflammation related Memory Dysfunction	N.A.	100 µM	1.0 ± 0.2	Rats serum protease	Tandem mass spectrometry (MS)	Rats serum	In Vitro	None	None	Potency IC50 = 0.1 μM for PNA5 (In vitro bioactivity ROS inhibition)
5454	30709867	2019	DRVYIHP	Ang-(1-7)	7	Free	Free	Linear	L	None	Ang-(1-7)	Decrease Brain ROS production and Inflammation in Preclinical models of HF	N.A.	100 µM	0.25 ± 0.05	Rats serum protease	Tandem mass spectrometry (MS)	Rats serum	In Vitro	None	None	Potency IC50 = 0.1 μM for PNA5 (In vitro bioactivity ROS inhibition)
5455	30709867	2019	DRVYIHS	PNA5	7	Free	Replaces the seventh residue (proline) with a serine, and has a glucose sugar moiety attached to the serine and is amidated on the C terminus	Linear	L	None	Ang-(1-7) analogs	Treating Vascular Cognitive Impairment and Inflammation related Memory Dysfunction	N.A.	10 mg/kg	18.2 ± 3	Rats serum protease	LC-MS	Rats serum	In Vivo	None	None	Potency IC50 = 0.1 μM for PNA5 (In vitro bioactivity ROS inhibition)
5456	30709867	2019	DRVYIHP	Ang-(1-7)	7	Free	Free	Linear	L	None	Ang-(1-7)	Decrease Brain ROS production and Inflammation in Preclinical models of HF	N.A.	10 mg/kg	20.9 ± 0.7	Rats serum protease	LC-MS	Rats serum	In Vivo	None	None	Potency IC50 = 0.1 μM for PNA5 (In vitro bioactivity ROS inhibition)
5457	30709867	2019	DRVYIHS	PNA5	7	Free	Replaces the seventh residue (proline) with a serine, and has a glucose sugar moiety attached to the serine and is amidated on the C terminus	Linear	L	None	Ang-(1-7) analogs	Treating Vascular Cognitive Impairment and Inflammation related Memory Dysfunction	N.A.	10 mg/kg	26.6 ± 3.6	CSF protease	LC-MS	CSF	In Vivo	None	None	Potency IC50 = 0.1 μM for PNA5 (In vitro bioactivity ROS inhibition)
5458	30709867	2019	DRVYIHP	Ang-(1-7)	7	Free	Free	Linear	L	None	Ang-(1-7)	Decrease Brain ROS production and Inflammation in Preclinical models of HF	N.A.	10 mg/kg	24.7 ± 5	CSF protease	LC-MS	CSF	In Vivo	None	None	Potency IC50 = 0.1 μM for PNA5 (In vitro bioactivity ROS inhibition)
5459	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin1	17	Free	Free	Linear	L	None	Native apelin 17	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.4	RHNEP	LC-MS	Apelin1	In Vitro	None	None	EC50(nM) = 1.9 ± 1.0
5460	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin2	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=H	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	1	RHNEP	LC-MS	Apelin2	In Vitro	None	None	EC50(nM) = 4.1 ± 1.0
5468	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin1	17	Free	Free	Linear	L	None	Native apelin 17	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.4	RhKLKB1	LC-MS	Apelin1	In Vitro	None	None	EC50(nM) = 1.9 ± 1.0
5469	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin2	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=H	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.7	RhKLKB1	LC-MS	Apelin2	In Vitro	None	None	EC50(nM) = 4.1 ± 1.0
5470	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin3	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=Me, Methylation at Glu8	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.9	RhKLKB1	LC-MS	Apelin3	In Vitro	None	None	EC50(nM) = 4.9 ± 1.0
5473	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin6	20	R1 = PALM-Lys-Phe-Arg	Free	Linear	L	None	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	1	RhKLKB1	LC-MS	Apelin6	In Vitro	None	None	EC50(nM) = 2.6 ± 0.8
5477	30690406	2019	KFRRQRPRLSHKGPMPF	Apelin1	17	Free	Free	Linear	L	None	Native apelin 17	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.02	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 1.9 ± 1.0
5478	30690406	2019	KFRKFRRQRPRLSHKGPMPF	Apelin2	20	R1 = NH2-Lys-Phe-Arg	Free	Linear	L	R2=H	Apelin analogs	Blood Pressure lowering agents	37 C for up to 72 h	N.A.	0.3	hplasma protease	LC-MS	hplasma	In Vitro	None	None	EC50(nM) = 4.1 ± 1.0
5512	30606721	2019	CYNEFGCEDFYDIC	BCY-B2	14	Acetylation	Free	Cyclic (Cyclized With 1,3,5-Trismethylbenzene On C1, C7, C14)	L	None	Bicyclic peptide derivative	For imaging and targeting of proteins overexpressed by tumors	Blood samples were taken from two animals per time-point, at 0.08, 0.5, 1, 2, and 4 hours post injection (p.i.),	5.925 mg/kg	14 (Elimination Half Life)	Mouse plasma protease	LC-MS/MS	Mouse plasma	In Vivo	None	None	KD(nM) = 25 ± 0.3
5513	30605634	2019	pGlu-RPRLSHKGPMPF	(Pyr)1-apelin-13	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Hemodynamic Effects In Humans	N.A.	50 mg/kg	13	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
5514	30605634	2019	pGlu-RPRLSHKGPMPF	(Pyr)1-apelin-13	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Hemodynamic Effects In Humans	N.A.	50 mg/kg	16	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	N.A.
5520	30543420	2019	(QLYSALANKCCHVGVOKRSLARFC)-DSWMEEVIKLCGRELVRAQIAICGMSTWS	R2	53	Free	Free	Linear	L	B-D1A Cys mutation	R3 based relaxin analogs	Role in Hemodynamics and Renal function and has shown preclinical efficacy in multiple disease models, including Acute Heart Failure, Fibrosis, Preeclampsia, and Corneal Wound Healing	N.A.	0.3 mg/kg	0.3	Mouse plasma protease	LC-MS	Mouse plasma	In Vivo	None	None	EC50(nM) = 0.025 ± 0.004
5523	30543420	2019	(QLYSALANKCCHVGVOKRSLARFC)-(ASWMEEVIKLCGRELVRAQIAICGMSTWC)	R3-02	53	Free	FA-02	Linear	L	B-S29C,D1A Cys mutation	R3 based relaxin analogs	Role in Hemodynamics and Renal function and has shown preclinical efficacy in multiple disease models, including Acute Heart Failure, Fibrosis, Preeclampsia, and Corneal Wound Healing	N.A.	0.3 mg/kg	1	Mouse plasma protease	LC-MS	Mouse plasma	In Vivo	None	None	EC50(nM) = 0.028 ± 0.18
5524	30543420	2019	(QLYSALANKCCHVGVOKRSLARFC)-(ASWMEEVIKLCGRELVRAQIAICGMSTWC)	R3-02	53	Free	FA-02	Linear	L	B-S29C,D1A Cys mutation	R3 based relaxin analogs	Role In Hemodynamics And Renal Function And Has Shown Preclinical Efficacy In Multiple Disease Models, Including Acute Heart Failure, Fibrosis, Preeclampsia, And Corneal Wound Healing	N.A.	0.3 mg/kg	1	Mouse plasma protease	LC-MS	mouse plasma	In Vivo	None	None	EC50(nM) = 0.028 ± 0.10
5550	30334171	2019	CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	rhIFN-α2b	165	Free	Free	Linear	L	None	Synthetic	Antiviral, Antitumor, And Immunomodulatory Effects	N.A.	500 μg/kg	0.54 (Elimination Half Life)	Rats plasma protease	sandwich ELISA	Rats plasma	In Vivo	PDB id: 1RH2	None	rhIFN-α2b had a high specific antiviral activity (2.5 × 108 ± 1.1 × 108IU/mg protein)
5651	30175919	2018	GRP-MeArg-AFTF-MeAla-CKKK	Myristoylated peptide	14	6FAM labelled	Additional C terminal cysteine linked to peptide using dislufide bond	Linear	L	MeAla, MeArg,Lys1 modified with Myr	Synthetic	Substrate reporter for PKB	RT	1 µM	12 ± 1	N.A.	N.A.	Axenic D. discoideum K-AX3 DB or SorCM after myristoylated peptide loading	In Vitro	None	None	N.A.
5652	30175919	2018	GRP-MeArg-AFTF-MeAla	Electroporation peptide	9	6FAM labelled	Free	Linear	L	MeAla, MeArg	Synthetic	Substrate reporter for PKB	RT	35 µM	53 ± 15	N.A.	N.A.	Axenic D. discoideum K-AX3 SorCM buffer after electroporation	In Vitro	None	None	N.A.
5653	30175919	2018	GRP-MeArg-AFTF-MeAla	Pinocystosis peptide	9	6FAM labelled	Free	Linear	L	MeAla, MeArg	Synthetic	Substrate reporter for PKB	RT	150 µM	19 ± 2	N.A.	N.A.	Axenic D. discoideum K-AX3 DB after pinocytosis	In Vitro	None	None	N.A.
5658	30161002	2018	LLTHTISRIAVSYQTKVNLL	P16	21	Free	Free	Linear	L	None	TNF-a cleaved fragment	Antitumor	Orbital blood samples were collected from 3 mice at different time points (0, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, and 48 h)	5 mg/kg	0.07	BALB/c mice plasma protease	LC-MS	BALB/c mice plasma	In Vivo	None	None	N.A.
5659	30161002	2018	SVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL	TNF-a	158	Free	Free	Linear	L	None	TNF-a	Antitumor	Orbital blood samples were collected from 3 mice at different time points (0, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 24, and 48 h)	5 mg/kg	0.43	BALB/c mice plasma protease	LC-MS	BALB/c mice plasma	In Vivo	PDB id: 6OP0	None	N.A.
5664	30041153	2018	GIVEQCCTSICSLYQLENYCN/FVNQHLCGSHLVEALYLVCGERGFFYTPKT	HI	51	Free	Free	Cyclic (3 S-S Bond)	L	None	Synthetic	Antidiabetes	At each time point (0, 0.5, 1, 2, 4 h), 50 µL of SCts were collected from the incubation mixture	1 µM	<0.5	Rats SCT protease	LC-HRMS	1 mg/ml rats SCT protein	In Vitro	https://sci-hub.st/10.1016/j.jpba.2018.07.009, PDB id: 1SF1	None	N.A.
5665	30041153	2018	GIVEQCCTSICSLYQLENYCN/FVNQHLCGSHLVEALYLVCGERGFFYTPKT	HI	51	Free	Free	Cyclic (3 S-S Bond)	L	None	Synthetic	Antidiabetes	At each time point (0, 0.5, 1, 2, 4 h), 50 µL of SCts were collected from the incubation mixture	1 µM	<0.5	Rats SCT protease	LC-HRMS	2 mg/ml rats SCT protein	In Vitro	https://sci-hub.st/10.1016/j.jpba.2018.07.009, PDB id: 1SF1	None	N.A.
5666	30041153	2018	GIVEQCCTSICSLYQLENYCN/FVNQHLCGSHLVEALYLVCGERGFFYTPKT	HI	51	Free	Free	Cyclic (3 S-S Bond)	L	None	Synthetic	Antidiabetes	At each time point (0, 0.5, 1, 2, 4 h), 50 µL of SCts were collected from the incubation mixture	1 µM	<0.5	Rats SCT protease	LC-HRMS	4 mg/ml rats SCT protein	In Vitro	https://sci-hub.st/10.1016/j.jpba.2018.07.009, PDB id: 1SF1	None	N.A.
5669	30041153	2018	GIVEQCCTSICSLYQLENYCN/FVNQHLCGSHLVEALYLVCGERGFFYTPKT	HI	51	Free	Free	Cyclic (3 S-S Bond)	L	None	Synthetic	Antidiabetes	At each time point (0, 0.5, 1, 2, 4 h), 50 µL of SCts were collected from the incubation mixture	10 µM	0.56	Rats SCT protease	LC-HRMS	4 mg/ml rats SCT protein	In Vitro	https://sci-hub.st/10.1016/j.jpba.2018.07.009, PDB id: 1SF1	None	N.A.
5674	30041153	2018	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK	Lixisenatide	44	Free	Amidation	Linear	L	None	GLP-1 analogs	Antidiabetes	At each time point (0, 0.5, 1, 2, 4 h), 50 µL of SCts were collected from the incubation mixture	10 µM	<0.5	Human SCT protease	LC-HRMS	1 mg/ml human SCT protein	In Vitro	None	None	N.A.
5678	30041153	2018	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK	Lixisenatide	44	Free	Amidation	Linear	L	None	GLP-1 analogs	Antidiabetes	At each time point (0, 0.5, 1, 2, 4 h), 50 µL of SCts were collected from the incubation mixture	10 µM	<0.5	SD rats SCT protease	LC-HRMS	1 mg/ml SD rats SCT protein	In Vitro	None	None	N.A.
5680	30041153	2018	H-Aib-EGTFTSDVSSYLEGQAAKEFIAWLVRGRG	Semaglutide	31	Free	Free	Linear	L	Aib modification at position 2, Lys26 side chain conjugated with (ADO-linker-Glu-C18)	GLP-1 analogs	Antidiabetes	At each time point (0, 0.5, 1, 2, 4 h), 50 µL of SCts were collected from the incubation mixture	10 µM	0.9	SD rats SCT protease	LC-HRMS	1 mg/ml SD rats SCT protein	In Vitro	None	None	N.A.
5682	30041153	2018	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK	Lixisenatide	44	Free	Amidation	Linear	L	None	GLP-1 analogs	Antidiabetes	At each time point (0, 0.5, 1, 2, 4 h), 50 µL of SCts were collected from the incubation mixture	10 µM	<0.5	Göttingen minipigs SCT protease	LC-HRMS	1 mg/ml göttingen minipigs SCT protein	In Vitro	None	None	N.A.
5697	29958697	2018	TLQPPASSRRRHFHHALPPAR	125I-TLQP-21	21	125I labelled	Free	Linear	L	None	Derived from the proteolytic cleavage of the 617-aa VGF	Isoproterenol stimulated lipolysis	At the time points of 0 min, 10 min, 30 min, and 60 min, aliquots of the incubated solutions were withdrawn (15uL)	1 mM	1.7 (T1/2 Initial Phase)	Rats plasma protease	LC-MS	Rats plasma	In Vitro	None	None	N.A.
5725	29752565	2018	YGGFM	Met-enkephalin	5	Free	Met substituition at C terminal	Linear	L	None	Synthetic	Involved in the pain modulating mechanism in the spinal cord	Incubated over 0, 30, 60, 90, 120 min at 37 °C	0.0413 mM	27 ± 1	NEP (5.687 Nm)	RP-HPLC	Tris–HCl buffer (50 mM, pH 7.4)	In Vitro	None	None	N.A.
5728	29752565	2018	YGGFM	Met-enkephalin	5	Free	Met substituition at C terminal	Linear	L	None	Synthetic	Involved in the pain modulating mechanism in the spinal cord	Incubated over 0, 30, 60, 90, 120 min at 37 °C	0.0413 mM	47 ± 1	NEP (5.687 Nm)	RP-HPLC	Tris HCl buffer with 0.156 mM [Ala1]sialorphin inhibitor	In Vitro	None	None	N.A.
5731	29752565	2018	YGGFM	Met-enkephalin	5	Free	Met substituition at C terminal	Linear	L	None	Synthetic	Involved in the pain modulating mechanism in the spinal cord	Incubated over 0, 30, 60, 90, 120 min at 37 °C	0.0413 mM	42 ± 2	NEP (5.687 Nm)	RP-HPLC	Tris HCl buffer with 0.156 mM[Ala4]sialorphin inhibitor	In Vitro	None	None	N.A.
5732	29752565	2018	YGGFM	Met-enkephalin	5	Free	Met substituition at C terminal	Linear	L	None	Synthetic	Involved in the pain modulating mechanism in the spinal cord	Incubated over 0, 30, 60, 90, 120 min at 37 °C	0.0413 mM	52 ± 2	NEP (5.687 Nm)	RP-HPLC	Tris HCl buffer with 0.156 mM [Ala5]sialorphin inhibitor	In Vitro	None	None	N.A.
5734	29752565	2018	YGGFM	Met-enkephalin	5	Free	Met substituition at C terminal	Linear	L	None	Synthetic	Involved in the pain modulating mechanism in the spinal cord	Incubated over 0, 30, 60, 90, 120 min at 37 °C	0.0413 mM	53 ± 1	NEP (5.687 Nm)	RP-HPLC	Tris HCl buffer with 0.156 mM [Ser4]sialorphin inhibitor	In Vitro	None	None	N.A.
5744	29721065	2018	WHSDMEWWYLLG	64Cu-DOTA-F56	12	64Cu-DOTA	Free	Linear	L	None	Synthetic	Antiangiogenic	At 10, 30, 60, and 120 min	7.4 mBq	0.4249	Mice plasma protease	Radioactivity assay	Mice plasma	In Vivo	None	None	F56 and F56-CM reduced the angiogenesis of zebrafish embryos in a dose-dependent way
5749	29685037	2018	DRVYIHP	Ang-(1-7)	7	Free	Free	Linear	L	None	Ang-(1-7)	Decrease brain ROS production and inflammation in preclinical models of HF	15 h at 37°C	100 µM	13.8 ± 5.7	Rats serum protease	HPLC	Rats serum	In Vitro	None	None	Ang-AA in combination with paclitaxel exerted stronger anti-tumor effects than Ang-(1-7), as indicated by reduced tumor growth, tumor weight, COX2 expression, and increased survival of the mice
5752	29685037	2018	DRVYIHP	Ang-(1-7)	7	Free	Free	Linear	L	None	Ang-(1-7)	Decrease brain ROS production and inflammation in preclinical models of HF	After a 30 min incubation at 37°C	0.1 mM	9.2 ± 0.5	ACE, LAP and NEP	HPLC	PBS solution containing all three hydrolytic enzymes (0.5 IU/mL), ACE, LAP and NEP	In Vitro	None	None	Ang-AA in combination with paclitaxel exerted stronger anti-tumor effects than Ang-(1-7), as indicated by reduced tumor growth, tumor weight, COX2 expression, and increased survival of the mice
5762	29669811	2018	MKYLLPTAAAGLLLLAAQPAMAAHHHHHHGSSGGGENLYFQGSSGQVQLVQSGAEVKKPGASVKVSCKASGYTFTDHAIHWVRQAPGQRLEWMGYFSPGNDDFKYSQKFQGRVTITADKSSSTAYMELSSLRSEDTAVYYCARSWIMQYWGQGTLVTVSSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSYPLTFGGGTKVEIK	125I-3E8.G4S	278	125I labelled	Free	Linear	L	125I-labeled, VH and VL joined by G4S linker	Derived from the 3E8 antibody	Optimizes biophysical properties, serum half-life and high-specificity tumor imaging	Blood samples (5 μl) were drawn from the saphenous vein by puncture, using a 30-gauge syringe needle, at 0.5, 1, 5, 24, 48, and 72 h postinjection for 3E8.G4S	5 μCi	0.67	Mice blood protease	Radioiodination assay	Mice blood sample	In Vivo	https://pmc.ncbi.nlm.nih.gov/articles/instance/5995523/bin/supp_RA118.002538_136163_1_supp_109995_p6kvvq.pdf	None	KD of 3.6 nM for 3E8.G4S
5766	29656472	2018	KVTAMTCFLL	[K6T]P8 peptide	10	Free	Amidation	Linear	L	K6T modification	Synthetic	IL‐15 antagonist peptide	At t = 0, 5, 8, 10, 20,30, 45, 60, 90, and 120 minutes	100 μM.	5.88 ± 1.73	Human synovial fluids protease	RP-HPLC	Human synovial fluids	In Vitro	None	None	IC50 values of 27.7 μM
5773	29602308	2018	HSTPSSP	P4-Chlorambucil	7	Free	Chlorambucil	Linear	L	None	Protein drug conjugate	Anticancer	37 °C	100 μl/ ml	21.5	N.A.	LC–MS/MS	Buffer pH 7.4	In Vitro	None	None	The efficacies of all P6-conjugates were significantly lower than those of P4–conjugates at concentrations above 10 µM
5774	29602308	2018	HSTPSSP	P4-Chlorambucil	7	Free	Chlorambucil	Linear	L	None	Protein drug conjugate	Anticancer	37 °C	100 μl/ ml	12.4	Mouse liver homogenate protease	BCA protein assay	Mouse liver homogenate	In Vitro	None	None	The efficacies of all P6-conjugates were significantly lower than those of P4–conjugates at concentrations above 10 µM
5775	29602308	2018	HSTPSSP	P4-Melphalan	7	Free	Melphalan	Linear	L	None	Protein drug conjugate	Anticancer	37 °C	100 μl/ ml	24.6	N.A.	LC–MS/MS	Buffer pH 7.4	In Vitro	None	None	The efficacies of all P6-conjugates were significantly lower than those of P4–conjugates at concentrations above 10 µM
5776	29602308	2018	HSTPSSP	P4-Melphalan	7	Free	Melphalan	Linear	L	None	Protein drug conjugate	Anticancer	37 °C	100 μl/ ml	10.6	Mouse liver homogenate protease	BCA protein assay	Mouse liver homogenate	In Vitro	None	None	The efficacies of all P6-conjugates were significantly lower than those of P4–conjugates at concentrations above 10 µM
5777	29602308	2018	HSTPSSP	P4-Bendamustine	7	Free	Bendamustine	Linear	L	None	Protein drug conjugate	Anticancer	37 °C	100 μl/ ml	19.3	N.A.	LC–MS/MS	Buffer pH 7.4	In Vitro	None	None	The efficacies of all P6-conjugates were significantly lower than those of P4–conjugates at concentrations above 10 µM
5778	29602308	2018	HSTPSSP	P4-Bendamustine	7	Free	Bendamustine	Linear	L	None	Protein drug conjugate	Anticancer	37 °C	100 μl/ ml	15.4	Mouse liver homogenate protease	BCA protein assay	Mouse liver homogenate	In Vitro	None	None	The efficacies of all P6-conjugates were significantly lower than those of P4–conjugates at concentrations above 10 µM
5786	29550018	2018	MSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGESGSMSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES	DTβ4	88	Free	Free	Linear	L	Dimerization using GS linker	Dimeric Tβ4	Protects post-ischemic cardiac function	N.A.	50 μg	59.1	Mouse serum protease	HPLC	Mouse serum	In Vivo	Uniprot id: P62328	None	In scratch wound and Boyden chamber assays, the migration of HUVECs induced by DTβ4 was significantly higher than that induced by wild-type Tβ4 at each applied concentration
5787	29550018	2018	MSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES	Tβ4	43	Free	Free	Linear	L	None	Synthetic	Protects post-ischemic cardiac function	N.A.	50 μg	53.3	Mouse serum protease	HPLC	Mouse serum	In Vivo	Uniprot id: P62328	None	In scratch wound and Boyden chamber assays, the migration of HUVECs induced by DTβ4 was significantly higher than that induced by wild-type Tβ4 at each applied concentration
5788	29540315	2018	HGDGSFTSELSTYLDALAARDFIAWLIQTKITD	GUB09-123	33	Free	Amidation	Linear	L	None	Synthetic	GLP-1/GLP-2 co-agonist	Blood samples were collected by decapitation of the animals at nine different time points after administration (0.25, 0.5, 0.75, 1, 2, 4, 6, 10 and 24 hours, n=3 for each time point)	800nmol/kg	0.9	Mice plasma protease	LC-MS/MS	Mice plasma	In Vivo	None	None	GLP-1R, EC50 (nM) = 0.07
5794	29531858	2018	KCRGDCFC	[68Ga]Ga-DOTA-RGD	8	CH2CO chemical group attached, DOTA conjugated with Lys1	CCPEG	Cyclic (C2-C6 Disulfide Bond)	L	68Ga labelling	Synthetic	PET imaging agent to visualize and quantify angiogenesis	Blood samples (0.5 ml) for radioactivity measurements (0.5 ml) were taken at 1, 3, 6, 9, 12, 15, 30, 60, 90 minutes after RGD injection	N.A.	24.6 (Slow Phase)	NHP plasma protease	UV-HPLC and LC-ESI-MS	NHP uterus plasma without NC-100717	N.A.	None	None	N.A.
5795	29531858	2018	KCRGDCFC	[68Ga]Ga-DOTA-RGD	8	CH2CO chemical group attached, DOTA conjugated with Lys1	CCPEG	Cyclic (C2-C6 Disulfide Bond)	L	68Ga labelling	Synthetic	PET imaging agent to visualize and quantify angiogenesis	Blood samples (0.5 ml) for radioactivity measurements (0.5 ml) were taken at 1, 3, 6, 9, 12, 15, 30, 60, 90 minutes after RGD injection	N.A.	1.1 (Fast Phase)	NHP plasma protease	UV-HPLC and LC-ESI-MS	NHP uterus plasma without NC-100717	N.A.	None	None	N.A.
5796	29531858	2018	KCRGDCFC	[68Ga]Ga-DOTA-RGD	8	CH2CO chemical group attached, DOTA conjugated with Lys1	CCPEG	Cyclic (C2-C6 Disulfide Bond)	L	68Ga labelling	Synthetic	PET imaging agent to visualize and quantify angiogenesis	Blood samples (0.5 ml) for radioactivity measurements (0.5 ml) were taken at 1, 3, 6, 9, 12, 15, 30, 60, 90 minutes after RGD injection	1 mg/kg	26.4 (Slow Phase)	NHP plasma protease	UV-HPLC and LC-ESI-MS	NHP uterus plasma after administration of NC-100717 (1 mg/kg)	In Vivo	None	None	N.A.
5797	29531858	2018	KCRGDCFC	[68Ga]Ga-DOTA-RGD	8	CH2CO chemical group attached, DOTA conjugated with Lys1	CCPEG	Cyclic (C2-C6 Disulfide Bond)	L	68Ga labelling	Synthetic	PET imaging agent to visualize and quantify angiogenesis	Blood samples (0.5 ml) for radioactivity measurements (0.5 ml) were taken at 1, 3, 6, 9, 12, 15, 30, 60, 90 minutes after RGD injection	1 mg/kg	1.9 (Fast Phase)	NHP plasma protease	UV-HPLC and LC-ESI-MS	NHP uterus plasma after administration of NC-100717 (1 mg/kg)	In Vivo	None	None	N.A.
5798	29528634	2018	HGDGSFSDEMNTILDNLAARDFINWLIQTKITD	GLP2-2G	33	Free	Free	Linear	L	Ala2 was substituted with Gly	GLP-2 analogue	Treatment of Short Bowel Syndrome	Plasma levels of the peptides at various time points (5 min, 30 min, 1 h, 3 h, 7 h, and 24 h)	10 nmol/kg	25	Mice plasma protease	In vitro cell based activity assay	Mice plasma	In Vivo	None	None	EC50(nM) = 0.035 ± 0.003
5803	29517911	2018	CSFPY-hArg-CAHQDLC	2d	13	Acetylation	Free	Bicyclic (Cyclized On C1, C7, C13 By 1,3,5 Trismethylbenzene)	L	Trp3 → Phe3, Pro4 → Aze4, Ala5 → Tyr5, Arg6 → HArg6, Leu8 → Ala(ψCH2NH)6 substituitions	2a analogue	Antidiabetes (Treatment of Diabetic Macular Edema)	Serial blood samples were taken from each animal via temporary indwelling tail vein cannulae at 5, 10, 20, 30, 60, 120, 180, and 240 min postdose,	5 mg/kg	48	Rats plasma protease	LC-MS/MS	Rats plasma	In Vivo	None	None	Ki Values (nM) = 30 ± 9 against PKal from Rats
5822	29461833	2018	X-RPR-X-SHKGP-Nle-PF	Pyr analogue 2	13	Free	Free	Cyclic (X1-X5 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	0.8 ± 0.2	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 5.7 ±3.5 for 2
5824	29461833	2018	X-PRL-X-HKGP-Nle-PF	Pyr analogue 4	13	pGlu = Pyroglutamate	Free	Cyclic (X1-X6 Bond)	L	X= allylglycine, Nle = Nor-leucine	Pyr-13 analogue	Effects on Cardiac and Renal Functions as well as survival in a Systemic Inflammation Model Of Sepsis and Septic Shock	At selected time points (0, 2, 4, 7, and 24 h or 0, 10, 20, 60, and 120 min).	1 mM	0.7 ± 0.1	Rats plasma protease	UPLC-MS	Rats plasma	In Vitro	None	None	Ki binding (nM) = 523 ±165 for 4L
5836	29436835	2018	(hpcdypewqwlcelGk)3	PIE 12-trimer	48	Maleimide joined by linker PEG24	Free	Linear	Mix	All D-amino acids except Gly	Synthetic	Antiviral (HIV Entry Inhibitor)	5 min to 24 h	1 mg/kg	0.6	Rats plasma protease	LC-MS/MS using an Agilent HPLC	Rats plasma	In Vivo	None	None	JRFL(nM) = 2.1 ± 0.28 (antiviral potency)
5837	29436835	2018	(hpcdypewqwlcelGk)3	PIE 12-trimer	48	Maleimide joined by linker PEG24	Free	Linear	Mix	All D-amino acids except Gly	Synthetic	Antiviral (HIV Entry Inhibitor)	15 min to 48 h	1 mg/kg	0.8	Rats plasma protease	LC-MS/MS using an Agilent HPLC	Rats plasma	In Vivo	None	None	JRFL(nM) = 2.1 ± 0.28 (antiviral potency)
5840	29436835	2018	(hpcdypewqwlcelGk)3	C16-PIE12-trimer	48	C16-Maleimide joined by linker PEG24	Free	Linear	Mix	All D-amino acids except Gly	Synthetic	Antiviral (HIV Entry Inhibitor)	5 min to 24 h	1 mg/kg	0.9	Rats plasma protease	LC-MS/MS using an Agilent HPLC	Rats plasma	In Vivo	None	None	JRFL(nM) = 0.11 ± 0.012 (antiviral potency)
5866	29421564	2018	RPKPQQFFGLM	SP	11	Free	Free	Linear	L	None	Synthetic	Therapeutic Angiogenesis in Diabetic Hindlimb Ischemia	0 to 72 h at 37°C	5 nmol	2	Human serum protease	ELISA	Human serum	In Vitro	None	None	N.A.
5868	29421564	2018	RPKPQQFFGLM	SP	11	Free	Free	Linear	L	None	Synthetic	Therapeutic Regeneration By Facilitating Mobilization Of Endogenous Stem Cells From Bone Marrow To The Injured Sites	0 to 72 h at 37°C	5 nmol	1.7	Diabetic rats serum protease	ELISA	Diabetic rats serum	In Vitro	None	None	N.A.
5877	29329072	2018	YFLFRPRN	Compound 1	8	Free	Amidation	Linear	L	None	NMU-analogs	Regulation of Feeding Behavior, the stress response and nociception	37 °C	112 µM	4.3 ± 0.2	Human plasma protease	RP-HPLC	Human plasma	In Vitro	None	None	EC50(nM) = 38.9, IC50(nM) = 0.78 for hNMUR1 and EC50(nM) = 30.8, IC50(nM) = 1.7 for hNMUR2
5885	29282303	2018	SIINFEKL	SCRAP-mCherry	N.A.	DD	mCherry	N.A.	L	None	Synthetic	Affects Antigen Presentation	N.A.	N.A.	41 ± 5	El4 cells protease	BD cytoflex flow cytometry	EL4 cells after Shield-1 removal	N.A.	None	None	N.A.
5890	29122441	2018	YGGEAAREACARCEAARE	FAMP1	18	FAM	Amidation	Cyclic (C10-C13 Disulfide Bond)	L	None	Synthetic	N.A.	37 C	10 µM	7	293T cells lysates protease	RP-HPLC-FD	293T cells lysate	In Vitro	None	None	N.A.
5891	29122441	2018	YGGEAAREACARCEAARE	FAMP1	18	FAM	Amidation	Cyclic (C10-C13 Disulfide Bond)	L	None	Synthetic	Increases Half Life	37 C	10 µM	21	293T cells lysates protease	RP-HPLC-FD	293T cells lysate	In Vitro	None	None	N.A.
5892	29122441	2018	YGGEAAREACARECAARE	FAM-P2	18	FAM	Amidation	Cyclic (C10-C14 Disulfide Bond)	L	None	Synthetic	N.A.	37 C	10 µM	16	293T cells lysates protease	RP-HPLC-FD	293T cells lysate	In Vitro	None	None	N.A.
5893	29122441	2018	YGGEAAREACARECAARE	FAM-P2.L5	18	FAM	Amidation	Cyclic (C10-C14 Disulfide Bond)	L	1,3-bis(bromomethyl)benzene linker (L5) for stapling i, i+4 spacing	Synthetic	Increases Half Life	37 C	10 µM	10	293T cells lysates protease	RP-HPLC-FD	293T cells lysate	In Vitro	None	None	N.A.
5895	29104145	2018	ATWLPPR	AS16	7	Free	Free	Linear	L	None	Synthetic	Antitumor	Blood samples were taken at 0 min, 5min,30 min, 2 h, 4 h, 6 h, 8 h, 10 h and 24h from orbit	45 mg/kg	1	Rats serum protease	ELISA	Rats serum	In Vivo	None	None	The activity value of AS16-Fc, as observed in vivo, is its significant inhibition of tumor growth and reduction in M2-polarized macrophages and vessel density in the MCA-205 tumor model
5896	29051342	2018	TGRAKRRMQYNRR	68Ga-NOTA-UBI	13	68Ga-NOTA	Free	Linear	L	None	Synthetic	Nuclear Imaging of Infectious Diseases	Image acquisition started 30, 60 and 120 min after IV	N.A.	29	NHP blood protease	PET-CT imaging	NHP blood sample	In Vivo	None	None	N.A.
5898	28948296	2018	EGTFISDYSIAMDKHIQDFVNWLLAQK	GIP(3-30)NH2	27	Free	Amidation	Linear	L	None	GIP analogue	GIP receptor antagonist	Blood samples were drawn 30, 15 and 0 min before and 20, 25, 30, 40, 50, 60, 67, 70, 75, 80, 95 and 125 min after the start of the GIP(3-30)NH2 infusion	800 pmol/kg/min	7.6 ± 1.4 (Elimination Half Life)	Human plasma protease	RIA	Human plasma	In Vivo	None	None	IC50 value of 87.6 nmol/l
5901	N.A.	2018	(GIVEQCCHSICSLYQLENYCN-OH)-(FVEQHLCGDHLVEALYLVCGERGFFYPK)	Example 7	49	Free	B29K(N(Eps)Tetradecanedioyl-4×gGlu), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond, B3E, desB27, modifications	Insulin Derivative	Treatment of Hypoglycaemia	Blood sample was collected at predose(-10,0),3,6,9,12,15,20,30,45,60,90,120,150,180,240,300,360,420,480,540,600 And 720 Minutes	1 nmol/kg	44	Pig plasma protease	ELISA	Pig plasma	In Vivo	None	US 201615754342 A	Lipogenesis 1% HSA (%rel to HI) = 10.5
5902	N.A.	2018	(GIVEQCCTSICSLYQLENYCA-OH)-(FVEQHLCGDHLVEALYLVCGERGFFYPK)	Example 8	49	Free	B29K(N(Eps)Tetradecanedioyl-4×gGlu), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond,A21A, B3E, desB27 modifications	Insulin Derivative	Treatment of Hypoglycaemia	Blood sample was collected at predose(-10,0),3,6,9,12,15,20,30,45,60,90,120,150,180,240,300,360,420,480,540,600 And 720 Minutes	1 nmol/kg	45	Pig plasma protease	ELISA	Pig plasma	In Vivo	None	US 201615754342 A	Lipogenesis 1% HSA (%rel to HI) = 11.8
5903	N.A.	2018	(GIVEQCCTSICSLYQLENYCA-OH)-(FVEQHLCGDHLVEALYLVCGERGFFYPK)	Example 8	49	Free	B29K(N(Eps)Tetradecanedioyl-4×gGlu), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond,A21A, B3E, desB27 modifications	Insulin Derivative	Treatment of Hypoglycaemia	Blood sample was collected at predose(-10,0),3,6,9,12,15,20,30,45,60,90,120,150,180,240,300,360,420,480,540,600 And 720 Minutes	1 nmol/kg	52	Pig plasma protease	ELISA	Pig plasma	In Vivo	None	US 201615754342 A	Lipogenesis 1% HSA (%rel to HI) = 11.8
5906	N.A.	2018	(GIVEQCCTSICSLYQLENYCA-OH)-(FVEQHLCGDHLVEALYLVCGERGFFYPK)	Example 8	49	Free	B29K(N(Eps)Tetradecanedioyl-4×gGlu), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond,A21A, B3E, desB27,modifications	Insulin Derivative	Treatment of Hypoglycaemia	Plasma was collected at the time points 0, 3,7,15,30,60,120,180 minutes after dosing	25 nmol/kg	29	SD rats plasma protease	ELISA	SD rats plasma with zinc ion	In Vivo	None	US 201615754342 A	Lipogenesis 1% HSA (%rel to HI) = 11.8
5907	N.A.	2018	(GIVEQCCHSICSLYQLENYCA-OH)-(FVEQHLCGSHLVEALYLVCGERGFFYPK)	Example 5	49	Free	B29K(N(Eps)Tetradecanedioyl-gGlu-2×OEG), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond,A21A, B3E, desB27, modifcations	Insulin Derivative	Treatment of Hypoglycaemia	Plasma was collected at the time points 0, 3,7,15,30,60,120,180 minutes after dosing	25 nmol/kg	35	SD rats plasma protease	ELISA	SD rats plasma with zinc ion	In Vivo	None	US 201615754342 A	Lipogenesis 1% HSA (%rel to HI) = 7.6
5908	N.A.	2018	(GIVEQCCTSICSLYQLENYCA-OH)-(FVQQHLCGSHLVEALYLVCGERGFFYPK)	Example 9	49	Free	B29K(N(Eps)Tetradecanedioyl-4×gGlu), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond, A21A, B3Q, desB27, modifications	Insulin Derivative	Treatment of Hypoglycaemia	Plasma was collected at the time points 0, 3,7,15,30,60,120,180 minutes after dosing	25 nmol/kg	30	SD rats plasma protease	ELISA	SD rats plasma with zinc ion	In Vivo	None	US 201615754342 A	Lipogenesis 1% HSA (%rel to HI) = 16.7
5909	N.A.	2018	(GIVEQCCHSICSLYQLENYCN-OH)-(FVEQHLCGDHLVEALYLVCGERGFFYPK)	Example 7	49	Free	B29K(N(Eps)Tetradecanedioyl-4×gGlu), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond, B3E, desB27, modififcations	Insulin Derivative	Treatment of Hypoglycaemia	Plasma was collected at the time points 0, 3,7,15,30,60,120,180 minutes after dosing	25 nmol/kg	30	SD rats plasma protease	ELISA	SD rats plasma with zinc ion	In Vivo	None	US 201615754342 A	Lipogenesis 1% HSA (%rel to HI) = 10.5
5910	N.A.	2018	(GIVEQCCTSICSLYQLENYCN-OH)-(FVEQHLCGDHLVEALYLVCGERGFFYPK)	Example 4	49	Free	B29K(N(Eps)Tetradecanedioyl-gGlu-2×OEG), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond,B3E, desB27,modificaitons	Insulin Derivative	Treatment of Hypoglycaemia	Plasma was collected at the time points 0, 3,7,15,30,60,120,180 minutes after dosing	25 nmol/kg	31	SD rats plasma protease	ELISA	SD rats plasma with zinc ion	In Vivo	None	US 201615754342 A	Lipogenesis 1% HSA (%rel to HI) = 9.3
5911	N.A.	2018	(GIVEQCCTSICSLYQLENYCN-OH)-(FVNQHLCGSHLVEALYLVCGERGFFYTDK)	Prior Art analogue 2	50	Free	B29K(N(Eps)Tetradecanedioyl-gGlu-2xOEG), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond,B28D, modifcations	Insulin Derivative	Treatment of Hypoglycaemia	Plasma was collected at the time points 0, 3,7,15,30,60,120,180 minutes after dosing	25 nmol/kg	45	SD rats plasma protease	ELISA	SD rats plasma with 3 Zinc Ion Per Hexamer	In Vivo	None	US 201615754342 A	N.A.
5912	N.A.	2018	(GIVEQCCTSICSLYQLENYCN-OH)-(FVNQHLCGSHLVEALYLVCGERGFFYTPK)	Prior Art analogue 3	50	Free	B29K(N(Eps)Tetradecanedioyl), desB30 modifications	Cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond, modifications	Insulin Derivative	Treatment of Hypoglycaemia	Plasma was collected at the time points 0, 3,7,15,30,60,120,180 minutes after dosing	25 nmol/kg	50	SD rats plasma protease	ELISA	SD rats plasma with 3 Zinc Ion Per Hexamer	In Vivo	None	US 201615754342 A	N.A.
5914	N.A.	2018	(GIVEQCCTSICSLYQLENYCA-OH)-(FVQQHLCGSHLVEALYLVCGERGFFYPK)	Example 23	49	Free	B29K(N(Eps)Hexadecanedioyl-4×gGlu), desB30 modifications	cyclic (C7-C12 disulfide bond in A chain)	L	A and B chain linked with disulfide bond,A21A, B3Q, desB27, modifications	Insulin Derivative	Treatment Of Hypoglycaemia	Plasma was collected at the time points 0, 3,7,15,30,60,120,180 minutes after dosing	25 nmol/kg	55	SD rats plasma protease	ELISA	SD rats plasma with Zinc Ion	In Vivo	None	US 201615754342 A	Lipogenesis 1% HSA (%rel to HI) = 1.54
5940	28899838	2017	GLSKGCFGLKLDRIGSMSGLGC	CNP(1-22)	22	Free	Free	Cyclic (C6-C22 Disulfide Bond)	L	None	Produced from recombinant DNA in Escherichia coli	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	0.02 mg/kg	1.96 ± 0.05	Rats plasma protease	RIA	Rats plasma without NEP inhibitor	In Vivo	None	None	CNP(6-22)ghrelin(12-28)amide maintained agonist activity comparable to that of CNP(1-22)
5941	28899838	2017	GLSKGCFGLKLDRIGSMSGLGC	CNP(1-22)	22	Free	Free	Cyclic (C6-C22 Disulfide Bond)	L	None	Produced from recombinant DNA in Escherichia coli	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	0.02 mg/kg	9.94 ± 1.40	Rats plasma protease	RIA	Rats plasma with NEP inhibitor	In Vivo	None	None	CNP(6-22)ghrelin(12-28)amide maintained agonist activity comparable to that of CNP(1-22)
5942	28899838	2017	CFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	CNP(6-22)ghrelin(12-28)	34	Free	Ghrelin (12-28)	Cyclic (C1-C17 Disulfide Bond)	L	None	Natriuretic peptide derivatives	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	0.02 mg/kg	14.9 ± 3.1	Rats plasma protease	RIA	Rats plasma without NEP inhibitor	In Vivo	None	None	CNP(6-22)ghrelin(12-28) exhibited NPR-B activity within one-tenth of that observed for CNP(1-22)
5943	28899838	2017	CFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	CNP(6-22)ghrelin(12-28)	34	Free	Ghrelin (12-28)	Cyclic (C1-C17 Disulfide Bond)	L	None	Natriuretic peptide derivatives	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	0.02 mg/kg	12.7 ± 1.2	Rats plasma protease	RIA	Rats plasma with NEP inhibitor	In Vivo	None	None	CNP(6-22)ghrelin(12-28) exhibited NPR-B activity within one-tenth of that observed for CNP(1-22)
5944	28899838	2017	GLSKGCFGLKLDRIGSMSGLGC	CNP(1-22)	22	Free	Free	Cyclic (C6-C22 Disulfide Bond)	L	None	Produced from recombinant DNA in Escherichia coli	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	10 nmol/kg	4.34 ± 0.20	Rats plasma protease	RIA	Rats plasma	In Vivo	None	None	CNP(6-22)ghrelin(12-28)amide maintained agonist activity comparable to that of CNP(1-22)
5945	28899838	2017	CFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	CNP(6-22)ghrelin(12-28)	34	Free	Ghrelin (12-28)	Cyclic (C1-C17 Disulfide Bond)	L	None	Natriuretic peptide derivatives	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	11 nmol/kg	15.03 ± 4.31	Rats plasma protease	RIA	Rats plasma	In Vivo	None	None	CNP(6-22)ghrelin(12-28) exhibited NPR-B activity within one-tenth of that observed for CNP(1-22)
5946	28899838	2017	VQQRKESKKPPAKLQPRCFGLKLDRIGSMSGLGC	Ghrelin(12-28)CNP(6-22)	34	Ghrelin (12-28)	Free	Cyclic (C18-C34 Disulfide Bond)	L	None	Natriuretic peptide derivatives	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	12 nmol/kg	17.75 ± 3.99	Rats plasma protease	RIA	Rats plasma	In Vivo	None	None	The activity of ghrelin(12-28)CNP(6-22) was about ten-fold less potent than that of CNP(6-22)ghrelin(12-28)
5947	28899838	2017	VQQRKESKKPPAKLQPRCFGLKLDRIGSMSGLGC	Ghrelin(12-28)CNP(6-22)	34	Ghrelin (12-28)	Free	Cyclic (C18-C34 Disulfide Bond)	L	None	Natriuretic peptide derivatives	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	13 nmol/kg	14.86 ± 2.64	Rats plasma protease	RIA	Rats plasma	In Vivo	None	None	The activity of ghrelin(12-28)CNP(6-22) was about ten-fold less potent than that of CNP(6-22)ghrelin(12-28)
5948	28899838	2017	CFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	CNP(6-22)ghrelin(12-28)amide	34	Free	Ghrelin(12-28)amide	Cyclic (C1-C17 Disulfide Bond)	L	None	Natriuretic peptide derivatives	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	14 nmol/kg	14.50 ± 0.85	Rats plasma protease	RIA	Rats plasma	In Vivo	None	None	The CNP(6-22)ghrelin(12-28)amide maintained agonist activity comparable to that of CNP(1-22)
5949	28899838	2017	VQQRKESKKPPAKLQPRCFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	Ghrelin(12-28)CNP(6-22)ghrelin(12-28)	51	Free	Ghrelin(12-28)	Cyclic (C18-C34 Disulfide Bond)	L	None	Natriuretic peptide derivatives	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	15 nmol/kg	18.40 ± 2.05	Rats plasma protease	RIA	Rats plasma	In Vivo	None	None	Agonist activity of ghrelin(12-28)CNP(6-22)ghrelin(12-28) was also the lowest
5950	28899838	2017	RPQLKAPPKKSEKRQQVCFGLKLDRIGSMSGLGCVQQRKESKKPPAKLQPR	Ghrelin(28-12)CNP(6-22)ghrelin(12-28)	51	Reversed sequence ghrelin(28-12) fused to the N-terminal side of CNP(6-22)	Free	Cyclic (C18-C34 Disulfide Bond)	L	None	Natriuretic peptide derivatives	Treatment of Growth Failure and Short Stature Disorders such as Achondroplasia	N.A.	16 nmol/kg	17.38 ± 1.00	Rats plasma protease	RIA	Rats plasma	In Vivo	None	None	Ghrelin(28-12)CNP(6-22)ghrelin(12-28) exhibited lower potency than that of ghrelin(28-12)CNP(6-22) and CNP(6-22)ghrelin(12-28)
5956	28800217	2017	DCLGAMRKCIPDNDKCCRPNLVCSRTHKWCKYVF	Peptide 22	34	Free	Free	Linear	L	Ala5 substituition in GpTx-1	derived from Grammostola porteri (Tarantula spider) (Lasiodora porteri)	Potently inhibits the voltage-gated sodium channels Nav1.7/Scn9A	At 0.5, 1, 1.25, 1.5,2,3, and 4 hours post-dose, 3 mice were euthanized and then blood samples were collected	5 mg/kg	0.605	Mice plasma protease	LC-MS/MS	Mice serum	In Vivo	https://sci-hub.se/10.1021/jm501765v	None	IC50=0.58-10 nM for GpTx-1
5957	28799326	2017	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG	GLP-1	31	Free	Free	Linear	L	None	GLP-1	Antidiabetes	Blood samples were collected from the tail vessel in time intervals of predose 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 144, 168 and 192 hours	5 mg/kg	0.03	NMR1 mice serum protease	AlphaLISA	NMR1 mice serum	In Vivo	PDB id: 5VAI	None	EC50 = 5.257*10-11
5961	28771355	2017	HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG	GLP-1 analogue 4	31	Free	Free	Linear	L	K34R substituition at GLP-1, Conjugated with indomethacin via γGlu attached to the ε-amine of Lys26 of the GLP-1 analog	GLP-1 analogs	Antidiabetes	Blood sampled at eight time-points within 24 h	5 mL/kg	55	Lean mice plasma protease	Luminescent Oxygen Channeling Immunoassay	Lean mice plasma	In Vivo	None	None	GLP-1R EC50 ± SEM (nM) = 0.068 ± 0.037
5972	28714475	2017	EYEKEYEACRWPARCVHQDLCG	tagPK128	22	tag	Free	Bicyclic(C9-C15,C15-C21 Disulfide Bond In Pk128)	L	Lys4 linked with Palm fatty acid	Synthetic	Inhibit plasma kallikrein	N.A.	0.5 mg/kg	0.9 ± 0.2 (T1/2a)	Rats plasma protease	RP-HPLC using a fluorescence detector	Rats plasma	In Vivo	None	None	Albumin binding (Kd) (nM) = 720±90 for rat albumin
5974	28714475	2017	EYEKEYEACSRYEVDCRGRGSACG	tagUK18	24	tag	Free	Bicyclic(C9-C16,C16-C23 Disulfide Bond In Uk128)	L	Lys4 linked with Palm fatty acid	Synthetic	Inhibit urokinase	N.A.	0.5 mg/kg	1.0 ± 0.1 (T1/2a)	Rats plasma protease	RP-HPLC using a fluorescence detector	Rats plasma	In Vivo	None	None	Albumin binding (Kd) (nM) = 780±110 for rat albumin
5976	28714475	2017	ACSRYEVDCRGRGSACG	UK18	17	Free	Free	Bicyclic(C2-C9,C9-C16 Disulfide Bond)	L	None	Synthetic	Inhibit urokinase	N.A.	0.3 mg/kg	0.30 ± 0.02 (T1/2b)	Rats plasma protease	RP-HPLC using a fluorescence detector	Rats plasma	In Vivo	None	None	Albumin binding (Kd) (nM) > 100,000 for rat albumin
5979	28714475	2017	EYEK(C14)EYE-(PEG24)3-XCFRLPCRQLRC	tag-3xPEG24-FXIIa inhibitor	N.A.	Tag-3xPEG24	Amidation	Bi-Cyclic(C2-7, C7-C12 Disulfide Bond In Fxiia Inhibitor)	L	None	Synthetic	FXIIa Inhibitor	N.A.	5 mg/kg	1.0 ± 0.2 (T1/2a)	Rabbit plasma protease	RP-HPLC using fluorescence detector	Rabbit plasma	In Vivo	None	None	(EC5x) at 4.2±0.5 mM
5981	28714475	2017	XCFRLPCRQLRC	FXIIa inhibitor	N.A.	Fluorescein (F)	Amidation	Bi-Cyclic(C2-7, C7-C12 Disulfide Bond In Fxiia Inhibitor)	L	None	Synthetic	FXIIa Inhibitor	N.A.	3.7 mg/kg	0.21 ± 0.04 (T1/2b)	Rabbit plasma protease	A single quadrupole liquid chromatography mass spectrometer	Rabbit plasma	In Vivo	None	None	Ki FXIIa = 4±0.9 nM in presence of albumin
5982	28711730	2017	MAFTEHSPLTPHRRDLCSRSIWLARKIRSDLTALTESYVKHQGLNKNINLDSADGMPVASTDQWSELTEAERLQENLQAYRTFHVLLARLLEDQQVHFTPTEGDFHQAIHTLLLQVAAFAYQIEELMILLEYKIPRNEADGMPINVGDGGLFEKKLWGLKVLQELSQWTVRSIHDLRFISSHQTGIP	rhCNTF	187	Free	Free	Linear	L	None	Synthetic	Treatment of Neurodegenerative or Metabolic diseases	At different time points (15min, 45min, 90min, 3h, 6h, 12h, 24h and 48h)	1 mg/kg	34.28	SD rats serum protease	ELISA	SD rats serum	In Vivo	PDB id: 1CNT	None	EC50±SD = 0.48±0.12ng/ml for rhCNTF
5997	28605180	2017	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	Exendin-4 analogs	Antihyperglycemic	Blood samples were drawn pre-dose and at 10 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h and 24 h after dosing	80 µg/mL	18	Rats serum protease	LC-MS/MS	Rats serum	In Vivo	PDB id: 7MLL	None	IC50(nM) = 0.21 ±0.0 for exenatide
5998	28605180	2017	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	Exendin-4 analogs	Antihyperglycemic	Blood samples were drawn pre-dose and at 10 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h and 24 h after dosing	80 µg/mL	50	Rats serum protease	LC-MS/MS	Rats serum	In Vivo	PDB id: 7MLL	None	IC50(nM) = 0.21 ±0.0
5999	28605180	2017	HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSSGAPPPS	[Gln28]exenatide	39	Free	Amidation	Linear	L	Substituiting Asn28 with Gln28	Exenatide analogs	Antidiabetes	Blood samples were drawn pre-dose and at 10 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h and 24 h after dosing	49 µg/mL	17	Rats serum protease	LC-MS/MS	Rats serum	In Vivo	PDB id: 7MLL	None	IC50(nM) = 11 ±3.7
6000	28605180	2017	HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSSGAPPPS	[Gln28]exenatide	39	Free	Amidation	Linear	L	Substituiting Asn28 with Gln28	Exenatide analogs	Antidiabetes	Blood samples were drawn pre-dose and at 10 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h and 24 h after dosing	49 µg/mL	48	Rats serum protease	LC-MS/MS	Rats serum	In Vivo	PDB id: 7MLL	None	IC50(nM) = 11 ±3.7
6016	28464043	2017	YNWNSFGLRF	KP-10	10	Free	Amidation	Linear	L	None	kisspeptin analogue	Treatment of Specific Human Reproductive Disorders	100 μl of blood was collected from the lateral tail vein from groups of mice (n = 4) for each time point (0, 1min, 2 min, 5 min, 10 min, 30 min, 60 min and 120 min)	1 nmol	4	Mouse plasma protease	RIA	Mouse plasma	In Vivo	https://www.jbc.org/article/S0021-9258(19)77047-1/fulltext	None	N.A.
6017	28464043	2017	GTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGLRF	KP-54	54	Free	Amidation	Linear	L	None	kisspeptin analogue	Treatment of Specific Human Reproductive Disorders	100 μl of blood was collected from the lateral tail vein from groups of mice (n = 4) for each time point (0, 1min, 2 min, 5 min, 10 min, 30 min, 60 min and 120 min)	1 nmol	32	Mouse plasma protease	RIA	Mouse plasma	In Vivo	https://www.jbc.org/article/S0021-9258(19)77047-1/fulltext	None	N.A.
6018	28457895	2017	HGEGTFTSDLSKQMEEEAVRLFIEWLKQGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	Exendin-4 analogs	Antihyperglycemic	1 hour	25 nmol/kg	~0.35	ICR mice retro-orbital sinus protease	Exenatide ELISA	ICR mice retro-orbital sinus	In Vivo	PDB id: 7MLL	None	both exenatide and exenatide-APTHSA groups at an equal dose effectively cleared glucose from the bloodstream, showing similar anti-hyperglycemic activity
6022	28416744	2017	RGDyK	cRGD-ZW800-1	5	Free	ZW800-1 fluorophore	Cyclic (RGDyK)	Mix	y = D-Tyr	Synthetic	Generic tracer for Intraoperative Near-Infrared Fluorescence Imaging of Solid Tumors	Time points -5, 1, 6, 10, 20, 30, 40, 50, 60, 90, 120, and 240 min. post injection	10 nmol	25.3 ± 6.4	Mice serum protease	Fluorescence assay	Mice serum	In Vivo	None	None	In vitro competition for binding cRGD-ZW800-1 (500 nM) with a 1:1 molar ratio of unlabeled cRGD (500 nM) resulted in a reduction of 32% on the HT-29 cells and 36% on the high integrin-expressing U-87 MG cells compared to cells treated without unlabeled cRGD
6025	28373972	2017	ONNRPVYIPRPRPPHPRL	Api88	18	Gu: N,N,N',N' tetramethylguanidino	Amidation	Linear	L	O denotes L-ornithine	Apidaecin analog	Antibacterial	After 10, 20, 30, 60, or90 min animals (n = 7)	5 mg/kg	17.3	Mice plasma protease	RP-HPLC-ESI-MS	Mice plasma	In Vivo	None	None	MIC = Api88 > Api137
6026	28373972	2017	ONNRPVYIPRPRPPHPRL	Api88	18	Gu: N,N,N',N' tetramethylguanidino	Amidation	Linear	L	O denotes L-ornithine	Apidaecin analog	Antibacterial	After 10, 20, 30, 60, or90 min animals (n = 7)	20 mg/kg	11.1	Mice plasma protease	RP-HPLC-ESI-MS	Mice plasma	In Vivo	None	None	MIC = Api88 > Api137
6027	28373972	2017	ONNRPVYIPRPRPPHPRL	Api137	18	Gu: N,N,N',N' tetramethylguanidino	Free	Linear	L	O denotes L-ornithine	Apidaecin analog	Antimicrobial	After 10, 20, 30, 60, or90 min animals (n = 7)	5 mg/kg	33.8	Mice plasma protease	RP-HPLC-ESI-MS	Mice plasma	In Vivo	None	None	The minimum inhibitory concentration (MIC) value for Api137 against E. coli ATCC 25922 is 4 µg/mL.
6028	28373972	2017	ONNRPVYIPRPRPPHPRL	Api137	18	Gu: N,N,N',N' tetramethylguanidino	Free	Linear	L	O denotes L-ornithine	Apidaecin analog	Antimicrobial	After 10, 20, 30, 60, or90 min animals (n = 7)	20 mg/kg	16.9	Mice plasma protease	RP-HPLC-ESI-MS	Mice plasma	In Vivo	None	None	The minimum inhibitory concentration (MIC) value for Api137 against E. coli ATCC 25922 is 4 µg/mL.
6036	28281868	2017	MALCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPTCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPD	eTGFBR2	112	Free	Free	Linear	L	None	Synthetic	Neutralize TGF-Β1 activity	Blood samples were collected through the eyes at 5 min, 15 min, 30 min, 60 min, 120 min	3 nmol/kg	41.42	Mice serum protease	Human TGF-b RII Duo Set ELISA	Mice serum	In Vivo	None	None	KD = 9.49* 10-9M of eTGFBR2 for TGF-B1
6038	28209419	2017	HADGSFSDEMNTILDNLAARDFINWLIQTKITD	Native GLP-2	33	Free	Free	Linear	L	None	Glucagon	Treatment of Short Bowel Syndrome	Samples were taken prior to GLP-2 administration and at 60, 90 and 180 min post injection on Day 3 of therapy or Day 42	2.5 μg/kg	~45	Human plasma protease	GLP-2 (1–33) specific radioimmunoassay	Infant human plasma	In Vivo	PDB id: 2L63	None	N.A.
6039	28138743	2017	ILKKWPWWPWRRK	CP-11	13	Free	Amidation	Linear	L	None	Synthetic	Antimicrobial	A plasma aliquot was withdrawn at each time-point(0, 0.16, 0.5, 1, 2, 4 h)	10 μM	0.21	Mouse plasma protease	LC-HRMS.	Mouse plasma	In Vitro	None	None	N.A.
6040	28138743	2017	ILRWPWWPWRRK	Omiganan	13	Free	Amidation	Linear	L	None	Analogue of indolicidin	Antimicrobial	A plasma aliquot was withdrawn at each time-point(0, 0.16, 0.5, 1, 2, 4 h)	10 μM	0.83	Mouse plasma protease	LC-HRMS.	Mouse plasma	In Vitro	None	None	N.A.
6042	28097629	2017	AGYKPDEGKRGDACEGSDGGPFV	TP508	23	Free	Amidation	Linear	L	TAMRA-labeled	Synthetic	Treatment of Diabetic Foot Ulcers	N.A.	2.16 mM	13.7	Male CD1 mice plasma protease	Fluorescence assay	Male CD1 mice plasma	In Vivo	None	None	N.A.
6043	28097629	2017	AGYKPDEGKRGDACEGSDGGPFV	PEG5k-TP508	23	PEG5K	Amidation	Linear	L	TAMRA-labeled	Synthetic	Treatment of Diabetic Foot Ulcers	N.A.	2.16 mM	11.5	Male CD1 mice plasma protease	Fluorescence assay	Male CD1 mice plasma	In Vivo	None	None	N.A.
6052	28010844	2017	fCFwKTCT	Octreotide	8	D-amino acid Phe	Free	Cyclic (C2-C7 Disulfide Linkage)	Mix	D-amino acid substituitons Trp	SST analog	Anticancer and treatment of Endocrine Diseases	The mice were sacrificed at 10, 20, 40, 60, 120, 240 and 360 min	50 mg/kg	28	Mouse stomach tissue lysate protease	HPLC-MS	Mouse stomach tissue lysate	In Vivo	https://sci-hub.st/10.1177/106002808802201001	None	N.A.
6053	28010844	2017	fCFwKTCT	Octreotide	8	D-amino acid Phe	Free	Cyclic (C2-C7 Disulfide Linkage)	Mix	D-amino acid substituitons Trp	SST analog	Anticancer and treatment of Endocrine Diseases	The mice were sacrificed at 10, 20, 40, 60, 120, 240 and 360 min	50 mg/kg	37.7	Mouse intestine tissue lysate protease	MALDI-TOF-MSI and LC-MS/MS	Mouse intestine tissue lysate	In Vivo	None	None	N.A.
6066	27815337	2017	pGlu-RPRLSHKGPMPF	pE13F	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Diuretic and Cardiovascular Effects	37°C	5 μM	7.2	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	None	None	Recruitment of b-arrestin2 by BRET, EC50 (nM) = 300 ± 182
6068	27815337	2017	KFRRQRPRLSHKGPMPF	K17F	17	Free	Free	Linear	L	None	Apelin analogs	Diuretic and Cardiovascular Effects	37°C	5 μM	4.6	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	None	None	Recruitment of b-arrestin2 by BRET, EC50 (nM) = 15 ± 3.6
6069	27815337	2017	KFaRqRPRlS-Aib-Ka-ProNle-PF	P92	17	Acetylation	Pro(4-Br)Phe substituition	Linear	Mix	Aib, DLeu,DGln, ProNle, D-Arg at position 3	Apelin analogs	Diuretic and Cardiovascular Effects	37°C	5 μM	24	Mouse plasma protease	LC-MS	Mouse plasma	In Vitro	None	None	Recruitment of b-arrestin2 by BRET, EC50 (nM) = 4 ± 2.4
6071	27784692	2017	MCGPGVG-(VPGxG)160-VPGWPGSG	ELP	815	Free	Free	Linear	L	x = Val,Gly or Ala	Synthetic	Carrier protein	Whole-animal fluorescence images were collected at regular intervals for 24 hours	100 mg/kg	52.6 (T1/2,Terminal)	Rats plasma protease	whole-body fluorescence imaging	Rats plasma	In Vivo	None	None	KTP-ELP, ELP, and SynB1-ELP show no toxicity in any of the renal cell lines tested, even at concentrations up to 40 μM for 72 hours
6075	27689406	2017	HSQGTFTSDYSKYLDSRRAQDFVQWLMNT	Glucagon	29	Free	Free	Linear	L	None	Produced by the alpha cells of the pancreas	Antidiabetes	A total of 19 other samples were taken at the following time points from the beginning of peptide infusion: 0, 30, 35, 40, 45,50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 95, and 100 min	30 nmol/ml	3.2	Surgical rats plasma protease (Wistar Rat)	RIA	Surgical rats plasma (Wistar rat)	In Vivo	None	None	N.A.
6076	27689406	2017	HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG	GLP-1	31	Free	Free	Linear	L	None	Synthetic	Antidiabetes	A total of 19 other samples were taken at the following time points from the beginning of peptide infusion: 0, 30, 35, 40, 45,50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 95, and 100 min	30 nmol/ml	1.2	Surgical rats plasma protease (Wistar Rat)	RIA	Surgical rats plasma (Wistar rat)	In Vivo	PDB id: 5VAI	None	N.A.
6077	27689406	2017	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exendin-4	39	Free	Amidation	Linear	L	None	Exendin-4	Antidiabetes	A total of 19 other samples were taken at the following time points from the beginning of peptide infusion: 0, 30, 35, 40, 45,50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 95, and 100 min	30 nmol/ml	35.1	Surgical rats plasma protease (Wistar Rat)	RIA	Surgical rats plasma (Wistar rat)	In Vivo	PDB id: 7MLL	None	EC50 (pM) = 1.8 ± 0.8
6078	27689406	2017	N.A.	X1	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Antiobesity	N.A.	N.A.	3.9	Surgical rats plasma protease (Wistar Rat)	RIA	Surgical rats plasma (Wistar rat)	In Vivo	None	None	N.A.
6079	27689406	2017	N.A.	X2	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Antiobesity	N.A.	N.A.	16.1	Surgical rats plasma protease (Wistar Rat)	RIA	Surgical rats plasma (Wistar rat)	In Vivo	None	None	N.A.
6080	27689406	2017	N.A.	X3	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	Antiobesity	N.A.	N.A.	21.3	Surgical rats plasma protease (Wistar Rat)	RIA	Surgical rats plasma (Wistar rat)	In Vivo	None	None	N.A.
6081	27539157	2017	VEPNCDIHVMWEWECFERL-Tz4-lfreW	Anti‐VEGF PCCs Bi‐LV	23	X1 = biotin-PEG3 label	lfreW = D and L -amino acids	Cyclic	Mix	Tz4 = triazole linker	Synthetic	In vivo imaging probe and an Anti‐PA peptide	Blood was drawn from each of three animals at the following time points: 3, 10, 30, 60, 120, 240, 360, 1,440 min	1 mg/kg	7 (Elimination Half Life)	Mice plasma protease	LC‐MS/MS assay	Mice plasma	In Vivo	None	None	N.A.
6082	27539157	2017	VEPNCDIHVMWEWECFERL-Tz4-eeird	Anti‐VEGF PCCs Tri‐LV	28	X1 = biotin-PEG3 label	eeird = D-amino acids	Cyclic	Mix	Tz4 = triazole linker	Synthetic	In vivo imaging probe and an Anti‐PA peptide	Blood was drawn from each of three animals at the following time points: 3, 10, 30, 60, 120, 240, 360, 1,440 min	1 mg/kg	36 (Elimination Half Life)	Mice plasma protease	LC‐MS/MS assay	Mice plasma	In Vivo	None	None	IC50 = 2.6 ± 0.5 nM
6083	N.A.	2017	ASDEEIQDVSGTWYLKAMTVDRFKIASWPRSVTPMTLTTLEGGNLEAKVTMNWWGRSQEVKAVLERTDEPGKYTAQGDRHVAYIIRSPVKDHYIFYSEGNLQGETVPGVWLVGRDPKNNLEALEDFEKAAGARGLSTESILIPRQSETSSPG	SEQ ID NO 62	152	Free	Free	Linear	L	None	Lipocalin muteins	Pcsk9-Specific Lipocalin Muteins	N.A.	N.A.	0.99	Rats plasma protease	Sandwich ELISA	Rats plasma	In Vivo	None	US 201715445066 A	IC50(nM) = 1.36 without HSA for LDLR binding
6084	N.A.	2017	GASDEEIQDVSGTWYLKAMTVDRFKIASWPRSVTPMTLTTLEGGNLEAKVTMNWWGRSQEVKAVLERTDEPGKYTAQGDRHVAYIIRSHVKDHYIFYSEGNLQGETVPGVWLVGRDPKNNLEALEDFEKAAGARGLSTESILIPRQSETSSPG	SEQ ID NO 82	153	Free	Free	Linear	L	None	Lipocalin muteins	Pcsk9-Specific Lipocalin Muteins	N.A.	N.A.	0.86	Rats plasma protease	Sandwich ELISA	Rats plasma	In Vivo	None	US 201715445066 A	IC50(nM) = 1.68 without HSA for LDLR binding
6112	27558296	2016	pGlu-RPRLSHKGPMPF	Compound 1	13	pGlu = Pyroglutamate	Free	Linear	L	None	Apelin analogs	Inotropic Agent	Time points (0, 0.17, 0.5, 1, 2, 4, 6, 24 and 27 h)	1 µg/mL	0.025	Wistar rats plasma protease	ESI-MS	Wistar rats plasma	In Vitro	None	None	EC50(nM) = 2.6 ± 1.0
6113	27558296	2016	pGlu-RPRLSHKGP-Nle-PF	Compound 2	13	pGlu = Pyroglutamate	Free	Linear	L	Nle = Norleucine at position 11	Apelin analogs	Inotropic Agent	Time points (0, 0.17, 0.5, 1, 2, 4, 6, 24 and 27 h)	1 µg/mL	0.13	Wistar rats plasma protease	ESI-MS	Wistar rats plasma	In Vitro	None	None	EC50(nM) = 2.0 ± 0.3
6114	27558296	2016	pGlu-CRPRLCHKGP-Nle-PF	Compound 26	14	pGlu = Pyroglutamate	Free	Cyclic (C2-C7 Disulfide Linkage)	L	Nle = Norleucine at position 12	Apelin analogs	Inotropic Agent	Time points (0, 0.17, 0.5, 1, 2, 4, 6, 24 and 27 h)	1 µg/mL	0.1	Wistar rats plasma protease	ESI-MS	Wistar rats plasma	In Vitro	None	None	EC50(nM) > 1000
6117	27558296	2016	QRPRLSHKKP-Nle-Aib-F	Compound 31	13	Palmitic acid conjugation	Free	Linear	L	Gly9 was exchanged with Lys, TAMRA = 5,6-carboxytetramethylrhodamine at Lys9 modification at Lysine , Nle= Nor-leucine at position 11, Aib = 2-Aminoisobutyric acid at position 12	compound 31 analogues	Inotropic Agent	37 C	0.00001 M	0.36	Wistar rats plasma protease	HPLC	Wistar rats plasma	In Vitro	None	None	EC50(nM) = 21.6 ± 4.5 for compound 31
6129	27217590	2016	CYIQNCPLG	OT (oxytocin)	9	Free	Amidation	Cyclic (C1-C6 Disulfide Linkage)	L	None	Produced in the hypothalamus and released by the posterior pituitary gland	Treatment of Psychiatric Diseases, Including Autism Spectrum Disorders And Schizophrenia	Time points postdose: 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours	0.1 mg/kg	0.12	Wistar rats plasma protease	LC-MS/MS	Wistar rats plasma	In Vivo	https://sci-hub.st/10.1016/s0079-6123(08)00417-2	None	EC50(nM) = 0.039 (OTR agonist)
6132	27217590	2016	CYIQNCPLG	OT (oxytocin)	9	Free	Amidation	Cyclic (C1-C6 Disulfide Linkage)	L	None	Produced in the hypothalamus and released by the posterior pituitary gland	Treatment of Psychiatric Diseases, Including Autism Spectrum Disorders And Schizophrenia	Time points postdose: 0.25 (OT only), 0.5, 1, 2, 4, 6, and 24 hours (6- and 24-hour sampling limited to PF1 only	10 ml/kg	0.5	C57Bl/6J mice plasma protease	LC-MS/MS	C57BL/6J mice plasma	In Vivo	PDB id: 2MGO	None	EC50(nM) = 0.039 (OTR agonist)
6138	27166982	2016	GGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY	ADM analogue 3	39	Tam (6-Carboxytetramethylrhodamine) labeling, Glycine substitution at position 1	Amidation	Cyclic (C3-C8 Disulfide Linkage)	L	None	ADM analogue	Treatment of Cardiovascular Diseases	37°C	0.00001 M	3.3	Porcine liver homogenate protease	RP-HPLC	Porcine liver homogenate	In Vitro	None	None	EC50 = 13.2 nM for ADM analogue 15
6139	27166982	2016	KG-Dpr-RFGTETVQKLAHQIYQFTDKDKDNVAPRSKISPQGY	ADM analogue 20	38	Tam (6-Carboxytetramethylrhodamine) labeling, Glycine substitution at position 1	Amidation	Cyclic (Dpr3-E8 Lactam Bridge)	L	Nα-Methylation of Lysine at position 33, K1, Dpr3 = Diaminopropionic acid,E8 substituitions and Pam = Palmitoylation modification at side chain of Lys1	ADM analogue	Treatment of Cardiovascular Diseases	37°C	0.00001 M	38	Porcine liver homogenate protease	RP-HPLC	Porcine liver homogenate	In Vitro	None	None	EC50 = 13.2 nM for ADM analogue 15
6160	26818056	2016	YPAKPEAPGEDASPEELSRYYASLRHYLNLVTRQRY	PYY1–36	36	Free	Amidation	Linear	L	None	Released from enteroendocrine cells	Anorexic effects	Blood was sampled at t = −15, 0, 60, 90, and 120 min relative to start of the infusion as well as frequently after the infusion was discontinued at t = 122, 125, 130, 135, 140, 150, 165, 195, and 240 min	PYY infusions for 2 h on four separate days of either 1) 1.6 pmol·kg−1·min−1 PYY1–36, 2) 1.6 pmol·kg−1·min−1 PYY1–36 after DPP-4 inhibition, 3) 0.8 pmol·kg−1·min−1 PYY3–36	10.1 ± 0.5 (Elimination Half Life)	Human blood plasma protease	RIA	Human blood plasma with 2 × 100 mg sitagliptin	In Vivo	https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1432-1033.1984.tb08298.x	None	The human Y2 receptor was activated by hPYY3–36 with an EC50 value of 3.5 nmol/l
6161	26818056	2016	YPAKPEAPGEDASPEELSRYYASLRHYLNLVTRQRY	PYY1–36	36	Free	Amidation	Linear	L	None	Released from enteroendocrine cells	Anorexic effects	Blood was sampled at t = −15, 0, 60, 90, and 120 min relative to start of the infusion as well as frequently after the infusion was discontinued at t = 122, 125, 130, 135, 140, 150, 165, 195, and 240 min	PYY infusions for 2 h on four separate days of either 1) 1.6 pmol·kg−1·min−1 PYY1–36, 2) 1.6 pmol·kg−1·min−1 PYY1–36 after DPP-4 inhibition, 3) 0.8 pmol·kg−1·min−1 PYY3–36	9.4 ± 0.8 (Elimination Half Life)	Human blood plasma protease	RIA	Human blood plasma	In Vivo	https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1432-1033.1984.tb08298.x	None	The human Y2 receptor was activated by hPYY3–36 with an EC50 value of 3.5 nmol/l
6162	26818056	2016	AKPEAPGEDASPEELSRYYASLRHYLNLVTRQRY	PYY3-36	34	Free	Amidation	Linear	L	None	Released from enteroendocrine cells	Anorexic effects	Blood was sampled at t = −15, 0, 60, 90, and 120 min relative to start of the infusion as well as frequently after the infusion was discontinued at t = 122, 125, 130, 135, 140, 150, 165, 195, and 240 min	PYY infusions for 2 h on four separate days of either 1) 1.6 pmol·kg−1·min−1 PYY1–36, 2) 1.6 pmol·kg−1·min−1 PYY1–36 after DPP-4 inhibition, 3) 0.8 pmol·kg−1·min−1 PYY3–36	14.9 ± 1.3 (Elimination Half Life)	Human blood plasma protease	RIA (total PYY assay)	Human blood plasma	In Vivo	https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1432-1033.1984.tb08298.x	None	The human Y2 receptor was activated by hPYY3–36 with an EC50 value of 3.5 nmol/l
6166	26808199	2016	LRHWLNLLTRQRW	PYY24–36	13	Free	Amidation	Linear	L	None	PYY analog	Antiobesity	An amount of 100 lL of plasma was removed from the incubations at 0, 1, 2, 4, 6,8, 12, and 24 h time-point	1000 ng/mL	<0.5	SD rats plasma protease	LC–MS/MS	SD rats plasma	In Vitro	None	None	HSA binding correlated well with plasma stability
6178	26774588	2016	IKPEAPGEDASPEELNRYYASLRHYLNLVTRQR	PYY3-35	33	Free	Free	Linear	L	None	Isolated and purified from porcine small intestine	Decrease appetite and food-intake	Conducted at 37ºC and aliquots were taken at 2, 5, 15, 30, 60, 120 and 240 min	1 µM	6	Minipigs heparin-plasma protease	LC-MS	minipigs heparin-plasma	In Vitro	None	None	N.A.
6179	26774588	2016	IKPEAPGEDASPEELNRYYASLRHYLNLVTRQR	PYY3-35	33	Free	Free	Linear	L	None	Isolated and purified from porcine small intestine	Decrease appetite and food-intake	Conducted at 37ºC and aliquots were taken at 2, 5, 15, 30, 60, 120 and 240 min	1 µM	39	Minipigs heparin-plasma protease	LC-MS	minipigs heparin-plasma with 10 mM EDTA	In Vitro	None	None	N.A.
6182	26752086	2016	GGLRSLGRKILRAWKKYGQRLGNQWAVGHLM	BB28	31	conjugating a truncated antimicrobial peptide B28 to the N-terminus of the tumor-homing peptide bombesin	Amidation	Linear	L	Biotinylation	Synthetic	Antitumor	N.A.	30 nmol	<5	BALB/c mice plasma protease	ELISA	BALB/c mice plasma	In Vivo	None	None	IC50 ranges from 2.5–3.0 mM (In the absence of FBS) for BB28
6183	26741458	2016	FEFQFK	Peptide 1	6	Free	Free	Linear	L	None	Synthetic	Hydrogelators	Degradation was monitored after 0, 1, 2, 3, 4, 5, and 10 min	34 μM	3.43 ± 0.06	Human blood plasma protease	HPLC	Human blood plasma	In Vitro	None	None	N.A.
6184	26741458	2016	FE-β3hF-FQ-β3hF-FK	Peptide 2	8	Free	Free	Linear	L	β3-homophenylalanine (β3-hPhe) at position 3 and 6	Synthetic	Hydrogelators	During the stability study of mixed α/β-peptides, samples were taken after 0, 5, 10, 15, 30, 60, 90, 120, 240, and 1500 min.	33 μM	19.53 ± 0.55	Human blood plasma protease	HPLC	Human blood plasma	In Vitro	None	None	N.A.
6185	26741458	2016	FE-β3hF-FQ-β3hF-FK	Peptide 3	8	Free	Amidation	Linear	L	β3-homophenylalanine (β3-hPhe) at position 3 and 6	Synthetic	Hydrogelators	During the stability study of mixed α/β-peptides, samples were taken after 0, 5, 10, 15, 30, 60, 90, 120, 240, and 1500 min.	33 μM	40.00 ± 1.28	Human blood plasma protease	HPLC	Human blood plasma	In Vitro	None	None	N.A.
6186	26741458	2016	FE-β3hF-YQ-β3hF-YK	Peptide 4	8	Free	Amidation	Linear	L	β3-homophenylalanine (β3-hPhe) at position 3 and 6, substitution of Phe with Tyr at positions 4 and 7	Synthetic	Hydrogelators	During the stability study of mixed α/β-peptides, samples were taken after 0, 5, 10, 15, 30, 60, 90, 120, 240, and 1500 min.	33 μM	18.71 ± 0.44	Human blood plasma protease	HPLC	Human blood plasma	In Vitro	None	None	N.A.
6187	26725426	2016	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS	Exenatide	39	Free	Amidation	Linear	L	None	Exendin-4 analogs	Antihyperglycemic	N.A.	23.88 nmol/mL	0.05784	Chymotrypsin	Mass spectrometry	Intestinal fluid buffer (pH 6.8) with Chymotrypsin (0.2 U/mL)	In Vitro	PDB id: 7MLL	None	N.A.
6223	26628555	2016	TGENHR	HLDF-6-NH2	6	3H labeling at N terminal	Amidation	Linear	L	None	Isolated from the culture medium of retinoic acid-treated HL-60 cells	Neuroprotective And Nootropic Activities	N.A.	N.A.	8	Wistar rats blood plasma protease	N.A.	Wistar rats blood plasma	In Vivo	None	None	ChAT activity, dpm/mg of tissue = 5.61±0.40 in (βA + HLDF-6-NH2,250 µg/kg)
6224	26628555	2016	TGENHR	HLDF-6-OH	6	3H labeling at N terminal	Free	Linear	L	None	Isolated from the culture medium of retinoic acid-treated HL-60 cells	Neuroprotective And Nootropic Activities	N.A.	N.A.	2	Wistar rats blood plasma protease	N.A.	Wistar rats blood plasma	In Vivo	None	None	ChAT activity, dpm/mg of tissue = 5.29±0.34 in (βA + HLDF-6-OH,250 µg/kg)
6239	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	20 mg	5.9	Human serum protease	HPLC–MS/MS	Human serum (Japanese)	In Vivo	Pubchem id: 86278343	None	N.A.
6240	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	80 mg	13.7	Human serum protease	HPLC–MS/MS	Human serum (Japanese)	In Vivo	Pubchem id: 86278343	None	N.A.
6241	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	240 mg	23.5	Human serum protease	HPLC–MS/MS	Human serum (Japanese)	In Vivo	Pubchem id: 86278343	None	N.A.
6242	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	20 mg	6.9	Human serum protease	HPLC–MS/MS	Human serum ( Caucasians)	In Vivo	Pubchem id: 86278343	None	N.A.
6243	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	80 mg	14.4	Human serum protease	HPLC–MS/MS	Human serum ( Caucasians)	In Vivo	Pubchem id: 86278343	None	N.A.
6244	26242382	2016	ARRCYNDPKCSDFVQADE	JNJ-54452840	18	Free	Free	Cyclic (C4-C10 Disulfide Linkage And Terminal Ala1-Glu18 Linkage)	L	None	Synthetic	Treatment for Chronic Heart Failure	Blood sample collected at the following timepoints relative to the start of the infusion: predose; at 1 min (end of infusion); at 5, 7, 10, 15, 20, 30 and 45 min; and at 1, 2, 4, 8 and 24 h postdose	240 mg	26.1	Human serum protease	HPLC–MS/MS	Human serum ( Caucasians)	In Vivo	Pubchem id: 86278343	None	N.A.
6258	133-353-120-049-121	2016	APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALRAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDRVEPKSGDKTSTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGPFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK	rHuEPO-Fc	399	Free	Free	Linear	L	Fusion with IgG Fc fragment	Human erythropoietic protein Fusion with IgG Fc fragment	Immunogenic	N.A.	5 ug/kg	35.24+/-5.15	Not mentioned	ELISA	Blood	in vivo	https://lens.org/133-353-120-049-121	US 9,375,487 B2	N.A.